0001558370-24-01562310-Q Sagimet Biosciences Inc. 20241114202411140800340800340800034 0 0001558370-24-015623 10-Q 57 20240930 20241114 20241114 Sagimet Biosciences Inc. 0001400118 2834 205991472 DE 1231 10-Q 34 001-41742 241457288 155 BOVET RD., SUITE 303 SAN MATEO CA 94402 (650) 561-8600 155 BOVET RD., SUITE 303 SAN MATEO CA 94402 3-V Biosciences, Inc. 20070521 10-Q 1 sgmt-20240930x10q.htm 10-Q http://fasb.org/us-gaap/2024#LicenseMemberhttp://fasb.org/us-gaap/2024#LicenseMember0001400118--12-312024Q3false0.012582306748551520490152049020137540200P38M0001400118us-gaap:RedeemableConvertiblePreferredStockMember2023-09-300001400118us-gaap:RedeemableConvertiblePreferredStockMember2023-06-300001400118us-gaap:RedeemableConvertiblePreferredStockMember2023-03-310001400118us-gaap:RedeemableConvertiblePreferredStockMember2022-12-310001400118us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-07-012024-09-300001400118us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-01-012024-03-310001400118us-gaap:CommonClassBMember2023-07-182023-07-180001400118us-gaap:CommonClassAMember2023-07-182023-07-180001400118us-gaap:RetainedEarningsMember2024-09-300001400118us-gaap:AdditionalPaidInCapitalMember2024-09-300001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001400118us-gaap:RetainedEarningsMember2024-06-300001400118us-gaap:AdditionalPaidInCapitalMember2024-06-300001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001400118182024-06-300001400118us-gaap:RetainedEarningsMember2024-03-310001400118us-gaap:AdditionalPaidInCapitalMember2024-03-310001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001400118182024-03-310001400118us-gaap:RetainedEarningsMember2023-12-310001400118us-gaap:AdditionalPaidInCapitalMember2023-12-310001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001400118us-gaap:RetainedEarningsMember2023-09-300001400118us-gaap:AdditionalPaidInCapitalMember2023-09-300001400118us-gaap:RetainedEarningsMember2023-06-300001400118us-gaap:AdditionalPaidInCapitalMember2023-06-300001400118182023-06-300001400118us-gaap:RetainedEarningsMember2023-03-310001400118us-gaap:AdditionalPaidInCapitalMember2023-03-310001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001400118182023-03-310001400118us-gaap:RetainedEarningsMember2022-12-310001400118us-gaap:AdditionalPaidInCapitalMember2022-12-310001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001400118us-gaap:CommonClassAMember2024-01-310001400118us-gaap:CommonClassAMember2023-08-310001400118sgmt:EmployeeStockPurchasePlan2023Member2023-07-132023-07-130001400118sgmt:PerformanceBasedStockOptionsMember2024-09-300001400118sgmt:EmployeeStockPurchasePlan2023Memberus-gaap:CommonClassAMember2024-01-010001400118sgmt:EmployeeStockPurchasePlan2023Memberus-gaap:CommonClassAMember2024-01-012024-01-010001400118sgmt:EquityIncentivePlan2023Member2024-01-012024-01-010001400118srt:MinimumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-09-300001400118srt:MaximumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-09-300001400118srt:MinimumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001400118srt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001400118sgmt:EquityIncentivePlan2023Member2023-07-132023-07-130001400118us-gaap:RestrictedStockUnitsRSUMember2023-12-310001400118sgmt:EmployeeStockPurchasePlan2023Memberus-gaap:CommonClassAMember2024-01-012024-09-300001400118sgmt:AtMarketArrangementMember2024-07-012024-09-300001400118sgmt:AtMarketArrangementMember2024-01-012024-09-300001400118us-gaap:CommonClassAMember2023-07-012023-08-310001400118sgmt:AscletisBioscienceCo.LtdMember2023-07-012023-07-310001400118sgmt:AscletisBioscienceCo.LtdMemberus-gaap:RelatedPartyMember2024-01-012024-09-300001400118sgmt:AscletisBioscienceCo.LtdMemberus-gaap:RelatedPartyMember2023-01-012023-09-300001400118182023-08-012023-08-310001400118us-gaap:CommonClassAMember2024-01-012024-01-310001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001400118us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001400118us-gaap:RetainedEarningsMember2024-07-012024-09-300001400118us-gaap:RetainedEarningsMember2024-04-012024-06-300001400118us-gaap:RetainedEarningsMember2024-01-012024-03-310001400118us-gaap:RetainedEarningsMember2023-07-012023-09-300001400118us-gaap:RetainedEarningsMember2023-04-012023-06-300001400118us-gaap:RetainedEarningsMember2023-01-012023-03-3100014001182019-03-120001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001400118sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001400118sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:USTreasurySecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommercialPaperMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001400118sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:USTreasurySecuritiesMember2024-09-300001400118sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001400118sgmt:LongTermMarketableSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300001400118sgmt:LongTermMarketableSecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300001400118us-gaap:FairValueInputsLevel2Member2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:USTreasurySecuritiesMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommercialPaperMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001400118us-gaap:FairValueInputsLevel2Member2023-12-310001400118sgmt:SeriesCommonStockWarrantsMember2023-07-012023-09-300001400118sgmt:SeriesCommonStockWarrantsMember2023-01-012023-09-300001400118sgmt:RedeemablePreferredStockWarrantMember2023-01-012023-09-300001400118sgmt:TimeBasedStockOptionsMember2024-09-300001400118us-gaap:RestrictedStockUnitsRSUMember2024-09-300001400118sgmt:TimeBasedStockOptionsMember2024-01-012024-09-300001400118us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-09-300001400118us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-09-300001400118us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-06-300001400118us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-06-300001400118us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-03-310001400118us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-03-310001400118us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-12-310001400118us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-12-310001400118us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-09-300001400118us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-09-300001400118us-gaap:CommonStockMember2023-06-300001400118us-gaap:CommonStockMember2023-03-310001400118us-gaap:CommonStockMember2022-12-310001400118us-gaap:CommonClassBMember2024-09-300001400118us-gaap:CommonClassAMember2024-09-300001400118us-gaap:CommonClassBMember2023-12-310001400118us-gaap:CommonClassAMember2023-12-310001400118sgmt:InducementGrantsOutsideOf2023PlanMember2024-09-300001400118sgmt:EquityIncentivePlan2023Member2024-09-300001400118sgmt:EmployeeStockPurchasePlan2023Memberus-gaap:CommonClassAMember2023-07-130001400118sgmt:EquityIncentivePlan2023Member2023-07-130001400118sgmt:EmployeeStockPurchasePlan2023Member2023-07-130001400118sgmt:SeriesCommonStockWarrantsMember2024-09-300001400118182023-01-012023-12-310001400118182022-01-012022-12-310001400118182023-09-300001400118182022-12-310001400118us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001400118us-gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember2024-09-300001400118us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001400118us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001400118us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001400118us-gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2024-09-300001400118sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-09-300001400118sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001400118sgmt:LongTermMarketableSecuritiesMember2024-09-300001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310001400118sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001400118us-gaap:FairValueMeasurementsRecurringMember2023-12-310001400118us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001400118us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300001400118us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001400118us-gaap:WarrantMember2024-07-012024-09-300001400118us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001400118us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001400118us-gaap:WarrantMember2024-01-012024-09-300001400118us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001400118us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001400118us-gaap:WarrantMember2023-07-012023-09-300001400118us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001400118us-gaap:WarrantMember2023-01-012023-09-300001400118us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001400118us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001400118us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001400118us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001400118us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001400118us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001400118us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001400118us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001400118us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001400118us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001400118us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001400118us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001400118us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001400118us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001400118us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001400118us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001400118us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001400118182024-04-012024-06-300001400118us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001400118182024-01-012024-03-310001400118us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001400118182023-07-012023-09-300001400118us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001400118182023-04-012023-06-300001400118us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001400118182023-01-012023-03-310001400118sgmt:AscletisBioscienceCo.LtdMemberus-gaap:RelatedPartyMember2024-09-300001400118us-gaap:RelatedPartyMember2024-09-300001400118sgmt:AscletisBioscienceCo.LtdMemberus-gaap:RelatedPartyMember2023-12-310001400118us-gaap:RelatedPartyMember2023-12-310001400118sgmt:AtMarketArrangementMember2024-08-012024-08-310001400118us-gaap:CommonStockMember2023-04-012023-06-300001400118us-gaap:CommonStockMember2023-07-

012023-09-300001400118us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-07-012023-09-300001400118us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-07-012023-09-300001400118us-gaap:RedeemableConvertiblePreferredStockMember2023-07-012023-09-300001400118us-gaap:RedeemableConvertiblePreferredStockMember2023-04-012023-06-300001400118us-gaap:RedeemableConvertiblePreferredStockMember2023-01-012023-03-3100014001182024-04-012024-04-3000014001182019-03-122019-03-1200014001182023-01-012023-09-3000014001182024-09-3000014001182023-12-3100014001182024-07-012024-09-3000014001182024-11-0800014001182024-01-012024-09-30xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesutr:sqftxbrli:pureTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORMÂ 10-Q(Mark One)â€‹â˜‘QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the quarterly period ended September 30, 2024â€‹ORâ€‹â˜TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the transition period fromÂ toâ€‹Commission File Number: 001-41742Sagimet BiosciencesÂ Inc.(Exact name of registrant as specified in its charter)Delaware20-5991472(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)â€‹â€‹155 Bovet Road, SuiteÂ 303â€‹San Mateo, California94402(Address of principal executive offices)(Zip Code)â€‹(650) 561-8600(Registrantâ€™s telephone number, including area code)N/A(Former name, former address and former fiscalÂ year, if changed since last report)â€‹â€‹Securities registered pursuant to SectionÂ 12(b)Â of the Act:â€‹Title of each classâ€‹Trading Symbol(s)â€‹Name of each exchange on which registeredSeries A Common Stock,$0.0001 par value per shareâ€‹SGMTâ€‹Nasdaq Global Marketâ€‹Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Yes â˜’Noâ˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â—»Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act.Large accelerated filer â˜Accelerated filer â˜â€‹â€‹Non-accelerated filer â˜’Smaller reporting company â˜’â€‹â€‹Emerging growth company â˜’â€‹If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). Yes â˜ No â˜’The number of shares of the registrantâ€™s Series A common stock, $0.0001 par value per share, outstanding at November 8, 2024 was 30,674,855.â€‹â€‹Table of ContentsTable of Contentsâ€‹â€‹PARTÂ IÂ - FINANCIAL INFORMATIONÂ Â Â Â Pageâ€‹â€‹ItemÂ 1.Condensed Financial Statementsâ€‹5â€‹Condensed Balance Sheets (unaudited) â€‹5â€‹Condensed Statements of Operations and Comprehensive Loss (unaudited) â€‹6â€‹Condensed Statements of Redeemable Convertible Preferred Stock and Stockholdersâ€™ Equity (Deficit) (unaudited) â€‹7â€‹Condensed Statements of Cash Flows (unaudited) â€‹9â€‹NotesÂ to Condensed Financial Statements (unaudited)â€‹10ItemÂ 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€‹20ItemÂ 3.Quantitative and Qualitative Disclosures About Market Riskâ€‹28ItemÂ 4.Controls and Proceduresâ€‹28â€‹â€‹â€‹â€‹â€‹PARTÂ IIÂ - OTHER INFORMATIONâ€‹â€‹â€‹ItemÂ 1.Legal Proceedingsâ€‹28ItemÂ 1A. Risk Factorsâ€‹29ItemÂ 2.Unregistered Sales of Equity Securities and Use of Proceedsâ€‹29ItemÂ 3.Defaults Upon Senior Securitiesâ€‹29ItemÂ 4.Mine Safety Disclosuresâ€‹30ItemÂ 5.Other Informationâ€‹30ItemÂ 6.Exhibitsâ€‹31â€‹Signaturesâ€‹32â€‹â€‹â€‹â€‹â€‹2 Table of ContentsFORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.In some cases, you can identify forward-looking statements by terms such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œwould,â€ â€œexpect,â€ â€œplan,â€ â€œanticipate,â€ â€œcould,â€ â€œintend,â€ â€œtarget,â€ â€œproject,â€ â€œbelieve,â€ â€œestimate,â€ â€œpredict,â€ â€œpotential,â€ or â€œcontinueâ€ or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about:â€¢our financial performance;â€¢our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and marketable securities to fund our future operating expenses and capital expenditure requirements;â€¢the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;â€¢the scope, progress, results and costs of developing denifanstat or any other drug candidates we may develop, and conducting preclinical studies and clinical trials;â€¢our ability to advance drug candidates into, and successfully complete, clinical trials within anticipated timelines, including our planned Phase 3 clinical trials of denifanstat;â€¢the timing and costs involved in obtaining and maintaining regulatory approval of denifanstat or any other drug candidates we may develop, and the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations or accelerated approvals for our drug candidates for various indications;â€¢current and future agreements with third parties in connection with the development and commercialization of denifanstat or any other future drug candidate;â€¢our estimate of the number of patients in the United States who suffer from the diseases we target, including metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), and the number of subjects that will enroll in our clinical trials;â€¢our relationship with Ascletis BioScience Co. Ltd. (Ascletis), and its affiliate Gannex Pharma Co., Ltd. (Gannex), and the success of their development efforts for denifanstat;â€¢the ability of our clinical trials to demonstrate the safety and efficacy of denifanstat and any other drug candidates we may develop, and other positive results;â€¢our plans relating to commercializing denifanstat and any other drug candidates we may develop, if approved, including the geographic areas of focus and our ability to grow a sales team;â€¢the success of competing therapies that are or may become available;â€¢developments relating to our competitors and our industry, including competing drug candidates and therapies;3 Table of Contentsâ€¢our plans relating to the further development and manufacturing of denifanstat and any other drug candidates we may develop, including additional indications that we may pursue for denifanstat or other drug candidates;â€¢existing regulations and regulatory developments in the United States and other jurisdictions;â€¢our potential and ability to successfully manufacture and supply denifanstat and any other drug candidates we may develop for clinical trials and for commercial use, if approved;â€¢the rate and degree of market acceptance of denifanstat and any other drug candidates we may develop, as well as the pricing and reimbursement of denifanstat and any other drug candidates we may develop, if approved;â€¢our expectations regarding our ability to obtain, maintain, protect and enforce intellectual property protection for denifanstat and for any other future drug candidate;â€¢our ability to realize the anticipated benefits of any strategic transactions;â€¢our ability to attract and retain the continued service of our key personnel and to identify, hire, and then retain additional qualified personnel and our ability to attract additional collaborators with development, regulatory and commercialization expertise;â€¢the impact of macroeconomic conditions and geopolitical turmoil on our business and operations;â€¢our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; andâ€¢our anticipated use of our existing cash, cash equivalents and marketable securities.We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions described in Part II, Item 1A. â€œRisk Factorsâ€ and elsewhere in this Quarterly Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this Quarterly Report, whether as a result of any new information, future events or otherwise.In addition, statements that â€œwe believeâ€ and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.â€‹Explanatory Noteâ€‹Reflecting the change in disease nomenclature from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and from nonalcoholic steatohepatitis (NASH) to metabolic dysfunction-associated steatohepatitis (MASH), we are using MASLD and MASH throughout this document other than when referring to titles of publications or other activities that utilized the term NAFLD or NASH.â€‹â€‹â€‹â€‹4 Table of ContentsPART I. FINANCIAL INFORMATIONItem 1. Condensed Financial StatementsSAGIMET BIOSCIENCESÂ INC.CONDENSED BALANCE SHEETS(unaudited)(in thousands, except for share and per share amounts)â€‹As ofâ€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹Â Â Â Â 2024Â Â Â Â Â 2023Assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Current assets:Â â€‹Â Â Â Â â€‹Â Â Cash and cash equivalentsâ€‹$ 77,014â€‹$ 75,139Short-term marketable securitiesâ€‹Â 75,472â€‹Â 19,758Prepaid expenses and other current assetsâ€‹â€‹4,704â€‹â€‹ 1,749Total current assetsâ€‹â€‹ 157,190â€‹â€‹ 96,646Long-term marketable securitiesâ€‹â€‹ 17,471â€‹â€‹ â€”Operating lease right-of-use assetsâ€‹â€‹ 114â€‹â€‹ 73Total assetsâ€‹$ 174,775â€‹$ 96,719Liabilities and stockholdersâ€™ equityâ€‹Â Â Â â€‹Â Â Â Current liabilities:â€‹Â Â Â â€‹Â Â Â Accounts payableâ€‹$ 1,152â€‹$ 186Accrued expenses and other current liabilities (includes nil and $31 payable to related parties as of September 30, 2024 and December 31, 2023, respectively)â€‹Â 2,824â€‹Â 5,403Operating lease liabilitiesâ€‹Â 116â€‹Â 65Total current liabilitiesâ€‹Â 4,092â€‹Â 5,654Commitments and contingencies (NoteÂ 6)â€‹Â Â Â â€‹Â Â Â Stockholdersâ€™ equity:â€‹Â Â Â â€‹Â Â Â Undesignated preferred stock, $0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023â€‹â€‹ â€”â€‹â€‹ â€”Series A common stock, $0.0001 per share: 500,000,000 shares authorized; 30,674,855 and 21,375,402 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectivelyâ€‹â€‹ 3â€‹â€‹ 2Series B common stock, $0.0001 per share: 15,000,000 shares authorized; 1,520,490 shares issued and outstanding at September 30, 2024 and December 31, 2023â€‹â€‹ â€”â€‹â€‹ â€”Additional paid-in capitalâ€‹Â 449,349â€‹Â 340,777Accumulated deficitâ€‹Â (279,110)â€‹Â (249,744)Accumulated other comprehensive incomeâ€‹Â 441â€‹Â 30Total stockholdersâ€™ equityâ€‹â€‹ 170,683â€‹Â 91,065Total liabilities and stockholdersâ€™ equityâ€‹â€‹ 174,775â€‹$ 96,719â€‹The accompanying notes are an integral part of these unaudited condensed financial statements.â€‹â€‹5 Table of ContentsSAGIMET BIOSCIENCESÂ INC.CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(unaudited)(in thousands, except for share and per share amounts)â€‹Â Â Â Â Three Months Ended SeptemberÂ 30,Â â€‹Nine Months Ended SeptemberÂ 30,Â â€‹â€‹2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023License revenueâ€‹$ â€”â€‹$ 2,000â€‹$ â€”â€‹$ 2,000â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

stockÂ â€‹ (1,373,730,625)â€‹â€‹ (214,620)â€‹â€‹â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹ 15,117,912â€‹â€‹ 1â€‹â€‹ 1,520,490â€‹â€‹â€‹â€”â€‹â€‹ 214,619â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹ 214,620Reclass of common stock to Series A common stockâ€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€‹ (210,315)â€‹â€‹ (1)â€‹â€‹ 210,315â€‹â€‹ 1â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”"Sale of Series A common stock in public offering, net of issuance costs of $10,267â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹ 6,026,772â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹ 86,161â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹ 86,161Issuance of Series A common stock upon exercise of stock optionsâ€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€‹ 7,614â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€‹ 6â€‹â€‹â€”â€‹â€‹ 6Exercise of common stock warrantsâ€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹ 12,789â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”"Stock-based compensation expenseÂ â€‹â€”â€‹â€‹â€”â€‹â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹ 1,855â€‹â€‹â€”â€‹â€‹â€”â€‹â€‹ 1,855Net lossÂ â€‹ â€”â€‹Â â€"Â â€‹â€‹ â€”â€‹Â â€"â€‹â€‹ â€"â€‹Â â€"â€‹â€‹ â€"â€‹Â â€"â€‹Â (6,353)â€‹Â â€"â€‹Â (6,353)Balance at SeptemberÂ 30,Â 2023Â â€‹ â€"â€‹$ â€"Â â€‹â€‹ â€"â€‹$ â€"â€‹â€‹ 21,375,402â€‹$ 2â€‹â€‹ 1,520,490â€‹$ â€"â€‹$ 339,466â€‹$ (241,593)â€‹$ â€"â€‹$ 97,875â€‹The accompanying notes are an integral part of these unaudited condensed financial statements.â€‹â€‹â€‹â€‹8 Table of Contentsâ€‹â€‹SAGIMET BIOSCIENCESÂ INC.CONDENSED STATEMENTS OF CASH FLOWS(unaudited)(in thousands)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023Cash flows from operating activitiesÂ â€‹Â Â â€‹Â Â Net lossâ€‹$ (29,366)â€‹$ (19,725)Adjustments to reconcile net loss to net cash used in operating activities:â€‹Â Â Â â€‹Â Â Â Accretion of discount on marketable securitiesâ€‹Â (1,197)â€‹Â (39)Non-cash operating lease expenseâ€‹Â 108â€‹Â 103Stock-based compensation expenseâ€‹Â 3,754â€‹Â 3,679Change in fair value of redeemable convertible preferred stock warrant liabilityâ€‹â€‹ â€"â€‹â€‹ 1Change in fair value of Series A common stock warrant liabilityâ€‹â€‹ â€"â€‹â€‹ (4)Changes in operating assets and liabilities:â€‹Â â€‹â€‹Â Â Â Prepaid expenses and other current assetsâ€‹Â (3,261)â€‹Â (390)Accounts payable, accrued expenses and other current liabilitiesâ€‹Â (1,351)â€‹Â (200)Operating lease liabilitiesâ€‹Â (98)â€‹Â (108)Net cash used in operating activitiesâ€‹Â (31,411)â€‹Â (16,683)Cash flows from investing activitiesâ€‹Â Â Â â€‹Â Â Â Purchases of marketable securitiesâ€‹â€‹ (94,329)â€‹â€‹ â€"Sales and maturities of marketable securitiesâ€‹Â 22,796â€‹Â 32,200Net cash (used in) provided by investing activitiesâ€‹Â (71,533)â€‹Â 32,200Cash flows from financing activitiesâ€‹Â Â Â â€‹Â Â Â Proceeds from sale of Series A common stock, net of issuance costsâ€‹â€‹ 105,750â€‹â€‹ â€"Proceeds from initial public offering, net of underwriters' commissions and discountsâ€‹â€‹ â€"â€‹â€‹ 86,161Payment of financing costsâ€‹Â (1,045)â€‹Â â€"Proceeds from exercise of stock optionsâ€‹â€‹ 114â€‹â€‹ 6Net cash provided by financing activitiesâ€‹Â 104,819â€‹Â 86,167Net increase in cash and cash equivalents â€‹Â 1,875â€‹Â 101,684Cash and cash equivalents at beginning of periodâ€‹Â 75,139â€‹Â 158Cash and cash equivalents at end of periodâ€‹$ 77,014â€‹$ 101,842â€‹â€‹â€‹â€‹â€‹Supplemental non-cash investing and financing activities:â€‹â€‹â€‹â€‹â€‹Deferred financing costs included in accounts payable and accrued expensesâ€‹$ 75â€‹$ â€"Right-of-use assets obtained in exchange for operating lease obligationsâ€‹$ 149â€‹$ â€"â€‹The accompanying notes are an integral part of these unaudited condensed financial statements.â€‹9 Table of ContentsSAGIMET BIOSCIENCESÂ INC.NOTESÂ TO THE CONDENSED FINANCIAL STATEMENTS (unaudited)1.Description of Business and Basis of PresentationSagimet Biosciences Inc. (the Company), a Delaware corporation headquartered in San Mateo, California, is a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Companyâ€™s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). In January 2024, the Company announced positive topline results from the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52. In June 2024, the Company presented additional 52-week intention to treat (ITT) and F3 subgroup efficacy data from the Phase 2b FASCINATE-2 clinical trial.In October 2024, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Breakthrough Therapy designation of denifanstat was supported by positive data from the Phase 2b FASCINATE-2 clinical trial in biopsy-confirmed MASH patients with stage 2 or stage 3 fibrosis.In October 2024, the Company completed successful end-of-Phase 2 interactions with the FDA, supporting the advancement of denifanstat into Phase 3 in MASH. The planned program will include two Phase 3 trials: FASCINATE-3, evaluating patients with F2/F3 (non-cirrhotic) MASH, and FASCINIT, evaluating patients with suspected or confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)/MASH. The Phase 3 program is expected to initiate by the end of 2024.In addition to MASH, the Company is exploring the use of its FASN inhibitors in acne and in select forms of cancer, diseases in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is currently being tested in China by the Companyâ€™s license partner, Ascletis BioScience Co. Ltd. (Ascletis), a subsidiary of Ascletis Pharma Inc. (Ascletis Pharma), in a PhaseÂ 3 clinical trial for moderate to severe acne vulgaris and a PhaseÂ 3 trial in recurrent glioblastoma multiforme (GBM) in combination with bevacizumab. In November 2024, Ascletis announced completion of enrollment of 480 patients in the acne Phase 3 clinical trial. The Company has completed Investigational New Drug (IND)-enabling studies for a second FASN inhibitor, TVB-3567. Â The accompanying financial statements have been prepared in accordance with accounting principles generally accepted (GAAP) in the United States. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) promulgated by the Financial Accounting Standards Board (FASB). Certain prior year amounts have been reclassified to conform to the current year presentation.These unaudited interim financial statements and accompanying notes should be read in conjunction with the Companyâ€™s annual financial statements and the notes thereto included in the Companyâ€™s Form 10-K, as filed with the Securities and Exchange Commission (SEC) on MarchÂ 25, 2024. The accompanying interim financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 are unaudited but include all adjustments that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a fullÂ year. Balance sheet amounts as of DecemberÂ 31, 2023 have been derived from the audited financial statements as of that date.The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Such estimates include accruals of research and development expenses, accrued costs for services rendered under agreements with third-party contract research organizations (CROs), preferred stock and common stock valuations prior to the Companyâ€™s initial public offering of Series A common stock (IPO) and stock option valuations and stock-based compensation. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.10 Table of ContentsEmerging growth company statusThe Company is an emerging growth company (EGC) as defined in the Jumpstart Our Business Startups Acts of 2012, as amended (the JOBS Act), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under SectionÂ 107 of the JOBS Act and has elected to use the extended transition period for complying with new or revised accounting standards. As a result of this election, the Companyâ€™s financial statements may not be comparable to those issued by companies that comply with the effective dates pursuant to public company FASB standards.LiquidityThe accompanying unaudited financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company will require substantial additional capital to fund its research and development and ongoing operating expenses. As of September 30, 2024, the Company has relied on public and private equity and debt financings and proceeds from licensing arrangements to fund its operations. The Company has incurred recurring losses and negative cash flows from operations since inception, and, as of September 30, 2024, had an accumulated deficit of $279.1 million and cash, cash equivalents and marketable securities of $170.0 million. The Company expects to incur additional losses and negative cash flows from operations for the foreseeable future.In July and August 2023, the Company completed its IPO, and inclusive of the partial exercise of the underwritersâ€™ overallotment option, the Company soldÂ an aggregate of 6,026,772 shares of Series A common stock at a public offering price of $16.00 per share and received $86.2 million in net proceeds. In January 2024, the Company completed a follow-on offering whereby it sold 9,000,000 shares of its Series A common stock at price of $12.50 per share and received $104.7 million in proceeds, net of issuance costs of $7.8 million. The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund the Companyâ€™s operating expenses for at least the next 12 months from the issuance of these financial statements. In the future, the Company will need to raise additional funds until it is able to generate sufficient revenues to fund its development activities, if ever. The Companyâ€™s future operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to predict the outcome of these actions to generate the liquidity ultimately required. In August 2024, the Company entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to establish an at-the-market offering (ATM Offering) through which the Company may sell, from time to time at its sole discretion up to $75.0 million of shares of its Series A common stock. There were no sales under the ATM Offering during the three and nine months ended September 30, 2024.2.Significant Accounting Policies The Companyâ€™s significant accounting policies are disclosed in the audited financial statements and the notes thereto, which are included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, as filed with the SEC on March 25, 2024. Since the date of those audited financial statements, there have been no material changes to the Companyâ€™s significant accounting policies. 11 Table of ContentsReverse stock splitA one-for-79.4784 reverse stock split of the Companyâ€™s issued and outstanding common stock was effected on July 7, 2023. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. Accordingly, all share and per share amounts for all periods presented in the accompanying unaudited condensed financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the effects of the reverse stock split. Shares of common stock underlying outstanding stock options and common stock warrants were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Companyâ€™s preferred stock were proportionately reduced and the respective conversion prices were proportionately increased.Net loss per share and reclassification of common stockBasic and diluted net loss per share is computed usingÂ theÂ two-classÂ methodÂ required for multiple classes of common stock and participating securities. The Companyâ€™s participating securities do not have a contractual obligation to share in the Companyâ€™s losses. As such, the net loss was attributed entirely to common stockholders for all periods presented. Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share attributable to common stockholders calculation, common stock options, restricted stock units and common stock warrants are considered to be potentially dilutive securities. As the Company has reported a net loss for the periods presented, basic and diluted net loss per share attributable to common stockholders is the same as all potentially dilutive securities would have an anti-dilutive impact.On July 18, 2023, each share of the Companyâ€™s common stock issued and outstanding became reclassified as one share of Series A common stock. Any stock certificate that immediately prior to July 18, 2023 represented shares of the Companyâ€™s common stock was deemed to represent shares of Series A common stock, without the need for surrender or exchange thereof. Additionally, in connection with the IPO, the Companyâ€™s outstanding redeemable convertible preferred stock automatically converted into 15,117,912 shares of Series A common stock and 1,520,490 shares of Series B common stock. The rights of the holders of Series A common stock and Series B common stock are substantially identical, except with respect to voting and conversion. Each share of Series A common stock is entitled to one vote and shares of Series B common stock are non-voting, except as may be required by law. Each share of Series B common stock may be converted at any time into one share of Series A common stock at the option of its holder, subject to certain ownership limitations. As such, basic and diluted net loss per share attributable to common stockholders is presented on a combined basis as undistributed earnings, when allocated to each series of common stock, result in the same net loss per share for all periods presented. Â The following table presents the calculation of basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 (in thousands, except share and per share data):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended SeptemberÂ 30,Â â€‹Nine Months Ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹2024Â Â Â 2023Numerator:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net lossâ€‹$ (14,619)â€‹$ (6,353)â€‹$ (29,366)â€‹$ (19,725)Denominator:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-average shares of Series A and Series B common stock outstanding, basic and dilutedâ€‹Â 32,143,336â€‹Â 18,194,682â€‹Â 31,036,271â€‹Â 6,131,541Net loss per share of Series A and Series B common stock outstanding, basic and dilutedâ€‹$ (0.45)â€‹$ (0.35)â€‹$ (0.95)â€‹$ (3.22)â€‹The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of Series A and Series B common stock outstanding, as their effect would have been anti-dilutive:â€‹12 Table of Contentsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended SeptemberÂ 30,Â â€‹Nine Months Ended SeptemberÂ 30,Â â€‹Â Â Â 2024Â Â Â 2023Â Â Â 2024Â Â Â 2023Options to purchase Series A common stockâ€‹ 4,322,367â€‹ 3,766,505â€‹ 4,322,367â€‹ 3,766,505Warrants to purchase Series A common stockâ€‹ 1,000â€‹ 1,000â€‹ 1,000â€‹ 1,000Unvested restricted stock unitsâ€‹ 844,382â€‹ â€"â€‹ 844,382â€‹ â€"TotalÂ 5,167,749Â 3,767,505Â 5,167,749Â 3,767,505â€‹Recently adopted accounting pronouncementsThe Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and either determined to be not applicable or expected to have minimal impact on the Companyâ€™s financial statements.In AugustÂ 2020, the FASB issued ASU No.Â 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entityâ€™s Own Equity (Subtopic 815-40); Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity, which address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for fiscalÂ years beginning after DecemberÂ 15, 2023, including interim periods within. The adoption of this standard had no impact on the Companyâ€™s financial statements and related disclosures.New accounting pronouncements not yet adoptedIn NovemberÂ 2023, the FASB issued ASUÂ 2023-07, Segment Reporting (Topic 280)â€"Improvements to Reportable Segment Disclosures. ASU 2023-07 requires disclosure of incremental segment information on an interim and annual basis and provides new segment disclosure requirements for entities with a single reportable segment. ASU 2023-07 is effective for all public companies for fiscal years beginning after December 15,Â 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The CompanyÂ is assessing the impact of the adoption of this standard on its disclosures.In December 2023, the FASB issued ASU 2023-09,Â Income Taxes (Topic 740)â€"Improvements to Income Tax Disclosures, a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions and applies to all entities subject to income taxes. The new standard is effective for annual periods beginning after December 15, 2024. The CompanyÂ is assessing the impact of the adoption of this standard on its disclosures.â€‹3.Fair Value Measurements and Fair Value of Financial InstrumentsThe authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:LevelÂ 1 - Quoted prices in active markets for identical assets or liabilities. LevelÂ 2 - Observable inputs other than LevelÂ 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. LevelÂ 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. As of September 30, 2024 and December 31, 2023, financial assets measured at fair value on a recurring basis consisted of cash equivalents and marketable securities. Cash equivalents consist primarily of money market funds and other investments that are readily convertible into cash and have maturities of three months or less at the time of acquisition. The fair value of cash equivalents was $76.4 million and $74.1 million as of September 30, 2024 and December 31, 2023, respectively. The Company considers marketable securities with maturities greater than three months at the time of acquisition to be available for sale securities. The fair value of available for sale 13 Table of Contentssecurities was $92.9 million and $19.8 million as of September 30, 2024 and December 31, 2023, respectively. These available for sale securities have expected maturities ranging from 0.3 to 16.8 months, and securities with an expected maturity greater than 12 months as of the balance sheet date, are classified in long-term. The fair value of marketable securities, which are Level 2 financial instruments, is based upon market prices quoted on the last day of the fiscal period or

other observable market inputs. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker-dealer quotes, bids and/or offers.The Company evaluates securities with unrealized losses, if any, to determine whether the decline in fair value has resulted from credit loss or other factors, including various qualitative factors. As of September 30, 2024, the Company has not recognized any impairment or credit losses on the Companyâ€™s available for sale securities. While the Company classifies these securities as available for sale, the Company does not intend to sell its investments and based on its current plans, the Company currently believes it has the ability to hold these investments until maturity.The carrying values of the Companyâ€™s accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these liabilities.Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.The Companyâ€™s LevelÂ 3 liabilities that are measured at fair value on a recurring basis consist of the Series A common stock warrant liability related to the warrant to purchase 1,000 shares of Series A common stock with an exercise price of $69.64 per share and an expiration date of July 18, 2026, the third anniversary date of the closing of the Companyâ€™s IPO. The fair value of Series A common stock warrant liability was immaterial as of September 30, 2024 and December 31, 2023, as well as the change in fair value during the three and nine months ended September 30, 2024 and 2023. There were no transfers within the hierarchy during the periods presented.The following tables set forth the Companyâ€™s financial assets that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â â€‹â€‹SeptemberÂ 30,Â 2024â€‹â€‹ValuationÂ Â Â AmortizedÂ Â Â UnrealizedÂ Â Â UnrealizedÂ Â Â Â â€‹â€ equivalents:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹Level 1â€‹$ 76,427â€‹$ â€"â€‹$ â€"â€‹$ 76,427Total cash equivalentsâ€‹â€‹â€‹â€‹ 76,427â€‹â€‹ â€"â€‹â€‹ â€"â€‹â€‹ 76,427Short-term marketable securities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Commercial paperÂ Â Â â€‹Level 2â€‹â€‹ 19,469Â Â Â â€‹ 56Â Â Â Â â€‹ â€"Â Â Â Â â€‹ 19,525Corporate debt securitiesâ€‹â€‹Level 2â€‹â€‹ 9,442â€‹â€‹ 20â€‹â€‹ â€"â€‹â€‹ 9,462U.S. Treasury securitiesâ€‹â€‹Level 2â€‹â€‹ 32,447â€‹â€‹ 133â€‹â€‹ â€"â€‹â€‹ 32,580Agency securitiesâ€‹â€‹Level 2â€‹â€‹ 11,396â€‹â€‹ 22â€‹â€‹ â€"â€‹â€‹ 11,418Asset-backed securitiesâ€‹â€‹Level 2â€‹â€‹ 2,480â€‹â€‹ 7â€‹â€‹ â€"â€‹â€‹ 2,487Total short-term marketable securitiesâ€‹â€‹â€‹â€‹â€‹ 75,234â€‹â€‹ 238â€‹â€‹ â€"â€‹â€‹ 75,472Long-term marketable securities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹U.S. Treasury securitiesâ€‹â€‹Level 2â€‹â€‹ 12,291â€‹â€‹ 165â€‹â€‹ â€"â€‹â€‹ 12,456Asset-backed securitiesâ€‹â€‹Level 2â€‹â€‹ 4,977â€‹â€‹ 38â€‹â€‹ â€"â€‹â€‹ 5,015Total long-term marketable securitiesâ€‹â€‹â€‹â€‹â€‹ 17,268â€‹â€‹ 203â€‹â€‹ â€"â€‹â€‹ 17,471Total cash equivalents and marketable securitiesâ€‹â€‹â€‹â€‹$ 168,929â€‹$ 441â€‹$ â€"â€‹$ 169,370â€‹14 Table of Contentsâ€‹DecemberÂ 31,Â 2023â€‹â€‹â€‹ValuationÂ Â Â AmortizedÂ Â Â UnrealizedÂ Â Â UnrealizedÂ Â Â Â â€‹â€‹â€‹â€ equivalents:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹Level 1â€‹$ 69,516â€‹$ â€"â€‹$ â€"â€‹$ 69,516Corporate debt securitiesâ€‹â€‹Level 2â€‹â€‹ 4,622â€‹â€‹ â€"â€‹â€‹ â€"â€‹â€‹ 4,622Total cash equivalentsâ€‹â€‹â€‹â€‹â€‹ 74,138â€‹â€‹ â€"â€‹â€‹ â€"â€‹â€‹ 74,138Short-term marketable securities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Commercial paperÂ Â Â â€‹Level 2â€‹â€‹ 9,879Â Â Â â€‹ 19Â Â Â Â â€‹ â€"Â Â Â Â â€‹ 9,898Corporate debt securitiesâ€‹â€‹Level 2â€‹â€‹ 2,945â€‹â€‹ 4â€‹â€‹ â€"â€‹â€‹ 2,949U.S. Treasury securitiesâ€‹â€‹Level 2â€‹â€‹ 6,904â€‹â€‹ 7â€‹â€‹ â€"â€‹â€‹ 6,911Total short-term marketable securitiesâ€‹â€‹â€‹â€‹â€‹ 19,728â€‹â€‹ 30â€‹â€‹ â€"â€‹â€‹ 19,758Total cash equivalents and marketable securitiesâ€‹â€‹â€‹â€‹$ 93,866â€‹$ 30â€‹$ â€"â€‹$ 93,896â€‹ â€‹â€‹4.Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As ofâ€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024Â Â Â Â 2023Prepaid clinical costsâ€‹$ 2,933â€‹$ â€"Prepaid research and development costsâ€‹â€‹ 684â€‹â€‹ 767Prepaid insuranceâ€‹â€‹ 680â€‹â€‹ 585Deferred financing costs (1)â€‹â€‹ 306â€‹â€‹ 323Otherâ€‹Â 101â€‹Â 74Total prepaid expenses and other current assetsâ€‹$ 4,704â€‹$ 1,749____________â€‹(1)Amount as of September 30, 2024 relates to deferred financing costs related to the ATM Offering entered into during August 2024. Amount as of December 31, 2023 relates to deferred financing costs related to the Companyâ€™s January 2024 follow-on offering.â€‹5.Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consisted of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As ofâ€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024Â Â Â Â 2023Accrued payroll-related costsâ€‹$ 995â€‹$ 1,105Accrued clinical costsâ€‹â€‹ 814â€‹â€‹ 2,668Accrued research and development costsâ€‹â€‹ 785â€‹â€‹ 632Accrued general and administrative costsâ€‹â€‹ 219â€‹â€‹ 442Accrued offering costsâ€‹â€‹ â€"â€‹â€‹ 323Otherâ€‹Â 11â€‹Â 233Total accrued expenses and other current liabilitiesâ€‹$ 2,824â€‹$ 5,403â€‹â€‹15 Table of Contents6.Commitments and ContingenciesLicense and other agreementsAscletis BioScience Co. LtdIn January 2019, the Company entered into a license agreement that became effective in February 2019 with Ascletis BioScience Co. Ltd. (Ascletis), a subsidiary of Ascletis Pharma Inc. (Ascletis Pharma), a biotechnology company incorporated in the Cayman Islands and headquartered in Hangzhou, China. Ascletis Pharma, through a subsidiary, was the lead investor in the Companyâ€™s Series E redeemable convertible preferred stock financing in February 2019. The parties entered into this agreement with the intention to develop, manufacture, and commercialize the Companyâ€™s proprietary FASN inhibitor, denifanstat, which Ascletis refers to as ASC40. Under the terms of the license agreement, the Company granted Ascletis and its affiliates an exclusive, royalty-bearing sublicensable right and license under the Companyâ€™s intellectual property to develop, manufacture, commercialize and otherwise exploit denifanstat and other products containing denifanstat-related compounds in Greater China, consisting of the Peopleâ€™s Republic of China, Hong Kong, Macau and Taiwan.The Company is eligible to receive development and commercial milestone payments from Ascletis in aggregate of up to $122.0 million as well as tiered royalties ranging from percentages in the high single digits to mid-teens on future net sales of denifanstat in Greater China. The license and the research and development services components of this license agreement are representative of a relationship with a customer, and therefore, the Company evaluated the license agreement under the provisions of ASC 606, Revenue from Contracts with Customers. The developmental and commercial event-based milestone payments represent variable consideration, and the Company used the most likely amount method to estimate this variable consideration because the potential milestone payment is a binary event, as the Company will either receive the milestone payment or it will not. Given the high degree of uncertainty around achievement of these milestones, the Company determined the milestone amounts to be fully constrained and will not recognize revenue until the uncertainty associated with these payments is resolved. Any consideration related to royalties will be recognized if and when the related sales occur. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.In July 2023, the Company recognized $2.0 million of revenue related to a development milestone triggered by the initial dosing of a Phase 3 trial for recurrent glioblastoma multiforme (GBM), of which $1.7 million was received from Ascletis in August 2023, net of applicable taxes, which are recorded in general and administrative expense in the statement of operations and comprehensive loss.In July 2023, the Company entered into an Assignment and Assumption Agreement with Ascletis and Ascletisâ€™ affiliate Gannex Pharma Co., Ltd. (Gannex) under which Ascletis, while remaining responsible for performance under the license agreement, assigned all of its rights and obligations under the license agreement to Gannex and Gannex assumed such rights and obligations, effective as of October 2019.Contract Research OrganizationIn June 2024, the Company entered into a contract with a globalÂ CRO to perform certain research and related services in connection with certain of the Companyâ€™s clinical trials and research studies (CRO Services Agreement). The terms of the CRO Services Agreement require the Company to pay to the CRO certain direct fees, investigator grants and other pass-through costs, generally on an upfront prepaid basis. These payments are capitalized at the time of payment and expensed in the period in which the research and development activity is performed. The Company may terminate the CRO Services Agreement or underlying statement of work at will with 60 daysâ€™ written notice.Facility lease agreementOn March 12, 2019, the Company executed a 38-month non-cancelable operating lease agreement for 3,030 square feet of office space for its headquarters facility in San Mateo, California, which commenced April 1, 2019. The lease provides for monthly payments of approximately $12,000 with annual increases. In December 2021, the lease agreement was amended to extend the term of the lease through June 2024; in April 2024, the Company amended the lease agreement to (i) extend the lease through June 30, 2025 and (ii) increase the monthly lease payment to approximately $13,000 beginning on July 1, 2024, which resulted in an increase in the Companyâ€™s operating lease right-of-use asset and corresponding operating lease liability of $0.1 million on the amendment date. Â 16 Table of ContentsOperating lease costs were $42,000 and $37,000 for the threeÂ months ended September 30, 2024 and 2023, respectively, and $116,000 and $111,000 for the nine months ended September 30, 2024 and 2023, respectively.Guarantees and indemnificationsIn the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Companyâ€™s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September 30, 2024, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.Legal ProceedingsFrom time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business. The Company is not party to any material legal proceedings as of September 30, 2024.â€‹â€‹7.Stock-Based CompensationThe 2023 Stock Option and Incentive Plan (2023 Plan) was adopted by the board of directors, approved by the Companyâ€™s stockholders on July 4, 2023, and became effective on July 13, 2023, replacing the 2017 Equity Incentive Plan. The number of shares initially reserved for issuance under the 2023 Plan was 2,585,968, which automatically increased by 855,016 shares on January 1, 2024 and will increase each January 1 thereafter, by (i) 4% of the outstanding number of shares of the Companyâ€™s Series A common stock on the immediately preceding December 31 or (ii) a lesser number of shares as determined by the compensation committee of the board of directors. As of September 30, 2024, the aggregate maximum number of shares reserved for issuance under the 2023 Plan was 3,440,984, of which 1,729,910 shares were available for future grant. Option grants issued under the 2023 Plan are exercisable for up to 10 years from the date of issuance.In March 2024, the Company established a pool of 1,000,000 shares of Series A common stock (Inducement Pool) from which grants of stock-based compensation awards may be issued as inducement for new employees to accept employment offers from the Company or individuals returning to employment after a bona fide period of non-employment with the Company. Inducement Pool grants are granted outside of the 2023 Plan and do not require approval from the Companyâ€™s stockholders pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). As of September 30, 2024, 364,672 shares were available for future grants from the Inducement Pool.Total stock-based compensation recorded in the condensed statements of operations and comprehensive loss related to stock options and restricted stock units for employees and non-employees was as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Three Months Ended SeptemberÂ 30,Â Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹â€‹2024Â Â Â Â 2023â€‹2024â€‹2023Stock optionsâ€‹$ 1,316â€‹$ 1,855â€‹$ 2,903â€‹$ 3,679Restricted stock unitsâ€‹Â 230â€‹Â â€"â€‹Â 851â€‹Â â€"Total stock-based compensation expenseâ€‹$ 1,546â€‹$ 1,855â€‹$ 3,754â€‹$ 3,679Included in:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹General and administrative expenseâ€‹$ 1,311â€‹$ 1,649â€‹$ 3,005â€‹$ 3,103Research and development expenseâ€‹Â 235â€‹Â 206â€‹Â 749â€‹Â 576Total stock-based compensation expenseâ€‹$ 1,546â€‹$ 1,855â€‹$ 3,754â€‹$ 3,679â€‹Stock optionsâ€‹The Company grants stock options which consist of (i) time-based options, which vest and become exercisable, subject to the participantâ€™s continued employment or service through the applicable vesting date and (ii) performance-based options, which vest based on performance measures against predetermined objectives that include successful completion of qualified equity offerings or announced 17 Table of Contentstopline results for clinical trials and positive clinical results over a specified performance period. The Companyâ€™s time-based options have vesting schedules that range from vesting immediately to vesting over a four-year period.The following table summarizes stock option activity for the nine months ended September 30, 2024 (in thousands, except share and per share data):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Â Â Â Â â€‹â€‹Â Â Â Â Weighted-Â Â Â Â Â â€‹â€‹â€‹â€‹â€‹NumberÂ ofÂ â€‹â€‹â€‹â€‹AverageÂ â€‹â€‹â€‹â€‹â€‹SharesÂ â€‹Weighted-Â â€‹RemainingÂ â€‹â€‹â€‹â€‹UnderlyingÂ â€‹AverageÂ â€‹ContractualÂ â€‹AggregateÂ â€‹â€‹OutstandingÂ â€‹ExerciseÂ â€‹TermÂ â€‹IntrinsicÂ â€‹â€‹Optionsâ€‹Priceâ€‹(inÂ Years)â€‹Val January 1, 2024Â 3,753,507â€‹$ 7.99Â 7.1â€‹$ 8Options grantedÂ 1,375,296â€‹â€‹ 4.43Â â€‹â€‹Â â€‹Options exercisedâ€‹ (17,995)â€‹â€‹ 6.36â€‹â€‹â€‹â€‹â€‹Options forfeited/expiredÂ (788,441)â€‹â€‹ 8.50Â â€‹â€‹Â â€‹Outstanding, September 30, 2024 (1)Â 4,322,367â€‹$ 6.77Â 7.5â€‹$ â€"Vested and exercisable as of SeptemberÂ 30,Â 2024Â 2,314,801â€‹$ 7.26Â 6.3â€‹$ â€"____________â€‹(1)Includes 492,729 performance-based options with a weighted-average exercise price of $6.42, of which 490,372 were fully vested and exercisable.During the nine months ended September 30, 2024 and 2023, the weighted average grant-date fair value per share of stock options granted was $3.42 and $10.28, respectively. The total intrinsic value of stock options exercised during the nine months ended September 30, 2024 and 2023, was $0.1 million and $0.1 million, respectively. Additionally, during the nine months ended September 30, 2024 and 2023, cash received from the exercise of stock options was $0.1 million and approximately $6,000, respectively. As of September 30, 2024, there was $9.5 million of unrecognized compensation expense, which is expected to be recognized over a remaining weighted-average period of 2.4 years. Restricted stock unitsThe Companyâ€™s restricted stock units generally vest over a four-year period in equal amounts on an annual basis, provided the employee remains continuously employed with the Company. The fair value of the restricted stock units is equal to the closing price of the Companyâ€™s Series A common stock on the grant date.The following table summarizes restricted stock unit activity:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-Averageâ€‹Â Â Â Â Restricted Â Â Â Â Grant Date â€‹Â Â Â Â Stock UnitsÂ Â Â Fair ValueOutstanding, January 1, 2024Â 1,132,410â€‹$ 2.96GrantedÂ 49,330â€‹â€‹ 5.23Vested/releasedÂ (281,458)â€‹â€‹ 2.96Forfeited/expiredÂ (55,900)â€‹â€‹ 4.96Outstanding, SeptemberÂ 30,Â 2024â€‹ 844,382â€‹$ 2.96â€‹As of September 30, 2024, the total unrecognized compensation expense related to unvested restricted stock units was $2.3 million, which is expected to be recognized over a remaining weighted-average period of 2.8 years.18 Table of ContentsValuation assumptionsThe fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023Expected volatilityÂ 91 - 96%Â Â â€‹89 - 91%Â Â Risk-free interest rateÂ 3.9 - 4.5%Â Â â€‹3.6%Â Â Dividend yieldÂ â€"Â â€‹ â€"Â Expected term (in years)Â 5.3 - 6.1â€‹5.0 - 7.0â€‹The expected term of the stock options represents the average of the contractual term of the options and the weighted-average expected vesting period. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected volatility rate was based on the historical volatilities of comparable companies in the Companyâ€™s industry. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero.Employee stock purchase planâ€‹The 2023 Employee Stock Purchase Plan (the ESPP) was adopted by the board of directors in July 2023 with an initial total of 215,497 shares of Series A common stock reserved for issuance. Under the ESPP plan, the amount of shares reserved will automatically increase each January 1 through January 1, 2033, by the least of (i) 215,497 shares of Series A common stock, (ii) 1% of the outstanding number of shares of the Companyâ€™s Series A common stock on the immediately preceding December 31 or (iii) such lesser number of shares of Series A common stock as determined by the administrator of the ESPP. On January 1, 2024, in accordance with the ESPP, the authorized shares were increased by 213,754 shares for a total of 429,251 shares of Series A common stock available under the ESPP. No shares of Series A common stock have been issued under the ESPP to date.â€‹â€‹â€‹8.Related Party TransactionsJinzi J. Wu, Ph.D., a member of the Companyâ€™s board of directors until June 2024, founded and serves as the chief executive officer of Ascletis, Gannex, and Ascletis Pharma. â€‹During the nine months ended September 30, 2024 and 2023, the Company recognized $0.1 million and nil of expenses, respectively, related to its portion of expenses owed under the Ascletis license agreement, which are recorded in research and development expense in the unaudited condensed statements of operations and comprehensive loss. As of September 30, 2024 and December 31, 2023, the Company recorded nil and $31,000, respectively, of accruals related to the Ascletis license agreement. During the nine months ended September 30, 2024 and 2023, the Company paid Ascletis $0.2 million and nil, respectively, under the Ascletis manufacturing arrangement. â€‹ Â Â Â â€‹â€‹â€‹19 Table of ContentsITEM 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsYou should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed financial statements and related notes included elsewhere in this Report on Form 10-Q for the quarter ended September 30, 2024 (Quarterly Report). This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and beliefs. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors,

including those set forth under â€œRisk Factorsâ€ and elsewhere in this Quarterly Report. You should carefully read the â€œRisk Factorsâ€ section of this Quarterly Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. OverviewWe are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). Denifanstat has been studied in over 740 people to date in our clinical trials, including our Phase 2 FASCINATE-1 and Phase 2b FASINATE-2 clinical trials.In January 2024, we announced positive topline results from the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in 168 biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52. The Phase 2b FASCINATE-2 clinical trial achieved statistically significant results on primary and multiple secondary endpoints at week 52 in MASH patients in the modified intention to treat (mITT) population, including:â—The primary endpoints of â‰¥2-point reduction in NAS (NAFLD Activity Score) without worsening of fibrosis (denifanstat 52% vs. placebo 20%, p=0.0003), and MASH resolution without worsening of fibrosis with â‰¥2-point reduction in NAS (denifanstat 36% vs. placebo 13%, p=0.0044).â—Multiple secondary endpoints of fibrosis improvement by â‰¥ 1 stage with no worsening of MASH (denifanstat 41% vs. placebo 18%, p=0.0102), MASH resolution with no worsening of fibrosis (denifanstat 38% vs. placebo 16%, p=0.0043), and a greater proportion of MRI-derived proton density fat fraction (MRI-PDFF) â‰¥30% responders relative to placebo (denifanstat 65% vs. placebo 21%, p<0.0001). MRI-PDFF responders are patients with â‰¥8% liver fat content at baseline who achieve a â‰¥30% relative reduction of liver fat at the end of treatment.â€‹Denifanstat showed also statistical significance in fibrosis improvement as measured by an artificial intelligence (AI) digital pathology-based qFibrosis assessment. Additionally, our precision medicine approach is core to our development strategy in MASH and includes the identification of pharmacodynamic and predictive biomarkers to confirm target engagement and clinical response in patients treated with denifanstat.â€‹In June 2024, we presented positive data from the Phase 2b FASCINATE-2 clinical trial of denifanstat versus placebo in biopsy-confirmed MASH patients at the European Association for the Study of the Liver (EASL) Congress. Â Our EASL presentation included the following 52-week data from the intention to treat (ITT), mITT, and F3 mITT patient populations:Â â€‹â€¢The primary endpoint of â‰¥2-point reduction in NAS (NAFLD Activity Score) without worsening of fibrosis (denifanstat 38% vs. placebo 16%, p=0.0035) or MASH resolution with â‰¥2-point reduction in NAS without worsening of fibrosis (denifanstat 26% vs. placebo 11%, p=0.0173) in the ITT population.â€¢Secondary endpoints of fibrosis improvement by â‰¥ 1 stage with no worsening of MASH in the ITT (denifanstat 30% vs. placebo 14%, p=0.040) and F3 mITT (denifanstat 49% vs. placebo 13%, p=0.0032) populations.â€¢Fibrosis improvement by â‰¥ 2 stages with no worsening of MASH in the mITT (denifanstat 20% vs. placebo 2%, p=0.0065) and F3 mITT (denifanstat 34% vs. placebo 4%, p=0.0065) populations.20 Table of Contentsâ€¢A statistically significant difference in progression to cirrhosis (F4) in mITT population (denifanstat 5% vs. placebo 11%, p=0.0386).â€¢A statistically significant difference in fibrosis improvement by â‰¥ 1 stage with no worsening of MASH for patients on a stable background dose of a GLP-1RA (denifanstat 42% vs. placebo 0%, p=0.034) in the mITT population.â€‹â€¢A statistically significant increase in beneficial polyunsaturated triglycerides at the end of 52 week of treatment (+42% denifanstat vs. -4% placebo, p<0.001) in the mITT population.â€¢A biomarker of denifanstat activity (tripalmitin) showed an early and sustained reduction in de novo lipogenesis at 4-weeks (-2.4ug/ml with denifanstat vs. -0.4ug/mL placebo, p=0.001) and 13-weeks (-2.2ug/mL with denifanstat vs. -0.1ug/mL placebo, p=0.005) in the ITT population.In October 2024, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Treatments that receive Breakthrough Therapy designation must target a serious or life-threatening disease and preliminary clinical evidence must indicate that the drug may demonstrate a substantial improvement over existing therapies on one or more clinically significant endpoints. Breakthrough Therapy designation of denifanstat was supported by positive data from the Phase 2b FASCINATE-2 clinical trial in biopsy-confirmed MASH patients with stage 2 or stage 3 fibrosis.In October 2024, we completed successful end-of-Phase 2 interactions with the FDA, supporting the advancement of denifanstat into Phase 3 in MASH. Based on our ongoing discussions with the FDA, the phase 3 program will consist of two double-blind, placebo-controlled multicenter registrational trials:â€¢FASCINATE-3 in patients with F2/F3 (non-cirrhotic) MASH: The trial is expected to evaluate the efficacy and safety of denifanstat in this population, with primary endpoints being liver biopsy assessments at 52 weeks, at which time Sagimet plans to seek accelerated approval in the U.S. and Europe. The trial will continue until such point in time that the required number of clinical outcomes is reached, which we estimate at 3.5 years. â€¢FASCINIT in patients with suspected or confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)/MASH: The trial is expected to evaluate the efficacy and safety of denifanstat in this population, with primary endpoints being safety and tolerability at 52 weeks. Non-invasive biomarkers will be assessed as part of the secondary endpoints, with no liver biopsy endpoint.The Phase 3 program is designed to comprise a minimum of 1,800 patients exposed to denifanstat and is expected to initiate by the end of 2024.We are also evaluating the promise of FASN inhibition, beyond MASH, in additional disease areas in which dysregulation of fatty acid metabolism also plays a key role, including in acne and certain forms of cancer. Denifanstat is currently being tested in China by our license partner, Ascletis BioScience Co. Ltd. (Ascletis), a subsidiary of Ascletis Pharma Inc. (Ascletis Pharma), in a PhaseÂ 3 clinical trial for moderate to severe acne vulgaris and a PhaseÂ 3 clinical trial in recurrent glioblastoma multiforme (GBM) in combination with bevacizumab. In November 2024, Ascletis announced completion of enrollment of 480 patients in the acne Phase 3 clinical trial and that it expects to announce topline results in the second quarter of 2025. We expect these results to inform our development strategy in these indications. We have completed Investigational New Drug (IND)-enabling studies for a second FASN inhibitor, TVB-3567.21 Table of ContentsComponents of results of operationsLicense revenueTo date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future. Our revenues to date have been generated solely from the license agreement with Ascletis. We expect that our revenue for the next several years will be derived primarily from this agreement and any additional collaboration into which we may enter.Research and development expensesResearch and development expenses represent costs incurred in performing research, development and manufacturing activities in support of our own product development efforts and include personnel-related costs (such as salaries, employee benefits and stock-based compensation) for our personnel in research and development functions; costs related to acquiring, developing and manufacturing supplies for preclinical studies, clinical trials and other studies, including fees paid to contract manufacturing organizations (CMOs); costs and expenses related to agreements with contract research organizations (CROs), investigative sites and consultants to conduct non-clinical and preclinical studies and clinical trials; professional and consulting services costs; and facility and other allocated costs.All research and development expenses are charged to operations as incurred in accordance with Accounting Standards Codification 730,Â Research and Development. We account for non-refundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received, rather than when the payment is made.We expect our research and development expenses to increase substantially for the foreseeable future as we advance our drug candidates into and through preclinical studies and clinical trials, pursue regulatory approval and expand our pipeline. General and administrative expenses Our general and administrative expenses consist primarily of costs and expenses related to: personnel (including salaries, employee benefits and stock-based compensation) in our executive, finance and accounting and other administrative functions; legal services, including relating to intellectual property and corporate matters; accounting, auditing, consulting and tax services; insurance; information technology; and facility and other allocated costs not otherwise included in research and development expenses.We expect our general and administrative expenses to increase substantially for the foreseeable future as we increase our headcount and continue to grow our corporate infrastructure. We also anticipate that we will incur increased expenses as a result of operating as a public company, including expenses related to audit, legal and tax-related services associated with maintaining compliance with Securities and Exchange Commission (SEC) rulesÂ and regulations and those of any national securities exchange on which our securities are traded, additional insurance expenses, investor relations activities and other administrative and professional services.Other income Other income consists primarily of interest income earned on our cash, cash equivalents and marketable securities offset by accretion of discounts to maturity on our marketable securities.22 Table of ContentsResults of operationsComparison of the three months ended September 30, 2024 and 2023The following table summarizes our results of operations for the periods indicated (in thousands):â€‹â€‹â€‹

permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practice (GCP), or other regulatory requirements;â—third-party contractors not performing data collection or analysis in a timely or accurate manner;â—third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; andâ—failure of our third-party contractors, such as CROs and CMOs, or our investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner.A change in the outcome of any of these or other variables could significantly change our costs and timing associated with the development of our drug candidates. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such change.We rely and will continue to rely on third parties in the conduct of our preclinical studies and clinical trials and for manufacturing and supply of our drug candidates. We have no internal manufacturing capabilities, and we will continue to rely on third parties for our preclinical study and clinical trial materials. Given our stage of development, we do not yet have a marketing or sales organization or commercial infrastructure. Accordingly, if we obtain regulatory approval for any of our drug candidates, we also expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution.We enter into contracts in the normal course of business for products and services, including contract research and contract manufacturing services, which include provisions allowing for termination under certain conditions and timelines. These contracts generally do not include payments for early termination and are considered cancellable contracts.Based on our current business plans, we believe that our existing cash, cash equivalents, and marketable securities as of September 30, 2024, will be sufficient for us to fund our operating expenses for at least the next 12 months from the issuance of this Quarterly Report.Cash flowsThe following table shows a summary of our cash flows for each of the periods presented below (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Net cash (used in) provided by:Â â€‹Â Â Â Â â€‹Â Â Operating activitiesâ€‹$ (31,411)â€‹$ (16,683)Investing activitiesâ€‹Â (71,533)â€‹Â 32,200Financing activitiesâ€‹Â 104,819â€‹Â 86,167Net increase in cash and cash equivalents â€‹$ 1,875â€‹$ 101,684â€‹Cash flows from operating activities. Net cash used in operating activities was $31.4 million for the nine months endedÂ September 30, 2024, and primarily related to cash used to fund clinical development, manufacturing and other non-clinical activities for denifanstat, inclusive of clinical-batch manufacturing and other trial start-up costs for our Phase 3 program of denifanstat in MASH, as well as costs to build out our corporate infrastructure and costs associated with being a public company.26 Table of ContentsNet cash used in operating activities was $16.7 million for the nineÂ months ended SeptemberÂ 30, 2023 and primarily related to cash used to fund clinical development and other pre-clinical activities for denifanstat, primarily relating to the Phase 2b FASCINATE-2 trial for which topline results were announced in January 2024, as well as other costs to support our corporate infrastructure. Cash expenses were offset by the net $1.7 million development milestone received from Ascletis in connection with the Ascletis license agreement during the nine months ended September 30, 2023.Cash flows from investing activities - Net cash used in investing activities was $71.5 million for the nine months ended September 30, 2024 and related to purchases of marketable securities of $94.3 million, partially offset by proceeds received from the sale and maturity of marketable securities of $22.8 million.Net cash provided by investing activities was $32.2 million for the nineÂ months ended SeptemberÂ 30, 2023, which related solely to proceeds received from sales of marketable securities.Cash flows from financing activities - Net cash provided by financing activities was $104.8 million for the nine months ended September 30, 2024, which primarily related to net cash proceeds of $105.7 million received from the sale of Series A common stock in our January 2024 follow-on offering and $0.1 million in proceeds from stock option exercises during the period, offset by the payment of financing costs related to the January 2024 follow-on offering of $1.0 million.Net cash provided by financing activities was $86.2 million for the nineÂ months ended SeptemberÂ 30, 2023, which related primarily to the proceeds received from our IPO, net of underwriters' commissions and discounts.Critical accounting policies and estimatesWe prepare our financial statements in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ significantly from the estimates made and changes in estimates may occur. During the nine months ended September 30, 2024, there were no material changes to our critical accounting estimates or in the methodology used for estimates from those described in â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ included in our Annual Report on Form 10-K for the year ended December 31, 2023.Emerging growth company and smaller reporting statusWe are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (the JOBS Act). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include an exemption from the requirement to provide an auditorâ€™s report on internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.We will remain an emerging growth company until the earliest of (i) the last day of our first fiscal year in which we have total annual gross revenues of $1.235 billion or more, (ii) December 31, 2028, (iii) the date on which we are deemed to be a large accelerated filer, under the rules of the SEC, which means the market value of equity securities that is held by non-affiliates exceeds $700.0 million as of the prior June 30th and (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.27 Table of ContentsWe are also a â€œsmaller reporting company,â€ meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.Recently adopted accounting pronouncementsSee Note 2. Significant Accounting Policies, included in our unaudited interim financial statements in Item 1 of this Quarterly Report for more information.ItemÂ 3. Quantitative and Qualitative Disclosures About Market RiskWe are a smaller reporting company as defined by RuleÂ 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.â€‹ItemÂ 4. Controls and ProceduresDisclosure controls and proceduresWe maintain â€œdisclosure controls and procedures,â€ as defined in RulesÂ 13a-15(e)Â and 15d-15(e)Â under the Securities Exchange Act of 1934, (Exchange Act), that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1)Â recorded, processed, summarized and reported, within the time periods specified in the SECâ€™s rulesÂ and forms and (2)Â accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in RulesÂ 13a-15(e)Â and 15d-15(e)Â under the Exchange Act), as of the end of the period covered by this Quarterly Report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of September 30, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in this Quarterly Report was (a)Â reported within the time periods specified by the SEC rulesÂ and regulations, and (b)Â communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding any required disclosure.Changes in internal control over financial reportingDuring the quarter ended September 30, 2024, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.PARTÂ II. OTHER INFORMATIONItemÂ 1. Legal ProceedingsFrom time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows, nor are we aware of any governmental proceedings involving potential monetary sanctions.28 Table of ContentsItemÂ 1A. Risk FactorsOur business is subject to substantial risks and uncertainties. You should carefully consider the information contained in this Quarterly Report on Form 10-Q, the risks and uncertainties described below, and the risk factors and other information contained in our other public filings in evaluating our business, including our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 25, 2024. â€‹Although we have received Breakthrough Therapy designation for denifanstat, this may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood of receiving marketing approval in the United States.â€‹In October 2024, the FDA granted Breakthrough Therapy designation to denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). A Breakthrough Therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval.â€‹The Breakthrough Therapy designation we have obtained for denifanstat may not result in faster development processes, reviews or approvals compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, the FDA may later decide that our denifanstat development program no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the FDA may later decide that denifanstat no longer meets the conditions for qualification.â€‹ItemÂ 2. Unregistered Sales of Equity Securities and Use of ProceedsRecent sales of unregistered equity securitiesThere were no unregistered sales of equity securities during the period covered by this quarterly report on Form 10-Q. Use of proceeds from initial public offering of common stockOn July 18, 2023, we completed our IPO. Our registration statement on Form S-1 (File No. 333-256648) relating to the IPO was declared effective by the SEC on July 13, 2023. We issued an aggregate of 5,312,500 shares of our Series A common stock at a price of $16.00 per share. The aggregate gross proceeds of the IPO were $96.4 million, inclusive of an additional 714,272 shares of Series A common stock sold upon the partial exercise of the underwriters' purchase option. We received approximately $86.2 million in net proceeds after deducting approximately $6.7 million in underwriting discounts and commissions and approximately $3.5 million in other offering costs. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their associates, or to our affiliates. Goldman Sachs & Co., Cowen and Company and Piper Sandler & Co. acted as joint book-running managers for the IPO, and JMP Securities acted as lead manager.There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on July 17, 2023.Issuer purchases of equity securitiesNone.ItemÂ 3. Defaults Upon Senior SecuritiesNot applicable.29 Table of ContentsItemÂ 4. Mine Safety DisclosuresNot applicable.Item 5. Other InformationRule 10b5-1 trading plans â€‹During the quarter ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as those terms are defined in Item 408 of Regulation S-K).â€‹30 Table of ContentsItemÂ 6. Exhibitsâ€‹ExhibitÂ NumberÂ Â Â Â DescriptionÂ Â Â Â Method of Filingâ€‹â€‹â€‹â€‹â€‹â€‹10.1Â Â Controlled Equity OfferingSM Sales Agreement, dated as of August 15, 2024, by and between Sagimet Biosciences Inc. and Cantor Fitzgerald & Co.â€‹Incorporated by reference to Exhibit 1.2 to the Companyâ€™s Registration Statement on Form S-3 filed on August 15, 2024 (File No. 001-281582)â€‹â€‹â€‹â€‹â€‹â€‹31.1â€‹Certification of Principal Executive Officer Pursuant to RulesÂ 13a-14(a)Â and 15d-14(a)Â under the Securities Exchange Act of 1934, as Adopted Pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002â€‹Filed herewithâ€‹â€‹â€‹â€‹â€‹â€‹31.2â€‹Certification of Principal Financial and Accounting Officer Pursuant to RulesÂ 13a-14(a)Â and 15d-14(a)Â under the Securities Exchange Act of 1934, as Adopted Pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002â€‹Filed herewithâ€‹â€‹â€‹â€‹â€‹â€‹32.1â€‹Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to 18 U.S.C. SectionÂ 1350, as Adopted Pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2022â€‹Furnished herewithâ€‹â€‹â€‹â€‹â€‹â€‹101.INSâ€‹Inline XBRL Instance DocumentÂ â€“ the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL documentâ€‹Filed herewithâ€‹â€‹â€‹â€‹â€‹â€‹101.SCHâ€‹Inline XBRL Taxonomy Extension Schema Documentâ€‹Filed herewithâ€‹â€‹â€‹â€‹â€‹â€‹101.CALâ€‹Inline XBRL Taxonomy Extension Calculation Linkbase Documentâ€‹Filed herewithâ€‹â€‹â€‹â€‹â€‹â€‹101.DEFâ€‹Inline XBRL Taxonomy Extension Definition Linkbase Documentâ€‹Filed herewithâ€‹â€‹â€‹â€‹â€‹â€‹101.LABâ€‹Inline XBRL Taxonomy Extension Label Linkbase Documentâ€‹Filed herewithâ€‹â€‹â€‹â€‹â€‹â€‹101.PREâ€‹Inline XBRL Taxonomy Extension Presentation Linkbase Documentâ€‹Filed herewithâ€‹â€‹â€‹â€‹â€‹â€‹104â€‹Cover PageÂ Interactive Data File (embedded within the Inline XBRL document)â€‹Filed herewithâ€‹â€‹31 Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.â€‹SAGIMET BIOSCIENCES, INC.â€‹â€‹Date: November 14, 2024By:/s/ David Happelâ€‹â€‹David Happelâ€‹â€‹President and Chief Executive Officerâ€‹â€‹(Principal Executive Officer)â€‹â€‹â€‹â€‹â€‹â€‹Date: November 14, 2024By:/s/ Thierry Chaucheâ€‹â€‹Thierry Chaucheâ€‹â€‹Chief Financial Officerâ€‹â€‹(Principal Financial and Accounting Officer)â€‹â€‹â€‹â€‹â€‹â€‹32 EX-31.1 2 sgmt-20240930xex31d1.htm EX-31.1 â€‹Exhibit 31.1CERTIFICATION PURSUANT TORULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, David Happel, certify that:1.I have reviewed this Form 10-Q for the Quarterly Period Ended September 30, 2024 of Sagimet Biosciences Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andc.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.â€‹Date: November 14, 2024By:/s/ David Happelâ€‹â€‹David Happelâ€‹â€‹President

and Chief Executive Officer â€‹â€‹(Principal Executive Officer)â€‹â€‹ EX-31.2 3 sgmt-20240930xex31d2.htm EX-31.2 â€‹Exhibit 31.2CERTIFICATION PURSUANT TORULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Thierry Chauche, certify that:1.I have reviewed this Form 10-Q for the Quarterly Period Ended September 30, 2024 of Sagimet Biosciences Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andc.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.[â€‹â€‹Date: November 14, 2024By:/s/ Thierry Chaucheâ€‹â€‹Thierry Chaucheâ€‹â€‹Chief Financial Officerâ€‹â€‹(Principal Financial and Accounting Officer)â€‹â€‹ EX-32.1 4 sgmt-20240930xex32d1.htm EX-32.1 â€‹Exhibit 32.1CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICERPURSUANT TO18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report on Form 10-Q of Sagimet Biosciences Inc. (the â€œCompanyâ€) for the quarterly period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned hereby certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: November 14, 2024By:/s/ David Happelâ€‹â€‹David Happelâ€‹â€‹President and Chief Executive Officerâ€‹â€‹(Principal Executive Officer)â€‹â€‹Date: November 14, 2024By:/s/ Thierry Chaucheâ€‹â€‹Thierry Chaucheâ€‹â€‹Chief Financial Officerâ€‹â€‹(Principal Financial and Accounting Officer)â€‹â€‹ EX-101.SCH 5 sgmt-20240930.xsd EX-101.SCH 995200100 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Prepaid expenses and other current assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Accrued expenses and other current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)) link:presentationLink link:calculationLink link:definitionLink 995200301 - Statement - CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Temporary Equity link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Description of Business and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Summary of significant accounting policies - EPS (Details) link:presentationLink link:calculationLink link:definitionLink 99940203 - Disclosure - Summary of significant accounting policies - Dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Fair value measurements and fair value of financial instruments - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - Fair value measurements and fair value of financial instruments - Fair value (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Commitments and contingencies - Licenses (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Stock-based compensation (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - Stock-based compensation - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - Stock-based compensation - Stock options (Details) link:presentationLink link:calculationLink link:definitionLink 99940704 - Disclosure - Stock-based compensation - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 99940705 - Disclosure - Stock-based compensation - Fair value input (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Related parties (Details) link:presentationLink link:calculationLink link:definitionLink 995200305 - Statement - CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Parenthetical link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Fair value measurements and fair value of financial instruments link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Prepaid expenses and other current assets link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Accrued expenses and other current liabilities link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Related parties link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Fair value measurements and fair value of financial instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Prepaid expenses and other current assets (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Accrued expenses and other current liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Commitments and contingencies - Lease (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 sgmt-20240930_cal.xml EX-101.CAL EX-101.DEF 7 sgmt-20240930_def.xml EX-101.DEF EX-101.LAB 8 sgmt-20240930_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address State Or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED BALANCE SHEETS Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Class A [Member] Series A Common Stock Common Class A Common Class B [Member] Series B Common Stock Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Short-term marketable securities Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total Assets, Current Total current assets Marketable Securities, Noncurrent Long-term marketable securities Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses and other current liabilities (includes nil and $31 payable to related parties as of September 30, 2024 and December 31, 2023, respectively) Total Accrued expenses and other current liabilities Operating Lease, Liability, Current Operating lease liabilities Liabilities, Current Total current liabilities Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 6) Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity, $0.0001 par value: Preferred Stock, Value, Issued Undesignated preferred stock, $0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Common Stock, Value, Issued Common stock Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Equity, Attributable to Parent Ending balance Beginning balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Related Party, Type [Axis] Related Party, Type [Axis] Related Party, Type [Domain] Related Party, Type [Domain] Related Party [Member] Related party Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Ending balance (in shares) Beginning balance (in shares) Common stock, shares outstanding CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Represents information relating to redeemable preferred stock warrant. Redeemable Preferred Stock Warrant [Member] Redeemable convertible preferred stock warrant Represents information relating to Series A common stock warrants Series A Common Stock Warrants [Member] Series A common stock warrant Revenue: Revenue from Contract with Customer, Excluding Assessed Tax License revenue Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Fair Value Adjustment of Warrants Change in fair value of stock warrant liability Change in fair value of stock warrant liability Interest and Other Income Interest income and other, net Other Nonoperating Income (Expense) Total other income Net loss Net loss Earnings Per Share, Basic Net loss per share, basic (in dollars per share) Earnings Per Share, Diluted Net loss per share, diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted-average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares outstanding, diluted (in shares) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income: OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Net unrealized income on marketable securities Unrealized gain (loss) on investments in marketable securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)) Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common stock Additional Paid-in Capital [Member] Additional paid-in capital Retained Earnings [Member] Accumulated deficit AOCI Attributable to Parent [Member] Accumulated Other Comprehensive (Loss) Income Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) In Stockholders' Deficit Reclassifications of Temporary to Permanent Equity Conversion of redeemable convertible preferred stock to Series A and Series B common stock Number of shares issued during the period as a result of the conversion of stock. Stock Issued During Period, Shares, Conversion of Stock Conversion of redeemable convertible preferred stock to Series A and Series B common stock (in shares) Amount of shares reclassified as common stock to series A common stock. Stock Issued during Period Value Reclassification Reclass of common stock to Series A common stock Number of shares reclassified as common stock to series A common stock. Stock Issued during Period, Shares Reclassification Reclass of common stock to Series A common stock (in shares) Stock Issued During Period, Value, New Issues Sale of Series A common stock, net of issuance costs Stock Issued During Period, Shares, New Issues Shares issued (in shares) Sale of Series A common stock, net of issuance costs (in shares) Stock Issued During Period, Value, Stock Options Exercised Issuance of Series A Common Stock upon exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Options exercised Issuance of Series A Common Stock upon exercise of stock options (in shares) Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance costs related to sale of Series A common stock Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Issuance of Series A Common Stock for vesting of restricted stock units Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Issuance of Series A Common Stock for vesting of restricted stock units (in shares) Value of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Exercise of common stock warrants Shares of stock issued as a result of the exercise of warrants. Stock Issued During Period, Shares, Warrants Exercised Exercise of common stock warrants (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Redeemable Convertible Preferred Stock [Member] Redeemable convertible preferred stock Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity Temporary Equity, Carrying Amount, Attributable to Parent Ending balance, Temporary equity Beginning balance, Temporary equity Temporary Equity, Shares Outstanding Ending balance, Temporary equity (in shares) Beginning balance, Temporary equity (in shares) Temporary Equity, Net Income Net loss Payments of Stock Issuance Costs Issuance costs CONDENSED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discount on marketable securities, net Amount of non-cash operating lease expenses. Non Cash Operating Lease Expenses Non-cash operating lease expense Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable, accrued expenses and other current liabilities Increase (Decrease) in Operating Lease Liability Operating lease liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Marketable Securities Purchases of marketable securities Proceeds from Sale and Maturity of Marketable Securities Sales and maturities of marketable securities Net Cash Provided by (Used in) Investing Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from sale of Series A common stock, net of issuance costs Proceeds from Issuance Initial Public Offering Proceeds from initial public offering, net of underwriters' commissions and discounts Payments of Financing Costs Payment of financing costs Proceeds from Stock Options Exercised Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Supplemental Cash Flow Information [Abstract] Supplemental non-cash investing and financing activities: Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Deferred financing costs included in accounts payable and accrued expenses Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for operating lease obligations Change in operating lease liability Description of Business and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Description of Business and Basis of Presentation Summary of significant accounting policies Significant Accounting Policies [Text Block] Summary of

significant accounting policies Fair value measurements and fair value of financial instruments Fair Value Disclosures [Text Block] Fair value measurements and fair value of financial instruments Prepaid expenses and other current assets Other Current Assets [Text Block] Prepaid expenses and other current assets Accrued expenses and other current liabilities Other Liabilities Disclosure [Text Block] Accrued expenses and other current liabilities Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Stock-based compensation Share-Based Payment Arrangement [Text Block] Stock-based compensation Related parties Related Party Transactions Disclosure [Text Block] Related parties Disclosure of accounting policy for Reverse stock split. Reverse Stock Split Reverse stock split Earnings Per Share, Policy [Policy Text Block] Net loss per share and reclassification of common stock New Accounting Pronouncements, Policy [Policy Text Block] New accounting pronouncements not yet adopted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities Debt Securities, Available-for-Sale [Table Text Block] Schedule of marketable securities, available-for-sale Schedule of Other Current Assets [Table Text Block] Schedule of prepaid expenses and other current assets Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses and other current liabilities Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock-based compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of option activity transactions Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of restricted stock unit activity Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of fair value assumptions Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Sale of Stock [Axis] Sale of Stock [Domain] Information pertaining to arrangement to sell stock under At the Market conditions. At The Market Arrangement [Member] At market arrangement Subsidiary, Sale of Stock [Line Items] Organization and description of business Cash, Cash Equivalents, and Short-Term Investments Cash and cash equivalents and marketable securities Shares Issued, Price Per Share Share price (in dollars per share) Sale of Stock, Consideration Received on Transaction Net proceeds Total value of shares that may be sold under the stock sales arrangement. Stock Sales Arrangement, Maximum Value Of Shares Maximum value of sales under the arrangement This table contain the information pertaining to significant accounting policies. Significant Accounting Policy [Table] Significant Accounting Policies [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Significant Accounting Policy [Line Items] Summary of significant accounting policies Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split Stock Issued During Period, Shares, Conversion of Convertible Securities Shares issued upon conversion (in shares) Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Denominator: Net loss per share attributable to common stockholders Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Stock options Warrant [Member] Warrants Restricted Stock Units (RSUs) [Member] Restricted Stock Units Restricted stock units Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities (in shares) Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Redeemable Convertible Preferred Stock Warrant Liability Class of Warrant or Right, Outstanding Warrants issued (in shares) Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrant (in dollars per share) Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring Asset Class [Axis] Asset Class [Domain] Represents the information pertaining short-term marketable securities. Short-term marketable securities [Member] Short-term Represents the information pertaining Long-term marketable securities. Long-term marketable securities [Member] Long-term Measurement Basis [Axis] Portion at Fair Value Measurement [Member] Reported Value Measurement [Member] Amortized cost Estimate of Fair Value Measurement [Member] Estimated Fair Value Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Financial Instrument [Axis] Financial Instruments [Domain] Money Market Funds [Member] Money market funds Commercial Paper [Member] Commercial paper Corporate Debt Securities [Member] Corporate debt securities US Treasury Securities [Member] U.S. Treasury securities US Government Agencies Debt Securities [Member] Agency securities Asset-Backed Securities [Member] Asset-backed securities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value on a recurring basis Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents fair value Investments, Fair Value Disclosure Marketable securities Assets, Fair Value Disclosure Total assets fair value Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gains Amount of prepaid clinical expenses current. Prepaid Clinical Expenses Current Prepaid clinical expenses Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Research And Development Prepaid research and development Prepaid Insurance Prepaid insurance Deferred Costs, Current Deferred financing costs Other Assets, Current Other Employee-related Liabilities, Current Accrued payroll-related costs Amount of accrued clinical costs current. This amount is expected to be consumed within one year or the normal operating cycle, if longer. Accrued Clinical Costs Current Accrued clinical costs Amount of accrued research liability current. This amount is expected to be consumed within one year or the normal operating cycle, if longer. Accrued Research Liability, Current Accrued research and development costs Amount of current accrued general and administrative costs. This amount is expected to be consumed within one year or the normal operating cycle, if longer. Accrued General & Administrative Costs, Current Accrued general and administrative costs Amount of offering costs received earlier, remained as of balance sheet date. Deferred Offering Costs, Current Accrued deferred offering costs Other Liabilities, Current Other Loss Contingencies [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Represents the information pertaining to Ascletis BioScience Co. Ltd, a subsidiary of Ascletis Pharma Inc. (Ascletis Pharma), biotechnology company incorporated in the Cayman Islands and headquartered in Hangzhou, China and a Company investor. Ascletis BioScience Co. Ltd [Member] Ascletis Loss Contingencies [Line Items] Commitments and contingencies Amount of maximum aggregate development and commercial milestone payments eligible to receive. Maximum Aggregate Development and Commercial Milestone Payments Eligible to Receive Maximum eligible development and commercial milestone payments Proceeds from Collaborators Amount received as reimbursement Leases Lessee, Operating Lease, Term of Contract Operating lease term Net Rentable Area Rented area (in square feet) Amount of operating lease payments per month. Operating Lease Payments Per Month Monthly lease payments Operating Lease, Cost Operating lease cost Plan Name [Axis] Plan Name [Domain] Represents the information pertaining to Equity Incentive Plan 2023. Equity Incentive Plan 2023 [Member] 2023 Equity incentive plan Represents the information pertaining to Inducement grants granted outside of the 2023 Plan. Inducement Grants Outside of 2023 Plan [Member] 2024 Inducement Grants Represents the information pertaining to 2023 Employee Stock Purchase Plan. Employee Stock Purchase Plan 2023 [Member] Employee Stock Purchase Plan Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for future issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Annual increase in reserved shares (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Increase in future issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Contractual term Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Domain] General and Administrative Expense [Member] General and administrative Research and Development Expense [Member] Research and development Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-based compensation Share-Based Payment Arrangement, Expense Total stock-based compensation Represents the information pertaining to time-based stock options. Time Based Stock Options [Member] Time-based options Represents the information pertaining to performance-based stock options. Performance-Based Stock Options [Member] Performance-based options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Balance at the end Balance at the beginning Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Options forfeited/expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Shares vested and exercisable at the end Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Balance at the end (in dollars per share) Balance at the beginning (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options forfeited/expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested and Exercisable at the end (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Term and Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted- Average Remaining Contractual Term, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted- Average Remaining Contractual Term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Intrinsic value options exercised Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Remaining weighted-average period for unrecognized compensation cost Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Balance at the end (in shares) Balance at the beginning (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested/released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited/expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average grant date fair value, ending (in dollars per shares) Weighted average grant date fair value, beginning (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, granted (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted average grant date fair value, forfeited/expired (in dollars per shares) Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized compensation expense Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Related parties Related Party Transaction, Amounts of Transaction License agreement payments EX-101.PRE 9 sgmt-20240930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 08, 2024 Document and Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-41742 Â Entity Registrant Name Sagimet BiosciencesÂ Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 20-5991472 Â Entity Address, Address Line One 155 Bovet Road, SuiteÂ 303 Â Entity Address, City or Town San Mateo Â Entity Address State Or Province CA Â Entity Address, Postal Zip Code 94402 Â City Area Code 650 Â Local Phone Number 561-8600 Â Title of 12(b) Security Series A Common Stock,$0.0001 par value per share Â Trading Symbol SGMT Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 30,674,855 Entity Central Index Key 0001400118 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace

Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED BALANCE SHEETS - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 77,014 $ 75,139 Short-term marketable securities 75,472 19,758 Prepaid expenses and other current assets 4,704 1,749 Total current assets 157,190 96,646 Long-term marketable securities 17,471 Â Operating lease right-of-use assets 114 73 Total assets 174,775 96,719 Current liabilities: Â Â Accounts payable 1,152 186 Accrued expenses and other current liabilities (includes nil and $31 payable to related parties as of September 30, 2024 and December 31, 2023, respectively) 2,824 5,403 Operating lease liabilities 116 65 Total liabilities 4,092 5,654 Commitments and contingencies (Note 6) Stockholders' equity, $0.0001 par value: Â Â Undesignated preferred stock, $0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Additional paid-in capital 449,349 340,777 Accumulated deficit (279,110) (249,744) Accumulated other comprehensive income 441 30 Total stockholders' equity 170,683 91,065 Total liabilities and stockholders' equity 174,775 96,719 Series A Common Stock Â Â Stockholders' equity, $0.0001 par value: Â Â Common stock 3 2 Series B Common Stock Â Â Stockholders' equity, $0.0001 par value: Â Â Common stock X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued expenses and other current liabilities $ 2,824 $ 5,403 Preferred stock, par value $ 0.0001 $ 0.0001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Related party Â Â Accrued expenses and other current liabilities $ 0 $ 31 Series A Common Stock Â Â Common stock, par value $ 0.0001 $ 0.0001 Common stock, shares authorized 500,000,000 500,000,000 Common stock, shares issued 30,674,855 21,375,402 Common stock, shares outstanding 30,674,855 21,375,402 Series B Common Stock Â Â Common stock, par value $ 0.0001 $ 0.0001 Common stock, shares authorized 15,000,000 15,000,000 Common stock, shares issued 1,520,490 1,520,490 Common stock, shares outstanding 1,520,490 1,520,490 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue: Â Â Â Â License revenue Â $ 2,000 Â $ 2,000 Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Â us-gaap:LicenseMember Â us-gaap:LicenseMember Operating expenses: Â Â Â Â Research and development $ 12,653 $ 4,958 $ 24,228 $ 14,121 General and administrative 4,249 4,494 12,031 9,153 Total operating expenses 16,902 9,452 36,259 23,274 Loss from operations (16,902) (7,452) (36,259) (21,274) Other income (expense): Â Â Â Â Interest income and other, net 2,283 1,095 6,893 1,546 Total other income 2,283 1,099 6,893 1,549 Net loss $ (14,619) $ (6,353) $ (29,366) $ (19,725) Net loss per share, basic (in dollars per share) $ (0.45) $ (0.35) $ (0.95) $ (3.22) Net loss per share, diluted (in dollars per share) $ (0.45) $ (0.35) $ (0.95) $ (3.22) Weighted-average shares outstanding, basic (in shares) 32,143,336 18,194,682 31,036,271 6,131,541 Weighted-average shares outstanding, diluted (in shares) 32,143,336 18,194,682 31,036,271 6,131,541 Other comprehensive income: Â Â Â Â Net loss $ (14,619) $ (6,353) $ (29,366) $ (19,725) Net unrealized income

on marketable securities 464 Â 411 84 Comprehensive loss $ (14,155) (6,353) $ (28,955) (19,641) Redeemable convertible preferred stock warrant Â Â Â Â Other income (expense): Â Â Â Â Change in fair value of stock warrant liability Â Â Â (1) Series A common stock warrant Â Â Â Â Other income (expense): Â Â Â Â Change in fair value of stock warrant liability Â $ 4 Â $ 4 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business). + ReferencesNo definition available. + Details Name: us-gaap_InterestAndOtherIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIndicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sgmt_RedeemablePreferredStockWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sgmt_SeriesCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)) - USD ($) $ in Thousands Common stock Series A Common Stock Common stock Series B Common Stock Common stock Additional paid-in capital Accumulated deficit Accumulated Other Comprehensive (Loss) Income Series A Common Stock Series B Common Stock Total Beginning balance at Dec. 31, 2022 Â Â $ 1 $ 35,001 $ (221,868) $ (84) Â Â $ (186,950) Beginning balance (in shares) at Dec. 31, 2022 Â Â 185,084 Â Â Â Â Â Â Â Increase (Decrease) In Stockholders' Deficit Â Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â 767 Â Â Â Â 767 Unrealized gain (loss) on investments in marketable securities Â Â Â Â Â 71 Â Â 71 Net loss Â Â Â Â (6,587) Â Â Â (6,587) Ending balance at Mar. 31, 2023 Â Â $ 1 35,768 (228,455) (13) Â Â (192,699) Ending balance (in shares) at Mar. 31, 2023 Â Â 185,084 Â Â Â Â Â Â Â Beginning balance at Dec. 31, 2022 Â Â $ 1 35,001 (221,868) (84) Â Â (186,950) Beginning balance (in shares) at Dec. 31, 2022 Â Â 185,084 Â Â Â Â Â Â Â Increase (Decrease) In Stockholders' Deficit Â Â Â Â Â Â Â Â Â Unrealized gain (loss) on investments in marketable securities Â Â Â Â Â Â Â Â 84 Net loss Â Â Â Â Â Â Â Â (19,725) Ending balance at Sep. 30, 2023 $ 2 Â Â 339,466 (241,593) Â Â Â 97,875 Ending balance (in shares) at Sep. 30, 2023 21,375,402 1,520,490 Â Â Â Â Â Â Â Beginning balance at Mar. 31, 2023 Â Â $ 1 35,768 (228,455) (13) Â Â (192,699) Beginning balance (in shares) at Mar. 31, 2023 Â Â 185,084 Â Â Â Â Â Â Â Increase (Decrease) In Stockholders' Deficit Â Â Â Â Â Â Â Â Â Exercise of common stock warrants (in shares) Â Â 25,231 Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â 1,057 Â Â Â Â 1,057 Unrealized gain (loss) on investments in marketable securities Â Â Â Â Â 13 Â Â 13 Net loss Â Â Â Â (6,785) Â Â Â (6,785) Ending balance at Jun. 30, 2023 Â Â $ 1 36,825 (235,240) Â Â Â (198,414) Ending balance (in shares) at Jun. 30, 2023 Â Â 210,315 Â Â Â Â Â Â Â Increase (Decrease) In Stockholders' Deficit Â Â Â Â Â Â Â Â Â Conversion of redeemable convertible preferred stock to Series A and Series B common stock $ 1 Â Â 214,619 Â Â Â Â 214,620 Conversion of redeemable convertible preferred stock to Series A and Series B common stock (in shares) 15,117,912 1,520,490 Â Â Â Â Â Â Â Reclass of common stock to Series A common stock $ 1 Â $ (1) Â Â Â Â Â Â Reclass of common stock to Series A common stock (in shares) 210,315 Â (210,315) Â Â Â Â Â Â Â Sale of Series A common stock, net of issuance costs Â Â Â 86,161 Â Â Â Â 86,161 Sale of Series A common stock, net of issuance costs (in shares) 6,026,772 Â Â Â Â Â Â Â Â Â Issuance of Series A Common Stock upon exercise of stock options Â Â Â 6 Â Â Â Â 6 Issuance of Series A Common Stock upon exercise of stock options (in shares) 7,614 Â Â Â Â Â Â Â Â Â Exercise of common stock warrants (in shares) 12,789 Â Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â 1,855 Â Â Â Â 1,855 Net loss Â Â Â Â (6,353) Â Â Â (6,353) Ending balance at Sep. 30, 2023 $ 2 Â Â 339,466 (241,593) Â Â Â 97,875 Ending balance (in shares) at Sep. 30, 2023 21,375,402 1,520,490 Â Â Â Â Â Â Â Beginning balance at Dec. 31, 2023 $ 2 Â Â 340,777 (249,744) 30 Â Â 91,065 Beginning balance (in shares) at Dec. 31, 2023 21,375,402 1,520,490 Â Â Â Â 21,375,402 1,520,490 Â Increase (Decrease) In Stockholders' Deficit Â Â Â Â Â Â Â Â Â Sale of Series A common stock, net of issuance costs $ 1 Â Â 104,731 Â Â Â Â 104,732 Sale of Series A common stock, net of issuance costs (in shares) 9,000,000 Â Â Â Â Â Â Â Â Â Issuance of Series A Common Stock upon exercise of stock options Â Â Â 114 Â Â Â Â 114 Issuance of Series A Common Stock upon exercise of stock options (in shares) 17,995 Â Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â 759 Â Â Â Â 759 Unrealized gain (loss) on investments in marketable securities Â Â Â Â Â (23) Â Â (23) Net loss Â Â Â Â (6,629) Â Â Â (6,629) Ending balance at Mar. 31, 2024 $ 3 Â Â 446,381 (256,373) 7 Â Â 190,018 Ending balance (in shares) at Mar. 31, 2024 30,393,397 1,520,490 Â Â Â Â Â Â Â Â Â Beginning balance at Dec. 31, 2023 $ 2 Â Â 340,777 (249,744) 30 Â Â $ 91,065 Beginning balance (in shares) at Dec. 31, 2023 21,375,402 1,520,490 Â Â Â Â 21,375,402 1,520,490 Â Increase (Decrease) In Stockholders' Deficit Â Â Â Â Â Â Â Â Â Issuance of Series A Common Stock upon exercise of stock options (in shares) Â Â Â Â Â Â Â Â Â 17,995 Unrealized gain (loss) on investments in marketable securities Â Â Â Â Â Â Â Â $ 411 Net loss Â Â Â Â Â Â Â Â (29,366) Ending balance at Sep. 30, 2024 $ 3 Â Â 449,349 (279,110) 441 Â Â 170,683 Ending balance (in shares) at Sep. 30, 2024 30,674,855 1,520,490 Â Â Â Â 30,674,855 1,520,490 Â Beginning balance at Mar. 31, 2024 $ 3 Â Â 446,381 (256,373) 7 Â Â 190,018 Beginning balance (in shares) at Mar. 31, 2024 30,393,397 1,520,490 Â Â Â Â Â Â Â Â Increase (Decrease) In Stockholders' Deficit Â Â Â Â Â Â Â Â Â Issuance costs related to sale of Series A common stock Â Â Â (27) Â Â Â Â (27) Stock-based compensation expense Â Â Â 1,449 Â Â Â Â 1,449 Unrealized gain (loss) on investments in marketable securities Â Â Â Â Â (30) Â Â (30) Net loss Â Â Â Â (8,118) Â Â Â (8,118) Ending balance at Jun. 30, 2024 $ 3 Â Â 447,803 (264,491) (23) Â Â 183,292 Ending balance (in shares) at Jun. 30, 2024 30,393,397 1,520,490 Â Â Â Â Â Â Â Â Increase (Decrease) In Stockholders' Deficit Â Â Â Â Â Â Â Â Â

Issuance of Series A Common Stock for vesting of restricted stock units (in shares) 281,458 Â Â Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â Â 1,546 Â Â Â Â 1,546 Unrealized gain (loss) on investments in marketable securities Â Â Â Â Â 464 Â Â 464 Net loss Â Â Â Â (14,619) Â Â Â (14,619) Ending balance at Sep. 30, 2024 $ 3 Â Â $ 449,349 $ (279,110) $ 441 Â Â $ 170,683 Ending balance (in shares) at Sep. 30, 2024 30,674,855 1,520,490 Â Â Â Â 30,674,855 1,520,490 Â X - DefinitionNumber of shares issued during the period as a result of the conversion of stock. + ReferencesNo definition available. + Details Name: sgmt_StockIssuedDuringPeriodSharesConversionOfStock Namespace Prefix: sgmt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares reclassified as common stock to series A common stock. + ReferencesNo definition available. + Details Name: sgmt_StockIssuedDuringPeriodSharesReclassification Namespace Prefix: sgmt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionShares of stock issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: sgmt_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: sgmt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of shares reclassified as common stock to series A common stock. + ReferencesNo definition available. + Details Name: sgmt_StockIssuedDuringPeriodValueReclassification Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3 + Details Name: us-gaap_ReclassificationsOfTemporaryToPermanentEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Temporary Equity - USD ($) $ in Thousands Redeemable convertible preferred stock Total Beginning balance, Temporary equity at Dec. 31, 2022 $ 214,620 Â Beginning balance, Temporary equity (in shares) at Dec. 31, 2022 1,373,730,625 Â Increase (Decrease) in Temporary Equity Â Â Conversion of redeemable convertible preferred stock to Series A and Series B common stock (in shares) 0 Â Net loss $ 0 Â Ending balance, Temporary equity at Mar. 31, 2023 $ 214,620 Â Ending balance, Temporary equity (in shares) at Mar. 31, 2023 1,373,730,625 Â Increase (Decrease) in Temporary Equity Â Â Conversion of redeemable convertible preferred stock to Series A and Series B common stock (in shares) 0 Â Net loss $ 0 Â Ending balance, Temporary equity at Jun. 30, 2023 $ 214,620 Â Ending balance, Temporary equity (in shares) at Jun. 30, 2023 1,373,730,625 Â Increase (Decrease) in Temporary Equity Â Â Conversion of redeemable convertible preferred stock to Series A and Series B common stock $ (214,620) $ 214,620 Conversion of redeemable convertible preferred stock to Series A and Series B common stock (in shares) (1,373,730,625) Â Net loss $ 0 Â Ending balance, Temporary equity at Sep. 30, 2023 $ 0 Â Ending balance, Temporary equity (in shares) at Sep. 30, 2023 0 Â X - DefinitionNumber of shares issued during the period as a result of the conversion of stock. + ReferencesNo definition available. + Details Name: sgmt_StockIssuedDuringPeriodSharesConversionOfStock Namespace Prefix: sgmt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInTemporaryEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3 + Details Name: us-gaap_ReclassificationsOfTemporaryToPermanentEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of net income or loss attributable to temporary equity interest. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityNetIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Parenthetical $ in Thousands 3 Months Ended Sep. 30, 2023 USD ($) CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) Â Issuance costs $ 10,267 X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Cash flows from operating activities: Â Â Â Â Â Â Â Â Â Net loss $ (14,619) $ (6,629) $ (6,353) $ (6,587) $ (29,366) $ (19,725) Â Â Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Â Â Accretion of discount on marketable securities, net Â Â Â Â (1,197) (39) Â Â Non-cash operating lease expense Â Â Â Â 108 103 Â Â Stock-based compensation expense Â Â Â Â 3,754 3,679 Â Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Â Prepaid expenses and other current assets Â Â Â Â (3,261) (390) Â Â Accounts payable, accrued expenses and other current liabilities Â Â Â Â (1,351) (200) Â Â Operating lease liabilities Â Â Â Â (98) (108) Â Â Net cash used in operating activities Â Â Â Â (31,411) (16,683) Â Â Cash flows from investing activities: Â Â Â Â Â Â Â Â Purchases of marketable securities Â Â Â Â (94,329) Â Â Â Sales and maturities of marketable securities Â Â Â Â 22,796 32,200 Â Â Net cash (used in) provided by investing activities Â Â Â Â (71,533) 32,200 Â Â Cash flows from financing activities: Â Â Â Â Â Â Â Â Proceeds from sale of Series A common stock, net of issuance costs Â Â Â Â 105,750 Â Â Â Proceeds from initial public offering, net of underwriters' commissions and discounts Â Â Â Â Â 86,161 Â Â Payment of financing costs Â Â Â Â (1,045) Â Â Â Proceeds from exercise of stock options Â Â Â Â 114 6 Â Â Net cash provided by financing activities Â Â Â Â 104,819 86,167 Â Â Net increase in cash and cash equivalents Â Â Â Â Â Â Â $ 1,875 $ 101,684 Cash and cash equivalents at beginning of period Â $ 75,139 Â $ 158 75,139 158 158 Â Cash and cash equivalents at end of period $ 77,014 Â 101,842 Â 77,014 101,842 $ 75,139 $ 158 Supplemental non-cash investing and financing activities: Â Â Â Â Â Â Â Â Deferred financing costs included in accounts payable and accrued expenses Â Â Â Â 75 Â Â Â Right-of-use assets obtained in exchange for operating lease obligations Â Â Â Â $ 149 Â Â Â Conversion of redeemable convertible preferred stock to Series A and Series B common stock Â Â 214,620 Â Â Â Â Â Â Series A common stock warrant Â Â Â Â Â Â Â Â Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Â Change in fair value of stock warrant liability Â Â $ (4) Â Â (4) Â Â Redeemable convertible preferred stock warrant Â Â Â Â Â Â Â Â Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Â Change in fair value of stock warrant liability Â Â Â Â Â $ 1 Â Â X - DefinitionAmount of non-cash operating lease expenses. + ReferencesNo definition available. + Details Name: sgmt_NonCashOperatingLeaseExpenses Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace

Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of debt issuance costs that were incurred during a noncash or partial noncash transaction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for loan and debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe

cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3 + Details Name: us-gaap_ReclassificationsOfTemporaryToPermanentEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sgmt_SeriesCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sgmt_RedeemablePreferredStockWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation 9 Months Ended Sep. 30, 2024 Description of Business and Basis of Presentation Â Description of Business and Basis of Presentation SAGIMET BIOSCIENCESÂ INC.NOTESÂ TO THE CONDENSED FINANCIAL STATEMENTS (unaudited)1.Description of Business and Basis of PresentationSagimet Biosciences Inc. (the Company), a Delaware corporation headquartered in San Mateo, California, is a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Companyâ€™s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). In January 2024, the Company announced positive topline results from the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52. In June 2024, the Company presented additional 52-week intention to treat (ITT) and F3 subgroup efficacy data from the Phase 2b FASCINATE-2 clinical trial.In October 2024, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Breakthrough Therapy designation of denifanstat was supported by positive data from the Phase 2b FASCINATE-2 clinical trial in biopsy-confirmed MASH patients with stage 2 or stage 3 fibrosis.In October 2024, the Company completed successful end-of-Phase 2 interactions with the FDA, supporting the advancement of denifanstat into Phase 3 in MASH. The planned program will include two Phase 3 trials: FASCINATE-3, evaluating patients with F2/F3 (non-cirrhotic) MASH, and FASCINIT, evaluating patients with suspected or confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)/MASH. The Phase 3 program is expected to initiate by the end of 2024.In addition to MASH, the Company is exploring the use of its FASN inhibitors in acne and in select forms of cancer, diseases in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is currently being tested in China by the Companyâ€™s license partner, Ascletis BioScience Co. Ltd. (Ascletis), a subsidiary of Ascletis Pharma Inc. (Ascletis Pharma), in a PhaseÂ 3 clinical trial for moderate to severe acne vulgaris and a PhaseÂ 3 trial in recurrent glioblastoma multiforme (GBM) in combination with bevacizumab. In November 2024, Ascletis announced completion of enrollment of 480 patients in the acne Phase 3 clinical trial. The Company has completed Investigational New Drug (IND)-enabling studies for a second FASN inhibitor, TVB-3567. Â The accompanying financial statements have been prepared in accordance with accounting principles generally accepted (GAAP) in the United States. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) promulgated by the Financial Accounting Standards Board (FASB). Certain prior year amounts have been reclassified to conform to the current year presentation.These unaudited interim financial statements and accompanying notes should be read in conjunction with the Companyâ€™s annual financial statements and the notes thereto included in the Companyâ€™s Form 10-K, as filed with the Securities and Exchange Commission (SEC) on MarchÂ 25, 2024. The accompanying interim financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 are unaudited but include all adjustments that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a fullÂ year. Balance sheet amounts as of DecemberÂ 31, 2023 have been derived from the audited financial statements as of that date.The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Such estimates include accruals of research and development expenses, accrued costs for services rendered under agreements with third-party contract research organizations (CROs), preferred stock and common stock valuations prior to the Companyâ€™s initial public offering of Series A common stock (IPO) and stock option valuations and stock-based compensation. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.Emerging growth company statusThe Company is an emerging growth company (EGC) as defined in the Jumpstart Our Business Startups Acts of 2012, as amended (the JOBS Act), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under SectionÂ 107 of the JOBS Act and has elected to use the extended transition period for complying with new or revised accounting standards. As a result of this election, the Companyâ€™s financial statements may not be comparable to those issued by companies that comply with the effective dates pursuant to public company FASB standards.LiquidityThe accompanying unaudited financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company will require substantial additional capital to fund its research and development and ongoing operating expenses. As of September 30, 2024, the Company has relied on public and private equity and debt financings and proceeds from licensing arrangements to fund its operations. The Company has incurred recurring losses and negative cash flows from operations since inception, and, as of September 30, 2024, had an accumulated deficit of $279.1 million and cash, cash equivalents and marketable securities of $170.0 million. The Company expects to incur additional losses and negative cash flows from operations for the foreseeable future.In July and August 2023, the Company completed its IPO, and inclusive of the partial exercise of the underwritersâ€™ overallotment option, the Company soldÂ an aggregate of 6,026,772 shares of Series A common stock at a public offering price of $16.00 per share and received $86.2 million in net proceeds. In January 2024, the Company completed a follow-on offering whereby it sold 9,000,000 shares of its Series A common stock at price of $12.50 per share and received $104.7 million in proceeds, net of issuance costs of $7.8 million. The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund the Companyâ€™s operating expenses for at least the next 12 months from the issuance of these financial statements. In the future, the Company will need to raise additional funds until it is able to generate sufficient revenues to fund its development activities, if ever. The Companyâ€™s future operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to predict the outcome of these actions to generate the liquidity ultimately required. In August 2024, the Company entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to establish an at-the-market offering (ATM Offering) through which the Company may sell, from time to time at its sole discretion up to $75.0 million of shares of its Series A common stock. There were no sales under the ATM Offering during the three and nine months ended September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies 9 Months Ended Sep. 30, 2024 Summary of significant accounting policies Â Summary of significant accounting policies 2.Significant Accounting Policies The Companyâ€™s significant accounting policies are disclosed in the audited financial statements and the notes thereto, which are included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, as filed with the SEC on March 25, 2024. Since the date of those audited financial statements, there have been no material changes to the Companyâ€™s significant accounting policies. Reverse stock splitA one-for-79.4784 reverse stock split of the Companyâ€™s issued and outstanding common stock was effected on July 7, 2023. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. Accordingly, all share and per share amounts for all periods presented in the accompanying unaudited condensed financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the effects of the reverse stock split. Shares of common stock underlying outstanding stock options and common stock warrants were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Companyâ€™s preferred stock were proportionately reduced and the respective conversion prices were proportionately increased.Net loss per share and reclassification of common stockBasic and diluted net loss per share is computed usingÂ theÂ two-classÂ methodÂ required for multiple classes of common stock and participating securities. The Companyâ€™s participating securities do not have a contractual obligation to share in the Companyâ€™s losses. As such, the net loss was attributed entirely to common stockholders for all periods presented. Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share attributable to common stockholders calculation, common stock options, restricted stock units and common stock warrants are considered to be potentially dilutive securities. As the Company has reported a net loss for the periods presented, basic and diluted net loss per share attributable to common stockholders is the same as all potentially dilutive securities would have an anti-dilutive impact.On July 18, 2023, each share of the Companyâ€™s common stock issued and outstanding became reclassified as one share of Series A common stock. Any stock certificate that immediately prior to July 18, 2023 represented shares of the Companyâ€™s common stock was deemed to represent shares of Series A common stock, without the need for surrender or exchange thereof. Additionally, in connection with the IPO, the Companyâ€™s outstanding redeemable convertible preferred stock automatically converted into 15,117,912 shares of Series A common stock and 1,520,490 shares of Series B common stock. The rights of the holders of Series A common stock and Series B common stock are substantially identical, except with respect to voting and conversion. Each share of Series A common stock is entitled to one vote and shares of Series B common stock are non-voting, except as may be required by law. Each share of Series B common stock may be converted at any time into one share of Series A common stock at the option of its holder, subject to certain ownership limitations. As such, basic and diluted net loss per share attributable to common stockholders is presented on a combined basis as undistributed earnings, when allocated to each series of common stock, result in the same net loss per share for all periods presented. Â The following table presents the calculation of basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 (in thousands, except share and per share data):â€‹â€‹â€‹

new standard is effective for annual periods beginning after December 15, 2024. The CompanyÂ is assessing the impact of the adoption of this standard on its disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurements and fair value of financial instruments 9 Months Ended Sep. 30, 2024 Fair value measurements and fair value of financial instruments Â Fair value measurements and fair value of financial instruments 3.Fair Value Measurements and Fair Value of Financial InstrumentsThe authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:LevelÂ 1 - Quoted prices in active markets for identical assets or liabilities. LevelÂ 2 - Observable inputs other than LevelÂ 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. LevelÂ 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. As of September 30, 2024 and December 31, 2023, financial assets measured at fair value on a recurring basis consisted of cash equivalents and marketable securities. Cash equivalents consist primarily of money market funds and other investments that are readily convertible into cash and have maturities of three months or less at the time of acquisition. The fair value of cash equivalents was $76.4 million and $74.1 million as of September 30, 2024 and December 31, 2023, respectively. The Company considers marketable securities with maturities greater than three months at the time of acquisition to be available for sale securities. The fair value of available for sale securities was $92.9 million and $19.8 million as of September 30, 2024 and December 31, 2023, respectively. These available for sale securities have expected maturities ranging from 0.3 to 16.8 months, and securities with an expected maturity greater than 12 months as of the balance sheet date, are classified in long-term. The fair value of marketable securities, which are Level 2 financial instruments, is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker-dealer quotes, bids and/or offers.The Company evaluates securities with unrealized losses, if any, to determine whether the decline in fair value has resulted from credit loss or other factors, including various qualitative factors. As of September 30, 2024, the Company has not recognized any impairment or credit losses on the Companyâ€™s available for sale securities. While the Company classifies these securities as available for sale, the Company does not intend to sell its investments and based on its current plans, the Company currently believes it has the ability to hold these investments until maturity.The carrying values of the Companyâ€™s accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these liabilities.Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.The Companyâ€™s LevelÂ 3 liabilities that are measured at fair value on a recurring basis consist of the Series A common stock warrant liability related to the warrant to purchase 1,000 shares of Series A common stock with an exercise price of $69.64 per share and an expiration date of July 18, 2026, the third anniversary date of the closing of the Companyâ€™s IPO. The fair value of Series A common stock warrant liability was immaterial as of September 30, 2024 and December 31, 2023, as well as the change in fair value during the three and nine months ended September 30, 2024 and 2023. There were no transfers within the hierarchy during the periods presented.The following tables set forth the Companyâ€™s financial assets that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹SeptemberÂ 30,Â 2024â€‹â€‹â€‹ValuationÂ Â Â Â AmortizedÂ Â Â Â UnrealizedÂ Â Â Â UnrealizedÂ Â Â Â â€‹â€‹
equivalents:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹â€‹Level 1â€‹$ 76,427â€‹$ â€”â€‹$ â€”â€‹$ 76,427Total cash equivalentsâ€‹â€‹â€‹â€‹â€‹ 76,427â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 76,427Short-term marketable securities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Commercial paperÂ Â Â Â â€‹Level 2â€‹â€‹ 19,469Â Â Â Â â€‹ 56Â Â Â Â â€‹ â€”Â Â Â Â â€‹ 19,525Corporate debt securitiesâ€‹â€‹Level 2â€‹â€‹ 9,442â€‹â€‹ 20â€‹â€‹ â€”â€‹â€‹ 9,462U.S. Treasury securitiesâ€‹â€‹Level 2â€‹â€‹ 32,447â€‹â€‹ 133â€‹â€‹ â€”â€‹â€‹ 32,580Agency securitiesâ€‹â€‹Level 2â€‹â€‹ 11,396â€‹â€‹ 22â€‹â€‹ â€”â€‹â€‹ 11,418Asset-backed securitiesâ€‹â€‹Level 2â€‹â€‹ 2,480â€‹â€‹ 7â€‹â€‹ â€”â€‹â€‹ 2,487Total short-term marketable securitiesâ€‹â€‹â€‹â€‹â€‹ 75,234â€‹â€‹ 238â€‹â€‹ â€”â€‹â€‹ 75,472Long-term marketable securities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹U.S. Treasury securitiesâ€‹â€‹Level 2â€‹â€‹ 12,291â€‹â€‹ 165â€‹â€‹ â€”â€‹â€‹ 12,456Asset-backed securitiesâ€‹â€‹Level 2â€‹â€‹ 4,977â€‹â€‹ 38â€‹â€‹ â€”â€‹â€‹ 5,015Total long-term marketable securitiesâ€‹â€‹â€‹â€‹â€‹ 17,268â€‹â€‹ 203â€‹â€‹ â€”â€‹â€‹ 17,471Total cash equivalents and marketable securitiesâ€‹â€‹â€‹â€‹$ 168,929â€‹$ 441â€‹$ â€”â€‹$ 169,370â€‹DecemberÂ 31,Â 2023â€‹â€‹â€‹ValuationÂ Â Â Â AmortizedÂ Â Â Â UnrealizedÂ Â Â Â UnrealizedÂ Â Â Â â€‹â€‹â€‹
equivalents:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹â€‹Level 1â€‹$ 69,516â€‹$ â€”â€‹$ â€”â€‹$ 69,516Corporate debt securitiesâ€‹â€‹Level 2â€‹â€‹ 4,622â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 4,622Total cash equivalentsâ€‹â€‹â€‹â€‹â€‹ 74,138â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 74,138Short-term marketable securities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Commercial paperÂ Â Â Â â€‹Level 2â€‹â€‹ 9,879Â Â Â Â â€‹ 19Â Â Â Â â€‹ â€”Â Â Â Â â€‹ 9,898Corporate debt securitiesâ€‹â€‹Level 2â€‹â€‹ 2,945â€‹â€‹ 4â€‹â€‹ â€”â€‹â€‹ 2,949U.S. Treasury securitiesâ€‹â€‹Level 2â€‹â€‹ 6,904â€‹â€‹ 7â€‹â€‹ â€”â€‹â€‹ 6,911Total short-term marketable securitiesâ€‹â€‹â€‹â€‹â€‹ 19,728â€‹â€‹ 30â€‹â€‹ â€”â€‹â€‹ 19,758Total cash equivalents and marketable securitiesâ€‹â€‹â€‹â€‹$ 93,866â€‹$ 30â€‹$ â€”â€‹$ 93,896â€‹ â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid expenses and other current assets 9 Months Ended Sep. 30, 2024 Prepaid expenses and other current assets Â Prepaid expenses and other current assets 4.Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As ofâ€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024Â Â Â Â 2023Prepaid clinical costsâ€‹$ 2,933â€‹$ â€”Prepaid research and development costsâ€‹â€‹ 684â€‹â€‹ 767Prepaid insuranceâ€‹â€‹ 680â€‹â€‹ 585Deferred financing costs (1)â€‹â€‹ 306â€‹â€‹ 323Otherâ€‹Â 101â€‹Â 74Total prepaid expenses and other current assetsâ€‹$ 4,704â€‹$ 1,749____________â€‹(1)Amount as of September 30, 2024 relates to deferred financing costs related to the ATM Offering entered into during August 2024. Amount as of December 31, 2023 relates to deferred financing costs related to the Companyâ€™s January 2024 follow-on offering. X - DefinitionThe entire disclosure for other current assets. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expenses and other current liabilities 9 Months Ended Sep. 30, 2024 Accrued expenses and other current liabilities Â Accrued expenses and other current liabilities 5.Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consisted of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As ofâ€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024Â Â Â Â 2023Accrued payroll-related costsâ€‹$ 995â€‹$ 1,105Accrued clinical costsâ€‹â€‹ 814â€‹â€‹ 2,668Accrued research and development costsâ€‹â€‹ 785â€‹â€‹ 632Accrued general and administrative costsâ€‹â€‹ 219â€‹â€‹ 442Accrued offering costsâ€‹â€‹ â€”â€‹â€‹ 323Otherâ€‹Â 11â€‹Â 233Total accrued expenses and other current liabilitiesâ€‹$ 2,824â€‹$ 5,403â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405/tableOfContent + Details Name: us-gaap_OtherLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and contingencies 9 Months Ended Sep. 30, 2024 Commitments and contingencies Â Commitments and contingencies 6.Commitments and ContingenciesLicense and other agreementsAscletis BioScience Co. LtdIn January 2019, the Company entered into a license agreement that became effective in February 2019 with Ascletis BioScience Co. Ltd. (Ascletis), a subsidiary of Ascletis Pharma Inc. (Ascletis Pharma), a biotechnology company incorporated in the Cayman Islands and headquartered in Hangzhou, China. Ascletis Pharma, through a subsidiary, was the lead investor in the Companyâ€™s Series E redeemable convertible preferred stock financing in February 2019. The parties entered into this agreement with the intention to develop, manufacture, and commercialize the Companyâ€™s proprietary FASN inhibitor, denifanstat, which Ascletis refers to as ASC40. Under the terms of the license agreement, the Company granted Ascletis and its affiliates an exclusive, royalty-bearing sublicensable right and license under the Companyâ€™s intellectual property to develop, manufacture, commercialize and otherwise exploit denifanstat and other products containing denifanstat-related compounds in Greater China, consisting of the Peopleâ€™s Republic of China, Hong Kong, Macau and Taiwan.The Company is eligible to receive development and commercial milestone payments from Ascletis in aggregate of up to $122.0 million as well as tiered royalties ranging from percentages in the high single digits to mid-teens on future net sales of denifanstat in Greater China. The license and the research and development services components of this license agreement are representative of a relationship with a customer, and therefore, the Company evaluated the license agreement under the provisions of ASC 606, Revenue from Contracts with Customers. The developmental and commercial event-based milestone payments represent variable consideration, and the Company used the most likely amount method to estimate this variable consideration because the potential milestone payment is a binary event, as the Company will either receive the milestone payment or it will not. Given the high degree of uncertainty around achievement of these milestones, the Company determined the milestone amounts to be fully constrained and will not recognize revenue until the uncertainty associated with these payments is resolved. Any consideration related to royalties will be recognized if and when the related sales occur. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.In July 2023, the Company recognized $2.0 million of revenue related to a development milestone triggered by the initial dosing of a Phase 3 trial for recurrent glioblastoma multiforme (GBM), of which $1.7 million was received from Ascletis in August 2023, net of applicable taxes, which are recorded in general and administrative expense in the statement of operations and comprehensive loss.In July 2023, the Company entered into an Assignment and Assumption Agreement with Ascletis and Ascletisâ€™ affiliate Gannex Pharma Co., Ltd. (Gannex) under which Ascletis, while remaining responsible for performance under the license agreement, assigned all of its rights and obligations under the license agreement to Gannex and Gannex assumed such rights and obligations, effective as of October 2019.Contract Research OrganizationIn June 2024, the Company entered into a contract with a globalÂ CRO to perform certain research and related services in connection with certain of the Companyâ€™s clinical trials and research studies (CRO Services Agreement). The terms of the CRO Services Agreement require the Company to pay to the CRO certain direct fees, investigator grants and other pass-through costs, generally on an upfront prepaid basis. These payments are capitalized at the time of payment and expensed in the period in which the research and development activity is performed. The Company may terminate the CRO Services Agreement or underlying statement of work at will with 60 daysâ€™ written notice.Facility lease agreementOn March 12, 2019, the Company executed a 38-month non-cancelable operating lease agreement for 3,030 square feet of office space for its headquarters facility in San Mateo, California, which commenced April 1, 2019. The lease provides for monthly payments of approximately $12,000 with annual increases. In December 2021, the lease agreement was amended to extend the term of the lease through June 2024; in April 2024, the Company amended the lease agreement to (i) extend the lease through June 30, 2025 and (ii) increase the monthly lease payment to approximately $13,000 beginning on July 1, 2024, which resulted in an increase in the Companyâ€™s operating lease right-of-use asset and corresponding operating lease liability of $0.1 million on the amendment date. Â Operating lease costs were $42,000 and $37,000 for the threeÂ months ended September 30, 2024 and 2023, respectively, and $116,000 and $111,000 for the nine months ended September 30, 2024 and 2023, respectively.Guarantees and indemnificationsIn the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Companyâ€™s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. In addition, the Company has entered into indemnification

agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by
reason of their status or service as directors or officers. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of
September 30, 2024, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.Legal
ProceedingsFrom time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business. The Company is not party to any material legal
proceedings as of September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data
Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1:
http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference
2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -
URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph
1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-
gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-
gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA:
XBRL DOCUMENT v3.24.3 Stock-based compensation 9 Months Ended Sep. 30, 2024 Stock-based compensation Â Stock-based compensation 7.Stock-Based CompensationThe 2023 Stock
Option and Incentive Plan (2023 Plan) was adopted by the board of directors, approved by the Companyâ€™s stockholders on July 4, 2023, and became effective on July 13, 2023, replacing the
2017 Equity Incentive Plan. The number of shares initially reserved for issuance under the 2023 Plan was 2,585,968, which automatically increased by 855,016 shares on January 1, 2024 and
will increase each January 1 thereafter, by (i) 4% of the outstanding number of shares of the Companyâ€™s Series A common stock on the immediately preceding December 31 or (ii) a lesser
number of shares as determined by the compensation committee of the board of directors. As of September 30, 2024, the aggregate maximum number of shares reserved for issuance under the
2023 Plan was 3,440,984, of which 1,729,910 shares were available for future grant. Option grants issued under the 2023 Plan are exercisable for up to 10 years from the date of issuance.In
March 2024, the Company established a pool of 1,000,000 shares of Series A common stock (Inducement Pool) from which grants of stock-based compensation awards may be issued as
inducement for new employees to accept employment offers from the Company or individuals returning to employment after a bona fide period of non-employment with the Company.
Inducement Pool grants are granted outside of the 2023 Plan and do not require approval from the Companyâ€™s stockholders pursuant to the Nasdaq inducement grant exception in
accordance with Nasdaq Listing Rule 5635(c)(4). As of September 30, 2024, 364,672 shares were available for future grants from the Inducement Pool.Total stock-based compensation recorded
in the condensed statements of operations and comprehensive loss related to stock options and restricted stock units for employees and non-employees was as follows (in
thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Three Months Ended SeptemberÂ 30,Â Â Â Â Â Nine Months Ended
SeptemberÂ 30,Â â€‹â€‹2024Â Â Â Â 2023â€‹2024â€‹2023Stock optionsâ€‹$ 1,316â€‹$ 1,855â€‹$ 2,903â€‹$ 3,679Restricted stock unitsâ€‹Â 230â€‹Â â€”â€‹Â 851â€‹Â â€”Total stock-based
compensation expenseâ€‹$ 1,546â€‹$ 1,855â€‹$ 3,754â€‹$ 3,679Included in:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹General and administrative expenseâ€‹$ 1,311â€‹$ 1,649â€‹$ 3,005â€‹$
3,103Research and development expenseâ€‹Â 235â€‹Â 206â€‹Â 749â€‹Â 576Total stock-based compensation expenseâ€‹$ 1,546â€‹$ 1,855â€‹$ 3,754â€‹$ 3,679â€‹Stock optionsâ€‹The
Company grants stock options which consist of (i) time-based options, which vest and become exercisable, subject to the participantâ€™s continued employment or service through the
applicable vesting date and (ii) performance-based options, which vest based on performance measures against predetermined objectives that include successful completion of qualified equity
offerings or announced topline results for clinical trials and positive clinical results over a specified performance period. The Companyâ€™s time-based options have various vesting schedules
that range from vesting immediately to vesting over a four-year period.The following table summarizes stock option activity for the nine months ended September 30, 2024 (in thousands, except
share and per share data):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Â Â Â Â â€‹â€‹Â Â Â Â Weighted-
Â Â Â Â Â â€‹â€‹â€‹â€‹NumberÂ ofÂ â€‹â€‹â€‹â€‹AverageÂ â€‹â€‹â€‹â€‹â€‹SharesÂ â€‹Weighted-
Â â€‹RemainingÂ â€‹â€‹â€‹â€‹â€‹UnderlyingÂ â€‹AverageÂ â€‹ContractualÂ â€‹AggregateÂ â€‹â€‹OutstandingÂ â€‹ExerciseÂ â€‹TermÂ â€‹IntrinsicÂ â€‹â€‹Optionsâ€‹Priceâ€‹(inÂ Years)â€‹Val
January 1, 2024Â 3,753,507â€‹$ 7.99Â 7.1â€‹$ 8Options grantedÂ 1,375,296â€‹â€‹ 4.43Â â€‹â€‹Â â€‹Options exercisedâ€‹ (17,995)â€‹â€‹ 6.36â€‹â€‹â€‹â€‹â€‹Options forfeited/expiredÂ
(788,441)â€‹â€‹ 8.50Â â€‹â€‹Â â€‹Outstanding, September 30, 2024 (1)Â 4,322,367â€‹$ 6.77Â 7.5â€‹$ â€”Vested and exercisable as of SeptemberÂ 30,Â 2024Â 2,314,801â€‹$ 7.26Â 6.3â€‹$
â€”_____________â€‹(1)Includes 492,729 performance-based options with a weighted-average exercise price of $6.42, of which 490,372 were fully vested and exercisable.During the nine months
ended September 30, 2024 and 2023, the weighted average grant-date fair value per share of stock options granted was $3.42 and $10.28, respectively. The total intrinsic value of stock options
exercised during the nine months ended September 30, 2024 and 2023, was $0.1 million and $0.1 million, respectively. Additionally, during the nine months ended September 30, 2024 and
2023, cash received from the exercise of stock options was $0.1 million and approximately $6,000, respectively. As of September 30, 2024, there was $9.5 million of unrecognized compensation
expense, which is expected to be recognized over a remaining weighted-average period of 2.4 years. Restricted stock unitsThe Companyâ€™s restricted stock units generally vest over a four-
year period in equal amounts on an annual basis, provided the employee remains continuously employed with the Company. The fair value of the restricted stock units is equal to the closing
price of the Companyâ€™s Series A common stock on the grant date.The following table summarizes restricted stock unit activity:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-
Averageâ€‹Â Â Â Â Restricted Â Â Â Â Grant Date â€‹Â Â Â Â Stock UnitsÂ Â Â Â Fair ValueOutstanding, January 1, 2024Â 1,132,410â€‹$ 2.96GrantedÂ 49,330â€‹â€‹ 5.23Vested/releasedÂ
(281,458)â€‹â€‹ 2.96Forfeited/expiredÂ (55,900)â€‹â€‹ 4.96Outstanding, SeptemberÂ 30,Â 2024â€‹ 844,382â€‹$ 2.96â€‹As of September 30, 2024, the total unrecognized compensation
expense related to unvested restricted stock units was $2.3 million, which is expected to be recognized over a remaining weighted-average period of 2.8 years.Valuation assumptionsThe fair
value of each stock option granted was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Nine
Months Ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023Expected volatilityÂ 91 - 96%Â Â â€‹89 - 91%Â Â Risk-free interest rateÂ 3.9 - 4.5%Â Â â€‹3.6%Â Â Dividend yieldÂ â€”Â â€‹ â€”Â Expected
term (in years)Â 5.3 - 6.1â€‹â€‹5.0 - 7.0â€‹â€‹The expected term of the stock options represents the average of the contractual term of the options and the weighted-average expected vesting
period. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected volatility rate was based on the
historical volatilities of comparable companies in the Companyâ€™s industry. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in
the foreseeable future. Consequently, the Company used an expected dividend yield of zero.Employee stock purchase planâ€‹The 2023 Employee Stock Purchase Plan (the ESPP) was adopted
by the board of directors in July 2023 with an initial total of 215,497 shares of Series A common stock reserved for issuance. Under the ESPP plan, the amount of shares reserved will
automatically increase each January 1 through January 1, 2033, by the least of (i) 215,497 shares of Series A common stock, (ii) 1% of the outstanding number of shares of the Companyâ€™s
Series A common stock on the immediately preceding December 31 or (iii) such lesser number of shares of Series A common stock as determined by the administrator of the ESPP. On January
1, 2024, in accordance with the ESPP, the authorized shares were increased by 213,754 shares for a total of 429,251 shares of Series A common stock available under the ESPP. No shares of
Series A common stock have been issued under the ESPP to date. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1:
http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI
https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -
Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5:
http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-
gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X -
ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType
Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Related parties 9 Months Ended Sep. 30, 2024 Related parties Â Related parties 8.Related Party
TransactionsJinzi J. Wu, Ph.D., a member of the Companyâ€™s board of directors until June 2024, founded and serves as the chief executive officer of Ascletis, Gannex, and Ascletis Pharma.
â€‹During the nine months ended September 30, 2024 and 2023, the Company recognized $0.1 million and nil of expenses, respectively, related to its portion of expenses owed under the
Ascletis license agreement, which are recorded in research and development expense in the unaudited condensed statements of operations and comprehensive loss. As of September 30, 2024
and December 31, 2023, the Company recorded nil and $31,000, respectively, of accruals related to the Ascletis license agreement. During the nine months ended September 30, 2024 and
2023, the Company paid Ascletis $0.2 million and nil, respectively, under the Ascletis manufacturing arrangement. X - ReferencesNo definition available. + Details Name: us-
gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party
transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal
owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -
Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards
Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -
SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4:
http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50
-Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10
-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7:
http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher
FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards
Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9:
http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -
URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -
URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph
6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards
Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -
Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 +
Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27
R17.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023
Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Net Income (Loss) $ (14,619) $ (8,118) $ (6,629) $ (6,353) $ (6,785) $ (6,587) $
(29,366) $ (19,725) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 +
Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of
income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -
Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3:
http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -
Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -
Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6:
http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -
Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -
SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9:
http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12:
http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15:
http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50

-Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies (Policies) 9 Months Ended Sep. 30, 2024 Summary of significant accounting policies Â Reverse stock split Reverse stock splitA one-for-79.4784 reverse stock split of the Companyâ€™s issued and outstanding common stock was effected on July 7, 2023. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. Accordingly, all share and per share amounts for all periods presented in the accompanying unaudited condensed financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the effects of the reverse stock split. Shares of common stock underlying outstanding stock options and common stock warrants were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Companyâ€™s preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. Net loss per share and reclassification of common stock Net loss per share and reclassification of common stockBasic and diluted net loss per share is computed usingÂ theÂ two-classÂ methodÂ required for multiple classes of common stock and participating securities. The Companyâ€™s participating securities do not have a contractual obligation to share in the Companyâ€™s losses. As such, the net loss was attributed entirely to common stockholders for all periods presented. Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share attributable to common stockholders calculation, common stock options, restricted stock units and common stock warrants are considered to be potentially dilutive securities. As the Company has reported a net loss for the periods presented, basic and diluted net loss per share attributable to common stockholders is the same as all potentially dilutive securities would have an anti-dilutive impact.On July 18, 2023, each share of the Companyâ€™s common stock issued and outstanding became reclassified as one share of Series A common stock. Any stock certificate that immediately prior to July 18, 2023 represented shares of the Companyâ€™s common stock was deemed to represent shares of Series A common stock, without the need for surrender or exchange thereof. Additionally, in connection with the IPO, the Companyâ€™s outstanding redeemable convertible preferred stock automatically converted into 15,117,912 shares of Series A common stock and 1,520,490 shares of Series B common stock. The rights of the holders of Series A common stock and Series B common stock are substantially identical, except with respect to voting and conversion. Each share of Series A common stock is entitled to one vote and shares of Series B common stock are non-voting, except as may be required by law. Each share of Series B common stock may be converted at any time into one share of Series A common stock at the option of its holder, subject to certain ownership limitations. As such, basic and diluted net loss per share attributable to common stockholders is presented on a combined basis as undistributed earnings, when allocated to each series of common stock, result in the same net loss per share for all periods presented. Â The following table presents the calculation of basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 (in thousands, except share and per share data):â€‹â€‹â€‹

32,580Agency securitiesâ€‹â€‹Level 2â€‹â€‹ 11,396â€‹â€‹ 22â€‹â€‹ â€”â€‹â€‹ 11,418Asset-backed securitiesâ€‹â€‹Level 2â€‹â€‹ 2,480â€‹â€‹ 7â€‹â€‹ â€”â€‹â€‹ 2,487Total short-term marketable securitiesâ€‹â€‹â€‹â€‹â€‹ 75,234â€‹â€‹ 238â€‹â€‹ â€”â€‹â€‹ 75,472Long-term marketable securities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹U.S. Treasury securitiesâ€‹â€‹Level 2â€‹â€‹ 12,291â€‹â€‹ 165â€‹â€‹ â€”â€‹â€‹ 12,456Asset-backed securitiesâ€‹â€‹Level 2â€‹â€‹ 4,977â€‹â€‹ 38â€‹â€‹ â€”â€‹â€‹ 5,015Total long-term marketable securitiesâ€‹â€‹â€‹â€‹â€‹ 17,268â€‹â€‹ 203â€‹â€‹ â€”â€‹â€‹ 17,471Total cash equivalents and marketable securitiesâ€‹â€‹â€‹â€‹$ 168,929â€‹$ 441â€‹$ â€”â€‹$ 169,370â€‹DecemberÂ 31,Â 2023â€‹â€‹â€‹ValuationÂ Â Â Â AmortizedÂ Â Â Â UnrealizedÂ Â Â Â UnrealizedÂ Â Â Â â€‹â€‹â€‹â€‹ equivalents:â€‹Money market fundsâ€‹â€‹Level 1â€‹$ 69,516â€‹$ â€”â€‹$ â€”â€‹$ 69,516Corporate debt securitiesâ€‹â€‹Level 2â€‹â€‹ 4,622â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 4,622Total cash equivalentsâ€‹â€‹â€‹â€‹â€‹ 74,138â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 74,138Short-term marketable securities:â€‹Commercial paperÂ Â Â Â â€‹Level 2â€‹â€‹ 9,879Â Â Â Â â€‹ 19Â Â Â Â â€‹ â€”Â Â Â Â â€‹ 9,898Corporate debt securitiesâ€‹â€‹Level 2â€‹â€‹ 2,945â€‹â€‹ 4â€‹â€‹ â€”â€‹â€‹ 2,949U.S. Treasury securitiesâ€‹â€‹Level 2â€‹â€‹ 6,904â€‹â€‹ 7â€‹â€‹ â€”â€‹â€‹ 6,911Total short-term marketable securitiesâ€‹â€‹â€‹â€‹â€‹ 19,728â€‹â€‹ 30â€‹â€‹ â€”â€‹â€‹ 19,758Total cash equivalents and marketable securitiesâ€‹â€‹â€‹â€‹$ 93,866â€‹$ 30â€‹$ â€”â€‹$ 93,896 X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid expenses and other current assets (Tables) 9 Months Ended Sep. 30, 2024 Prepaid expenses and other current assets Â Schedule of prepaid expenses and other current assets Prepaid expenses and other current assets consisted of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As ofâ€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024Â Â Â Â 2023Prepaid clinical costsâ€‹$ 2,933â€‹$ â€”Prepaid research and development costsâ€‹â€‹ 684â€‹â€‹ 767Prepaid insuranceâ€‹â€‹ 680â€‹â€‹ 585Deferred financing costs (1)â€‹â€‹ 306â€‹â€‹ 323Otherâ€‹â€‹Â 101â€‹â€‹Â 74Total prepaid expenses and other current assetsâ€‹$ 4,704â€‹$ 1,749_____â€‹â€‹(1)Amount as of September 30, 2024 relates to deferred financing costs related to the ATM Offering entered into during August 2024. Amount as of December 31, 2023 relates to deferred financing costs related to the Companyâ€™s January 2024 follow-on offering. X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amounts of other current assets. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expenses and other current liabilities (Tables) 9 Months Ended Sep. 30, 2024 Accrued expenses and other current liabilities Â Schedule of accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As ofâ€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024Â Â Â Â 2023Accrued payroll-related costsâ€‹$ 995â€‹$ 1,105Accrued clinical costsâ€‹â€‹ 814â€‹â€‹ 2,668Accrued research and development costsâ€‹â€‹ 785â€‹â€‹ 632Accrued general and administrative costsâ€‹â€‹ 219â€‹â€‹ 442Accrued offering costsâ€‹â€‹ â€”â€‹â€‹ 323Otherâ€‹â€‹Â 11â€‹â€‹Â 233Total accrued expenses and other current liabilitiesâ€‹$ 2,824â€‹$ 5,403â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation (Tables) 9 Months Ended Sep. 30, 2024 Stock-based compensation Â Schedule of stock-based compensation expense Total stock-based compensation recorded in the condensed statements of operations and comprehensive loss related to stock options and restricted stock units for employees and non-employees was as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Three Months Ended SeptemberÂ 30,Â Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹â€‹2024Â Â Â Â 2023â€‹2024â€‹2023Stock optionsâ€‹$ 1,316â€‹$ 1,855â€‹$ 2,903â€‹$ 3,679Restricted stock unitsâ€‹â€‹Â 230â€‹Â â€”â€‹Â 851â€‹Â â€”Total stock-based compensation expenseâ€‹$ 1,546â€‹$ 1,855â€‹$ 3,754â€‹$ 3,679Included in:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹General and administrative expenseâ€‹$ 1,311â€‹$ 1,649â€‹$ 3,005â€‹$ 3,103Research and development expenseâ€‹â€‹Â 235â€‹Â 206â€‹Â 749â€‹Â 576Total stock-based compensation expenseâ€‹$ 1,546â€‹$ 1,855â€‹$ 3,754â€‹$ 3,679 Schedule of option activity transactions The following table summarizes stock option activity for the nine months ended September 30, 2024 (in thousands, except share and per share data):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Â Â Â Â â€‹â€‹Â Â Â Â Weighted-Â Â Â Â â€‹â€‹â€‹â€‹â€‹NumberÂ ofÂ â€‹â€‹â€‹â€‹â€‹AverageÂ â€‹â€‹â€‹â€‹â€‹SharesÂ â€‹Weighted-Â â€‹RemainingÂ â€‹â€‹â€‹â€‹â€‹UnderlyingÂ â€‹AverageÂ â€‹ContractualÂ â€‹AggregateÂ â€‹â€‹OutstandingÂ â€‹ExerciseÂ â€‹TermÂ â€‹IntrinsicÂ â€‹â€‹Optionsâ€‹Priceâ€‹(inÂ Years)â€‹Valâ€‹ January 1, 2024Â 3,753,507â€‹$ 7.99Â 7.1â€‹$ 8Options grantedÂ 1,375,296â€‹â€‹ 4.43Â â€‹â€‹Â Options exercisedâ€‹ (17,995)â€‹â€‹ 6.36â€‹â€‹â€‹â€‹â€‹Options forfeited/expiredÂ (788,441)â€‹â€‹ 8.50Â â€‹â€‹Â Outstanding, September 30, 2024 (1)Â 4,322,367â€‹$ 6.77Â 7.5â€‹$ â€”Vested and exercisable as of SeptemberÂ 30,Â 2024Â 2,314,801â€‹$ 7.26Â 6.3â€‹$ â€”_____â€‹â€‹(1)Includes 492,729 performance-based options with a weighted-average exercise price of $6.42, of which 490,372 were fully vested and exercisable. Schedule of restricted stock unit activity â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-Averageâ€‹Â Â Â Â Restricted Â Â Â Â Grant Date â€‹Â Â Â Â Stock UnitsÂ Â Â Â Fair ValueOutstanding, January 1, 2024Â 1,132,410â€‹$ 2.96GrantedÂ 49,330â€‹â€‹ 5.23Vested/releasedÂ (281,458)â€‹â€‹ 2.96Forfeited/expiredÂ (55,900)â€‹â€‹ 4.96Outstanding, SeptemberÂ 30,Â 2024â€‹ 844,382â€‹$ 2.96 Schedule of fair value assumptions â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Nine Months Ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023Expected volatilityÂ 91 - 96%Â Â â€‹89 - 91%Â Â Risk-free interest rateÂ 3.9 - 4.5%Â Â â€‹3.6%Â Â Dividend yieldÂ â€”Â â€‹ â€”Â Expected term (in years)Â 5.3 - 6.1â€‹â€‹5.0 - 7.0â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock units. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended Aug. 31, 2024 Jan. 31, 2024 Aug. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Dec. 31, 2023 Organization and description of business Â Â Â Â Â Â Â Â Accumulated deficit Â Â Â $ (279,110) Â $ (279,110) $ (249,744) Cash and cash equivalents and marketable securities Â Â Â 170,000 Â 170,000 Â Issuance costs Â Â Â Â $ 10,267 Â Â Series A Common Stock Â Â Â Â Â Â Â Organization and description of business Â Â Â Â Â Â Â Shares issued (in shares) Â 9,000,000 6,026,772 Â Â Â Â Share price (in dollars per share) Â $ 12.50 $ 16.00 Â Â Â Â Net proceeds Â $ 104,700 $ 86,200 Â Â Â Â Issuance costs Â $ 7,800 Â Â Â Â Â At market arrangement Â Â Â Â Â Â Â Organization and description of business Â Â Â Â Â Â Â Net proceeds Â Â Â $ 0 Â $ 0 Â Maximum value of sales under the arrangement $ 75,000 Â Â Â Â Â Â X - DefinitionTotal value of shares that may be sold under the stock sales arrangement. + ReferencesNo definition available. + Details Name: sgmt_StockSalesArrangementMaximumValueOfShares Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashCashEquivalentsAndShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=sgmt_AtMarketArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies (Details) Jul. 18, 2023 shares Jul. 07, 2023 Summary of significant accounting policies Â Â Reverse stock split Â 0.012582 Common Class A Â Â Summary of significant accounting policies Â Â Series B Common Stock Â Â Summary of significant accounting policies Â Â Shares issued upon conversion (in shares) 1,520,490 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: sgmt_SignificantAccountingPolicyLineItems Namespace Prefix: sgmt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - EPS (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Â Â Â Â Â Net Income (Loss) $ (14,619) $ (8,118) $ (6,629) $ (6,353) $ (6,785) $ (6,587) $ (29,366) $ (19,725) Denominator: Â Â Â Â Â Â Â Â Â Weighted-average shares outstanding, basic (in shares) 32,143,336 Â Â 18,194,682 Â Â 31,036,271 6,131,541 Weighted-average shares outstanding, diluted (in shares) 32,143,336 Â Â 18,194,682 Â Â 31,036,271 6,131,541 Net loss per share, basic (in dollars per share) $ (0.45) Â Â $ (0.35) Â Â $ (0.95) $ (3.22) Net loss per share, diluted (in dollars per share) $ (0.45) Â Â $ (0.35) Â Â $ (0.95) $ (3.22) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies - Dilutive (Details) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Antidilutive securities Â Â Â Â Potentially dilutive securities (in shares) 5,167,749 3,767,505 5,167,749 3,767,505 Stock options Â Â Â Â Antidilutive securities Â Â Â Â Potentially dilutive securities (in shares) 4,322,367 3,766,505 4,322,367 3,766,505 Warrants Â Â Â Â Antidilutive securities Â Â Â Â Potentially dilutive securities (in shares) 1,000 1,000 1,000 1,000 Restricted stock units Â Â Â Â Antidilutive securities Â Â Â Â Potentially dilutive securities (in shares) 844,382 Â 844,382 Â X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurements and fair value of financial instruments - Warrants (Details) - Series A common stock warrant Sep. 30, 2024 $ / shares shares Redeemable Convertible Preferred Stock Warrant Liability Â Warrants issued (in shares) | shares 1,000 Exercise price of warrant (in dollars per share) | $ / shares $ 69.64 X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sgmt_SeriesCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurements and fair value of financial instruments - Fair value (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair value on a recurring basis Â Â Cash equivalents fair value $ 76,400 $ 74,100 Unrealized Gains 441 Â Level 2 Â Â Fair value on a recurring basis Â Â Marketable securities 92,900 19,800 Amortized cost Â Â Fair value on a recurring basis Â Â Cash equivalents fair value 76,427 Â Total assets fair value 168,929 Â Amortized cost | Level 1 | Money market funds Â Â Fair value on a recurring basis Â Â Cash equivalents fair value 76,427 69,516 Amortized cost | Level 2 | Corporate debt securities Â Â Fair value on a recurring basis Â Â Cash equivalents fair value Â 4,622 Short-term Â Â Fair value on a recurring basis Â Â Unrealized Gains 238 Â Short-term | Level 2 | Commercial paper Â Â Fair value on a recurring basis Â Â Unrealized Gains 56 19 Short-term | Level 2 | Corporate debt securities Â Â Fair value on a recurring basis Â Â Unrealized Gains 20 4 Short-term | Level 2 | U.S. Treasury securities Â Â Fair value on a recurring basis Â Â Unrealized Gains 133 7 Short-term | Level 2 | Agency securities Â Â Fair value on a recurring basis Â Â Unrealized Gains 22 Â Short-term | Level 2 | Asset-backed securities Â Â Fair value on a recurring basis Â Â Unrealized Gains 7 Â Short-term | Amortized cost Â Â Fair value on a recurring basis Â Â Marketable securities 75,234 Â Short-term | Amortized cost | Level 2 | Commercial paper Â Â Fair value on a recurring basis Â Â Marketable securities 19,469 9,879 Short-term | Amortized cost | Level 2 | Corporate debt securities Â Â Fair value on a recurring basis Â Â Marketable securities 9,442 2,945 Short-term | Amortized cost | Level 2 | U.S. Treasury securities Â Â Fair value on a recurring basis Â Â Marketable securities 32,447 6,904 Short-term | Amortized cost | Level 2 | Agency securities Â Â Fair value on a recurring basis Â Â Marketable securities 11,396 Â Short-term | Amortized cost | Level 2 | Asset-backed securities Â Â Fair value on a recurring basis Â Â Marketable securities 2,480 Â Long-term Â Â Fair value on a recurring basis Â Â Unrealized Gains 203 Â Long-term | Level 2 | U.S. Treasury securities Â Â Fair value on a recurring basis Â Â Unrealized Gains 165 Â Long-term | Level 2 | Asset-backed securities Â Â Fair value on a recurring basis Â Â Unrealized Gains 38 Â Long-term | Amortized cost Â Â Fair value on a recurring basis Â Â Marketable securities 17,268 Â Long-term | Amortized cost | Level 2 | U.S. Treasury securities Â Â Fair value on a recurring basis Â Â Marketable securities 12,291 Â Long-term | Amortized cost | Level 2 | Asset-backed securities Â Â Fair value on a recurring basis Â Â Marketable securities 4,977 Â Recurring Â Â Fair value on a recurring basis Â Â Unrealized Gains Â 30 Recurring | Amortized cost Â Â Fair value on a recurring basis Â Â Cash equivalents fair value Â 74,138 Total assets fair value Â 93,866 Recurring | Estimated Fair Value Â Â Fair value on a recurring basis Â Â Cash equivalents fair value 76,427 74,138 Total assets fair value 169,370 93,896 Recurring | Estimated Fair Value | Level 1 | Money market funds Â Â Fair value on a recurring basis Â Â Cash equivalents fair value 76,427 69,516 Recurring | Estimated Fair Value | Level 2 | Corporate debt securities Â Â Fair value on a recurring basis Â Â Cash equivalents fair value Â 4,622 Recurring | Short-term Â Â Fair value on a recurring basis Â Â Unrealized Gains Â 30 Recurring | Short-term | Amortized cost Â Â Fair value on a recurring basis Â Â Marketable securities Â 19,728 Recurring | Short-term | Estimated Fair Value Â Â Fair value on a recurring basis Â Â Marketable securities 75,472 19,758 Recurring | Short-term | Estimated Fair Value | Level 2 | Commercial paper Â Â Fair value on a recurring basis Â Â Marketable securities 19,525 9,898 Recurring | Short-term | Estimated Fair Value | Level 2 | Corporate debt securities Â Â Fair value on a recurring basis Â Â Marketable securities 9,462 2,949 Recurring | Short-term | Estimated Fair Value | Level 2 | U.S. Treasury securities Â Â Fair value on a recurring basis Â Â Marketable securities 32,580 $ 6,911 Recurring | Short-term | Estimated Fair Value | Level 2 | Agency securities Â Â Fair value on a recurring basis Â Â Marketable securities 11,418 Â Recurring | Short-term | Estimated Fair Value | Level 2 | Asset-backed securities Â Â Fair value on a recurring basis Â Â Marketable securities 2,487 Â Recurring | Long-term | Estimated Fair Value Â Â Fair value on a recurring basis Â Â Marketable securities 17,471 Â Recurring | Long-term | Estimated Fair Value | Level 2 | U.S. Treasury securities Â Â Fair value on a recurring basis Â Â Marketable securities 12,456 Â Recurring | Long-term | Estimated Fair Value | Level 2 | Asset-backed securities Â Â Fair value on a recurring basis Â Â Marketable securities $ 5,015 Â X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CarryingReportedAmountFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=sgmt_ShortTermMarketableSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=sgmt_LongTermMarketableSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid expenses and other current assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Prepaid expenses and other current assets Â Â Prepaid clinical expenses $ 2,933 Â Prepaid research and development 684 $ 767 Prepaid insurance 680 585 Deferred financing costs 306 323 Other 101 74 Total $ 4,704 $ 1,749 X - DefinitionAmount of prepaid clinical expenses current. + ReferencesNo definition available. + Details Name: sgmt_PrepaidClinicalExpensesCurrent Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: sgmt_PrepaidResearchAndDevelopment Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredCostsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued expenses and other current liabilities Â Â Accrued payroll-related costs $ 995 $ 1,105 Accrued clinical costs 814 2,668 Accrued research and development costs 785 632 Accrued general and administrative costs 219 442 Accrued deferred offering costs Â 323 Other 11 233 Total $ 2,824 $ 5,403 X - DefinitionAmount of accrued clinical costs current. This amount is expected to be consumed within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: sgmt_AccruedClinicalCostsCurrent Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of current accrued general and administrative costs. This amount is expected to be consumed within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: sgmt_AccruedGeneralAdministrativeCostsCurrent Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accrued research liability current. This amount is expected to be consumed within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: sgmt_AccruedResearchLiabilityCurrent Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of offering costs received earlier, remained as of balance sheet date. + ReferencesNo definition available. + Details Name: sgmt_DeferredOfferingCostsCurrent Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and contingencies - Licenses (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Aug. 31, 2023 Jul. 31, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Commitments and contingencies Â Â Â Â Maximum eligible development and commercial milestone payments Â Â Â $ 122,000 Â License revenue Â Â $ 2,000 Â $ 2,000 Amount received as reimbursement $ 1,700 Â Â Â Â Ascletis Â Â Â Â Â Commitments and contingencies Â Â Â Â Â License revenue Â $ 2,000 Â Â Â X - DefinitionAmount of maximum aggregate development and commercial milestone payments eligible to receive. + ReferencesNo definition available. + Details Name: sgmt_MaximumAggregateDevelopmentAndCommercialMilestonePaymentsEligibleToReceive Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash received from collaborators during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromCollaborators Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=sgmt_AscletisBioscienceCo.LtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and contingencies - Lease (Details) 1 Months Ended 3 Months Ended 9 Months Ended Mar. 12, 2019 USD ($) ftÂ² Apr. 30, 2024 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Leases Â Â Â Â Â Â Operating lease term 38 months Â Â Â Â Â Rented area (in square feet) | ftÂ² 3,030 Â Â Â Â Â Monthly lease payments $ 12,000 $ 13,000 Â Â Â Â Change in operating lease liability Â $ 100,000 Â Â $ 149,000 Â Operating lease cost Â Â $ 42,000 $ 37,000 $ 116,000 $ 111,000 X - DefinitionAmount of operating lease payments per month. + ReferencesNo definition available. + Details Name: sgmt_OperatingLeasePaymentsPerMonth Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LesseeDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionNet rentable area for properties owned. + ReferencesNo definition available. + Details Name: us-gaap_NetRentableArea Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset

obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation (Details) - shares Jan. 01, 2024 Jul. 13, 2023 Sep. 30, 2024 2023 Equity incentive plan Â Â Â Stock-based compensation Â Â Â Common stock reserved for future issuance (in shares) Â 2,585,968 3,440,984 Annual increase in reserved shares (as a percent) Â 4.00% Â Increase in future issuance (in shares) 855,016 Â Â Available for grant (in shares) Â Â 1,729,910 Contractual term Â 10 years Â 2024 Inducement Grants Â Â Â Stock-based compensation Â Â Â Common stock reserved for future issuance (in shares) Â Â 1,000,000 Available for grant (in shares) Â Â 364,672 Employee Stock Purchase Plan Â Â Â Stock-based compensation Â Â Â Common stock reserved for future issuance (in shares) Â 215,497 Â Annual increase in reserved shares (as a percent) Â 1.00% Â Employee Stock Purchase Plan | Series A Common Stock Â Â Â Stock-based compensation Â Â Â Common stock reserved for future issuance (in shares) Â 215,497 Â Increase in future issuance (in shares) 213,754 Â Â Available for grant (in shares) 429,251 Â Â X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=sgmt_EquityIncentivePlan2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=sgmt_InducementGrantsOutsideOf2023PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=sgmt_EmployeeStockPurchasePlan2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stock-based compensation Â Â Â Â Total stock-based compensation $ 1,546 $ 1,855 $ 3,754 $ 3,679 Stock options Â Â Â Â Stock-based compensation Â Â Â Â Total stock-based compensation 1,316 1,855 2,903 3,679 Restricted Stock Units Â Â Â Â Stock-based compensation Â Â Â Â Total stock-based compensation 230 Â 851 Â General and administrative Â Â Â Â Stock-based compensation Â Â Â Â Total stock-based compensation 1,311 1,649 3,005 3,103 Research and development Â Â Â Â Stock-based compensation Â Â Â Â Total stock-based compensation $ 235 $ 206 $ 749 $ 576 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Stock options (Details) - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Number of Shares Â Â Â Balance at the beginning 3,753,507 Â Â Options granted 1,375,296 Â Â Options exercised (17,995) Â Â Options forfeited/expired (788,441) Â Â Balance at the end 4,322,367 Â 3,753,507 Shares vested and exercisable at the end 2,314,801 Â Â Weighted-Average Exercise Price Â Â Â Balance at the beginning (in dollars per share) $ 7.99 Â Â Options granted (in dollars per share) 4.43 Â Â Options exercised (in dollars per share) 6.36 Â Â Options forfeited/expired (in dollars per share) 8.50 Â Â Balance at the end (in dollars per share) 6.77 Â $ 7.99 Vested and Exercisable at the end (in dollars per share) $ 7.26 Â Â Term and Intrinsic Value Â Â Â Weighted- Average Remaining Contractual Term, Outstanding 7 years 6 months Â 7 years 1 month 6 days Weighted-Average Remaining Contractual Term, Exercisable 6 years 3 months 18 days Â Â Aggregate Intrinsic Value, Outstanding Â Â $ 8 Weighted average grant date fair value $ 3.42 $ 10.28 Â Intrinsic value options exercised $ 100 $ 100 Â Proceeds from exercise of stock options $ 114 $ 6 Â Time-based options Â Â Â Term and Intrinsic Value Â Â Â Vesting period 4 years Â Â Total unrecognized compensation cost $ 9,500 Â Â Remaining weighted-average period for unrecognized compensation cost 2 years 4 months 24 days Â Â Performance-based options Â Â Â Number of Shares Â Â Â Balance at the end 492,729 Â Â Shares vested and exercisable at the end 490,372 Â Â Weighted-Average Exercise Price Â Â Â Balance at the end (in dollars per share) $ 6.42 Â Â X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=sgmt_TimeBasedStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=sgmt_PerformanceBasedStockOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Restricted Stock Units (Details) $ / shares in Units, $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) $ / shares shares Restricted Stock Units Â Stock-based compensation Â Vesting period 4 years Balance at the beginning (in shares) 1,132,410 Granted (in shares) 49,330 Vested/released (in shares) (281,458) Forfeited/expired (in shares) (55,900) Balance at the end (in shares) 844,382 Weighted average grant date fair value, beginning (in dollars per shares) | $ / shares $ 2.96 Weighted average grant date fair value, granted (in dollars per shares) | $ / shares 5.23 Weighted average grant date fair value, vested (in dollars per share) | $ / shares 2.96 Weighted average grant date fair value, forfeited/expired (in dollars per shares) | $ / shares 4.96 Weighted average grant date fair value, ending (in dollars per shares) | $ / shares $ 2.96 Unrecognized compensation expense | $ $ 2.3 Remaining weighted-average period for unrecognized compensation cost 2 years 9 months 18 days Employee Stock Purchase Plan | Series A Common Stock Â Stock-based compensation Â Granted (in shares) 0 X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=sgmt_EmployeeStockPurchasePlan2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Fair value input (Details) - Employee Stock Option 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Stock-based compensation Â Â Expected volatility, minimum 91.00% 89.00% Expected volatility, maximum 96.00% 91.00% Risk-free interest rate Â 3.60% Risk-free interest rate, Minimum 3.90% Â Risk-free interest rate, Maximum 4.50% Â Dividend yield 0.00% 0.00% Minimum Â Â Stock-based compensation Â Â Expected term 5 years 3 months 18 days 5 years Maximum Â Â Stock-based compensation Â Â Expected term 6 years 1 month 6 days 7 years X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Related parties (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Aug. 31, 2023 Jul. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Related parties Â Â Â Â Â Â Â Research and development Â Â $ 12,653,000 $ 4,958,000 $ 24,228,000 $ 14,121,000 Â Accrued expenses and other current liabilities Â Â 2,824,000 Â 2,824,000 Â $ 5,403,000 Amount received as reimbursement $ 1,700,000 Â Â Â Â Â Â Â Maximum eligible development and commercial milestone payments Â Â Â Â Â 122,000,000.0 Â Â License revenue Â Â Â $ 2,000,000 Â 2,000,000 Â Ascletis Â Â Â Â Â Â Â Related parties Â Â Â Â Â Â Â License revenue Â $ 2,000,000.0 Â Â Â Â Â Â Related party Â Â Â Â Â Â Â Related parties Â Â Â Â Â Â Â Accrued expenses and other current liabilities Â Â 0 Â 0 Â 31,000 Related party | Ascletis Â Â Â Â Â Â Â Related parties Â Â Â Â Â Â Â Research and development Â Â Â Â Â 100,000 0 Â Accrued expenses and other current liabilities Â Â $ 0 Â 0 Â $ 31,000 License

agreement payments Â Â Â Â $ 200,000 $ 0 Â X - DefinitionAmount of maximum aggregate development and commercial milestone payments eligible to receive. + ReferencesNo definition available. + Details Name: sgmt_MaximumAggregateDevelopmentAndCommercialMilestonePaymentsEligibleToReceive Namespace Prefix: sgmt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 - SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash received from collaborators during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 - Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromCollaborators Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 - SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 - SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=sgmt_AscletisBioscienceCo.LtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{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}(,ZGDDŸ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v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

MM!A*2Z"T%$K+H#0&I7$43>X=P@QT:3/P-1:(T"%'WR!!;40H+78U3JBZ("'! MADRAM Q*8U :'VA<6?#"}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|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|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|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|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

<*H]G0FT4+;Q$&/94K1KSLV@Z+]UJ6K=][M$3\U?"C./W0DT GU5=6I;@94W4:TE0@/>$T#,N>TV#)_(]PFI-V%$M7#]K<$8+VA"0R&0X'LI\Q,SAB+CI M:M)T2QP1\'O99/*+*T(F
@9$,B,I:RIOTJK.V,:9'[OI7[II23@?,EC99!I/ M']>GCY/3N_PKGB;>=!8]T.@=#=V2&@)OU8+IH[8"7P?)6-6E#1+PE)+ 8,0M M(V(B48'6O*-AX1*.6JVI,$(SZN&C""7!0(S.;SS0X>3+2U3EO&2R\
[A/Z& M&=F9('NS()6.-<16([*M4'4(R*KK@%D<_I$D.J"^/N_[. `=8V Z998MY3W M'O'VKO>W$7+^8;/=6W$>^MJ@%V;_ZA'B28RTYCXCU3G/D:<(8NW6-=ZBO]5GM43I*[J(Z]V20948UJ(N^,E?
[Y6O]! ME;#UG,U19DBA<%^R_6MUD)\X#/>>1EBC_X@V.*KG0LA6O.^70%\UN(?]Q^((C?0:U\4]H<HD!1 MV7%9MD*'#BB$3J<\]Y@1F!>2\%]V5(:Z.8+#Y..F678Y*S-7K$I((0N2KEY]
MXLL4VYRF07)#W,FRK#H<2Y%X0]T(!5_TQR;:IEBA,ED@"E#])OXV5:/9O(>7 M_0XT$)2_FXU*S8$N6R:7^Z[:!&/E2K6$B=<2^SIFD'&-.#(D!8MZS":E3+)
MK(=PRV'HNE^VE"VKKCZC6FV/&I,ON!YAC9IIA_Y5[1ND&4>0 $DR9 4EB:LP M\5L=B-\RD&.Z%1,O:HHT_1.9SK^ILS@=EGZ6>:=<$KQ1 M@TJQ./8FP-U2:1!ZCOR$&AV1=C:?
HPD,QP?, 4EP'*$KO4,> M"X2)%T>1%T]=(4[]\VOQ"=/->7]C\C#A#71/\V>T1Y9&*'=56";>/ CW=!1- M23(T(_'^<^1[FE?Z30B6434^A(/.Z;%D.@-K$M)ZP2]VI!FR/9 [Z.IGT3" MZ;J310#3B$Q?
@02#V'I]D&%?O.[]?K[SH.A(",OPB+;TO(F>.#:-.TZM2ZEK M) 0R_UW([/O:@EJD5>]03'W3"HS#PH[F@"10E)\I>^=8$_Y9+(3UX]#EA MA'=GW-GOYI!I"N"$A<[S?
G3G+MRF[T66:3J>QE3>_W%P*ILUM6Y*\W"E;_X& MS8^X/4@IM\1?=6&2ZZ,I#R=&)-\U X+"&/,"/M1C!G174ENY*I%Q#Q>B?D@0(TO?31,B/S$C&_]8AW.H2CG2E:Y, V"=XEBI01VS MHE),R
(%5\NS19X]E+0(7]6H#FCHH$F?K! .;V%J>A@H5M00.LV^S [,0+FIV M[F+G'4?()Z$R7;8T3M&>.D_B&V]]=9"FH=#Z\VJAH;"X70HX MYO #L_':+0%,(_.)Y?:6!/R
=!OZ81OY21@X<3WRD61_L*$J67AQ/,Y6$Q_= MO,DKY[7*S83Z<30/O60R'V<\1OEVG"(G$S3VP1@^(?C[,N&03A/DPWETFX.A
M5AI&UR:-:NNO[O2G*VTN.6*?'#$BI,4A2!X+!]0,.))L8&,VEHV=@>?U>Y6] MFS6H8RB8,&O,_3#7F'197]$'X92[1/E^FZXH:$HN)O(8 BBI3N0.\\P&'MC_,9OG_7),EYB%'16EE>5U"-
SJG/683B3$#/W^X.84$K(58^Z,:SV9(&7,B=BG2' M=@R"BGT"21#A=[MBGW"\I@$PLI78:I5G0VWCDD:/ R'4\7()O#4E\ 0V<(8" M*3S@*@'>S/RQ$WU<*\=*"*$UU/U\5RN^%*2HS-V]#0H6-G7:
Q>'.[%TJO>G MM.IE:MM0M^NL!P&RW*BG-*]-I;8:L YGHXM7^V>3$PPS!%K^Y%\">\T3A*T5 M=-K5UXK3#U_-"33.[*KHN0>S]OD:+G=W,LKV
MS1F< ZKJRA=O^]OM3&S3U>F:;@F9(-7'QP&M< MXHRO7!FU*?C+ MK4OF:]?E\)EROF]UXL'R.\TU#+7K2F"][P\>%S:'[/+XO
M/7SK.KX]-5.VO30:QU[/-27"81CX0$X\,Y,+_Y;6%#1=.#WV$WL45T#\[P^54MV=-OGA?W;N91X-72I7CZUJV2'@]%Y^'/NPX=[Z[*52]XJ^+ MJ+*&Y9I/<(;5X0.F%^:[G1VX^?KI1UFOJ"K/U1);
W\V.4%0YR^*S$-:;?@K MGJNJA>7SS[62(04 \'Y956W_0 <,GW4]_Q]02P,$% @ #D!N61$_L,!@ M P_0< !D !X;"]W;W)K&ULK55M:]LX#/XK MA#?
LDV$[3M9U:1*@+_ =68$#0WMT^*S)M"Y,EGR0O[7[ID7+BY8HV&(:[8DLB M^? A*5++G75??(L8X+'3QJ^2-H3^(L^:)+&3/K.l&I+4UG4BT-8UN>\=BBH:
M=3HOB^(LX0RR7H9SS9NO;1#T,K@QH$?NDZXIVO4=K=*9LGAX%XU;>"#?+WL M18,/&/[J-XYV^812J0Z-5]: PWJ57,TNKA>L'Q7^5KCS1VO@2+;6?N'-'l4J M*9@0:I2!$03]ON(-:LU
1..?/68RN63#X_4!_=<8.\6R%1YOK/ZLJM"NDO,$ M*]S%H,.]W?V.^WC>,YZTVL24X:(\!$=2179A?8]:!*R@%RXH M],L\$"B+2%PE=.\]NJ^8K-^]F9T5ER?H+29Z MBU/H/T+O),#+],XS.
!O"/@)_G3">!$[P<.=,M\4W&7P>4AATV:W60H".NRV MZ,#6$&$J&&]OUPCRI>W->SCY<>MA:X2H65LI11UGG83!!:;@:,#.9:I5#:@2\! M"%-!).)!^(@F6X4UX"/*@;N0<&HE1V=77FH,RJ?PFS &'l-
H?C@E>H*:+P,F M4LPOX79PRC01U% FH!MO'T;'='2"&,7A D4P6LS3XZAHG$C;&/6-:-X6V8PZ M2^LX)$C;4%"6R=+@\TBI**L]ONFAGW@WYC584,%#:UT<+T<68'3!B*%2 MS$9;JSLF1--;R?
&JC.6I/@=MCO4J0K:>I\1/59\)76W*/>GL_25 M/$;2G#36?TMZ15$\3OHY$%*Z06A_G,#3VS^F^4+M. MF*&F!AH9"4?]U.Q9OC0%\J.1W*%KXL/C*?_4-,-TGDZGM^UJ'.G?U<>'\9-P
MC:+Z::S)M,@^O$_ C8 -N FVCP-^:P,]%W'9TON,CA5(7EL;#AMV,+WXZW\! M4$L#!!0 (Y ;EF;?<7SY@($X+ 9 >&PO=V]R:W-H965T$/K,8(0Y>LA2S@1%SGO=,DX4QRB"[M(3G"XLF*T
ORT:5KD^44P4A!66K:K99O9C#!1M!78PL:]$G!TP2C!06LR#(/ M7X"/PG;LKTVD"MY(N19=N;1P&C)":$4A5PZ0/&W074_?*GV80^PC@%V!=@? ?<(X%2 TQ1P*\!M"G@5X#4%__KP
MFP+M"F@WW:5.!72:1NA60%>E0WE^ZO!'D,.@3\D64*D6;K*A,DC1XLP3+'-] MR:EXF@B.!POX"C8,+!!5[PT.$1@E+$P)*R@"U^!Q.0*7%U?@ B08_(Y)P2". M6- D(K9T,.,JSK",8Q^)XX!
[@GG,P!A'*-+PL]-\]P1OBC77"[=W"Q_:)PV7 M*+\!3NL:L%NVJYG/W6G\1X%/XJ/3^#VD K>.XN/FDW(UU*L=S#E43 MG:K=\0Y54YW*Z/10/53.-
RNXZOG\HF^OVHMNVWV.6QV#N7:X9HFM5F3$0D@+S M\BM3C]:%WZVJ>3Z,#ZW>U-*,ST2Q6-9V[_9EI2D^M.L$,Y"BE0C5NFF+(H*6
MU5O9X2175_L3X:)04,U8%+R(2H%XOB*$[SHR0%U"!V]02P,$% @ #D!N M60!ZCZM# @ B@8 !D !X;"]W:W)K&ULG95- MCYLP$$# _BD6EGG8#(5]M"DC)ME5SV"I*MNW9P0-8:VQJF[#
[[VL;0M.J8:5< MP;#SSV^,&*)&R&=5 &CT4C*N8J 0NEKZODH+*:B0JX>9(066)MIC+W524! M$Y=4,C\,@KE?8LJ])\6YE$HM:,ZOQ0@Q+.=;$CL M!58(&*3:$K"Y'>$!&+,@H_&
[8WK]EC;Q?'RB?W6UFUH.6,+\HT47L?? 0 M@0S73.]$\PVZ>F:6EPJFW!4U;>SDHX?26FE1=LG&H*2\O>.7[AS.$@SG1% V2-MK0[,"5ZK*-'.7VI>RU-$^IR=/)AQO 8F>)":4
MYV@E)>8YF&/7*OUV<'&^6E'6[>T\ IM@AX%UX5"7S@!\F^:;QZO?"DMPX' M@7NH1F@2W*$P"*<#O$E?[L3Q)E=XE]\0X=7M.&$'BFI,;M4=0N=7H;:[V:I M*IQ"[)D/0X$\@I>\?
S>>!Y\&E*>)\G2(GNQ[!F@<'&;WXW-MM"BTO\?0YBO"5]R&F6^Y+7JWQ=K)UI4KML&PO=V]R:W-H965T-OOFW@E,FYZ MJA
YGBR4SKC%K5[V3:$%3]RF+.U'83CI9USFG8LSM_:@+\Y4:5.9BP?-3)EE M7#]=B51MSCN#3KWP02Y7EA:Z%V<%7XI'83\5#QIW_89+(C.1&ZERIL7BO',Y M>'LU(7I'*
<4&],Z9F3)7*DO='.;G'=\4DBD(K;$@>-O+:Y%FA(CJ/%7Q;/3 MB*2-[>N:^V _=M@RYT9=%A<&JNR:C,TR&3N__G7"H?6AM/PF0U1M2%R>GM!3LL;;OG%F58;HID:
MW.C"F>IV0SF9DU,>K<93B7WVXM$[@ZD%,W*9RX6,>6X!5]S*W,]\R0J5RE@* MP]X\5%]ZCP[PIK]Z:@L?BO(/$,4*O1>?B MUU\&D_#=$:C8]PO/HBUT$8PA$K\A9DBE?:0BM_-
A%TRE8LN\K[+IK/>_M.'IZ#.=QH^WXJ* [U)E4&<,*@=*PXEHPGB=([SCEQCC87;:"#[*.EPYE0Y9 M]%,$L2MN9.Q($YF65B0L_Y;3-+2I<(]+0]%A5X+9C>HZ[BP3=J5(V%^EU* !
MB"Q#G9!%*]@C03[M2R:9!=<6459P%W)&O*66%D'78Q\AX!HR>?[TCR^GT6#Z MSXO+S1+%\#0N4T[*S)_@O+5,:LN5HND"WPTCAZ6E]D< M8EL>(B
"E&FXN+0%L)/1H(JI0E@"!P4\^C'#R['CS MYOG8>]VY=?S],&-= _!U7? <0]"FYZ=B2'7F-G[5/ &NPF MBRIHT03(,0,^,0GQ3\I<6F_,SH8-UOH5'4\@NW88-D'R7+SL,"1!*T>060:2
M"Z5)+M^;MXM)*\P#ZAU>+BRO=#Z),#P#O?%9]8+;-JI,DZHK2]_*G?LE8@=A:4Q):,#"=IC,14R:;@LOT1@Z M6[:\'P$7U+S<80C0@;3G'0M4.E>S UD+PMD-$T5/?9^ M)\0/*X)\
(^XV1!%]@MNOIXUP7'G;[IRKA??:(<0R_@3%9ZF14"U3OGF&8WV MN%9[M]Y#0E!5LAB7O"=?SB[:0WIPA93(J&QZKP0$[W\]Y"CU,-POMA>)ZH2!OXXY?7J4/*@U63!-SVQYX*RG!
MR'CREE%!"8?O_F__'YVA[0EQS[Z;\(YP> 5=_>]P:=T,=Y^XE;LRH\Y-Z9^/ M0S.3U_O_8F\&HV RF)VTER;!<#S<68EFP7 RV5D:S()I-#YA-R)7F&O2C:+NR6CI[S06J&\(Y
M+2GT%UIEOL:X4:"I,,6RWS3^_]O9W!4SB0YFL:!CH=5/.IUV.LJ?'X8_O%YL MJ\'VZMŸ/&'2&8*I!XV;$,R=IS644#*,(B3K=!FDPG4R'<3A^%D1YO4@D M01A^O]TG=
R&@N.9L:FF/AU!T5:VN98S>O?B\X_*I2AC9Q,@^EHHYS/.N,_ MK!UYG3I7B=-7GC+L]EY1Z=5CNL8W3OA2.] GE *>(()N9_^UHW^)=)S!Q&# M$5*RXG!$5NO]3#->^A: %T6*WG0N4VF?
7.;YD8L2D=[*R\=/U$?AURF,QB8N_MC:%NAUZ9(XWIV*97.:::KH2D^0%#BA4Z/Y=RJ @5W- V[47CB;&X0_6M, M5<6/]+^+9 GPN]?5*RU#O=M[ZLZWVM]OL(2N&F!OF9X.OMU1>/*.76X]2'W6
M=6M6NLV1$Z5W)PG;$<*/R?FN,"0@[]3:5R$_:1^"DIYTPVF "K D/NR#>]] M_-\\=#9%I^%)E7BW&62N*WEPMJ=U85!OOT%/ M+;G_@/0'UX@-PU*QP-:P-QUW_,Q9WR 2W(>0N:
(8@MWE2G#D*1'@^4+A$*YN M2$#S9>SB;U!+ P04 "_0&Y9NYT)TH0# *"P &0 'AL+W=O=:Z?F M4]D:P6NX4T2W5<74EP4(N9UYD;=G?.";TEA&,)\V; -+_!^;.X54T%LI> 6U
MYK(F"M8S[R:Z6]16W@E\XK#51VMB(UE)^6B)WXN9%UL (" WU@+#WQ.\!2&L M(83QY\ZFU[NTBL?KO?5?7>P8RXII>"O% R],.?/&'BE@S5IA/LCM;["+QP', MI=#N2[:=;$H]DK?:R&JGC
@J7G=_)GEW#D<*X_ 9!;I3H YWY\BA?,<,FT^5 MW!)EI=&:7;A0G3:"X[6]E*51N,M1S\R7W640N2;::VJ^YCFK#1Y6+MO:\'I# M&BEXSD&3-_=L)4 /IH%!QU8]R'=.%IT3^HR3"7DO:U-
]\DM=0'&]'R#@'C7= MHU[0BP:7T Q)'/]$AC2Y8" N3R%V1N) ?0KG@N1L)^=MVZJZT@W+8>9AV6A0 M3^#-7[^*LO#Z O^D1YYNO7XUI&%^3_^1 7RJ
D^0A>/4&]A7&9.] +WB+P%\BM_ ;O#DFXM,= MQ[EM*U#,2'7UW>,\O>[K[FK/(F\B1(_BR:#8U;FQVE\P$3\ZRS8T\48.V)!GC/COC,DI(QY2.KC0#-*^&;0O;@:--("MBPGQI4.) MCQ_1D+>*FV?
ZV&7C_[M:/U3R8?5'8V2N+'E&*1 MC0X)YH^RS$_#]$4R#TPI?$N^QB4FVV5GL:VY.325 M<8) CRK%_B-Z_8_[]](P05(_RD;^*)FXX$8NN#.\&UL[1C9:MLX\%<(M2A:0(DEZK"5
MPT"2;ML%6B^HD=V]F1&%)9+HDE1<[]?OD)(5);(=)M$*2[&)?3'$X]\4QCQ9< M7,L$0)&?>5;(8RM1:G[0ZX0BQ&9S)?3Z' D^F7.1,X5;,>G(N@$T,49[UJ..$ MO9REA34\,K!S,3SBI.
[$\A8POCBW76@&^I[-$:4!O>#1G,OB! MNIR?"]SU&BZ3-(=*IKP@ J;'UHE[<.IK?(-PE<)"MKZ)MF3,^;?>_#DYMARM M$&00*\!X7(#9Y!EFA&]\;/F:34B-6'}>\7]D[$=;1DS"6<\^RN=]J.38&EAD M
E-69NH[7WR!VIY \XMY)LTO652X?<\B<2D5SVMBU"!/BVIE/VL_M @&S@8" M6A-0HW$GE@IRP[(2 M2 Ÿ,E@+0XTH25DS(]/:,3)DT+5@1IRPC:2&5*"N\]Q=LG(\<-13[(WFV8MK
MR:>59+I!^,&SN$6<_S&"\;]^$(MZWE29D9AK=]K4#IR1$)@>5ON>9!FL,V*[F(L$R)1G6.QI M,2-&AD0A"H%")43A\1G/ŸZQ8OGLSH&[_4+; MX;M=.;$5Y&,0379O1+U"4YEI=RM]F_)?W0]FF_!3
U0P^W0FJB"ZZPHN](#MA9WWNBVVM;W$/PFLTH MP6S<4R#R]:WGY>*"S2@'8;K/G,VOQNY&@W8(W.CVPZC9!N%&'R!F0 ,4(.9< M, 4X+8Q5R^@-"= 5B1+]+I0Z.T=!JTS)Y?
YHGUP(TU*73'#HZA(-R=]4&-O6ZUP/U!KM7;&#[?8HMO9B\RH)]=A:[U*:1VP6'P>XI MA,'#PG]N"OEVU,\FS"X-B%=B,&]0YE&7V,[^=?LV#;LJX, N[NEC"KF;;B] M/S]-Q;<3($=T;@%\)?WVA7E?
(TT1V5Y_?:M\S>M'B.N9SS4SWWKOZ_7_F>_N M^B^?^3!? S=L ;HYW8741,\?-7P[?,15N@E><7GN!.K;[B-ZX29XS>8_-(%& M]!_VP+=:*,+$#$:_(*DH';D=R_']?]"U)X\ZD1\]_^(.[F7NN%$9-U9MY1
M)5X/9:&JQ\8&VCS5GE0OE+?HU3OO-R9F^AD8(]DSGX_L(BHWDZKC>)S\UXY MYDKQW'PFP"8@- *>3SE7JXT6T#Q@# .\!4$L#!!0 (Y ;EDWA0T>,0. M %8(9 >&PO=V]R:W-
H965THN9L]WIO4PUMA02[C0S355Q_>,:2K69>Z7'&3Z*=6')X"]F-5_# M/=A/]9W&E=^S9*("8223$,^]Y;AY75"_[IALX"-V7EGE,F*]6^T>)?-O8 $ M00FI)0:.CT>X@:(D(I3Q?L;]QN6,N*V[@1I5?
1&:+N3?U6 8Y M;TK[46W>PC:?$?&EJC3NEVU:WU'BL;0Q5E5:,"JHA&R?_&E;AQW -/@#(-H" M(J>[#>14ON*6+V9:,9@F;V2C%Y>J0Z,X(6E3[JW&KP)O=G&GH>8B8_"$VVS M,"XSIFP!&J-K#=
(R;@Q8P\X>^*H$,+_[<(OW)OJ9/CU'2F M+DW-4YA[>&@,Z$?P%B^>A>/@ZH3PI!>>G&)?W.,9S9H2F,I9_3])G [S]TV2 M*CRNQD)&BM^!Y;K$ BCG?6]!9&5SV0 M=ICKM' %RN
1[[RZHO+L$W7A30YL$W&DYY,2--H+E,X@@P.;*/"!/- 3S;GTR\]%F7#[N8Y_N"]@KX-5ZC2W& M2L@1&@PG(X_I=HJU"ZMJ-SE6RN(<&ULK55M3]LP$/XK5]0@02!UY;6E+&ZF%3=L'-$39]ME-
+HV%8V>V0^'? M[YPT:4=+);9]B7/GN^>>.Y_/D[54CSH'..2YX$)/G=R8*Z*HHJ']9 Y?K MJ>.[K>*>K7)C%6X*>D*%F"^EW<*);=#25D!0C,IB()LZLS\\3RR]K7!#P9K MO?-
/;"9+*1^M\#6=.IXE!!P28Q$H+D]P#9Q;(*3Q:X/I="&MX^Y_B_ZYSAUS M65(-UY+_9*G)\[0(2EDM.+F7JZ_P":?OL5+)-?'UEZP;V_[((4FEC2PVSLB@ M8*)9Z?.F#CL.0^\-AV#C$-2\FT
UROMJ:#Q1)8F](\"7PC,>L01,J4B)-#@JC*P7'$,[HDG%F&.Z>/= E!WT^<0T& MMQ!NL@DT;P(%:D5L13*])Y%"^]>_BZ0[YD'+?!X4%"KT<'+XB. MX(5=)<(:+_POE3A4@
8_.HQO;]=8ES2!J8/71X-Z B<^/?$'WM41E"/CJ& M'B_PMJ85!R(S[/1_S>1XK'2V3'+Q"FN##L@-K4@F."%5W^]SK2<5J+G6*@6"(IVRZM]@:2C=+O[:G8GK*?D+3)EO1%(>^/ M"CBUN212&IW9?
R"GI^C47]\'GN^U^]\$ZP@2RA_Y=2N0S_:)I ;#(8=@.T7JI*\ MKG0*3SA+R\+6^3#@Y;"_IQN$00>W @$*Z5@TFN)4P>-1U(('-P #?[2GBZ(M MH,PR4/9 #[O;U0_VCRO$^GZK^Z;5^/XV9AB2!VDLS??
UV_84@MXPB';D?B_R MPE8^=.G&O>/&>W5*V8T(1#A]]>O67? M(;IY(AK!R+(>RTMI<,7COSF^JI"L > YG4II6L &Z=SK^#5!+ P04 " . M0&Y9+7P9'.(% 5$P &0
'AL+W=O" /G7FQXN)>S@$4>2CR4EX.YDHMSH=#F'X8D%G, 'U97$M<#1L43)60"D9+XF Z>7@M7M^%6MY
M(_"5P4IVGHD^R1WG]WKP,;L<.%HAR"%5&H'BSQ+>0)YK(%3CSP9ST$ZI%W:? M-^COS=GO+'=4PAN>?V.9FE\.1@.2P916N;KAJU^@.4^H\5*>2_--5K5L$ Y(
M6DG%BV8QI<E"PLOZE#XT=.@M&SH$%7K/ ,WK7&QDMWU)%QO>"KXC0THBF\Q1 MS6I4CI7:*1,E\'W#=6H\43R]/]/GRDC*" 2UI,9<)[?T+@=Y>C%4N(T6']8- MY%4-Z1V
3.@G7JJY). .*#+++]4-4K]71V^AXY1T%G,#"}KYC$< _Q@B-X?GMF MW^#Y__#,?4>MD8^))TQYW)!4[@<+8$I(<$L8C%_^Y$;.JR-Z!JV>P3'T\00S M,*MR('Q*Y"$_P8-^AC[=CZ/?:FD
M5@SI09@5DM"RQA PUUF[!)S*1$IQP494;S>#9=LY=%]2K!4&5S]LBH9 B/; M$"@6.5\#U((E+\^V,RN*LUHL1U:1Y,0HR2N)DO+TG+S\:>0Y_JL?]GL[%P [M84\P:-%*=R!,Y'Y&XQ]
[_QA01[K^\G=G.@.?3':,N7GU@KB6[T8]XU$8=L:> ME3A^9^Q;49R0FWY'M#OZSHZ2KK=5=A2Z>^^>B*XF;G>T#(-C6OM6' 9[6G\L
MT[RJH_3[>_T#E!CKN0E'FB$9,S09U56E]SR^Z^Z,HR#9T=]Q=L_GHE?0"T!% M.C=[9+#$HKG0J:,W@>>'G6C8&B[N:!+&T0_RPQ&R"UNR"Y]-=G5,UQ6;J35! M*Z/"IHS+/J([CGR+
[%43!2MG1.FRUO0@[^"DDBXG;;?4!*1]K]2)6]2)"SV) M:])RAWXL-&]*,D3,J0#C2*3(9I1AC?X?^&GS^\TT*9"=/2GYN3)'1&<\)?EZ MB4DQ@V?K,-&&D$=4N@'=3&I?/1?
R"SI&Y.ONDL=:O4$7"O1NA=G0RLQF F98 MF_8 ?ZL45KDRZR*^>P"1LDZNW((HVL%'&A=8]-)]K$<$?8TLNP71H?,[IKP\ M,:>^TKR"K@H6^966%;;,F(QUP.DD]W0B3N)&-
M)@E]=SAFUF\\P@S2U(RO% MH>4ET9Z;@1WX!PV\@8'&!ME6?S>VDB0\W5L2V?[^)D_A8]9-@;&B0R0F)G"? MDW@TLH+ W=]@9(?,8<"NI?
HR%@$#R_<\RX^Z1HSL,$8C=@EO4]&^8H%$A70^ M-V8P3$)-%]2S!4*[@35RW!T?>9&V3 _\YU/O[JGFO(G29!X5NPEFDW.G[$R MA8;2-SW BBFL'&2U22G:),'&;61A8@_U?1'9@4@:'BX%EEJ
M6N7YFBQ[#VP?X?JHY?KHV5S?VP"V/-S'\L>QOSMU/F:63N/T06>=MEE+I) M^\)ZJ?>4B>=DMVNYOF<%KM,)$\ &G/W09'&06+Z_'_RAC5UA':9#;+K!Q,.) M-W*M(!SM)Y"!?+^?<6&
(#:*S+Q]H^:<2]\W. --KY#TZP9'8B=O8B9\=.U-M MT*4Q*)58TA<'.X3CF/]5C/RK+K\S\+'(+,"$TI+CGR:6ZU8D<85_Y#*R9!!G+?UT M5=/C5A&EJYRN4NNZ2H7(7F?(86Y/^#GX)K;;P.SS]K!S55&
F)D+&8E-:56J M^M:BG6WO?%[75QU;\?K"Z!,5,RRY)(*K8(6P/=3SM5FH#=H;\+&?P2-P, $% @ #D!N6?^OL2!-!0 N2< M !D !X;"]W:W)K&ULM9IK;]LV%(;_"N$50PNT
MT<6V9&>.@<2Z=4"WH%FWSXQ,VT0DT26I)-NO'RDILF4KC(V\LT7R?0YDO M+SK@[GQ!$A1*+G/"O$U6 CY?;2LD2Z(3D6%VQ+"O7-
BO$<2W7+UY;8V/2O'M!C,9U779+9 /6"DS6!!;CD29YYC _>T,R]G0U< 8O!5_I>B-U M@36?;?&;W!'Y;7O+U9W54I8T)X6@K$"-]*/< M, .@;SXOKP:V;A')"2"HU JN/1[(@6:9)JAW?
&^B@C:F%^]/4P]UB0 M!7!Z\&'KVF6WY&MDMNO1H]LE_=%CW\L>F*6!R1][=D#2@^U97<6WC?#L& 0U.11/UDO=9=BBU-R-=CJ4M"TY["3)H?&+0I*_>:.J/
M1FVlC@/&K0/&1@ZP3'M]7?@4$@8\:GQ4R 8G9,Y+4F\HPF^BQ$B8N4 MH)0)V>L/H_Y_;1>TY53M MM[19EBS+,!=H2WAMG%[?F*'G&J>A3?:W)N[%^_ V3:W.#L8[L QHNR)06@O*
M2Z!H7=OL97D=HVW^(%*9AJ6$O)*)-<>5@M!&<O>! MTF)06@)%Z[K$W;G$_<$W.3/@;)^X1_WO3XY= ADS!*5%H+08E)9 T;IFVJ6X M'6/N",":%062_5*)S?D MS>7S.%/LCX_>XA?
F5ISM*M$.2@M J7%H+0$BE9[S=H[IY,3OJ[.@ FU>R\+ M61)&:$O;F]@_(;YW+A))2'SF54GR+;X>M#;5\P7]-"H(RL5"C[PE>#_MB?GQ.H;R;;5]:-(]B7#X]L\-PO/_ 5!+ P04 M" .0&Y9]M=+IKP"
#I"@ &0 'AL+W=O)0%@$)//65RZ11*5=>N*[."2BPGO *FO^1<_ME%CIKMBYLA* MU944C?PO)E;8L*<-+'O[D6:\%I1PN!>(%F7)1: _;H'RP]+Q MG><7:[(KE'GAIDF%=[!]:VZ%
[KG=BY;4@*3A#,D(%\Z- [U*C:C[8#O! [R MJ(T.R0/GCZ;S>;MT/+,@H) IXX#U8P\KH-08ZG7\:#V=;DHC/&X_NW^T]KE M 4M8@,*'R M7>(J/:/1NUD[RVTS2W!FEB\UG2! \1X%7A B66
!LL=E]11QX3_N]S>&[EA7.8.GHTR5![,%)W[[Q9]Z'/O"1S$["9A M"(?R1R0K2E0?[Z#]I;R-66S-S$6S3[V)YP?1(DC%GJRV%%L93HI@]C4'\IQDAF)ZA1AQ]8O9&8X9A)+.3,,RZ,,P&=WQC M+Q-
$I*QAB^[*[W[&F6HUU=)2&?N3[\]C_DX8-X>_;.I%P MWA'.APE!F.OW%K7)O3'GM(]FT.;2/1W)[(1XT1$O7C&U%V.&822SDS#$71CB MUTOMN"U V\:>R\R>W)EP*Z1X6(*0*_8K$C3"
(*N:;W)G.]'M$45DU\%PO=V]R:W-H965T9@T:/T%8N>< MHPSR#MT@(N\L*O6/PQ%' T8'0/6(Z6:OE%X:""+=<P>1U >[&2$"<\GO9?EN,P=V' M>_ !F("O(9.@3, :P8(_R$YY_?
>:,:CDD"1^80F:,QS3C*K,G,C/[2F8.>*%$ MK#F8D 0E"GI4S \;^*: 2/FR3)X]3)XC;5CC B5K_&KU::O$YLZ]>V1]NKQY]BP$ZC EW G7WTK=-CNR:\G+N3^3FX4' */ M#ÆR#.[GM*^\]2TP9QSMZK!S:
GT+FT=U9C2 MK8[2*3:Y',(51^F,.M,I%BE60>VH2V"CHX+:4<%/]S>IW->_#6*E6XX+4D+3 M%+*CFTHGE1&"XU=^M^.>[3*>& .XU48ZQ2;*_)VS_*]1 T*R[7"":(Y0!Y?TFI.#3R M
/71^>@_4$L#!!0 (Y ;EGMXVI3FP, *84 9 >&PO=V]R:W-H M965TTTZ[^?;2@-":7IYMTDX/@\![^O.8$SWU%VQS< OTNBXHOK(T0 M];EM\VP#)>9GM(9*_K*BK,1"GK*US6L&.-=!96%[CA/:)2:5%
<_UV#6+YWD1M"E+!-4-6Y:8/5Q"07<+R[4>]V[(>B/4@!W/:[R&O]3639W9'R4D)%2>T M0@Q6"^O"/4]=7P7H&3\([/C>,5)+N:7T3IU\1>6HZX("LB$0F#Y=0174!2* M)*_C5PNUNIPJ":?#; / 4
M#$$;$)R:8=(&Z*7;S=]U< D6.)XSND-,S98T=:#5U]%2+U*IC(43/Y*9)R(ME\T&072%.%E79$4R7 GI7T:WE2#5&M6T(!D!CCZBA!1;Y2MZEX# I.#OY2#? M8 9\;@MY-
8II9VWFRR:S]TQF'WVCE=APE%8YY /OR7C\;"3>EBIT4GB/4EOZ MH\<(P=SX@S_&"@>>NY,CW<'UK.OV5/_SI[3PR_VQ>^YOG/\"ZD^?FCW1RR M+2,"#-
O<@()AD"ITY[S&&2PL6BSHWH?]:'Z.@^#?S\\HH#XFI,.S6FHVK\Q(S)AYC!S3@:^=K-:!*6F(2EAF]^6>=_#-3I6%F MT@V3L,0D+#4$Z[GA.D]/^,[_+ XM??\N=1W'.2@-)\U*3IJ5OC2KK\>FXX[
MJL.-<,%()B!'7#!:"LR7"3&0:_=ET9IB5%;:HK6M\1[LL0S52I:DBE/3-(2 MH[34%*WOR=-+GSOZ)O//Y<(_NGFG0>1/O<.*8?1-[\2L]:FLC::V7M^E!+;6 M#2^.=.ND>=7N1KNFVH5N1V.7[KG5^[
>**:<+KAX1O.GC?,%N3BJ."5C*5 MF)LC?5U3ZW)ZH!%UK,OX#4$L#!!0 M (Y ;EF$8!1H<@(#'% 9 >&PO=V]R:W-H965TDT/9@2T<*^4K59!J6US448FJS$2IB);K#FDT)3 M)2R[M U-
0RARGU2I,(ZB15@)60=IXO=6E":ZM4K6N"(P;54)>KQ"I;ME, V> M-N[DMK1N(TR31FQOC?9GLR+VPA$EEQ761NH:"(ME<#F]N)][>!_P2V)G#FQP M2C9:/SCG6[X,(D<(%%;6(0A>=GB-
2CD@IO%[P S&DB[QT'Y"O_7:6I,"@6R-I;,/NX#W LBXXP1[[N&X5PK>L=DI7.7O$=02+,8>T5 M#&+ANQ0;J:1]/*:EKS0_7LE-V85I1(;+@,?((.TP2-^]F2ZBSZ_HF(TZ9]^A MI^/?
D..T3/M$UD.33N'/T7:UG'O4,X_J!GF73J,H2L+=$2[SD$">:%:Y5DJ0@0:IY^4(/O_:8R3[?)HOY?RS#@VEP#\L/ M05N^LJ"PX+QH\%54C^LO6-UXP=DHRV/FS=+?M^07 "?%UK;)\?W-ABIG\!
M4$L#!!0 (Y ;ED-1B(5.0L (%S 9 >&PO=V]R:W-H965TTF ;GI[=\ N4#3MWFO% M81*AMN65Y&1[N]_DF-[2#V,1&7XIK43:L@ ,51^GJ'&ER]Y\:U\4JKR_MRL
MM^75XJFJ=N^7RW+UI#9I>9'OU+;^S4->;-*]?EL\+LM=H=+[PT6;]9+[?K3< MI-EV<7UY^-FGXOHRWU?K;*L^%5ZYWVS2XOO/:IV_7"W8XO2#S]GC4]7\8'E] MN4L?U:VJONX^%?
6[Y=G*?;91VS++MUZA'JX6'[C[&\8/5QR:_)ZIEU)[[35: M[O+\6 /FW_=7"[\9DEJK5=782.O_GM6-6]\;4_5 _CA:79P[;2[47Y^L_W\0 M7ZNY27MUD_]U\73U>+9.'=]X=TOZX^YR__4D=%86-
OE:_+P[_>R[&MO_!6 M^[+*-\>+ZQ%LLNWK_F?QYG0+F!BX)^O(!/O2 X7A O:6O/B,#>]VLUV;99Q]NJ]^:U=+5U[^D6>$]l^N]\C8J+?>%JA>I
M*KUT>^\]P._R!^\AVZ:,59:NO6Q;5L7^M=T[3[/PXT=5I=FZ_*G^\=?;C]Z/ M/_SD_5 W][X\Y?NR-EE>+JMZT$W7Rl5Q@#^_#I /#/!6[2Z\P/^,OWTN>BZ_ MP2__]%;UY>QP>6!>QJRGZCQ?_#Q?
_& O&\)^OQ@EK5U[MBR+/;C;.E/7]>S4H M^@TV^_1]N4M7ZFI1;\12%<]T M=?9?=>_]L[Z7]2[+]X50ZU@(UAHURŠ!DSI,JS5$GMBI)2.Y$Q
M0SOS&0)\REO[T5IHWMMYW/))O-.YHC2T8:BH+WE5TTI:EFI<$.MNGRBI]UE; M$=KC7$4 'PS]^][:C][_O-<_$JQ^]5N^5=]K,FQN*M[#?HBU2&&$RIHY&X C M+*#>L@PE'&O]1-9, 0 Y#*
<3=MM%LF01?U_21C@#,-Y9L!W>?WJ M)B]V>9%6]OX =E>-_#G$N[%>0A?XPX!_&#D ,5("HK)FZ@<&8C@$V;HP:LU: M>Y>91,3Y@*,#,S&&)RIJI'^")HW RS5NC[MVW'3KI:2,&G!7 AN-@
M,^"L7R]N+[POQ2'2_GW,5TEAA]:.1\ 13PA]U524]*R9NH'4N(HB4SS5=F] M:P9!VUF[C>)^9PT 8P(<8P:<]<.CVJ[&O!0W;;M*5-:,B0 ."ABUEP:D_$-E MS=0/ !/@\:4!7GHT8=1Q>1-
I>6I<(P9\N#5IG(C* MFCD= $Z!(/=]4DZBLF;]!TX*\,C3)*\,D=OJ484+V@F =@*<=@RG'D_,X-:L M5]!%F"@ F@IB<@\FI2[1AN'/) M%W9!0P% $,!#D.(M*UO'' "NK-?913Q) (@)G]K/!2E_45DS]0-
_"3P.-=G/14^^3HJHG;[K:2:3 M>" 2(0"3!(Y)T_W7(C2!]VF]D"X(3 "!"?+4G"!%+BIKIG[M_!$>]YKNR-UL MFQ2BS=,]K;@4X8 ? Q@)'(RF^K%-U +OTGH973"7 .

5810!6$7E"_"+%+2IKIG[K0B/>TW&Y*B;%60Q MCSJ>[.09.NTA.IR>ACUY-H;@/5HOMPLJBX#*(O+L842*85363\V 81%1]C#] M9@\9Y[+]5"S>W5PY0%413E43W=T&3TA#7E36S*=*
=9B\AQB3(IG5-9_.8!G M,5$,.>XF!X6.VR%KO+>Y;@"V8ARV/Il6KUR*RIJI%'@L)D\9QJ101F7- MU_l0%N/1KBE8C9NP%MS-*@8##XS'P%8OSE9GAYV$U;@Q:T$N."P&#HO)LX4Q M*6=163/U;P4-
2!_FPZU9:^^F%F/!M ^=IBB IQB')XN'R'%+UH*Z,":#)!IX M#C<&?(IQ?-(WZ#_**MND5;U!#[[[^Z R4D"BLF:6M ! 2L@!*2$%)"IKIGX MI 0'),MMFG0QJ>^Q\;YFP_LO 0!*< "RV'I)-
^C$(AG$[;163[MZ9\F!G94 MP21X1&EL9\VHUX#W:.UX+@@G <)>,R-."2GP4%DS]0,.)3@:V6ZG\GB/I?1NO MVPRIUY S21X5&FR-UN?=.,0[MEY4%]"3 /0DY,&EA!1\]*R9^K4*43@?V3HU M;
<&H+B,-5W!( )&2Z8B$5W/ #5G+<0%&$L!(DH.1) 4C*FNF?@ CB8/1E$_@ MN EKP5UH&OH$+H&8Y,20D>&]DSZ.XY:MU;D(*$G ,4D>4)*DN$5ES=0/N"6) MSJ#C=]Q5=Z-*3,9\X(. !'[2TP-
+AEM/_1"+V[>6Z2+6)(',)'FL29)B%Y4U M4S]@ER0ZF2Y[XD*AB-M/6/0T]|TV'/):P".)XY&5UUH__(9W;KVD3NIO:@4X MZ2MPTI;@=%,#4R_"271;_63(=->0M\^-];63B1SP:N9KI35]G)7>XM[G-
89N14=@OL(LP%_.U2I\^^7'VDTFR.7!2U]/7"GOZ>/C, MPLF[!lL#'G8>QCBUTTOE1Y*Q(2_7:G#Z,$:0-]_))#]2-=&^_M"X"7LS7ZGOZ MY,?:3R;)YL!)W4]?*_SIXR$R"_?N.>#.!&N?H1SI<*XDO03Z2
WT-VR#Z4?- M1@9A[0B.2]SK-=;)3\,SJBKJISEP G5Z5?:1LNS3-P/K*9XEDDX);C>%U??* MZGCI/EV^SEP@G5Z ?>1*NX6;MYW M;E[$[8/$(OW.EJ11&E[?W,K/Y_,|<-&54U=Z/ M<^"D>#S3JL>SD?
+QT_?"T9#^&3;T62=L25L&?JE]/6+SY93UFMU4-M MWK]HC@T7KU_W^/]FRG>';TR\RZLJWQO>/JGT7A5-@_KW#WE>G=XT7\)X_M;- MZ_\#4$L#!!0 (Y ;EF&PO=V]R:W-H965T
MFYJKJ5=IW5[YOBHJ_M:*BZ%"UPG%D)V5"-7;GV52N!EA;4U'X4!*G?4.;]?&+'%C*?B(VN&8>%)&K3 M-%3^OH9:[*9>Z#T-W+!UIC\CPU>(6ME?LNMBL\PC MQ49IT?1@5- PWGWI8U^'/4"8O "
(>D#T6D#< V)KM%-F;-F%9=:XBO#G,X7$EK*2@*/N"\4*$)Y282NO&)V*8%K0I4"K7[/Y$]]T(\5"$^Q3Y4H<)5M!Z*(?+=4>56BIS8VSS MZ$,.:
['==W,RW0Z208WR:O<&&JB\]N:0E;O+];O(VTRU3'.-HSE8Z3 T_) MD?$LS88:89U)'@]31JZ0RKC:2\@)]^\N=^H7./F(36L M$!9<9NA'=N]8U\&BM4_!O=#XL-AFA4_2\ .\RLA]%/'O"[#GXG\#U!+
P04 M " .0&Y9Y<)H?>L" L"0 &0 'AL+W=O@(W/^_HY!VPSW0GYI#(_39YS7JB9E6E=7MFV2C+(J;H4)10X MLA(RIQJ[[:.M'E@Q].2KF$!^K&\D]BS6Y>4Y5 H)@HB836SKMVK^<3$5P&_
M&.S47IN83)9")/)G.]W1F.08(."3:.%"\:6$.G!LCQ/C3>%KME$;XWWYU_UKE MCKDLJ8*YX+]9JK.9%5DDA17=<'TO=M^@R6=D_!+!574ENR;6L4BR45KDC1@) M*
<* $;@5XG69%5:MU33>"K%CD@3C6ZF4=6F4F,V MK#!O<;$ECC+4Z?@Z2>0&4@+/^%TH4(06*1$Z XFS2PF%)IS1)>-,.OP]OP5- M&5>?R 5Y7-R2\|-/Y(RP@CQD8J-0JZ:V1BQC;B<-PDX-YX
T@+*")+[SF7B. M%_3(Y\?EMY"@W*WD_ENYC<5H*^*U%?$]/_]=*M*7;NT?]/N;97FE2IK $,)U MIT!NP8H_?G!#YTM?\N]D]J84?EL*_YA[6XJ2ODC!^84$3C7V$Z%T;^:U75C9 MF?
UC&T\FHZFIW4^H&^.ZSK^@-Z!!"QJX>1PVX!W)CUJ^+]+==Q)R3<[4E]*49M2=#2EGV:?Z0./.G.YID&%NR&>/X S:7$F M1W$>A*:\#V?26=1>Y!VNJV[0*'
,B>R|L\S\1_R~0+LCK>ED+C85DU_R= 6D"<'PE4'[MF!.S_4&*_P)02P,$% @ #D!N M63+TX]OZ P 6!([D !X;"]W:W)K&ULK9AK MCYLX%(;_BL5652MUAY +F:0)TDP ::N.-.IL=S\
[<))8Q9BU33+]]WL,#)O, M,#3I^DMB#.]S[/.:?%D,Y M3Q5?V7:G384;+ JZA0?0WXI[B5=N2TD9AUPQD1,)FZ5SX\WCF7F^>N O!@=U M5";F)VLAOIN+3^G2&9@&00:)-@2*?
WM80989$#;CGX;IM"&-\+C\1(^KOF-? MUE3!2F1_LU3OELZU0U+8T#+37\7A#VCZ,S&\1&2]^B6'^MFI[Y"D5%KP1HPM MX"RO_^ECDXAG^JA?/^O1NYC(-IO#IVS>#GN! M-^7VBHR\#V0X&
(XZVK/JEW\NLUYV"]_@ +E@U?ET?GR<8<\,N7H@[DJX*FL#2P2^P KD')WC[F^/6X'$?;BCCXR7G$#&MFR= 4X(>YSH"F-YXSCG(!-&_ SR98#?PAQ(M07]48Z)K!/3&NW0$V(2%-F%1#?,KF%DX[
-OB N)P<++='WMK*>:)MY/6VTFO MM\VT@4N//>0E=)G5"[C4+)NP35OOIOW> MJ20#S3H_NZP5<;NGLC.DIM!DQL@F+++<%]]IWRCG2^N%;?5&87"=PRGOGJK MT=:VQR WU>[_6?VM-UJY'?61-
X_K4X[_\/69RQV56Y8KDL$&0PVNICB)R_H< MH[[0HJCVW6NA<1=?%7= 4Y#F ;R_$4(_79@ [6%2\"]02P,$% @ #D!N M6;#91)F5 P %Q(!D !X;"]W;W)K&ULK9AK M;]LV%(;_"]$-0P)LT=67>+:
Q+:\ BL;)&CWF9%HFZ@D:B0=-\!^? \16;4C MA;4Q?HDEZKP/+^\);],]XU_%EA")OA5Y*6;.5LIJXKHBW9("BQM6D1*^K!DO
ML(17OG%%Q0G.M*C(W=&SAFZ]:>G$4UWVP.,IV\FW):2T8*4@K(2<;*>.7?^9#56\3K@"R5[M&?NJ7CYD,\=3#2(Y2:4B8/AY(7.2YPH$S?BW83IME4IX_'R@)[KO_MT)=G+,B"L(WA&$C2 \5Q
U@NA,K9'G$5#33UH/W5:G"$EBH3GR2'KQ1T,IZSHJ_24DL* MA,L,I:R4M-R0,J5$H#_0WP1\1E<+(C'-Q?74E5"IDKI4\&\KB!XIP(??03D M5J!EF9&L1[\PZ\.?Z1.S_M:@=V&PVA$++#B-
V'QB!'S&_07[P.PH_O9]?E]@ MJU^OT5K^]HL_&O_9-T!FWET%O-!3O" Z\/K&R8QY(M59F.7YF-" 2>RT9OO_ M6W/B8=AF?:BYX3MGN- M_C--^ *#!:D/XB%+=>Z$W=E^\
\.-9^:3[8A"UMPA*;L)4EV$D^#-M\&!KS M06\F\M=F@JCP]IXZ]=E?WY0O_,G2[RE/ M_,FJOJ3X@:^O3.!4M]&E %/74)5W,X)%@M?7$/6+9)4^!3\S"6=J_;@E."-< M!<#W-6/R*(J:.^"XN]02P,$% @
#D!N68ALT%YH! 11P !D !X M;"]W:W)K&ULO9G=;MLV&(9OA=" (0562]2?[(CVB)B:RSI:Q 0IZRG M[!8H(\YBIJ^MV&)&*Y%G!*\8X%51(/:\ >?
T,'>@\W+A2[;,"W7!7N8W*)BLPX1DE@.'MW+F#MXPO W2)OS)\"?'0'7E@=)'=7*_F3N> M:A',<2J4!)(_3WB)\UPIR79\K46=IDX5>'K\HOZ;[KSLS /B>$GSO[.-V,^= MB0,V>(NJ7'RAAS]PW:%
(Z:4TY_H_.!S+1J$#THH+6M3!L@5%1HZ_Z%L-XB0 M7@KPZP#_>P."_B#XWH"P#@@UF6-7-(<$";28,7H 3)66:NI P]31LOL94<]
M+9B\F\DXL5@+FCZ^5^0V(*6%'$XCN']!_!,B(^#!7X#O^6%/^/)*>)6/ QT>- 3GIC#U[@<@<#KJ]V5E!I4 M?H/*UWKA!3W5"O#Q;Y6)9Y"1%!,U8D&9())'QJBE9O,M+U&*YXZN 9(];7M"26FM'!
M-&TP3:\E$2&X)YLJQ3)[%N!W-9AZ4RNCSE!8-L422V(=?M!K$U;/6@I12UF" M:%4ML:76O7B2]_)X\PUS.8L4VUI%;K+':>_NM?[&#K!:#9#/$ %\&L.!B4
M54]0JW42LSB,Q_X%3FV^#XW)\.)C4>;T&6.@IRU852S=JZ1C=<$VF>4&0[*; M]MM2ZZ)L$W\8VEOXK&;W5M426VI=C*U5@&:O8& ALVH8:K6.A8)1.!V?609;
MM7;IM:8!FEV#%:=EKF,PN;C7:\%S<&_A(&!K(:#90Y@60O /6&279WH!Z> MNE0O.ZO.PJI:8DNMB[AU('!B;X&TZD6LJB6VU+H86X<"$1;%W@)IU<+4;M<7
MR+>P)WYK3WQCWOY?/JO4RMT>!N/H[*O1TMR"P9^#W*'^*T^\@E;:.D=.[LF6C=I@^XS8+B,LCB>"EGH7 MYX$*00M!N,=H@YDJ(.JO*14O)VICJ-DY7/P+4$L#!!0 (Y ;EDO8&0A M_P, (@8 9
>&PO=VIR:W-H965T_?:!2=!!TY3F27.*^LY5S/W:'EG,Y$D5?DCB&^*TO,_KTA!3TL+-=ZF;C/ M-UNA)NSEO,8:LB+BH:YC7K_0?!?)RV0>
M,2>WM/@GS\1V84TME)$UWA7BGA(^)&U"H>*EM.#Z+SHTMA/'0NF."UJVSO()MRKQJ/O%S6X@3!\DQ.WBM@S=T"%YO\)%L'_ZT1@M8A>&N$L'70J=M-[KIP,19X M,6?
T@)BREC1UH:NOO66]\DHME)5@\FXN_<1R)6CZ]%65.D,I+>7ZXUAW\"M* MGM6(H,\Q$3@O^!>/7]!'E%?HYY;N.*XR/K>%?!0%M-,V[$T3UGLE MK{]^T$IL.4JJC&0& WCO+NZ+UB^-
VB\#7/OW!1F/K,/=.#3OB=X.W='=SGM$QS>]B+A#U3%81<%L M\"9BL/(=)QS*B<'*/7EAZ:=^W(FYXULQ^39",$NW6B*;_ H?F&WRBJ."K&4HYVHB^\F:8^]F(&BMSW4?
MJ1"TU)=:@C/"E(&\OZ94O Q4@.Z?#\O_ %!+ P04 " .0&Y9KBB4?Y,& M #2*@ &0 'AL+W=OCM92;2\L2P9HF1(S9AJ;]SI+QA$AURE>6 MV'!*PCPHB2UDVZZ5D"@=S:_R:W=\?
L6V,HY2>L>!V"8)X<^W-&;[ZQ$<'2Y\ MBU9KF5VPYE<;LJ+W5'[?W'%U9E4J89305$0L!9PNKTC^PL(QK30&821/W;T06-XTO)Y?%/*3]JRLP"CX\/ZG_F
ME5>5>22"+EC\,PKE^GHT'8&0+LDVEM_8_B];5FB2Z04L%OE?L"^?M4<@V K) MDC)899!$;?&?/)4@C@+0Y$0 *@-0*P Z)P)P&8#;)> 3 4X9D*.VB]KD''PB MR?R*LSW@V=-
*+3O(8>;1JOI1FKWW>\G5W4C%R?F]9,&OBXQ<" *6J.8D2/Y" M+D!^"[!-=BK >Y]*$L7B@[KS_=X'[]]] ,^ !<2:<"I E(+O.23%1W51'3^L MV5:0-!17EE199F5909G1;9$1.I'1#'QAJ5P+\"D-
:=@3[^OC(=((6 I/O0@= M&-TBK>(]W8P!MC\"9".G)Z'%^>&XKS[Z<)\&*ASVA3=]@ZLWCG,]?$+O[VWR M2#E@2W"?O[J^-U0H,/T*65=T*38DH-(DE:V_V]M)APE44-#,;3'1%C24B2&Q!A.W
M8N*>Q80^41Y$HI^*VZ%R ;W9;-*"HBUI*!1#8@TH7@7%.PN*\BQ+&JFF8M&G M3<3[X7A=,-YTZCBP14=;Y% ZAL0:=*85G>F0/H:FO5BF'2P.1@B[[=Y%6]90 M+-
U"VUU:H\;SJL8S;8V+40CLJ%!M 2C/W.Pl5\X>1^X;N&=/!>F=B0Q3'A FR47ND4)TZ-&Z(UGLU8+U.@/>=0Y#>$WZ MVIG7]A/Z%Y& 8#F^A[SB:
(VG1#O>O^43N)3[U.8@@7MR=%U/GY&37GIM2;^&I[M#CVMP7B@/,GA?4XECU(1!> 'B;?]SL*D[UX85?--]34QUCX>ZHU\Y=/ P:A] MH]EWV,Q<+)A"2P*Y)3'(<'\$7[=22 7]O->$%\KRP#/-
VK(+DOS+5R]K8]=.%85R/.H!>KOJRW+(:N.0*X+2G(B5?HW,.4VK- M[YWU) -I;??\9K7B=$4D;7<"+[94O?#0'L&HFE^JN<>>H'^P0?4$ NDG$(?F M"$C9&G-/K%J)8K[4WTGZLX;\-
A!K:&EYREHC]&T^9BOS_*U[>$"#] MA*!N)7EUJT4#[8>O4M-M5,UNU_^,AWQ]=[^9W6WPD=[@WW$64!HJQ\J94M4Y M^\(NCI=0>AG@;O6@TV:0?[D_6, #6%]TL^Q#O6M0ZHM%I?
=T#MX3.2>]IUYJ,&]#:DW>M<%' M>M-]1WF^G24-SAE23+KNA5$UWY1:_0I M# ;V%A,$?+3C1K_EYA5K=MCL%ARS>W#>8K*!Z\D&'K0-9]@'W5+[>#[M=F?= M^@P&\S(ZM["_-OLEE*_R39-
"V8QM*HL];=75:F/F3;X=L77]%EXNBNV5M4RQ MV_,+X2LU"0$Q72I)>^RIGRLO-E 6)Y)M\BV%CTQ*EN2':TI"RK.'U/TE8_)P MDA50;6.=_P=02P,$% @ #D!N6>+/U@\-! 50\ !D !X;"]W:W)K
M&ULM9=M;^,V#(#M_ NA[0UI;BM$F7!.C+W>

font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 209 202 1 false 39 0 false 5 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - CONDENSED BALANCE SHEETS Sheet http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 995200105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 995200300 - Statement - CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)) Sheet http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)) Statements 5 false false R6.htm 995200301 - Statement - CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Temporary Equity Sheet http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Temporary Equity Statements 6 false false R7.htm 995200305 - Statement - CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Parenthetical Sheet http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Parenthetical Statements 7 false false R8.htm 995200400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Sheet http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows CONDENSED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 995210101 - Disclosure - Description of Business and Basis of Presentation Sheet http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation Description of Business and Basis of Presentation Notes 9 false false R10.htm 995210201 - Disclosure - Summary of significant accounting policies Sheet http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 10 false false R11.htm 995210301 - Disclosure - Fair value measurements and fair value of financial instruments Sheet http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments Fair value measurements and fair value of financial instruments Notes 11 false false R12.htm 995210401 - Disclosure - Prepaid expenses and other current assets Sheet http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid expenses and other current assets Notes 12 false false R13.htm 995210501 - Disclosure - Accrued expenses and other current liabilities Sheet http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued expenses and other current liabilities Notes 13 false false R14.htm 995210601 - Disclosure - Commitments and contingencies Sheet http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingencies Commitments and contingencies Notes 14 false false R15.htm 995210701 - Disclosure - Stock-based compensation Sheet http://sagimetbiosciences.com/role/DisclosureStockBasedCompensation Stock-based compensation Notes 15 false false R16.htm 995210801 - Disclosure - Related parties Sheet http://sagimetbiosciences.com/role/DisclosureRelatedParties Related parties Notes 16 false false R17.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 17 false false R18.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 18 false false R19.htm 99920202 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 19 false false R20.htm 99930203 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of significant accounting policies (Tables) Tables http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies 20 false false R21.htm 99930303 - Disclosure - Fair value measurements and fair value of financial instruments (Tables) Sheet http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables Fair value measurements and fair value of financial instruments (Tables) Tables http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments 21 false false R22.htm 99930403 - Disclosure - Prepaid expenses and other current assets (Tables) Sheet http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid expenses and other current assets (Tables) Tables http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 22 false false R23.htm 99930503 - Disclosure - Accrued expenses and other current liabilities (Tables) Sheet http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued expenses and other current liabilities (Tables) Tables http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 23 false false R24.htm 99930703 - Disclosure - Stock-based compensation (Tables) Sheet http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationTables Stock-based compensation (Tables) Tables http://sagimetbiosciences.com/role/DisclosureStockBasedCompensation 24 false false R25.htm 99940101 - Disclosure - Description of Business and Basis of Presentation (Details) Sheet http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails Description of Business and Basis of Presentation (Details) Details http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation 25 false false R26.htm 99940201 - Disclosure - Summary of significant accounting policies (Details) Sheet http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of significant accounting policies (Details) Details http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 99940202 - Disclosure - Summary of significant accounting policies - EPS (Details) Sheet http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEpsDetails Summary of significant accounting policies - EPS (Details) Details http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 27 false false R28.htm 99940203 - Disclosure - Summary of significant accounting policies - Dilutive (Details) Sheet http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveDetails Summary of significant accounting policies - Dilutive (Details) Details 28 false false R29.htm 99940301 - Disclosure - Fair value measurements and fair value of financial instruments - Warrants (Details) Sheet http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsWarrantsDetails Fair value measurements and fair value of financial instruments - Warrants (Details) Details http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables 29 false false R30.htm 99940302 - Disclosure - Fair value measurements and fair value of financial instruments - Fair value (Details) Sheet http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails Fair value measurements and fair value of financial instruments - Fair value (Details) Details http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables 30 false false R31.htm 99940401 - Disclosure - Prepaid expenses and other current assets (Details) Sheet http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails Prepaid expenses and other current assets (Details) Details http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 31 false false R32.htm 99940501 - Disclosure - Accrued expenses and other current liabilities (Details) Sheet http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued expenses and other current liabilities (Details) Details http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 32 false false R33.htm 99940601 - Disclosure - Commitments and contingencies - Licenses (Details) Sheet http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLicensesDetails Commitments and contingencies - Licenses (Details) Details 33 false false R34.htm 99940602 - Disclosure - Commitments and contingencies - Lease (Details) Sheet http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLeaseDetails Commitments and contingencies - Lease (Details) Details 34 false false R35.htm 99940701 - Disclosure - Stock-based compensation (Details) Sheet http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails Stock-based compensation (Details) Details http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationTables 35 false false R36.htm 99940702 - Disclosure - Stock-based compensation - Expense (Details) Sheet http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails Stock-based compensation - Expense (Details) Details 36 false false R37.htm 99940703 - Disclosure - Stock-based compensation - Stock options (Details) Sheet http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails Stock-based compensation - Stock options (Details) Details 37 false false R38.htm 99940704 - Disclosure - Stock-based compensation - Restricted Stock Units (Details) Sheet http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails Stock-based compensation - Restricted Stock Units (Details) Details 38 false false R39.htm 99940705 - Disclosure - Stock-based compensation - Fair value input (Details) Sheet http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails Stock-based compensation - Fair value input (Details) Details 39 false false R40.htm 99940801 - Disclosure - Related parties (Details) Sheet http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails Related parties (Details) Details http://sagimetbiosciences.com/role/DisclosureRelatedParties 40 false false All Reports Book All Reports sgmt-20240930.xsd sgmt-20240930_cal.xml sgmt-20240930_def.xml sgmt-20240930_lab.xml sgmt-20240930_pre.xml sgmt-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sgmt-20240930x10q.htm": { "nsprefix": "sgmt", "nsuri": "http://sagimetbiosciences.com/20240930", "dts": { "schema": { "local": ["sgmt-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["sgmt-20240930_cal.xml"] }, "definitionLink": { "local": ["sgmt-20240930_def.xml"] }, "labelLink": { "local": ["sgmt-20240930_lab.xml"] }, "presentationLink": { "local": ["sgmt-20240930_pre.xml"] }, "inline": { "local": ["sgmt-20240930x10q.htm"] } }, "keyStandard": 187, "keyCustom": 15, "axisStandard": 16, "axisCustom": 0, "memberStandard": 26, "memberCustom": 11, "hidden": { "total": 21, "http://fasb.org/us-gaap/2024": 16, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 209, "entityCount": 1, "segmentCount": 39, "elementCount": 432, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 512, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets", "longName": "995200100 - Statement - CONDENSED BALANCE SHEETS", "shortName": "CONDENSED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical", "longName": "995200105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_ZQgAnNOPxUykH5XMAQGS9A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "unique": true } }, "R4": { "role": "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_2qA0r1eGKkyxd2i-JXjfAw", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "longName": "995200300 - Statement - CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT))", "shortName": "CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT))", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1gefOqnsP0qj2BAcV297Ug", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yKamVMRSKkakMk5_h6nQ7Q", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "unique": true } }, "R6": { "role": "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity", "longName": "995200301 -

Statement - CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Temporary Equity", "shortName": "CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Temporary Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_O0asLvAfs0uxAXCPreObkA", "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_O0asLvAfs0uxAXCPreObkA", "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "longName": "995200305 - Statement - CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Parenthetical", "shortName": "CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - Parenthetical", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_2qA0r1eGKkyxd2i-JXjfAw", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows", "longName": "995200400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "unique": true } }, "R9": { "role": "http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation", "longName": "995210101 - Disclosure - Description of Business and Basis of Presentation", "shortName": "Description of Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of significant accounting policies", "shortName": "Summary of significant accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments", "longName": "995210301 - Disclosure - Fair value measurements and fair value of financial instruments", "shortName": "Fair value measurements and fair value of financial instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "longName": "995210401 - Disclosure - Prepaid expenses and other current assets", "shortName": "Prepaid expenses and other current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "longName": "995210501 - Disclosure - Accrued expenses and other current liabilities", "shortName": "Accrued expenses and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210601 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensation", "longName": "995210701 - Disclosure - Stock-based compensation", "shortName": "Stock-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://sagimetbiosciences.com/role/DisclosureRelatedParties", "longName": "995210801 - Disclosure - Related parties", "shortName": "Related parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of significant accounting policies (Policies)", "shortName": "Summary of significant accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "sgmt:ReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "sgmt:ReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of significant accounting policies (Tables)", "shortName": "Summary of significant accounting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables", "longName": "99930303 - Disclosure - Fair value measurements and fair value of financial instruments (Tables)", "shortName": "Fair value measurements and fair value of financial instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "longName": "99930403 - Disclosure - Prepaid expenses and other current assets (Tables)", "shortName": "Prepaid expenses and other current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "99930503 - Disclosure - Accrued expenses and other current liabilities (Tables)", "shortName": "Accrued expenses and other current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationTables", "longName": "99930703 - Disclosure - Stock-based compensation (Tables)", "shortName": "Stock-based compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role":

"http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails", "longName": "99940101 - Disclosure - Description of Business and Basis of Presentation (Details)", "shortName": "Description of Business and Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_1_31_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_cV5Yd-rJdEekf7TEOw3RBw", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "unique": true } }, "R26": { "role": "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "longName": "99940201 - Disclosure - Summary of significant accounting policies (Details)", "shortName": "Summary of significant accounting policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "Duration_7_18_2023_To_7_18_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_AbWIP4lOxkukOssBxO3CuQ", "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_18_2023_To_7_18_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_AbWIP4lOxkukOssBxO3CuQ", "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEpsDetails", "longName": "99940202 - Disclosure - Summary of significant accounting policies - EPS (Details)", "shortName": "Summary of significant accounting policies - EPS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveDetails", "longName": "99940203 - Disclosure - Summary of significant accounting policies - Dilutive (Details)", "shortName": "Summary of significant accounting policies - Dilutive (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsWarrantsDetails", "longName": "99940301 - Disclosure - Fair value measurements and fair value of financial instruments - Warrants (Details)", "shortName": "Fair value measurements and fair value of financial instruments - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_sgmt_SeriesCommonStockWarrantsMember_E5U8sJc8h0SWwuWQIGapbQ", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_sgmt_SeriesCommonStockWarrantsMember_E5U8sJc8h0SWwuWQIGapbQ", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails", "longName": "99940302 - Disclosure - Fair value measurements and fair value of financial instruments - Fair value (Details)", "shortName": "Fair value measurements and fair value of financial instruments - Fair value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "99940401 - Disclosure - Prepaid expenses and other current assets (Details)", "shortName": "Prepaid expenses and other current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "sgmt:PrepaidClinicalExpensesCurrent", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "sgmt:PrepaidClinicalExpensesCurrent", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "99940501 - Disclosure - Accrued expenses and other current liabilities (Details)", "shortName": "Accrued expenses and other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_LXp57zIQPkyWFLE9SOxtTA", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLicensesDetails", "longName": "99940601 - Disclosure - Commitments and contingencies - Licenses (Details)", "shortName": "Commitments and contingencies - Licenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "sgmt:MaximumAggregateDevelopmentAndCommercialMilestonePaymentsEligibleToReceive", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLeaseDetails", "longName": "99940602 - Disclosure - Commitments and contingencies - Lease (Details)", "shortName": "Commitments and contingencies - Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_3_12_2019_nx_SsGEpkEC6yqC5ppx3Ew", "name": "us-gaap:NetRentableArea", "unitRef": "Unit_Standard_sqft_jSPjMxXjwEG2A3mkPJ0gCw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_3_12_2019_nx_SsGEpkEC6yqC5ppx3Ew", "name": "us-gaap:NetRentableArea", "unitRef": "Unit_Standard_sqft_jSPjMxXjwEG2A3mkPJ0gCw", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails", "longName": "99940701 - Disclosure - Stock-based compensation (Details)", "shortName": "Stock-based compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_7_13_2023_us-gaap_PlanNameAxis_sgmt_EquityIncentivePlan2023Member_R85u-8o_fkaOxckJuGOl-w", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_7_13_2023_us-gaap_PlanNameAxis_sgmt_EquityIncentivePlan2023Member_R85u-8o_fkaOxckJuGOl-w", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails", "longName": "99940702 - Disclosure - Stock-based compensation - Expense (Details)", "shortName": "Stock-based compensation - Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "longName": "99940703 - Disclosure - Stock-based compensation - Stock options (Details)", "shortName": "Stock-based compensation - Stock options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_12_31_2023_1g_9rpVjeEu3T5wGtREDqw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_y4BIwgLjEUS86xDidR1UWQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_a4pmSdfqmE2XmPpQHDex-w", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "unique": true } }, "R38": { "role": "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "longName": "99940704 - Disclosure - Stock-based compensation - Restricted Stock Units (Details)", "shortName": "Stock-based compensation - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sj6DZ4edJ0CfWZwxyUUQMQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_sj6DZ4edJ0CfWZwxyUUQMQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails", "longName": "99940705 - Disclosure - Stock-based compensation - Fair value input (Details)", "shortName": "Stock-based compensation - Fair value input (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y0UGxGKnXk-jSQWeo4Z0sw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "Unit_Standard_pure_ZBwXKiRnlEeDbtnRvafpxA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y0UGxGKnXk-jSQWeo4Z0sw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "Unit_Standard_pure_ZBwXKiRnlEeDbtnRvafpxA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails", "longName": "99940801 - Disclosure - Related parties (Details)", "shortName": "Related parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_svFEmHBWo0u0SjZTyM8pPA", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil":

"false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_sgmt_AscletisBioscienceCo.LtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_g2cjKh8G-kG-JsIRdnqIPg", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_eAjGGnh4GEqes5Z6ltzw5g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "sgmt-20240930x10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of significant accounting policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r34", "r545"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Accretion of discount on marketable securities, net", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r57"] }, "sgmt_AccruedClinicalCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "AccruedClinicalCostsCurrent", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued clinical costs current. This amount is expected to be consumed within one year or the normal operating cycle, if longer.", "label": "Accrued Clinical Costs Current", "terseLabel": "Accrued clinical costs" } } }, "auth_ref": [] }, "sgmt_AccruedGeneralAdministrativeCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "AccruedGeneralAdministrativeCostsCurrent", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of current accrued general and administrative costs. This amount is expected to be consumed within one year or the normal operating cycle, if longer.", "label": "Accrued General & Administrative Costs, Current", "terseLabel": "Accrued general and administrative costs" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities (includes nil and $31 payable to related parties as of September 30, 2024 and December 31, 2023, respectively)", "totalLabel": "Total", "verboseLabel": "Accrued expenses and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r36"] }, "sgmt_AccruedResearchLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "AccruedResearchLiabilityCurrent", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued research liability current. This amount is expected to be consumed within one year or the normal operating cycle, if longer.", "label": "Accrued Research Liability, Current", "terseLabel": "Accrued research and development costs" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r12", "r13", "r50", "r89", "r392", "r410", "r411"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r6", "r13", "r292", "r295", "r339", "r406", "r407", "r659", "r660", "r661", "r665", "r666", "r667", "r668"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r596"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r45", "r545", "r758"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r424", "r665", "r666", "r667", "r668", "r733", "r759"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r609"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r609"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r609"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r609"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r27", "r28", "r240"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Issuance costs related to sale of Series A common stock", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r7", "r63"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r642"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r568", "r578", "r588", "r620"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r571", "r581", "r591", "r623"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r643"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r609"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r616"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r572", "r582", "r592", "r616", "r624", "r628", "r636"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r634"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r269", "r275"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r133"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r20"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive securities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r20"] }, "sgmt_AscletisBioscienceCo.LtdMember": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "AscletisBioscienceCo.LtdMember", "presentation": [

"http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLicensesDetails", "http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Ascletis BioScience Co. Ltd, a subsidiary of Ascletis Pharma Inc. (Ascletis Pharma), biotechnology company incorporated in the Cayman Islands and headquartered in Hangzhou, China and a Company investor.", "label": "Ascletis BioScience Co. Ltd [Member]", "terseLabel": "Ascletis" } } }, "auth_ref": [] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Asset-Backed Securities [Member]", "terseLabel": "Asset-backed securities", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": ["r528", "r546", "r683", "r688", "r689"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r71", "r78", "r85", "r106", "r136", "r140", "r144", "r145", "r181", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r287", "r289", "r326", "r386", "r458", "r518", "r519", "r545", "r559", "r702", "r703", "r745"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r82", "r91", "r106", "r181", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r287", "r289", "r326", "r545", "r702", "r703", "r745"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "verboseLabel": "Total assets fair value", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r302", "r303", "r534"] }, "sgmt_AtMarketArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "AtMarketArrangementMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to arrangement to sell stock under At the Market conditions.", "label": "At The Market Arrangement [Member]", "terseLabel": "At market arrangement" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r154"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r631"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r632"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r627"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r627"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r627"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r627"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r627"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r627"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r630"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r629"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r628"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r628"] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Reported Value Measurement [Member]", "terseLabel": "Amortized cost", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": ["r29", "r30"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r16", "r84", "r509"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents fair value", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r735", "r736"] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash and cash equivalents and marketable securities", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r658"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r16", "r54", "r104"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r54"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r607"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r604"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r602"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r79", "r86", "r87", "r88", "r106", "r127", "r128", "r130", "r132", "r138", "r139", "r181", "r205", "r207", "r208", "r209", "r212", "r213", "r218", "r219", "r221", "r222", "r224", "r326", "r416", "r417", "r418", "r419", "r424", "r425", "r426", "r427", "r428",

"r429", "r430", "r431", "r432", "r433", "r434", "r435", "r446", "r467", "r489", "r500", "r501", "r502", "r503", "r504", "r647", "r663", "r669"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsWarrantsDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r23"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsWarrantsDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r225"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants issued (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r608"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r608"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r61", "r204", "r553", "r554", "r555", "r556"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 6)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r40", "r72", "r388", "r445"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r60", "r196", "r197", "r505", "r697", "r699"] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Series A Common Stock", "verboseLabel": "Common Class A", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": ["r759"] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Common Class B [Member]", "terseLabel": "Series B Common Stock", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": ["r759"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance (in shares)", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r549", "r550", "r551", "r553", "r554", "r555", "r556", "r665", "r666", "r668", "r733", "r757", "r759"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r44", "r446"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r44", "r446", "r464", "r759", "r760"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r44", "r390", "r545"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r613"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r612"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r614"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r611"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r14", "r95", "r97", "r101", "r383", "r399", "r400"] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r528", "r530", "r534", "r546", "r548", "r756"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLicensesDetails", "http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "auth_ref": ["r109", "r110", "r214", "r220", "r346", "r364", "r385", "r511", "r513"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terseLabel": "Deferred financing costs included in accounts payable and accrued expenses", "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction." } } }, "auth_ref": ["r17", "r18", "r19"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of marketable securities, available-for-sale", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r690"] }, "us-gaap_DeferredCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCurrent", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Current", "terseLabel": "Deferred financing costs", "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r657"] }, "sgmt_DeferredOfferingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "DeferredOfferingCostsCurrent", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of offering costs received earlier, remained as of balance sheet date.", "label": "Deferred Offering Costs, Current", "terseLabel": "Accrued deferred offering costs" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-based compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r238", "r242", "r270", "r271", "r273", "r532"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri":

```
"http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-based compensation" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r563" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r595" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r606" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net loss per share attributable to common stockholders" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEpsDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r102", "r116", "r117", "r118", "r119", "r120", "r121", "r125", "r127", "r130", "r131", "r132", "r135", "r283", "r286", "r299", "r300", "r384", "r401", "r515" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEpsDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r102", "r116", "r117", "r118", "r119", "r120", "r121", "r127", "r130", "r131", "r132", "r135", "r283", "r286", "r299", "r300", "r384", "r401", "r515" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net loss per share and reclassification of common stock", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r20", "r21", "r134" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll-related costs", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Stock-based compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Remaining weighted-average period for unrecognized compensation cost", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r272" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement, Excludes share and unit options." } } }, "auth_ref": [ "r732" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r732" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails", "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "sgmt_EmployeeStockPurchasePlan2023Member": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "EmployeeStockPurchasePlan2023Member", "presentation": [ "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 2023 Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan 2023 [Member]", "verboseLabel": "Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r561" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r561" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r646" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r561" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r645" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r561" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r561" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
```

"http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r561"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r561"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r600"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r641"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r641"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r641"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r80", "r98", "r99", "r100", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r137", "r182", "r183", "r192", "r226", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r339", "r397", "r406", "r407", "r408", "r424", "r489"] }, "sgmt_EquityIncentivePlan2023Member": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "EquityIncentivePlan2023Member", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Equity Incentive Plan 2023.", "label": "Equity Incentive Plan 2023 [Member]", "terseLabel": "2023 Equity incentive plan" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r610"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r568", "r578", "r588", "r620"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r565", "r575", "r585", "r617"] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimated Fair Value", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": ["r215", "r325", "r524", "r525"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r616"] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of stock warrant liability", "verboseLabel": "Change in fair value of stock warrant liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r0", "r5"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value on a recurring basis", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r302", "r303", "r316", "r534"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r302", "r303", "r316", "r534"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r304", "r305", "r306", "r537"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r304", "r305", "r306", "r537"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r307", "r308", "r309", "r310", "r311", "r312", "r317", "r535"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r307", "r308", "r309", "r310", "r311", "r312", "r317", "r535"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r215", "r230", "r231", "r232", "r233", "r234", "r235", "r301", "r303", "r304", "r305", "r306", "r315", "r316", "r318", "r351", "r352", "r353", "r524", "r525", "r528", "r529", "r530", "r534", "r537"] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": ["r215", "r524", "r525"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r302", "r303", "r304", "r306", "r534", "r738", "r741"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair value measurements and fair value of financial instruments" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurements and fair value of financial instruments", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r311", "r313", "r314", "r315", "r318", "r319", "r320", "r321", "r322", "r382", "r534", "r538"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r215", "r230", "r235", "r303", "r316", "r351", "r528", "r529", "r530", "r534"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r215", "r230", "r235", "r303", "r304", "r316", "r352", "r524", "r525", "r528", "r529", "r530", "r534"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r302", "r303", "r304", "r306", "r534", "r738", "r741"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r215", "r230", "r231", "r232", "r233", "r234", "r235", "r301", "r303", "r304", "r305", "r306", "r315", "r316", "r318", "r351", "r352", "r353", "r524", "r525", "r528", "r529", "r530", "r534", "r537"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r534", "r735", "r736", "r737", "r738", "r739", "r741"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r217", "r223", "r297", "r323", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r398", "r521", "r534", "r535", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r546", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r690", "r691", "r692", "r693", "r734", "r737", "r738", "r739", "r740", "r741"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r572", "r582", "r592", "r624"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype":

"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r572", "r582", "r592", "r624"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r572", "r582", "r592", "r624"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r572", "r582", "r592", "r624"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r572", "r582", "r592", "r624"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r605"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r52", "r469"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r52"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r193", "r194", "r195", "r308", "r312", "r317", "r403", "r405", "r474", "r508", "r536", "r755"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r194", "r195", "r308", "r312", "r317", "r403", "r405", "r474", "r508", "r536", "r755"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses and other current liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r648", "r662"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) In Stockholders' Deficit", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Temporary Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r572", "r582", "r592", "r616", "r624", "r628", "r636"] }, "sgmt_InducementGrantsOutsideOf2023PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "InducementGrantsOutsideOf2023PlanMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Inducement grants granted outside of the 2023 Plan.", "label": "Inducement Grants Outside of 2023 Plan [Member]", "terseLabel": "2024 Inducement Grants" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r634"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r564", "r640"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r564", "r640"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r564", "r640"] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndOtherIncome", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Interest and Other Income", "terseLabel": "Interest income and other, net", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure", "terseLabel": "Marketable securities", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r735", "r736", "r740"] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLeaseDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r743"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r11", "r35", "r36", "r37", "r38", "r39", "r40", "r41", "r106", "r181", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r288", "r289", "r290", "r326", "r444", "r516", "r559", "r702", "r745", "r746"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r49", "r73", "r394", "r545", "r664", "r694", "r742"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders' equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r37", "r83", "r106", "r181", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r288", "r289", "r290", "r326", "r545", "r702", "r745", "r746"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "sgmt_LongTermMarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "LongTermMarketableSecuritiesMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining Long-term marketable securities.", "label": "Long-term marketable securities [Member]", "terseLabel": "Long-term" } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLicensesDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "terseLabel": "Commitments and contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r198", "r199", "r200", "r203", "r276", "r523", "r700", "r701"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLicensesDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r198", "r199", "r200", "r203", "r276", "r523", "r700", "r701"] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Short-term marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r656"] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Noncurrent", "terseLabel": "Long-term marketable securities", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": ["r656"] }, "sgmt_MaximumAggregateDevelopmentAndCommercialMilestonePaymentsEligibleToReceive": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "MaximumAggregateDevelopmentAndCommercialMilestonePaymentsEligibleToReceive", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLicensesDetails", "http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of maximum aggregate development and commercial milestone payments eligible to receive.", "label": "Maximum Aggregate Development and Commercial Milestone Payments Eligible to Receive", "terseLabel": "Maximum eligible development and commercial milestone payments" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r199", "r200", "r201", "r202", "r237", "r276", "r306", "r380", "r402", "r404", "r412", "r436", "r437", "r495", "r496", "r497", "r498", "r499", "r506", "r507", "r520", "r526", "r531", "r537", "r538", "r542", "r543", "r547", "r704", "r747", "r748", "r749", "r750", "r751", "r752"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",

"localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r608"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r608"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r199", "r200", "r201", "r202", "r237", "r276", "r306", "r380", "r402", "r404", "r412", "r436", "r437", "r495", "r496", "r497", "r498", "r499", "r506", "r507", "r520", "r526", "r531", "r537", "r538", "r542", "r547", "r704", "r747", "r748", "r749", "r750", "r751", "r752"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r627"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r705"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r635"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r609"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r103"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r103"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r54", "r55", "r57"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEpsDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r51", "r57", "r74", "r81", "r94", "r96", "r100", "r106", "r114", "r116", "r117", "r118", "r119", "r120", "r123", "r124", "r129", "r181", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r283", "r286", "r300", "r326", "r396", "r466", "r487", "r488", "r557", "r702"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEpsDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEpsDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "auth_ref": [] }, "us-gaap_NetRentableArea": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetRentableArea", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLeaseDetails"], "lang": { "en-us": { "role": { "label": "Net Rentable Area", "terseLabel": "Rented area (in square feet)", "documentation": "Net rentable area for properties owned." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New accounting pronouncements not yet adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "sgmt_NonCashOperatingLeaseExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "NonCashOperatingLeaseExpenses", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of non-cash operating lease expenses.", "label": "Non Cash Operating Lease Expenses", "terseLabel": "Non-cash operating lease expense" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r608"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r572", "r582", "r592", "r616", "r624"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r599"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r598"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r616"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r635"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r635"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r77", "r517", "r671", "r672", "r673", "r674", "r675"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLeaseDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r337", "r544"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r336"] }, "sgmt_OperatingLeasePaymentsPerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "OperatingLeasePaymentsPerMonth", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLeaseDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of operating lease payments per month.", "label": "Operating Lease Payments Per Month", "terseLabel": "Monthly lease payments" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r335"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Description of Business and Basis of Presentation" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Business and Basis of Presentation", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r33", "r69", "r413", "r414"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r90", "r545"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Net unrealized income on marketable securities", "verboseLabel": "Unrealized gain (loss) on investments in marketable securities", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair

value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r92", "r93", "r180"] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"], "lang": { "en-us": { "role": { "label": "Other Current Assets [Text Block]", "terseLabel": "Prepaid expenses and other current assets", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r36", "r545"] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Accrued expenses and other current liabilities", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": ["r36", "r39", "r696"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r53"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r608"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r570", "r580", "r590", "r622"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r573", "r583", "r593", "r625"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r573", "r583", "r593", "r625"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r597"] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Financing Costs", "negatedLabel": "Payment of financing costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": ["r15"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r15"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r676"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r607"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r607"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r599"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r616"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r609"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r598"] }, "sgmt_PerformanceBasedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "PerformanceBasedStockOptionsMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to performance-based stock options.", "label": "Performance-Based Stock Options [Member]", "terseLabel": "Performance-based options" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r600"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r644"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r599"] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": ["r324"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r43", "r218"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r43", "r446"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r43", "r218"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r43", "r446", "r464", "r759", "r760"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Undesignated preferred stock, $0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r43", "r389", "r545"] }, "sgmt_PrepaidClinicalExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "PrepaidClinicalExpensesCurrent", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of prepaid clinical expenses current.", "label": "Prepaid Clinical Expenses Current", "terseLabel": "Prepaid clinical expenses" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r658"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r510", "r522", "r695"] }, "sgmt_PrepaidResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "PrepaidResearchAndDevelopment", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Research And Development", "terseLabel": "Prepaid research and development" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollaborators": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromCollaborators", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLicensesDetails", "http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Collaborators", "terseLabel": "Amount received as reimbursement", "documentation": "Cash received from collaborators during the current period." } } }, "auth_ref": ["r56"] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from initial public offering, net of underwriters' commissions and discounts", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": ["r3"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of Series A common stock, net of issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r3"] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Sales and maturities of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r3", "r10"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":

"Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r597"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r597"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r199", "r200", "r201", "r202", "r229", "r237", "r265", "r266", "r267", "r276", "r306", "r354", "r363", "r380", "r402", "r404", "r412", "r436", "r437", "r495", "r496", "r497", "r498", "r499", "r506", "r507", "r520", "r526", "r531", "r537", "r538", "r542", "r543", "r547", "r551", "r698", "r704", "r738", "r748", "r749", "r750", "r751", "r752"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r199", "r200", "r201", "r202", "r229", "r237", "r265", "r266", "r267", "r276", "r306", "r354", "r363", "r380", "r402", "r404", "r412", "r436", "r437", "r495", "r496", "r497", "r498", "r499", "r506", "r507", "r520", "r526", "r531", "r537", "r538", "r542", "r543", "r547", "r551", "r698", "r704", "r738", "r748", "r749", "r750", "r751", "r752"] }, "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationsOfTemporaryToPermanentEquity", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "label": "Reclassifications of Temporary to Permanent Equity", "terseLabel": "Conversion of redeemable convertible preferred stock to Series A and Series B common stock", "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2." } } }, "auth_ref": ["r62", "r70"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r565", "r575", "r585", "r617"] }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableConvertiblePreferredStockMember", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable convertible preferred stock", "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer." } } }, "auth_ref": [] }, "sgmt_RedeemablePreferredStockWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "RedeemablePreferredStockWarrantMember", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to redeemable preferred stock warrant.", "label": "Redeemable Preferred Stock Warrant [Member]", "terseLabel": "Redeemable convertible preferred stock warrant" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "terseLabel": "Related Party, Type [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r149", "r236", "r343", "r344", "r387", "r395", "r439", "r440", "r441", "r442", "r443", "r463", "r465", "r494"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r107", "r108", "r343", "r344", "r345", "r346", "r387", "r395", "r439", "r440", "r441", "r442", "r443", "r463", "r465", "r494"] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "License agreement payments", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r32", "r343"] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related parties", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r149", "r470", "r471", "r474"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related parties" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "terseLabel": "Related Party, Type [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r149", "r236", "r343", "r344", "r387", "r395", "r439", "r440", "r441", "r442", "r443", "r463", "r465", "r494", "r744"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureRelatedParties"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related parties", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r340", "r341", "r342", "r344", "r347", "r421", "r422", "r423", "r472", "r473", "r474", "r492", "r493"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLicensesDetails", "http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "auth_ref": ["r109", "r110", "r214", "r220", "r346", "r364", "r385", "r512", "r513"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r277", "r508", "r518", "r753"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "verboseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r566", "r576", "r586", "r618"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r567", "r577", "r587", "r619"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r574", "r584", "r594", "r626"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units", "verboseLabel": "Restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r46", "r63", "r393", "r409", "r411", "r420", "r447", "r545"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r80", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r182", "r183", "r192", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r291", "r293", "r294", "r296", "r298", "r333", "r334", "r406", "r408", "r424", "r759"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLicensesDetails", "http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "License revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r75", "r76", "r136", "r141", "r142", "r143", "r145", "r146", "r147", "r148", "r227", "r228", "r381"] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer." } } }, "auth_ref": ["r527"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "auth_ref": [] }, "sgmt_ReverseStockSplit": { "xbrltype": "textBlockItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "ReverseStockSplit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for Reverse stock split.", "label": "Reverse Stock Split", "terseLabel": "Reverse stock split" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureCommitmentsAndContingenciesLeaseDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations", "verboseLabel": "Change in operating lease liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r338", "r544"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r635"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r635"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities

[Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r20"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r20"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted loss per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r670"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r26"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r26"] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock unit activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": ["r66"] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://sagimetbiosciences.com/role/DisclosureRelatedPartiesDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r31", "r32", "r470", "r471", "r474"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r239", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of option activity transactions", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r8", "r9", "r65"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of fair value assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r68"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r560"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r562"] }, "sgmt_SeriesCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "SeriesCommonStockWarrantsMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsWarrantsDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Series A common stock warrants", "label": "Series A Common Stock Warrants [Member]", "verboseLabel": "Series A common stock warrant" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r532"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited/expired (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r259"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, forfeited/expired (in dollars per shares)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r259"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r257"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, granted (in dollars per shares)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r257"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r254", "r255"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant date fair value, ending (in dollars per shares)", "periodStartLabel": "Weighted average grant date fair value, beginning (in dollars per shares)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r254", "r255"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested/released (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r258"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r258"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype":

"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r266"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r267"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stock-based compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r239", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in future issuance (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Available for grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r24"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Term and Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Shares vested and exercisable at the end", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r248"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested and Exercisable at the end (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r248"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r261"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options forfeited/expired", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r252"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r250"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r260"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r24"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r246", "r247"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Balance at the end (in dollars per share)", "periodStartLabel": "Balance at the beginning (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r246", "r247"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Annual increase in reserved shares (as a percent)", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationExpenseDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268"] }, "us-

gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r251"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options forfeited/expired (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r252"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Options granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r250"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Contractual term", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r533"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationFairValueInputDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r264"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r24"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r67"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Share price (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "sgmt_ShortTermMarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "ShortTermMarketableSecuritiesMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining short-term marketable securities.", "label": "Short-term marketable securities [Member]", "terseLabel": "Short-term" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r58", "r105"] }, "sgmt_SignificantAccountingPolicyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "SignificantAccountingPolicyLineItems", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Significant Accounting Policy [Line Items]", "terseLabel": "Summary of significant accounting policies" } } }, "auth_ref": [] }, "sgmt_SignificantAccountingPolicyTable": { "xbrltype": "stringItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "SignificantAccountingPolicyTable", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "This table contain the information pertaining to significant accounting policies.", "label": "Significant Accounting Policy [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationDetails", "http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r79", "r86", "r87", "r88", "r106", "r127", "r128", "r130", "r132", "r138", "r139", "r181", "r205", "r207", "r208", "r209", "r212", "r213", "r218", "r219", "r221", "r222", "r224", "r326", "r416", "r417", "r418", "r419", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r446", "r467", "r489", "r500", "r501", "r502", "r503", "r504", "r647", "r663", "r669"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r44", "r47", "r48", "r80", "r98", "r99", "r100", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r137", "r182", "r183", "r192", "r226", "r278", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r339", "r397", "r406", "r407", "r408", "r424", "r489"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r111", "r112", "r113", "r137", "r334", "r381", "r415", "r435", "r438", "r439", "r440", "r441", "r442", "r443", "r446", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r465", "r468", "r469", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r552"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT))" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets", "http://sagimetbiosciences.com/role/StatementCondensedBalanceSheetsParenthetical", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r111", "r112", "r113", "r137", "r149", "r334", "r381", "r415", "r435", "r438", "r439", "r440", "r441", "r442", "r443", "r446", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r465", "r468", "r469", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r552"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r569", "r579", "r589", "r621"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "verboseLabel": "Shares issued upon conversion (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r7", "r22", "r44", "r47", "r63", "r216"] }, "sgmt_StockIssuedDuringPeriodSharesConversionOfStock": { "xbrltype": "sharesItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "StockIssuedDuringPeriodSharesConversionOfStock", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of stock.", "label": "Stock Issued During Period, Shares, Conversion of Stock", "terseLabel": "Conversion of redeemable convertible preferred stock to Series A and Series B common stock (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued (in shares)", "verboseLabel": "Sale of Series A common stock, net of issuance costs (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r43", "r44", "r63", "r416", "r489", "r501"] }, "sgmt_StockIssuedDuringPeriodSharesReclassification": { "xbrltype": "sharesItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "StockIssuedDuringPeriodSharesReclassification", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Number of shares reclassified as common stock to series A common stock.", "label": "Stock Issued during Period, Shares Reclassification", "terseLabel": "Reclass of common stock to Series A common stock (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of Series A Common Stock for vesting of restricted stock units (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r7", "r43", "r44", "r63"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails",

"http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised", "verboseLabel": "Issuance of Series A Common Stock upon exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r7", "r43", "r44", "r63", "r251"] }, "sgmt_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Exercise of common stock warrants (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Sale of Series A common stock, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r43", "r44", "r63", "r424", "r489", "r501", "r558"] }, "sgmt_StockIssuedDuringPeriodValueReclassification": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "StockIssuedDuringPeriodValueReclassification", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Amount of shares reclassified as common stock to series A common stock.", "label": "Stock Issued during Period Value Reclassification", "terseLabel": "Reclass of common stock to Series A common stock" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of Series A Common Stock for vesting of restricted stock units", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r25", "r43", "r44", "r63"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Issuance of Series A Common Stock upon exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r7", "r44", "r47", "r48", "r63"] }, "sgmt_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Exercise of common stock warrants" } } }, "auth_ref": [] }, "sgmt_StockSalesArrangementMaximumValueOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "StockSalesArrangementMaximumValueOfShares", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "documentation": "Total value of shares that may be sold under the stock sales arrangement.", "label": "Stock Sales Arrangement, Maximum Value Of Shares", "terseLabel": "Maximum value of sales under the arrangement" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r44", "r47", "r48", "r59", "r448", "r464", "r490", "r491", "r545", "r559", "r664", "r694", "r742", "r759"] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' equity, $0.0001 par value:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r64"] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": ["http://sagimetbiosciences.com/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Organization and description of business", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental non-cash investing and financing activities:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r615"] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Ending balance, Temporary equity", "periodStartLabel": "Beginning balance, Temporary equity", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r205", "r207", "r208", "r209", "r212", "r213", "r274", "r391"] }, "us-gaap_TemporaryEquityNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityNetIncome", "crdr": "credit", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "label": "Temporary Equity, Net Income", "terseLabel": "Net loss", "documentation": "The portion of net income or loss attributable to temporary equity interest." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesOutstanding", "presentation": ["http://sagimetbiosciences.com/role/StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTemporaryEquity"], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Ending balance, Temporary equity (in shares)", "periodStartLabel": "Beginning balance, Temporary equity (in shares)", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r42"] }, "sgmt_TimeBasedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://sagimetbiosciences.com/20240930", "localname": "TimeBasedStockOptionsMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to time-based stock options.", "label": "Time Based Stock Options [Member]", "terseLabel": "Time-based options" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r607"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r614"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r634"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r636"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://sagimetbiosciences.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r217", "r223", "r297", "r323", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r398", "r534", "r535", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r546", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r690", "r691", "r692", "r693", "r734", "r737", "r738", "r739", "r740", "r741"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r637"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r638"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r638"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r636"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r636"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r639"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r637"] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "Agency securities", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to,

Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r514", "r528", "r754"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsFairValueDetails"], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r514", "r528", "r530", "r534", "r754"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r633"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r603"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r549", "r550", "r553", "r554", "r555", "r556"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEpsDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares outstanding, diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r126", "r132"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://sagimetbiosciences.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEpsDetails", "http://sagimetbiosciences.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding, basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r125", "r132"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r601"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r60": {

"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" },

"r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r445": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",

"Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r647": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405/tableOfContent" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic":

"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 59 0001558370-24-015623-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-015623-xbrl.zip M4$L#!!0 (Y ;EF" \P000P 1X 1 E,T6#.Z$&&A9()OLT)6P!JO&%D>1. M)[^?(!D&&^,;IA,RZZJI-%CGJN_XZ.B"YMVO3Y;)'@GCU+%O:^U&JX:(K3L& MM=>W-5>LZF]KO[!_UT_O_EVO?[F;C9#AZ*Y%;(%T1K @!OI*Q08MG.T6VVA, M&*.FB>X8-=8$H7:K\;:1:EQ?H7K]O9)OASGP.#92PCJ-=M#0]\4Y]@UJMYOM M;K/3ZKQ&W9L._/<&3<]-LR-"$&J&SK7Y#=BR4_KUZ]?&UV[#86M0U&HWOXQ'6#N/36A0M@6$G(FZ>-X2OB-?8;Y4DG=-$0:#;!G192]'K%%*?'NN MF\PQ27-/&?#J+F/01<_'30M:H^H$2]$#K0$A(ZM$PC=-:-WU(S08(FJ"3W25 M]!IWI&:BR&[SRXC:?P;4+J^O,=[&,]%OB/CDIOKD[GWB5#_>5= 015%L60(E MM$1(3: ZQ2O9O(37:P>9X]"2'F-4;D$]NU.L=ZM]-JDB=!;$Z7)JE+,L*P M@(3!ZQV9,'8=*8/G2#@&+1%M-J8Z/VZ<:HH2Y5LT"R!_^PI_PWKGU]?=U4 MK2&C$]ZAH.4PI@_H(]9 -%[MT[^PZSTQJDX72 MP=%$$(7X2=\<[W/9$DLQ"7CNFB(,.:+EOBMH2B!3FPL,Z7B?/FEV^JP?)Q++18WC_$T]J!,.V[0CUJLE' MPJ/?0 MU]#\HZ8MYN^:AQ(,9+N@?6*_5Y]AB.(@3O6.3,@^LT^2PJAC4W?-XGQ[LQ+9 M_(X)GZPFVR3]VRC[UC0)QN9IQ_)R.&)^!60D EN)P7<^:*WT,:: MPV*.)O=H,M5FO<5P\C!'O8OO =4W=8OK>YA2:GDU9=JQ4(M[W2@K:^D@ON,<&O;_CMF M##!(2@UGDIH5*]WX*"UH>IEDAW:HV6.W;()16@0&([BT "8$150"]9 #M MFL\:03&QV2$4&W/*AU!(0A5$>8(9G\6%0'&?4=E=:,"&E#ZBNMH=2(B3 IO9 MH? FGDU"TA7\>E@^M IQ%F@_G)D I&X,%"!=S)X_@YA(0P/M><+*AC$\+D]"$28 GO *U!*CJZ40ML"1,_G(S9L.;?QG/;T*.IZ("N03(,P(E M"]6%OTS_"0PL!G::@&S07Q< ?:_)QU_IJM O@?ZN4![:6U<4POTX:S;B5P40M#U705&JIL,Z%]8R8\BSV%+.4LSW'B;+P>QLOJ'Q!:,.M)JC#Z7ANWN0Z+O)B^_M^)NVR4=-7F[3-F)D%9'GV?&7%2?MLVSU54"77O8_;9T_&]Y2>WH5KN=? M@SW3FFLV\N=?IZ_"H>0Q_U/.IV<#7>9D?P7I.<[SGWR0/QO1C6+178X*M,)K*_F64;*A*K"'4:&4>U4D?3DD&Y7LA9 *C-)SD')SD7QS_MDNM.R1-GKP(]U8)7><03#H@7X4U'NUOR:%EUA/SE9J+'P2\G+"L:NO%H*'OR MIPJ1,\U.C\=# H5[N(!]D MU*1S0GG9LH_PO>]YS"-\4O[_R]:E_$=.'F=DA=3]8S?RFK#:&]?6UI175JEG M&W43GKRXJA[<3/4'N-IXLLR1(I/N3I+1<5A[_B* Q&8Z3$IL?O10(BS)6I6 MU0R,KZ'FN;P"'(IZ=0#=!3H%05+4J6A<7:!/)EX6]0E8B/FB[I1>/()\A)DA M,Y[+A6/UGB@?.!:FMG]MW9$#.=DLZ3E2_8S_8$G)DXE */*D(BD6>7)1(/B?MF1G?-0^NLO,?1"Z\4]?=4?D;<('LZ/VM_."*RFXX0=3;C78->=>_CAQ=/=NS M'<1MG+4!:OV@2['@^#V+24J5PAA]DP# ZCY%^:VXWN@=I?ETAWD\_<'-AB?; M(*'EY8U08HI9D79[Y#%+CK+(;[O((^OR4;W=]7?SQT'6#9UY+#$9BW!),ZZE M'>TWI]EQ]#+27._$$4[UG>H]K]JZV5^MO:@V/+&P3]ZR+MM2K?@UFB-US* MRN&/##]O[E WP-Y8C@W%/WL>"F+)@0&,=Y=<4.%*TS\PQ]T&I!1(:LBFIBGG M@K\]&YN DJRE#?\)+GK M+TKT8>22Q]@"!_QI<,C?+,(7=MC+6]*TO\G+O,]^AWR.)LT[+,\0&ZO,STV MQ,T&VIGN+LFP!-@>[0E>0O6B%/-\GH:(3_"V7$"G^^BOK@0!V7>X.!*VJ527 M$K,Z(T9:T/:@FB:"\KM=O=]W&B-AC(FU)"SL;0:AY_#N22FL_6O#I2+*_"R4&R.*=1, D":XF>UV**9="U/%2^<&=$) M?0R_NN<4>C&9/"M*HD-1X-&4L+%CBTVH=[((+\;CC%R^@#FP.O40_E58[)U(M;K %P)P4-=:0@]D.Y>'^)]U*RMZ3P3[^#*U&7Z1@8BH"YGJ3GXB/='S38S[FI+] 3Y690\[A=1NXLHB=*G'S#682--O_ M7T1-5HHP#&M!QDBYK(B^S1A:T'%US@&*'1-SKN8 ^P,&:6XGL%U,Z9"5]%+1 M+-X=27R7%@0# V6=K. O6)\P;THG^U$&HP_$86OR&^0BD\0RV+'&"TQ7,R+S MBE?ZS+')S7"!F\XW#Q((P:XS9G_!V@/@YT2%:R-V^>+F0A_H"O1PY]CJWDWF(+]#' MM,$QJ,]T)[F6P.7V1ZY!\PC?/V/4/*%#$ADO:=SL"2]R>]+2M6]J+[XETUQ] M:,^Q27C87F_=S#_[Z]%SB&(^GA\FI/U]C6#JW;.-T&)A?/\CB>Y2;]*.)3-_MH>$#L0G#9L^PJ$VE0#D)3U!S\%R*7T0@MP[:.'M%;[_&U!+ P04 "_ M0&Y98'#GC@4* "T>P %0 '-G;70M,C R-# Y,S!?8V%L+GAM;.5=6W/BMN!)^WZK]#UKVY9P'P-R2D,K,%@&R0Q4!"C([^S:EV)TOI99R_E,;,$CS8JQ4DX!Y1BDT3W%)L M+! -:UR5=$J[18HES][.FXAXV5L CQE]4HM^*#KJ[/)-:C5JK5&M:[5FZ!Q M7>=?%V!R'PC><]OF.%/2Q.3'M?CVR&L$'"1AUR\,?RHM'6=U7:T^/S]7GAL5 MFRYX<:U6_?M^.-.7R()E3)@#B8Y*@,M?,^_AT-:AXWDH5/SED9J!@D9U4U>B MA/BK'(B5Q:-RK5YNU"HOS"CY)HJ/2H)Q.6G,$4^A&4MOZ7?IT&MW6Y7O4]+ MGW\IX(:;)UJB.?>73NO*_2IQ+"U,H4J[]F2HCE_MK">XA5=-NJ"K%]MIC(/EI3#JGO'M7G"QO/Q"E$O0EB'&%W;6E&TY$+X"0UMMC/H/#6IXI$N9,L[_MTW[>*_B0TL/A[&&FFS9S*9I0M(+8Z+^LA&6"@+&S1+3K4LKMZS#&8[*'(C- MG*@+5G$,'W1TG;HHR<

AAH_8Q Y&NSHB?SUYO>$!AE0/O.+_NC&5<2TA#?5& MU9>H,M>RO#98QCPT2YG^#+2]LXEKU*&IN^9:5ZWB#06_O]>^MC8D.>2:??W" MG#WUI"$,Z,5!7,K8/,6.]*:=;HFQ4M-&6ST\=^[XU&O/YKU>^"V_^R,NGTP M^]+O/\QR4"(@"DIL/6*(*<9=F\9[TU,UA^S1T^>R\@+"E9<,5)'IL.")%\B> M8_T'W]>M*%]PD=D\EPG\N'WFN_W_QOEAW>J:;[,]XO&U<5E3;NJ:RVM76NVMVR&;0]'2H5'S>1 'ZOUX+A;N?I: R[@Y]DK4!LT2 M>$9XL72\3PY+AQAIQ #+?_3_/M5%0?I$U]4A^A[2'SQA>#31#.DN]3*(=()3 M2IP^L7G!^80VU"'4GP^1Q1#Q1&(JK!C/O_(@%=Y(H#2UC(]DQH^K^6&<L< MV43/W23?'IT.0<5D]-< 0U,Q/C#,'%O_L;1-;B4368'SFL!A5K'#9^!=\[*P MXZTT>$LK1#0M/HWB%B8E>LDEHN356ZVK8P:AC+-C$KR<\-1+ZZ2C,<8E9T"@ M)"KU1@6>;\X1[P372-/F6C&2:C$GR4%LSBV%3+U6)_H-FV12]U[L3'B3@[5> MD^L8!EX:,>$SO0'IPA5VA$7Q*U'QTF="81YTZB5D'5UW+>%HY"^9AS>)!D2W M+6^K:(3X;.$!OB0QG$_+N3"_!]1^1#35B8BIV"(AR.A#2G@*QT(H>VB.=9PT MT"K6(W+ MV(6-%3X3.G. 4W .LSXS(MW!)LI\'39:3>WJ1.G,@4]ZI+RIOCN,\C$'5'*=M>@N1D'IZI9YR>F7VT'GHW_='#S,PO@/C27_;>1B,1S/0&?6XV/UDVO_")0=__M]<%P/%/V>$O,G"5CKI=2ZO+2NW#+\@GSKJ^$(FCB?Y'QA6>%?,#YDV'L@OTQ>=L]MZ5#,^$<]_B=93!#%MI&!_:.]4ZL+R6 X9E@_I%O42PBXN6^S_83(B M#N1X_@U2"DGBN.8H\9?R,D52+S$+|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l'-Z!!, M:RV5CF&EK\I1:M1<,[9JE%<;)=]JK,1.I\E*K*#H]#"*4'J6,%/CW?8FFGO8 MHTN,.311QB5O'$R0FO!"328>&/8U")\C:D2O;$)^(T=_#JFMY&-^@U1$QDRO M:YY.3^\&)JQOM9!*CVB!: "5+M>2?=R%RT<#,$-9:>ZP\TPAC=<6]\UA'Y,5 M1]RK2^QSB# JS]M=K,R6GZ;FU7.AR6E7)*4 B)\05240(X0K5) $Z M7:H*EAL'FGE+%*N4K+E4-50=@*"K7%3D';Q0KD^-#3@0FL+2NNK)@2][G1KH M3M6E^#0N0 \"!4!=9I+O(.5BC7[RX&' A-86E=7>3 %]5%#72W M-\$)W1*98R\>O=# _:#8726OY+;"\0Q@@XGO(GD;-4P?AY7K;YM%9\PL^ M!O@6^L![I$Q:@[/4:% #4\F5KZ')]NJM3#+"YD%O7='W<-U1[X9PK'JEB$A< MT"/Z::M#],/O4X;]>+:-]1:L"M]V!]*K;-D51K_A>,&?2K 700N\FH:C(&9O MTT7*7F(§,RKHQRBKFB;L"4M#U9K6*=!@FE<2_$ZWVER_%3MML8ET,]AOU"$J MRAW2<&^K?U>24#%4S=GZ=K(+9'$W:6,9&?L:!UX5W9FD<^,2Y7L,MU\1>%4)L/ M()41NR$Z)I)2*0X;&B%=GW*4XD:H@ZIU];%!HZA<8O A*IB]1I51(2 Z4X#(M6'T.^MCBWKA2F0$1$Y"(H"[76(""HK9];KE@6&416#"*)@25K)6390U;0F>" M5@EQ% 2H.)P3E"66VH5(>E@Q[BM$W*IWE0.*AA5A"7!:/9F(X<\/)E9P=[KU MW 9NN$2:!RX&ET]*'M+E5],'#M[*K4?9QQ:W^K8>,X:$%A"UOO4H42AN/5K0 M.U6F[%8EHEK3"9XOE"]MY*VU[W*$_> @K')$T11#SNLZU.@$S8(G%P4.P:'$;!.V$QHOTI9M891-^S6(5LCE*;VE9IJT MK1@S5>LJ9IB.N*'!_*W:71* <\-+"6CK(CYAMS\2L=~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}3 ^DQ^+T MW%JQPBZV!!V3$^GV8/.6 9:IM* LE_8RZ"ZOB(@CECF_P"Q@<@E2IT3I',' M0\X&?#CQ),*JS)\LG@,X52[UVQ4G<>$8^?Q>YL\ ;C1[:2\,XB[$A.6F2($ ME7\SY=8@(,#[=1E%BQ:.\ P"?9GG^Y$C YLTX MB:/8"9C_W8)!.[U W"J4Y=(.)G!850@LL-RKC'JVR,*_5V&9$38@V6:X12E[MM.FF'VIB$^3-Z0!,Y\(\B/H-2=VE5<_"AUJY8[<7M7+= MN?DFE&L^RMQAAD$8P%T(F6+"$Q?7G1T4&PZ?!<#]Z'SU.GP;CF\'X<3093F`_'M#T^#X<.U;7; .!G!0EO> CH:W(V?^A2'E6 @JH>E/JK[446$.Y#ZRF9#<7C MK14QPP+:U7@C2;H[01Y"2R8GN^>"# !Y'E[#C@![89[*7 @.@(Z8\>@0=#CG MEPRVM+1HP.'[#<>+]R2*PR4B;>E1:M"SC"GT'T\>]EU}) ";C$S^!!RTP^UH MF/Q{0B]Q8Q:WBL@+=M&V@@^K^E,.W!I!X,"^C/!;2(>6$G $99.N(,N7IUN4 M%>V/YBY1@0,&402Q54V0>__FG%;.]2J0H=.+SZ M&044+9_".?26E+0,)59G6\TM;2\ YHX5O[0(P>'8 5ZFRQV(9PB#"4F7%@@ L'P;/,B.,M,G6(H89:L,0#3H!27%@0 +6NY$57(@>`QW1#R9_+NG\FF*![A_R!>-3I]C6B MA*V&?0&89>4EN$+D)>=.$_I)\>1PL^`>B1F@Z`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{G/^.O MD \\IR# 50F.!8U'!"NF64]%@<]QC/L/L=N.),++8[' E$<I+.1&UYUK'?' MEXID#E?Q<@A 0[FT=!UDV7BTY7&RTHO2 X^HX@O#FV&%Y5:RC:VVC=V#=0 UF=4 %*W>3>TWC2GD9J M!S)KZY&8+YB.5I?KKQ24VV!3W6KHQO@EO7C7%(XJ,1 ;3,NVV&-')QC&/18 M!#%GRDOF4117 [4B9IV M?3Z$ <-N@\T=)@LXLR01Y=]AYQC[7 M!V.Y,!L,@ E7MQR8(0Y9#G8-S1QL642)17*W _=W);B"H?IYIM=9<\[" NN M&HMMD 7/X 1X7X,7?3D0 +6NY$57(@>`QW1#R9 +

*6]\/A8@19=";-M% P1}?)S*1*>_M009RZMJ5$FIUZ^)RD?5<'Y!T=.,?A25599+B?*<85SVL'(MD<7K?'(^/N\]-[ADC#F1?[Y)#TXP9QN4U/IR@2%?S(A\U%Z)*\)DL'[#*!>MC"@3,J9%_ATKF:1HS=EL]XF_>(EC#;A,=(4TY?6+_7T%G,__&"\X/3Y-G^;? MYO=/CX/%S6#Q.%].GVX7]X^#Z?TU2Q;M83G_%;6_6T^N%L\]N&)I\@E^A"R M^%-NOS2^4GKFH:.071#3$Z^K6M8FR'P_NX;WT> ^&YQE{8H\$*F0<4U/3*ZM% MN@JH#DB7W=Y8$%,C)PT8HG9(!'^U"8AVAY?C M(=$P_N2/); V&##F9[=#8I$*SYWY,_9"WPQ]{35>4^;N/&2@IVG\$'CYUVT!3 M8TE\NMY+LFBF\2K22CIQ#Y4;?5!K>,.<72P!GQ%3@A*O_Z3"9LCIF-MJZO(O8A#,+F#=[=NZ=W-E=5AL0(K!3B66#WXP'IRV7=+/S!18<G>SM

*4XPMHFL<^IDGEUJ.#,; M ;RLI">=89A6#M<"?5E=?!M'<0.}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t;D0(;?P[!VW3,39IEH7DI&<*25^A5X?1+AMOQ2_^S8_8C,/NQ5S)P(,+>]1*$,W#:K"1E3+D7&9>[-[O89 MPGC[OL2]V.9RFUC)/#D(;=^:%7$98*N1!?JF#"+ MXW$R8+V_>DK]>&$$^BD-LZW6M;^(73!6N:"ASOC)V\K8H;FRKEN\,.%EMK MV5EV1H-B7"9R-W$XV)N/2B$N%5)}^T/"SF_22R<-'@=GT%V@ `+,2M]W@)N%NDSV"=R[H+6OK=0\>^]HNO.G3TD=4_5[5 M;M$^7A&94L>*,((" $MS07B)3/\B2]_<'H8Y;S!3ZFU"GPOT1WU\1DNK)[+ M67_5 X&=_+U-/R7DID#Y33=!2L& [@N&4AS,%B *R:%<4VH[9CbGO\8\%]CY MA)OT<((7[80>Q6WG*):%8>]A2+1F;$6%?D!KO#!:<]PO$W:'KSVI2P&<$*C M&,2+D!Y^V2)P<VKIS*A$X1%1K'!Z Q0#O/(F;<'9!."N!^Y*Q8 ;[M^D+A:T M!3!4]XOY-BZ7%A2]6R%'?8&P5UL$VKF&S3S/"2$>OH9 M>GHZ$DV-U$P[7C<[>+Q77@V[),'(O=!L?AWE_(R@,]3(-US/]4B]5# ^?!N38 MB-3,M PUD^^-0C/YE33QXR[!##7P[;Z3<[P@@S$@V:U&A*WK#^P2,P2,TO# MG)CE"P^WD,4)]? V3PQ^%]4&ZN;.@ZN,IY(ZHP[@TIVID7K-)^G>T*F4QWD MC)O5O9>'X,NIXK? +Z01;$'T>912$#8M0((MX@&X^U(]fIVIB>7=H2|&5O' M/B]=.F,Z@1[.1L4P22.E"3&W+=.(SV6)_!N!W^:%2%E/I99).IOC\T/-&MO$ M3P"W\=:,>H8K5 O_ SB(.F.HPV|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{YTN]S&AYT{\-YEX:X*,Y'>3). MP3_B<2Z;'"6Y%$$ +A4CP6@DEP$GYX<+]X5P6 %I(]Z>GPR/A$C_7SQQ^V M7NK0.8S!I#LT\|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d&C@]GUXSZ(,ZN\3=7A]ZM)D7?)Z,EZ?EL&JA;(90%+$#R"Z$0X#QAK V!+&.#,(U_|>+"T@D*_X6AEIQFCUL?_^:-$ ^U8(N(M1CODO=# [N4C4CS;KN;'L$_>G1^K$.$FPC@SDE&*M115$?8HBMPNX/[*OXOYT MVNDZ4T).SL?[/[>A 0?1_)\L"S.4G":[_V'_9T3'[F:6V)+SO9D>&-O HX./_M-VE'2.6WFW'[7!5)GL*S2[!&PR?]O>(Z:.]M=()EH C>4E!6#0_D'?_OY8 M[^)1DT^[2WK0*[TW|H0EI.[",37:D?IQ+Y2"XP_?)6;G4<\P7_U[^.M#+MK88\'E9@>1954X>Y9C'WTC.Q/>L4+EBL*M_3%V(H XTW.U(& 5M:)F*1B MDF5BPL1- 7/P5JL2)*&;&4D!(<=%@8$G 1L*X83O!&@6?T0 023]! MU,+Q15V.99?R+%&BK6QOWNXGTQOY."FE+O8<98_3+'VIU+(EFZN&7!K#D@>3 M4]I, NE3<(S)F@# QOD2DT?FQ*3X\1#.58? 9^2Y,^1S2:&;5=GE?TZI@!/TF MV@]E&]H"\2Z,[8@P8[-MUN7NOW_B#"">KB6^.6!G-:HE%!H3Y*7!^,K I8AF;+DGDD%;20 0^/W'VE7"=RBQIA7l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`X^Y1_+^VJ#WU)/N3/4Y!?]\W#%5QG,!T-MWL 6O& (#M%P.5/DY\^!\]236$'1AKR">9>'W8\XPKF9-M%W:#G!)P2171>BR #1U.F !!QF.H3)/E!+AKU5!0O+,&_"?AQ\L3WL1&D@<C M:U!Y1_"0P"KKGMH1":AAI#X%? %\'W53;'W;SMY"/,>"=XWV$/Q.'+!T Y"_M3(2_0L\;%=4 (/#7#R=(KPYW!Y)_80U0TW!3!M2..0$0XO:.[N8K EO/>W/ MDM!O &]O||#?L]^NAGOQ^1.OX=0Z6"AX13V"CWDEH=/HO;XE:`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t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k-M/.?1O7':HER6&-[!&#FSIK ([J4T.]-^%9@&&#OOYQ39!=TG#_FL#P&:BFOW(# M\Y]V,% IK-E3IT;DL7VSDLR!MOXX>Z9FVN MG;4T['0&A/PZ\R#7%5F-5_FO2QG;E>0YR11L[U9X%+.D55YO3.GU1!Z9!K&/ MMX4&E6D#TU:>IDE"V@DP[9#2BG80.5 MM"=+LMP%1A"T*/B?T*(5S33-MY+ M.]37H9WKBFRW8I=!=JK&MG6C_2Q#S;,\$R"QMF3*(:L$F562WXU5HFC]M*$1 M)@1QT]$("+8SG4:,X2@]GDQ0[R:$}-TKES4$G1(N M)B24^\3RO&!I1L@$@6:"[[#T8P_D)*L^7HC(\ HPM9&WJO'Q6!|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}^:KI:0H M3[\S)Y]MB_#D3D]@<(IVW+T:VP-MCY!:%+-MA9SH.F[WR!U=2>N.!OS94S(3LH;"&ON((AV_0S;NN?%F9U]<@:(33UM113B-M*0_IZ'}<2_NU6QV/]MG? O_8"]/=YH[N["QXS=!-G35N(R(*[Z!FC:05$(^1 MSHY+MG'K/<=G/XOI%TL>I+/>U8FGN1#4/#^ZX2K W9(]7<.(6\+EFP++Z7L&6>ZP!? M8GA$&"(\1/BS"$>XY06(.GX'M+ [KL!OV:!#WZ]$Y70#H!$_S:PF\7G^^1!C .;[^_$S*R$8Y 4&#@3RPP$$"9Y.Z>PPS192< >CZ;G,W=X7>O\DF M-2BQKY][<\-USS7>_#Y#&3?]Y$,XA/D MO9ZL=YH#G]U/2>Z\:P3U3QUI[+V3S=7B^WXZ8@D:;;_B8";]"<:((3'21 MB)O8=3 O-E"0$PVY*C0!%33TY;C[O>\(6DVDI4(D>%6%"!J$C/$AKTO-U< ML#N+X'G;/'1_=B9N4&:.$#&=-]PX$>H>=%U4?Z[%+P#V4ON>QLYFP$"@EM8> MUD_IH/_F?4"'N UQ>]+?V<2-F]D^U9X-(9C0W!2$G#]aX_["JF["UCW;':JZ MHKFY$P0_7BXE^A6/CZ&O =&ZZSP_M332^#l;2R(\;@:CKSR 5&_M#"4V@6X(;T#?!^%_I FVOVQE\'T-K0EQD.U M08>A0*=E%}(Z1/?1,/JCH4?916#YN(/=<;<;-\N?!H*E'B!T' .W*X1>\[*"A M" $5XNM9?.WXC/O$Z2V;<[*F+K+;,)FDBG!$#&>7 Q]1^91$? 5_50^H(-[D M:@$]W"T0[A:XQ=T"(>\U_=]H_[BR["X]MPW.'GV2AX& M8V=QR-QS.MB(FO[-$U.H#*9:DAW.#8:(>YEO_^OT/:\5 SU.H#*9:DAW.#8:(>YEO_^OT/:\5[CL1]YY%G@+R[1=.35Y(UL-MZQ+GTRR>.T;&3O)$1+320K>|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|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aI ZAQA'6/NRIVU#HU^A:.Z; S;%=L&W+ M=7[%NG3I)2&AD3SMH#IL;'O1^_M+M:++AT.URZ?8M+M_V#WN/B$(\"G.>$-MDHGBVF6YWL-(=EB_5T_5L M*5W%2O5\HUU+=T]-NCLL7A]0 H/(;W)!S-;E957>%E%]%0/S:621=*:,]#94H-)ENBZUF;\>Z!*]6S-M=SLRSS;],K.T+E,NII&I8HTW6&X9]G8E<6]"MZLVTEYC<3\]]YTY%'D"0(-M@D@FKWRIP:X]QP_,^:.EHY*>]:>E?5P]$WM%*_>DV29T>V' #KPTDQO,3WA_ M(:H.M)[FT#1.YA4[!)I[?]#1-5\IPM&N4=<'AS$1MS$<^+=DB&!%)85SN M.MX+R9.K2"f.3]LS%"(;4C3W4!3P.[T9GH/T0KR?2L&3L:4DBOO.&GEO@ M.)EHY! [$ZGA9Y<8<=5AG:S]:TU9_3N%DM8]WG4A5'=10R8.ZF4*O9**P@. MLBR@^.^OE.T6%^7PIR5+CFXG>YU:GIY(^HH]Z-6C\_&2BOV6[(ZF:0TG8W6< M+W+W3E-D@%,.PY$&/+*W373:K.8K-EL8]C%Z0E;[4XA*:\/F!DP;;R_7\BQN MM):K\CA?CXRYY&'):A-T.!$)-Z,K>L[JKL6L]0 EGSHLB9Q$]+$<)E;L?)!] MJ!=@IG:TL{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|M#U7SB%;FVS<.GMSDZTW@Y(-M0F0S5-U:+UM=ZV93P_-F]74>ONR(+|_M !:RRA29G*;WLG?]1MS/"BK6!/D1(P_R_0;<.Q;_+;NXOW9;,0 X_G1BW]_LH=*.6DHK<$5U_TW-%V]N|SBMNGO^&-M7.O>P3]IQ1V-A)4W:\_96FUN6%T)FZ&K$=1GM7>8*^\I4L1@47]+3[$/<%=$ MM6=&\#<8K"VZKM A\"FVGAL#6E1L2;IM#$KYHK](M'4SP5TQ_?.GU,)V7.A, M8;R\.5/LCT?T"<=VJZ%$=3UWQ*.R<3?V8MBH4>>TGG(ON M2%U2<(<JZ3#\;2P0_CWWER1 MHF;GYN;O[$Z!05B@E$_1;-7[=@H+_.4F71MM^W1+0(C^0)NMJ;\A1,XN-)#W4\0L/"'#\ MX 4+JO2OTWV>Z>^9B>$6@O?/KJ+N\9Z|(1#X3^2SOYO*R%=EOL28'FEP)8U>Y,$YN#7;?04E*

MWR0ZO2%8N%,4N%^G_^D9W+1/,!-4>L"WX\I%@!E'E[]X:+]URT5;B>GQT,\= MH3T70)[FESW7AI[*.5HK=M.],'MGM&X?
NIHX.O1,LZ%MU^/2P2_X6.(467/L/;HR>_; M,QRYM"/Y8[$G85IY5>LZJD^7YS*1AQD02SS0U)M[A@@9$#+<&#+<5.[T2R#Q
M$AOZ#=5TY"%N\,6-GRWM*XG;F7Y00SPU$<%943H(W8V]Z(M15:,K/CS6_&GGK(?RPF.ZQYQ^/%!<'Z5G?
_-7P_1!$*4CO[Y^/J"E5 M>3HJ-T#E!O>RKU$[NK,P>T;.>B)37U68^DZH^:;9(.R)N"#GR[+ R2017U-(
M/[#T6ZDZ0@>$#O>##I^^+N''Q, F&8H5F853BU#!4G ##S.F3^E!$ +NK?U M@,8__^+L@:0) #_CRL;M,=;G-$$X--, %
(PZ*O/#&Z6\!]9\1U;\:=>:SZ5 MN-;BX-2)8I-P#TGMB\+ B3Q2 O\PTJ.Q(";45W1UV9C @4<\P#<8+D]+8F
M^W&],0S8WQ>:;W<2?T=9^419^W_Y^XY-M?:=[JN%'*_'QO7CN M"OKO#4R?[[0J^'J'=U)S,>?$X
N*\0>RQ]=63L1R%05,KW:\SU/6H>-X;I" MV!J8C9@022O&D/NC]P?N7_:5R7>Z_Z51:?C>IU*V12%@L2UUQ5OMIM#
M]V>^_//6B:!/O1#QXJ# \^,!IVO?;G#B@HJ 41'PS65 KQO!/RUGO%D$W&)4 MIZ)98YS'L&UWEW=[VYW&R20=EQ9D'W)DM
80/"!H0-GR$]^B-LZ#6K(<4= M^GO3'JOLLM)0E@1C#K'A<=>&O>$# C!3,H[4UI"1. MBW4;!=8WNA%]0S?R70.9X#64QW_--
NUL4%A[E%1TU8)OUK!Y7?[]:^(A+L'_ MY[][4D_W \]0 UV#?^ <[<7ZG6B%4"?@07:?>4P*=G\UT M-
3@U#=3P079%B[RDT^7R?#3O1K4N@#Q UM@+-G5YHLM]/+H8@GB M@H'*^+,R> MYTG$7,Y[J\%2YT.J3V\K08\OK:^$H"<
<:#8A*3Q-0O7B ML&3I!X)""SX('Q ^7 @?2'E<.HR[#6W+\HWLQID3?G4^SZ4''RH=&M]ZP8(U M&8LB3+^=]8M:A \P8:*3-
W%]JB6?-S,C'=YB?NZRAUNV8^V&YR>=%81?TK[3\5[$]GY&!-_YB(C"X4!-73>&
MY<5I>C*3\J1!%872,#1%9K*0;'!F1"PYZ.+'I9QV3WR.Y_31*?8/+]9KV%&*Y6E@[/XBE6!D1P+)JA/V.N!I/S4X6JWU#Y
M18HW9J_FV)_4BY'Y(O/]Q.;[">=8+T^$EO29[GFZ]I*H 18#6J$6W:X PD], MJY19*?
OHIB@8G<"77@C^KN]6NN.C(Q27WC6[I46H%(XU/35*EST_4=*GP2.A M343]4'/4$"(Z
80:MMU8"8J>!W%@V0WQW_W/<7OX^&>6*IB%7)-SX7#@%]K M@2_.^I-58\#!+!8CAQ M:J ?JQ(A
&7H@^6T"5/TTZ)9CE7V,H4&1T= MR%ZN@ XY.W+V*X;I?T57,5Z@.\00#XS9_L_M[^P]4W4 65[\C>&]P;?(BJ% M%PD"3
Z.LNLO]&A]P :=VL/0[[@!O&C:@ZL$($,(]+D'"9W!=)6FP4+'2O& MH:.$&C ?#6*D!IIE1GDW^_]*,S>-_P7\>?ZV"],># M?
K(XON+)"^"K'KT$_Y^+V/I1A<>QD=EG.5T\T/S+KO^?YWW_GG!CJFNYWK=' M=WTVJ$6\E4%&GCO7L:FG*R:FS,!
[ORG65MG[QT'F2B&#/TU ME_N?S/>/4!@)2=K*#GLFKR-.8)8^"[[%OWK*G+QQ^]&BDE<%??2
#"%]+)"Y^AOFO@/TIFX<&LX+_Z00$4VV#T&: J"/?6OY_O M'AV_ FX7K<,!ARK")".B/#^:I?+<--\TRDB*&
(#K[[T]BO'[ES^*/R'7^(\@ M-JA_P1:9_Y ;YQQ?&7[WR^$>U*%%"TA;ZO-@7^E5>:G-2 MJ=;G2T6A7>+;
(E\JU]I(R7[,=,2O+GB&(?H M04 549EW] _.T3H>P#HGB/[Y1+BI6.(3O)4,7[5VC1X+-;9]Y,GV1J]1:?#]3J
EBL<:WB[P8U^/7VL5SHOVO]_%93(M,+.Y6 M7\@ 2\L\65CFR<0RP,;Z?(MO]\7,7T\!+:9 C1*')T2-$R& II:R\050CQ_^ M?
09T>3IB +$X>BMF*7LW#+[-C)VNG0IZSWSJ$9=C4/IQ5>*\TG^10D;= O#[M1A*92Z2%Q->7B>F+M'%ZOKZ_"L#'[?
L2<"S/B,BW(@70A_,K_SX%HJ"XAL^ M_/:Y_\?;]A=*+=\R]D>U_T)*]RK[[5/T$94YZ%"0*1BNKQJZHX+NUASU:^8O MD-
^!D!0E@W_9)1,"4#Y%B:#JNNMW!AP,PM=T=8AR AU+UY%$L'[6@ 5W8=, M$70;S',=0WG(#$J&=4RG,AT0%HXUS-3PUTM%-
/50\CD\H<::P*"B9GX&M+1@EJD$P1XDK 8PHKT3+. RU5]E3FS_#?JQ #E?X'H^ M^*429 (@(#!&;>_/0B>:V(*7V?!^=A?
>31)7:$P]%S5^&'PS/Y?<2@D6,$&" MH]8,'TZ]_0RPD]"*ULTB7E8H0S ;^6Y6J@^VAC\]GOO'T!&;=D&#"5?,_WO
M0H]F,NR_?;@"IV4>DX*?=.OY(NLL^C_04\T+YT!JC@8#FOX Q.L8,\6!R7FL M&= KD-D_9%R@?
DQ3@.5F5H9E18+Q=4N'-2MZ!LKVNVBC94(XD@"DC,$C2?QW MH3X3-J;XO@0B)9PE^ %H[2YT(#V0(?B9OUJ<6 7V!1=$= ^\V
3@X604'Y;2 M@&3$741/2_RL#7_V%9AJIJXXP #W&1CJ'S+/K!9TWP&24,%;XWP$C $@%3!" M_:@G_[N6.I']D%,XRB((#'T>
(Y\,%HP1SF;TC6*%\:KH,Q%"_4-3]O<@,#@S M XQ#R\!196!GHR,Z6R-89&*C+Y- UIDR%1L#] M?
CB%AK+*Z+,9&*,*O$X)E%\2R->+3F!_ ^Z J 0U<*>Z]TQ:TE?Q:Z;LNEHT M\A+T!4ZSP3C\X AB?Y5+W-\9,+F-9%F 4Z!@
60S7T!_!, #$0G>5:X\RO.Y M^D_Z050'9GC> F)*; V1$=BN!M?JH"$"I6V4R#HM8)G>=X/X"Y@1^%^HOF>6 MXT/3 ;]Z9CK
_G_:6="7YYW= L?RPQ7 [R"F4'SRC%_6_J_9?63V\F=4@*X2^\(QGD;1H5GZ^U_?!?$XSD=!@!? LI6H T!X\:UCP+^ M:4-
A'T]&0IVFQ]A^".(G(S8PQT=(AZ.*%?+<).-A6Z[W:%5A3/YN +7\&*?] MN.S'B4M]P._B>PX V()E7%U!9GCX/K299R/:K4MS/
MWJ+(M8N=L4.*)J M'$);F4:I01NDE_9WV'H:SO?1Q7J#M".]0@^V1S^W9W!ZR)\@N-X=+,7 M ?]Y?IH!39Y!8RTN>
(XWB<$/H#-%P?:O6KOT-Z8[8)H$]>X'8'H-K Q*$:A(MA\O&+TSV(=,?%#"*9MBOF5AXF;1E&HFU\E-KWD!"
(+!.==V!J5J%C&"+MVQ%ZOCONI*H>GLC*S,H&X M@Y,.U#=1GD$2_U-@V<:_MGR"T4OP(?)!.0\1%G#$ABF 2"/\,8"%O@\?6ALS
M8/F*R)NA>*K_>B GA@RL'OAW]%WX WP)M+_'$).V+V/W<]P&3!T@")(*;4?? MB);A6] 1?B[!]R^@/XABQE,::NEZ-NS Q=
MZ S?SK-8#+)&5..\5 8IG_C/,[$\G3 #G@X$B0??,QIL%GO39KG V QH.@ M^-*;X'<"
(03FJ8SVZ'T^ZKDGYB$+2")6CB(Q5.%A?_?Z-L1.='\"/7T;!8B'L,6)#R!4(NH; 9$3S;U,*\=0;@[T#Z$L3?C/\7T&6\M_
M8LO^]FK"LZ4!.#MQH.D!U?/\5^&U5119V_-LY+D[BTZ AV\)"H(_#>3% &($ MS&<$W2-95\&N@Q0;,,R4H54*]SD?
5<>">BRP6Z^#7R'"V9\\ M+1/ -(*\+_A5/<@30:KD;"4$$G+GHWI)I\\]V0;R:'K!M+:9Y!')VUFH_I?0
M+H>D\"'2]H"1N5_/3OAA.CHP*@-9DZ$6^TV!?;<@(L?V#=%=]KJ?[Z%$K!T MH8K(&P>;#
(._H6;#4!>FKLCR[N1+6E&+0LUR@8 \]O^S=:!_$@L&]E6W5H M5<[L;9J]WV<)E61!3="##X)S$OR.O_<$F\ESE'NA/[(/-
S9D"GO\X']*C;J_ MP1YV>#I\W^YOL9'@!)8?()*_947J)G+TF8H%7S."KNWC,T5PQ(.< !0ZEK.I
M)RF(+*5HFLF1\OJ*]6K5%SP!R"CW8P!H27;@K;=\NHJT-6"O0Q@G MQ7(.E,G'CG\?A1CO-"F)'!6 ,X*N,>L *!]04S$V?S
M.:RZX DB&, !1%$@[@+56X*M9QOI@ANKYX3P.''H:0)+DU^8_S]< 9[ZP$8O MC[>)Y!".'P&8@[79;J3NV?
N@:AM^Y,T*Y\&Z/[S7T;2QD M#B$?#3KJ(*O'!$($/@7V&FPS=>A]<+:G;;!_0E^>OWOZ,U&#-X-G1_:,V>- M14@?
2+F1'(2YMN3VMU]P8/-\#\ SBOM3WI_Z9&35!F$*,&CFV?#>$[**CWBV
MAJZDS,%*OB@1Y1,@HJ("*06GG748T>#HQ+P_L[[5ZX6LN^U!8*L*(:Q38)" M&!#Q;5,1QJ%M%X"-4U#AVA_EX,;4?;=ZZ/
A@[Q@"TC !BD,O9A?8O-(7W05E1 MF$$^0W$=(Z^:Z[Q\M/'M8Y\4^WLXVP,/TLVS/HEC:QYBAOT-9V1L!TH"'PU.
M)0MXR(,SAMY\]/:1N[\V[3##AO,^FYX5,#"MJ'#)0#3@_7L>7'J)E:#FXF! MZQO=*[(<)Z"]*2N^"+T1?=,U'P5G@.
M@7+K&3"" 4-28(L2581G_WG[FH.)]UP"D?U;'YQ@P_KG#KM?5^7NC[IGRKVQIM2> .NA(]N&']@PCFJ['1+76*V'
M5$K0IWS;+B_Z1=FMDN4F.(FD)&7;^/72_&48;K18(&/K37I.(TWJ]V8-'W*'>PQNT
M"I\Y#4@$P!OTV7EVN.MAHQ>G2"Z;92FKNF[6=04"&_- G $V $$^.P(7L2@C M5_YG;P:WU85W;2QM0-+@S?!"@2H%(-
T*:%,WSQ5C.-Q;$LU<9MV<+?-$5IF2 MR?HB+21(%C:Q>SBC#-M]&]BOINSN++B'-T#AQ3S*/1(+8/$
')M2:KSB)G+>;8&=./IQK-/).QCZ$+M_M];EW@BF?.]5"ER[<3=[M M3'@Q_08YW4;0WP9O+ZA!@@3R19US3I^ZT?
SL%1>5M_'3)4Q #;#D;?K.+@5E MIU [S_[9^^W0A$+G;G36CIYZ.DW9]]K; CRD'ASPX:R/8P1;+[F? ^@>+7.7
M9W'H>SMR'^XJS$8CZC@"DU//WROR9WI F\-OBI8WVR5>P5? #'1G/_^M1Q-0 M$7GOG_D0H\CU/_/;-Q]Y,[9>
[JV7=4NOB;6$4PU(O,VDWX9>@&$$I!P&!X'LH M8=3<*=(](D?\K&+/_1GG7X(&R Q5710V*@$[%P)MCOC[0#PG_
ML)WJ[BW_BFROK/@>?O=92,V1=3T:;""@& H8P?\&, *% ::KB[:?UNS-X(BK
M[5ZI@]TK=;I[[9+,#^P%M'LYBN$.6;>**,'NW>;!#C9TTE1UN9J0O*#*0Y$I MK++MQ_=[,>%;_+,$8MWA>X25:GA&5]
].']DCI[=R^II3ZTYHOI$%'2'ZA33 MTX&4:L)Z?QO<F@,.:R*TD;9.110/ZHW)*PLLS,:*:RZ1"Q;MHRDE+=S8.SYA_3 M.F/-
G3@A$6;N<]$.H>XP _)]><+[E+3#I)BKE\%H@^T'9?6;[CX1OP$O;P'E M/BUN4JT2CRM:@2@7BMV&_FO,SA2W.#_NA>
(6N.C"%8HN4"$JNG @9(?7 M/;9B%KEJC85/RXW:6=+.P7(.;_-LEP.M6,FO$+-/D;J=\8O[9^Q=<=G>U(K*_5=%&X?GC!'*8X7-
I MD5%_70?Y(B;,<8?7$6#*!+K7X;R4/OT*RO.[_'LD])(XH1$L]'=@<9(UTQ%@N.D9QY.E,!9FF"'<9/1U+"P"@IS4R,

MJ'<>ZZ,FURH,73CR9/$=W(BKS\5.#*I#)G3D5-MUI[GZ%6&,#;] MI%FEE.Q :H+CS2I:T,GGR+[#8J;#S+5@"8MD?=CK
MJM(C;\1F?"76K3;,F'*EPG>OV(!G=H.WI_*>L7>#50?A4P>N.VP>?A:8=7(, MV(:QH^7!DW=,7<7\VJF_B^@_0[W:=3U2R;%
<.3=4-,YIYBNSYEG27.<#(5WU'3K]YEG]+[F:-X?P_/ST%'2;>>BQ+'_1SD@W@WK)KCIZ#[V;0H M>2WI&\G
]H5C)H#1X)70TZJZNN_I'P<> FCU^IXRX7E:O7QVJKLPK> '2V9^ M= K:^KHJ>_[%2#C$+S3V["T/Z$AEPV7HZRBZ2[R/
!_$@X.[FR@0 L: M%X0XF_M]N=ZO[^8XNO=]>._>M2T4;8"^=/^BLRQ%_4R2@XL9T: P@;Z]TNHS MP;E .\".G5/RB(?(/>-?
@SCD\^%=RGTF^ 'GH?,*7AB%,YO9%KI3 H@=1 $D M3PR$QY\/JH4#DQ-
WV8@H4<(/Q1PN[.SSP"$*7FX\7R8">9#DH&@+XLO^.JL" MTQ9-M!YXIW8?07N1')#)-KIJ'41PT(N\F;6+KD#2'EP=?
ZXWSR_"OI= !V_P M2?0*2<[?T+RR,VR;<+U-W4 .BO6I%VPQD^;%-L6TB-Y"+C8LH52;J3792Q?)IX$E3:$'O##THJA9?
N_&K([L8+4X6W\T"\F! .+,W Z1(//*"L";ICF MC&Y5(S4_T/!S'JF71D+^\Q#QN7!$^>T3?,D*WK*-
M[YY[O(H*AHK!'9#1&C!TH4I;E_SNV4$5&E^892DFP#QP!0SPD%/^@",!GA[L
M(0VMR]W*Y*LA;\&JE/;,"X49^PK];YY:G*#W_2%F"01Q>"'/ NMO4Q]LL[ILF!F$=1+897P>:-S/?ONAG^ M?
3JH5:^P;8DJ(_AP8*+*#;'=,!6L2'2_\-H(=7DWJ@>6-YG:^J=E 5H[B#XO MF"E'G'[!UA_)(J38434HF'EDROMGOQ#
<9M$=;OAL>!W9W][D(.'),&1)]:V8 M7260H_E#.=D9V_M8^JO+6*+[UK(1Y!-M'_+;98@]*OE@$.P^#JIR!6.7X)==
M$S!DM%MCL,)=[@X\3/@5:TSY65$H=#0G;.+5 9F!3H%)(_GUC3]7A3^?5%3Q M8#4\%.
[2U]N1V]R5Z]ZM2>TN%.Q_^:LL17;4*S7B>GVE>5K3<3*K.IWUKG6Y M)KNSJ.OC[)[^XI9YV]Y9)EX/EM(=
A#Z<]33;WXJ%;97W_(1)0DD]$T^9%; M-T#![H13F8!3SBA7J.M6V>;71M46YVMM,NBSH>)489&8JS6U97%&N1I?/RZ7 MN5I1
9R*)B@B&D^?R=4Y853F-#DG@ASZ.^39[B47F7OV:6C_/+@ #4]O$-:A M)D)I_WGAEX4%>
MH1GS7[^;G>"7+$!%A@(#'=A*NK!\84;/GAI\=X]9\/H9V"%0\AK"K]?W%/@= ME)^X:TD C1:?*
["6\&@:4&Y;_\):FH!J$W46T5541MZ_@KVSS3_3NMAO5_!Z M<%"=%!()-4H04!(,K*N]-?
V#XS/R[)C0'K%$(2A>X6_=/@6>G7>B6Q=9G$*VN!#L>TY0D40^-&=1I8&W\.QORP_^@\AK M>0[XQ-FIP#E7(:P-_J_?
B)K7SCX2)[+DP6RNYZX7=!9D32DX'Z%PZJDCQDSS
M3[;U2#3X.3$9:]UYLERWEE=RK1BJ&0LBZX1@8I3F_J=!LG'IC4I9:/!V'F@^=#
M%R:\TKXER?;W&$QK^NUG+,#\OU>3!8+)GMY-O9?IBD M\K>M-RG,B# P@GRXV/H9\^&K^$ ^D G,B1!P D!3$C,B!
(P@'^@T9D08&(&Q M*22GO+=K:"M1M4*;*] MHG9%@J5F%V[9!2\YOO%ZG,C805&5JA],X8Z#*<$U22*Z#3.-/DF&+F[M/U&&
M$GV!A0.9N]8>&#;&T'HUX;AO:(49#%@XL'#< M/7*D3F3CTLI\:^'TWY/5?HX8D/-!?UGK1L+^@];.!;T
M'[9N/[!WMPL/NQ=W5V:0\4\9P0V3;^"+_<(#Q='IF :G8\GRX*V-+S@>GQ+A M/S]Q>[GUP@X._NB:RO%*
(_]\;T9X..NMJ:M9@+U2LOGP[M%.A:R83M!RI X4Y[=]*_M@7AI&*'EU2VTM&HI)R.4XEQE4O""GOTKS]D/,J0 MZ9-
+G_^Z!Z]7.!3X-$2--?C;:#!]J,'TD)JSA$W*A;*V7DF4&GOL3\?L\OH: M7*C'XGW:I'B>6A2%3F=&"H0 JVDRL+$EG:"Q
F,%Q@K\\OO$UU9@L58:"PV- M*!.J)59RG;16[[>A J=__:'249IAL 9C#3Y_=+WUPFZLP<^V8&?6Y#ES6I.)
M0CY1Y%6[D2[S7[%DZ4-I4PVZ2(_7XCCC!;K5C%&#\]L[0"'W4K^_*I6_%)TDWN%7V6HTZRMT M#16%KX^#PHM^!=OZ7F^?
UZJ%44M[$V^M]69"4YFU7-U46Q7>8(<,C%K25)2, MTU&:/G6;8J_I_7I-L;Y?4]_?'L[Y\2^OQ:?
5^WE7FFZMISHD%UOV>,#/D^N*G;3S5,6" M]CP,H#)1$NA\(GY)W^\PA/I"=01!5?Q0>3CNUMWUZ9'9FR/+U?+!0KC6OTLP
MR<'N=#)*+PG <]!46+-6;ZSXM59,]*MLL]!.LY_L#*'> 9[/VU $J'F:;K)' M2V_Z5$^WQB.%$%;M.9?EY%@O 1N#T[_^$
0B[DF.,KQ65&.FZL&AH&OA8%W M^TBN# /U/+M9/78G4UXVF7Q\VK4[HJ> V3(0!F@, Q@&, Q\(@Q\U'5R91A8 MVH2N.--
RCZTT ORD(0RD,0Q@&/CD-(>;KS4,,/!NC\J584!B MN/33LJA7N,)B;*][FW*R0D-K +I0Z ?J-#KR/ /]WZ@=W)_MN* %WY?U-
P2; MSF?H=_BZ,;[6(1OUQA[)L@D[).H>K.(ZMBW#;]N(6JWOVC9NFS6>-%;_>$Z, M@/I#JG8$:#9L_'G0KQO-
Z:AC]Q>W:&3!N[>OW0>NY0(JY0&1LGOZG'9T/.W> MZ$CK9%H=T LMEBC20K^6R&^\X(Z):GJRQ+H7Q@WA,/).>ST^U^ISOP=D$
+G MZD'=]H-R]*(N"S;K10UBBCXH?N%%]0L%NTL:A, 1GW'QZ3_X2N_A]AZ]Q_X(C(_XM0Z)O_>D;Q(\:1
M!V9/\$+_HQ<>0V6+L N&D"V'\PA;T!AG06K-M3);&DL(J+]\ NQ&QI6T332> MI (_7Y=R3_IFH+$"',D\'\DV+:XS9$25RSH-
9U-9\\WL;#FD3I^IJA,R[]$: MP7GIISI)SW-%/@M'QI^/5%9-KV/(K0WAD>O.V*QQ1G/3!"-/WOY46/76J76Z
M2PAT@L@0)267K2I@9.KYR"XWB]7H)F-JGOI(6([N<2+/#NDA\7QDMDW5.B,N M\:BM)W9)6I4JTV8-
WKD[&:DUEVK6*CTIR1&N32N6XM50)U,TGW2%22S#R9$6-<8DVQYMT MFO<6/7NU9)BY6U>&S.
[MSW!WNU65J\3CBE8@RH5BMZ$_&8,FVH(@SU[X MUF(FS8MMBFD1O85<;%A"J393MQO7B]^ZN-U]7IO@(\4$BD2DJ40*GB._OG\P
M[JSSS)*X4:\IDL2," $C2.J!8# G0L)K!(A8016B;!P JM$2!A!QA_BN!%> M&#B!52(DC,"
[Q,U[OUX\RMU7:YWK@,%]T6#75X;^<%L_YL M>Y=]96[1&A++ MT!$]4@_WW=ONZSI#8OR]MNY4T=?Q3K_:/_
M?:,,>:SW6^0=:.2]1Q3=\;IT 6Y_!$[\3<:W(S+/%B>#(^P2PPYRO3Y/Z6Z\X M=-;?
5CV^GB[AN&!_HYKLWL$9,]U:RW(;"KJO$55T MT!FZ!9&V32J;)XR6_F3%*XE*@CK*S2_5\N](R_W+U; &D _WW$V>]%QK><(T
M3WA:K= 59\E%UFL.:9B=$X_2%!6EF>1UJAU@G<8Z_<8+;^'0:4J)UWI2H:]J M#.AW_]8>.)ADFFB!.[^9@
MG;Z:3@'3Z9BA;PJ%A4SQ M!M\PC>ZFQ<\T!>@T@_=IO$^'I;A/.'2Z*LY+DI%>E++A/I]ZV3W^6*^%+-;DGV+9@NE_I.,!
(=3%/Y#O! MTNU= H%\;\T+LRHR3\+*)-96VZ)J?&PZM4-X9'BJ9'H\,UW1Q)HFC(Z^-J;E MU7(8AVX
,DH0Q/5,"ZR=/TT[;V@T'&MGMES@\G,Q0=2$RHJ2FVXA/XTOPZ>= M.7O8$"U7U[EU*I6MI@:/XP4-+YS%L79^Q^5T.W,?:F9B3
M<7>S+(QYK]Q/MN>;0D>MA% [,Q:S&A+=W)10 S%L<\5A9R!"[4R]KIT?RDB\ MM:N,-Q>R RNU !%S;56$/_K%5Z
T.M_3)7ACG]\-,U1"!%&W/WRW=B*/0()P M24ZKS0>0)#Q*7ZO?"%;KNU5K2!62^HPF!C]6#%Z,TMZ1&'SKX^%E=*\[5:U5
M$N8U/L:Z.4%.\BM*"R&Z*S$ARPE29LK'[&G5,1(6MUFS -T9C.X8W=^([B&_ M*_6LP4C'<@7]/IT>G]<;Z%PN>[@*V-
[\J/!Z>XMP0'A]YGJ&66I7.<:SZ63" M-;6Y NK 0,]$2699#093W\3KQ]6@% UOPR' B3'JU0Z45=80BVMQYG)=#:L M=9M
8(,T^1U,TSO5 '.763[L0KPT98&X5 8ZEF:2\V7FM,_I',JXGF4YID M_:ZP> ? .\ 5VR.&0P&RS=0JD=*X)E&GM@.6JD.-
ETU2TS9O-*->1/(L 7*?V\:\%+A;I5<&Y413"@)<.KM_HZ(DC6 M#$:TA!U)(K,CFGQY0P;R^,KTN88,4,4$XX"UCV3=6D:6L@V>
3Y G\&ORRIX MK V@PI5M0S7!IZX%!J-O;U\&:YO;$7DUDU%@$ Q _1; <(@>NQF8:(;!O)'W M(?G?3F2LFH(IJF"<
P##I_=#:"A=,B.LIX#0^1L64#$BBI:19]N9B.HX'E@P
M(&>D9CWLA\0(YG_42Z(7C>3DD1N#_T26@,*P,#S8^!RX'4"JUQ'1M]>A_VE[M(]>: 2"()XD81?P+CM+ M\-'<@[*Q?
VB*3,3BQ+_^.[*'!+@7!'-R5HEPX3T =<%J MP?8M3H">26!'"J,+7LZDM1MJQ!=7B$Q=AP+2 CJ% *) M!>5N#6=98-
D&FJH(YBF F>R%23V8,/J2"+8>,&% -" $(NHMHJN^HJ@!!64T MXX=(9Z*"#\!W)?A],-V@FOAL= +?-E;AUN6S>RT+0/5&,B
]W.0BJ*\"X(UX M4)N(3$0C<"..@EG!/1*.4^&E?]6 [7%52_+GJ)KPW;*/1T&+%!?.Q0EL J!7 M$M"\#V@46A\JNB=+2.MUR_$
P;]0T\YX\]Z.UF?*(,")08C8")_6LKO%]K A M.,"5FK4XD!%?/LX@R_[/,2(9C5S&E;:L()%MR3/+1F3YIX-TG$H1_PH('TEX?
M%B(.6+$.Q^U6%#SEX6@%)PH-=\89."X@4PLJ$WSF7M,CEY4\ O3[D(EHUSVK MWM0G;3^]]$0XVW@TT-N
XK;LVI8S"V8>;+^(NH"/:!'@N?;N\3/P'5A-VY'U1V0(124HX\]J:I$#$$#3X#G%D@,Z#J
M6($BP2.O@ZPN!%%0Q61GJUX[O'&\T11V%SLB^I;4"+T.%O4,:WS4>S,$?(5^
MOMX\ZQ8:_')Z,+D;MXNTPO96X3A;YP75[@JZ)Q_H\.E!VK),S2!IIJN5<"_B#3@C7/"^I:[E3SLQ^,[P._@(
M=@9[0;I@J\AS3L903QD*4 1)4*0J"U!^]B;\P=^ =N=W^_G!^>P%?U@8]F!T MN/'@BKR0@[,H&8E% J!K>A;<
MU8$]*,K^&=W?@<"K-3FPGOWS-[1'X6X"/@2?'1R)'R+?@RK4GBKU$9C= H&D M:LX\N&3D: %F@ADY(J1/N"C8Z*'?
PHG,C^@)J>>H@!*"?9YVT6=?O":'3WED MD@AVX$%#7(G";_LS":;U&V3M9PS='&":(^@:L6T+H#@RW(!1=##(?TM$$ES!

MGZ4W@KM_T*X5G0$\8,A_9][.7/C.S*?WS.=-ZX3].SH[W@S:NCX]_0EH?[9&'&MT>_>\4!6>"'&W@"[M=_MS:=Q<&#?QI,
A0XY?YAL-T;_^0(/G]:\"ZH=^"A@)CPG89ERNLM(\?@"?Y;_MMQH'CQ?!&6K+5UL6)/AE\<_%"LXFEC]]^&7?PRVXVZ['B-
>PS#UX&2Q2#KD-_M?9W@@5_&7,__Y(,7P63]QA:!6/KV_;'4G!!I"2#H/]\8-X2-P&5V6BB8DWB!
MF\M.8L#H[F:94(Z#AJPSK(\/K-M*?Y9(;DK-AK;NY2M-;I?S_M5-T8$6UC0\W=D239BR:@4_R!O$"G=ZH_.,$$3B=]?
70>/8@^G=5AWS%WH"8*_MT"QWN^,>*-VH&_M1_.<3%')NE=3ZZJJ#,EAXOG(KI*J3P@V'2=Z;4<1FX5$*3:!;9_IYR.]43(V
MY"LQD:L7]:FD9HIMCH3-G$^>R?+%)]$>I29(?)=V;YYKFVST)G9?_5_M622S=CFMNI0=,R18K^MDHF2LE5XU_MBVZ=8Y):IRK--
_UF;PE&GDPTIR0'/=&;//+U_C7+CZ1>ID6R?@VPXY%CK>96_M"_-2C9M;BMI:)Q)*5H0C3R=*UFFI)[9C=)-6DWTF:3>
MR:VX=FJ^5MF%7>!R9WM9.Y59<:.84IHK;S+Z4Z(E-!^IY;E>UANGS3/6J&)K_M];12*RRSP]:HV#SH.[T;.63&G06?
WC2U=C/WV!HIRF09@R-/*)H>QR2W;JE3_MQM[N5#JU3:-K#^#($XI:MLR.!AM%Y^N$:(0)-EXD%MEE^LF$27SIYR,3T]1Z,A
46RO4C%+R,4'3,K\$(T]IW\KF-;'6GHYX_MID5;A6&Q0!_H-YP\Z7=>\.K)J56KN%K!,G+L(FMN1-LC;?,OAY
MC;':O!CO.PMVF#PEZ7QHT_M-GS3YGI>=,:-U;U'DFV#DR:+BT[Y#YD:+OF:4_M*V7]:.(WYQ9\YNE,D]-ZRJ5-
F^>$HIILK,=B6J\LAZG3U[>,6)YU'C6.4)<,_M4R(\QF_K36"ZGG91KV>:8YI22*X-B]E4,U(\02G0R'T^DFIY7D%H%0J$MU)6
M0V)H]=P^?.;I1&E7R[FY1M'FU4>0-E5RF54KN1R2Q.G[%:>1[YEES=9ZR1XW_MY!\)QK45./1D
HS2JXJ;YBS+]YYXF^,9*J5IZ*EG9C!-UK2:',]ILMTM.T^Z_MD6\#W2/),QHU'-:(0):W^%B2X.U))LZ79
4./17__HANE*9TFQ#BCVPNTRA2_M^4QV@_,_L/M54M^L1KFXQFB_;DXJS3-<6_M$HLLZ!-E<09V/=Q.>;5#5-R:D]S]ZF)_MAI[1
ZDSW$RY1(&?SS9JH>Q6$KT4&'L&!+-/CS.VE6LM>*.:L(>;\DJ7,H_&_M9U_PD1'$]J!A/7*>6%NVA;RY[K>;
<.@)#59K4WFLD_,^)Z^\8G*TEIN;I_*'_MGDXVSNL+J:-);;[.69MQ710Z=AE,]@QHY-:NUDK-Z*S62]B+45;0$VV@DV#H
MR0P>GPR&=N?Q">]Y3Z-50Z4MET-//2.)A8G3RJ4G%N?52&U9LX<)J09F>P8W_ME_J;
<3*)LDKTRA93[B>>VLL>&GKZV#9;%RFAE6MRU$"BGO@UUW44,/8,R"SE_MHKC)20ZIM=7>)BX\#;55CX5#3_8-
J6I,C*YD$9SK)QQ_H3_M30&G44TKL*J9K,_EY.II"8>>[@>;:7.=R18,EFOGG%)_.M#DB3^#TX6E6LVE
MG)'D!%=O2.13OE*K;E+^V.V.\"S:=SE$M0T]O2-015WCA/1Z_NCA,?0+_"?;_M&\6[HWMFO?NQN_U/(-?DT07DW9@2I'}]2=-
/9O>1?A:/\P5Z)U._M686:U7#'P'KQXF3#&,]M4OE*>D_<_=-VU1ZI>:O!=..V!VDVOP3'_?1#ZHK^_M'.
<5]XKO[MQE^!XX=&S!5%#"J&T9$>*!ALX:DGE(!6X=/X'IN4,(G).?/VM]_M[!HBJ9U?R-GZT4>"CD*%SD3V0QQR%#EK15T_M@#*
(U7-B&Z!XRB,;YQS"9UU_M4NW24\&SD#A$J/.)I%&8S3$28&JT-[.V(9UMC">(^_1)F6!.<([K[>2/,K_V_M\9[3T(T?
F3CVLEDCF-WJH#?YR:/[Q!I$>!4EXFZE#3S*%!391K179!/H_HS^_M['*XG3.!BH-
O'W#+0RDF^_R1YP&4PXQ6/UL(YN[8@@2I.K(M8*_&)!G(DNV3_M!WZJ^N[W?T,:C,>R':(XB\%-V)'J8+HY?#&"3,WU),M!SX,
<=SURR9'_J?KH8I+H#4\Z.M<_/_M\OCJ&B0^P;@47-@,_(ES_,S@3T!-1K*NRC"I'JP;T@B%\((+%?!J@Z5+P:P/
MWP6SD/4=F(5+I$6PLZQ]J=$]>8>G)VSTDZEA;MX:41]EP(FB#9,C(5Z;CGP8_M.=M2\RB-?C:SK178#%W$Q2
M2OU]!XUQ8>1/DP5!XR57I.W:-4@T/!_MV(62/Q_IWS+J;_<#<)9!)3/W%-K=ZPAHN!UPV_SA\^^+SYM&-
:Z^5)MSXA/-7_//#,H*FP9JW>6/%KK9CH5]EFH9UF0\(9_MZF_YP@4$:D#Z[/[H!']UR+/,YLJATD?\-M"[#ET0-V
)E"5A/CVPGN1+71E145WM,3[/5N,+JL_M!@PDJ,8O[*RE1OW<:>2M^@V]%ZH!]U3;3\%YWVGO(",?S16_HP'6C>;^^^P&?
OTS0/7GAR_M7>7A*]*TX=W+@YIP6Y,S;]EM(&(H,'N:M;V43#?#AD^!V)R_M-K'W'_1'<.@!$N?\RT_9?5O"^P&E8)9_D/<
H^*B'W8_SD@XC6N?)GRX]O:M_MP=-(/R7@S:73XO2EBAL',?>#YUO@F6/_HNWMANWO,9B1_]M/WU@"(KR:.1$D
MLAQ%ZX618^F>^SQ:?YTJ;@]$XM+-S^T=C[<6\SM(X/G;2BAT$O,%\P7SY6U_M23ZD+M:_Q'S!^H+YQWP)'U^2#^F+%=
P7S".8;Y@'_L[7S".A9,O_M&,?"R1>,8^'D"\:Q@<1K@K@?TV!U.S"/>:S)/&S9T[_O8?57KZV'4H)>,UE_Q-I\KWE1+1T^.'_
M_B)A_LV'"!2//R1.VHQ\:7>S]^/*_XR.WGE<(FB7R!+D[A'["J[Q__GWZ(" M>(_!VH1ITD_4!?/!:%C?.L_>L@_M;V
9>LQZS_L.LOR/CYT06WF,-X>-"Z-3B#DUC3).7C@O?_MQP6QJU%Q+]M+.)Q8?VE_?!_Y$2W'Q:*#1><#HE._U42P[_^8#L5%
I$"P_M7R4\WTEV8!4L_X"):F%]1J#EL"V_*,KR>'S;P]1%-R*Z)_NIJG.#Y?^%-GWA_MV0D3YJ4#U%T1YJ]\,5B$/ILP?I[A?
1'F-B+D9S!C2F%EP\J&E2TTE,+*AI4-_M*QM6-JQL]R%"_@62'T2I^XN?/^]!^?LG^$5Q%/R+W38AIL(M-]<0D^4+=](0_M4^&6-
BHF"]89K#-89[#.8)W!.H-U!NM,&(3CM9H8]TV6.\]B8=_KJI8IK[<-_MR<9@5@[VAF(W\8],6$$-_[I0C^GB]\RD,2"<(-
XP0U3(U_U"__G-6-MMU[X_MNS3DK=VG0M!YEPR:'9UY9'7?_2T#.Y<9DR"_M,V%-"?
Z'VP=*#"4,EADH,E>>A$K57HCZ0^!E6$:PB6$6PBF_5^;M\FULO'!OR,!T5&_M(W,#Y29FO")G[)Y=;%=Y@TVR,<;
(F@39!&8\F7B#'7]/65NPZR5X1\=R!3TB_M/DO>PL$/'_*ZY]RMD[TA!$3_HG!@4H78?KJ%>J_#"3:M+II6G^IX+&>3N12A
M)*O$>F$,2VW6R[8:M_$<"J.5;38VXRS?BZF5IU'_L:I9RV'R*SR'/TO/,/9\
M#^SY;,_'S^(XU@*L!5@+L!:\Z/6[*RT(F1T:#G^<9#_QSJ#4H@@UDTTP!;Z^_MY$>WL6Y7J7E3,/F&RZ0E3;<^3F-A8A7+\
%PO!RH:5[3Y$""L;5C:L_M;%C90D8IK&Q8V7_9K.];!LN_,YJU#$.V80Y<9";,9/M;N.?OOC=YN_#0]NE0
M+]S>I#!#_V('^UEK_O*;'Z$,!J%>%EE=AEFK-#$NNX-XOE&O3_6FA\.297,A>RX_MQMOC4$^K]*/6U16W;HQZ&/7"_M@WH?0B5=
[:7[>7:0XV-J(].TS4R^-_XX*K$+0=7ARO.6W08_E)-'[IX(K"AZ_MAJ<+_&L+MN4X^\
[*L!%=1@:OD3O"Z@QXU316');,E<0Q;,Z3DP2939_LX%'Z_MUY\$@X$+_]==_M=WRF##XGK?U='P/ONYIXMP),+]G770=E<-
[6DY+A*]92K3_MJA7;J^+@XVET[SZS4$4G/XN7LP80%.@5]52:$Y4D/+/_W#EP:$E0B>^;.[=U_MI]K@=
KD"!!]Y!XDS=US0"9<4(O)$)I\N*_WT_YXMM\L^!@N,H0AC(]-L'MQ_M_9[\K%[(WB*\-AVGY+==)%;+]@A:ZXZUM1E0\YHUR-
NA39_MUGH?/R)>RX&<6<4=3TSE'KEUK:KFFK'B9OJ{0#']ZP]%8$3$B(@1\7O45_P7_MW['XAR9QQL/]O#?V^\L2YA_:#Y&.C?
BZOH97^V?!ZT]<_M,TXB_F8,_9EA_O!EI6_C*_0^9KZ]W1U/5KUNU/A2*S/L$D*VFLS7>V2VG/E"_M!
[,TE[H3;]JH$_4EP>4Z^739I=@A24(',TU%XW%)'XQ$M&SUH0.:X]L5#7W3Q"MO2O/R1-8UC#_ML/:=8.T[Y1]C*
<9IR3]Y<_Z63ML+)L6CTDZT._DVP\U%.;/H#_*K-OF%]REK_MBR*9:#\^VD2LLL@-A$I[TVPIT%:_'EMP#$JD+H65OT5R,JM
]N.D9)R4C).2_M<5(RCIK_T*01;("%PF%@/<%\&JSX;ZIY/'R5UO*GSO+=ZDEUF\SOC_M-E]XJ:N729!LR^N/"'(9=-
{EU>9GJ]II#DD*5*,@HG;[BA>X?#RD863&RWANR_M?A;R;0KS7KZW]QLMFG1IDKG2],_M!4JWEIEFCE@D"$I1,AUVX&R
M]L2GB'+"*8UR4E8H/'W\?'E!=@V^+;NZTL6C5*F<[&IKJ9X^9$O%TAJP@_K7UAH
M8Q!/ILQ%P9GR]:G4;1ITCM/SR%2!'FMXBKMDK]QYUC9)H7=T+%?0(PX4_9@+_M9#]B[(0?YW+C7.X?E?69/I!YM^GNL;7\=)C
MTFT[!A=K-.KC[E,G);%?F(]M=0VF$%\O*OP\1N?6:DV8605E2,:A6SN9B%)T_M'*
<<8M3#J/>C4(]+V\;L26VQO*=VB$E[*I#*,'P5.SISBGU,RHK&"YW5:++D
M%L1@M83@!7.EZ4O)1QBY,')AY,+)UEA]PDRF%Y.Q;TVF[[KQWZ=KFJH-
S=G71&7YD(/?/RA.CF%EQ]J?;C_6QF52\VH1T"W_[Z;Z.:!'HN_W[(=,@#$5+A)UO1[J8">M)3A3@_6HTO_C87C_MBTVI$%/A-
L+QY14'[X,L6&>P5F"=P3J#=0;K#-89K#,WTIDOKJ/[I62Y\S2Y_M+VI1%9KUWM:U\>/)$,J\.%SC%%?;P<6FPA;_@5[W\-
]6N$%/K&6F/F>\F#7B_M"M9B->N;[=QC[_OOALMLHUDP[+F@R2LA5E@VZW*^OQR2#"IJ2D6I-(E343"4
M8BC%4/JW4*=T!N6L8<5KG)#G>F*F4QGD[/#="2\,YL.6'/-,PJA.F=8B%QN2_MB29$1-A+BTE@.,1PB.$09]9A\
<=E3'^\-7!7N7:?8,,\J4FQ2JT-EILK;L8=_M]E,F5?G".T]TK%02FS-;):CUT$J/Y'YCW$'&":I;2D7CB4M-*.XI7O_7+;W7
MT%ZXUHSKEGXSAN)".M^CG!0VH&[OF;Y4\6;:KJPSDA'/:FN[Q-N5.E^L?F6_M+<%S^;BI*PF^O"9*C73V<53W@*V3A*[I>#2=Q
7Z,*)B1,6(^FF()V;DA#H2_MJ2)1Y[)/U6*OZK&#C]?XNI:'>C!=M.>)I*P0:KJ<<]E1B4R/6_B,Z5]_KGEU_M_&
M,'12]2;M)2&,>+:<;?2%N:@,R11*MTY&*097_L.@AT'O1X%>MS]?UM*]98K+_MYH0\H*[BD5[X$J.IR<
;IN8\S=>SZ55YP.25IRO+L0N6+"5H#%P8N#!PA=!A_MC=4'JP\N61J^??\^W=+%N&W52(?A^7IJU27R_WZ>G*ZCVE0).I

P>R*#B3":N@ $ =2* #F^LB Y M9\'?
3USS[9.C0T"$G\CX+JSK@S'O5(;&^A&B0 O4G'K]B81N,!!@)PH$$./D52 :'\EE#+]DALY+# MX9R3["?>&91:%*%FL@FFP->7 .AK;.]\K<92ZV5#Y^Q^I)L +]S=RKQT(]3.$\?^R\WK#9,ZW
M@HZ R)IG@&F)_N]0UE33$X)52^IB^R X9 M*49<%&ZKKY+^/WT[#^0681!# M=16=.ZZT3,6W:+-3.3+NKVX]_]S./E]X"
F6KIE][BQL&J)GYA9@I!B"+' M1L"6TV+"&+SXMZ 0A;43K#*5>J!VT/M[ASV0#I'$0RKU7Y']CY :)Z0TA%7L M@&
!8,5T>>S^]K^U 0AAS?8SRU$AAW[;,K XU84,GWWT5,05UYK]IL@'YDI, M>8;W])X% R-$)C:$J HU+/G*E^CGX'P
077 <<&M;"#CW[]Z2!0L36.9"'Z M 0S92:[PYX" %Z4243%& D#>S38@X [#8 *?T-7 (P 1\1\X(0+ (A3ZYK^> M4?
R(<>3!WA.\T/ HA<=0V2(@D!JF:&9$)%+$4!K'D\-X7""'(T(>#Y.DE*:) MN"C$Q^E?/B&$+:R)F;RJV++
[R!>ZE>)T1IF;,LS8&B:>C^SWF4)-:+@RWZ-J M55.LK(8)EQU20 KYR*:9,5=MII3AZX39*Q.Y#EGAX8ZR&N1S=7DFL6#DR41;
[666G"IY69N3 M^9'1Z:9:\YX"1IY,M)JM2/D^V$VX;*\Y;VPZY;PHP;>?3I2JC:0]A3AN$3UJ M:',&,U9U#[Z>C#\?
*C^MLVHQ-9[R\ B(7 6\84.EE&%\2#P?:=D9=MR/Q2TB M1E7K [?MKL3>'6P'"O+-/?4$Y0ABHTXJCYY\N:/KI>J+L'($XI*I+
[0),#'0$S95^W.M $0E^IQ*J3TV+O=I0F>!G)VRJ69G5+6Z&6NR7JBQ
MI#-06K,F&'E"TM:DDQX7N$1,4PU[W1LE!P2960Z3I\L7%'5:%C)%BJCW3-T< MK]==MP3??KJF$?_8626X_("
()9R2H9*LE>VQP]3I1 >ERF+)I!(DD2W;=J$A MK?,Y5AFF3E^?:O2=_)"/5S6J4%P6F7)Y6"[!9YZ^/AVOQF@^,WSD8D)76?!9
M=UGN+H%Y>O+Z%3^N5%0F6>,*G4==E-IGO MU+A92X%#3VCZ2%H:5UGE'*[M35=2XFG<,G(L''HZ5WD^,8;4B"CPO4G,Z=4%
MT92I)A"ITQDL%9WL\&))YF6SQ=$3.E^P2TLX]&0&;LH1.$>V=%X>$OW!AFO+
MJ2X+AY[.X'&UYA>Y@ASCC>EP2#=-8:C+8&'4ZOPT95A&+0B>GJ94R+U47*Z.1 M!S2@3V?0HK41262L"D_-BH34>RJ-
R"F4\VJT7"::11(\\39"DEC6IIGILFM7;"(52[DTGI.GKJ M";28[72-3/"5D=:+3?N3Q&,ZNWY44'O0TVU%J%8K1ILPM79%Z-
JDNYP4URP: M>PH96EILI88%@Y_7-B,Q-B.*4]L?N\6,9S:S_\W1T+),S2!IIJ?)BK HM)K- M6J>_',*A\"TO?&LIYYR<49XW-
#G18_BV&VMXECLPCP7.M8]L(?7)DSYR:,Z=VOFMO)Q:\D/0M
MP4_*7S@PM0Z>;X%GCG5KN3WF;'^/0:_!;]]J7P(ZO6HP!^>7(R--&#F6[KG/ MC;3/MIV?G^<.!K[C*'=P4+NN_PPS
C/B9S'BM>O3S BL3^+:\UG<.,^#)H MNMP:$C,"0]//8@2&II P D-32!B!H2DDC,#0%!)&8&@*"2,P-(6$$1B:0L*(
MU_J68T:\CQ%AOT;Y\JI3[UCU'23,OIC A8D0&B)\^2W+,!+AFTF":.GPP__]
M19*_/DB1>/PA0=VTCG#J#10;';TDR"8<6;H$_IB3191W_'__@V2(_Z;)J/\# M15#T__Q[].=9+GZ0?F BA'>[^%NUAYF[^T
^Y80D3+<;%P8.$X*QRPI(Z# MI0-+QUGIJ%B.(V/QN)YXW+5TP#(A_ND,%0OYC # 32N7O^HI0\51/E4;;MNN MZU4%^=X-
ND)'B3"T<'L;:'[4-X&%Y'J]#<)$B=L(R8OM0#!IL/Y@_<'Z@_4' MZP_6'ZP_6']"*2OO]J/Z-J2Y@]AL]EG;H=_?
TO7W0R.LWR.=\4[@[(>R_[4K M<#^%_:]=COTI=,!J$))E8S7 :H#5 *L!5@.L!K<]XG\;.MQAEL.NQP>#GE^U
M3'D=M!6.C,&4/J^;<,@=.=CO^>.2&\YWF=HU6ZG("UF/D)CMW\'=?;3N3VP' M&&8!ODZ/--@K@81-TNAS?K
MIF"*JJ"73,>U/?CPH^>BC;"*]L$\W :#KR^+H_13D6P:?-FL-@O-<;MM>1]O M?
0J]ZZPIP?]P>Q_[VQJN#14NO\YD>84OY):S)&^W-I8"V[XPO_XPZ6B"9*[7
MX!1#&8:RKX6RSVYDBB482S"68"S!X9'@VR<[8',R)&U_])(!8:IT$MVQWW" M(,158V'T5SWY-D:J*JW=^(I9.UQ]
[13H;IY\I>K* M5R9$WY@(W]/@H4+F/]OMA3FP%;9W.V'PE*F\>%P6O;+.>0EO+6G+BCW/-6]B
MH8P6CV+E4=_07+8[&>CLH#:JS91A$KK1XE&&HJ[G1<,HB%'P#E#PLQT76.RQ
MV&.QQV+_0\0^==NB/]CFO7,GWV5+>DQ7F(I5C?>)LM0N==S8>E"8+V]B21>? MRBEZT6JT.$HQCK>\V4ON?4.9)"+^A8KJ!'Q&
<7YG"\!^?/ M_9#\.2P28;"W3BEQ:^OCYJKR0G+ K>D2;JOL.F[#S[:BJ$6M55E*R2FA]L2%
M*M"/XGAP&_MG13XMGVQ>M315G*UCJ>Q3V0/V3PIZ$I/Q*$FGOE5"'D:[4-+E M.Z#=-
TB5PMH12KI@[<#:@;7CW4F(MZ;+'5O*X7 VCGKCWCK[6" T>:".;+FX MZ=0>;V,F3W+KE37B.CE-?I3&6EHNMTAN"TH@>&9[
HY$,5>V MC> BK3#2Y8-L0%Q""R\[Y.F (2T7\$/9CZM%X*(I6 VP&F UP&J U0"K 58# MK :XA%;X\H"VMP
-0[9A0E=D)LQD^]OX:=_4C/N>%XBS>,XX5#_[ZM_/8W(X MBA2$*-86'N&^1;0]8W,ZH+CQPD[++C=
M,AMPQPR^G36R\371'$WY]L1^:N;KL8[153X>YXEZ/X1##8'*\Y;=!LAT?/N#%47/\'0!@'#!MAR'-VT9L'@# M?
A54,R.#U\@=874&U>JDYAKY:9LG8M;3L*$!2!Q.68AJZ5]_2 QI&-*^%Z1] MMVPI+,;?LM$/676$C=H:=.LE\O$;*NX_E&36
MG^HY:LRO%4]4IH].WAZ@XP],U +GG_0]YVE]N])M/R(SZ_8;!2[+=K_L^YJ0 MX<>;SY*=RL=]%^^V-?J/&34] M-(D1P2C2NO-
8'!AJI:+I>.)^J[!AT,.@]U-![Z] B9B)C[PL#G): MG::=DDFKN6DK? [5I;,DJDG92VN ?_J*7^DYBD#8E?
[U)XYQ"^/6'>'6016] MPT+Z#3,,\>;ZDWVAETR".IE:NN![)B?NFZ<^0H# MF(P+;7S?,C38"@N#7Y=0;[?CDU4G&N5V><2[0-
:.-SML39Z0$L,O#" SK4%M M4U >LP33KIA#.FD378N%+(8=:J-IXHK.$0RUH8$4#+48:K_$FWP!"ENS#%VL M%(OG?
CY941.M5Z&4O[A*<"U7#5'O+U)?*G;4G1]S<5R MJ:6^3!'I_C)\B<=Z3JXWXBK/\.UB?UVP\VYU!I.1:.@MI@D,7!BX?A!PX]
[,YA];1:^ISKLQZ;XWJ/9;%8Z'+,:O"%"<;+_I3H9$MC@3 T9 Z?=Y%.P(D^\I.U)\7YONIZPYCZC$6
M@/#%MVE@"DB6!_'F)@;1?WY=0L<-EAINL^<^_*>?W/T:V7IO=9UR8TW->]** MJV^$07^Q6IF+-;!4XJ@Z+AU-
,0Q.6,.0A2'K%I#U%Y!2;"PV_1XI=K18DM.[M1)TNM?L?3Q2YEO,SP80\)LMEYUS!6M:2B^E3ICE=00BYLO,30T]X]!%##\Y_
MQ1+_%2FMX9;XL)T/PN'+_.2>W^\Y')0JW721,)ZJG*=/N"114Q+4F(6[,ZH= M"TX'Z4NG ^3&_#?R]/U!PR!W5-,3_'&?
I$JJ&9OX7C3 MM6#J ;$:K_V/5!.\V/V-G*9'$X]\""ZO1.-WS_YH\OY?=H$9ZNVT%Y @#E/T M6&)D8CP<4V-
Z&!=%>I@:B\0P0<@D)1%I(241X)W_%K;? **[J.2RXH+H]_AR MO:=V\N6%6Q;
N79(/1]9:QN35JT\J'%&N95H9KI4RUHTA]3IR'(_LVANRDQ? M\[I*>9T;MU."JH"1B>420=;C69C,DQ)C9Q- M4%:ED9S,R&/-
#FXB3? NO/."Q\YLG;S4TFJ7])L,S M3T]D5_W.DD/CF2>C_3&)8TETS.;B"V=>;W>RG&NRPX3I_-<4ZWU($4;,3Z6
M;E8WEMTO#=;-(7,ZK%'M:J->&$Y3)V.['='7<92DP-"+JU8WE9R*=)2ANG3D7IRK768:C*OK;N3
MG#:+Q=L*Q8*1)_1T=4:QLD^UN=:.&?:@Q;M*?]H$([?T]+&RYAE S\2CW2KG
MV4AG@8BB[2H^[%C@BS3A_[*.9TI+I3+E^':*6>54J47RO>9S<*^[$]G.@NT# M7BE 0-\!S_HEJ@%H#X:2E2LR1?X<5NCZL-
TAFX44S3#_HK(/YGX%FN[_M#8%[\)J#.7PQ8(;QPK=D%:RUU+1,$_7K8R?(, M(@4?@1G^?@'Q?
OV)/YRSU$(]Y88MSP15BG"KF6PZLA^ 0U(2"<0DXLO)"[OV ME>6U+4YDR=.!A75&ND^;E3E1'R_9..CF=,8 M*&1-8-!NB2\?
$M]"Q!<#X@MHJ9"PP/AT9?#G<00, .:>S^%CS7VGZ #'7_DT"Z_3$' MAX1@#/S$5]\4\5\^"&SG%;R/]-7B;9'L!/E
7$S:D=3%F>=;X)EC0*^M,;'] M/0;AY3>PF04MM@1D^N^9Y:A0:'_;L@ZD=R$_>V:@7NC%VZ'"R+%TSY6W,$7X M"[WV"?E@X-L-
IG^#M>S^_:L#)?U 7KS'@AGQ18P@']()S(@P,"+]0%^L\HHY M@;'I9S$"8U-8&
&P"3/B\QCQS@3,5\W6KUMUZMSA\4NB+:^A\E 3X-3+.#IZ MY.&*+S58'!VO%IR7(G^]U?BUP=7'D\\)*F;)J"GCL^J(CCY7G
M;P4F)XN'\D*>E1>,K5A5,+;",&]X.BU;<\?C)@P->8'K.%Q7U;XD^VX?$*[T9XGDIM1L
M:.M>OL*EV_65VWE_C2!XT@?'PFD6T1+Q?I4HUM$E2E-N2G MDLA7%LUA?$BC=C\T?8U$(_=]R%9-Q[,% M4Y2_IYT>!H?
KS@1#J?W* M2EO3DBY,JG.C&EL.&=\DN^F;/@3DRA=^#"8-U.)'*>9O&&Y!JU MFE>1[1&\0P8,H$0J\>D&T)?J?
DX>R[8M2Y&QWS'&5 +/B./-3B4]^9 W])5 M4]Y>B$5)=]O[0<\09%DS*!'_D/\"*N#-\!D.G^&PM^6S#)JMXF:AMKX
OKZ+=9)/:S)5Q\48=[3JK?I9N M.FU.W3O24IXM%YYD!>@H,#!HZE+@\#X]+.@B[O<\/=WV>'3K^N1'=-GF(UW1
M&W+K]=X:N:YF7" -]>_(OPQ;I-:VZPL^)A+U1JY@5C:&NQG!.AC M"")2TT: ML<9CC?
^0G^/6R[VUPE_/5'F3QO/K\JJ1:G1JO+?*EPQVXOJUK (T'H:"+L5L MP^X(V;468-#S_AV*W+!5XM]_+6"
[LU.ET[>!,D8;*F]":T M8F9IJ<=6[9H6ZXW:66M>K+!/L%(6L$_BT22!DTRP(I^U.VZ]KEOK\=6C+>]4 M9*I#/>4%-0/,#MO-

#Z-5BK(D/F# M'YD_J2D_Q"5)5H_^;5_/G&IQ^M+>CUWL+@_24G.6>+OF@STQX2D[XJ%54A#Q
MQ[J&QU;9POV_+T3/N^5MF2C#"+%P=S#HT=U0*![JN=:3'(R86))%3H22[4FP:EU/!0>5NEMIHR92DII_/Z-*<^BD.6#QTL;\N%
MAK';,'7'TLM9[U&,QA=RLG2PO&U@&8^$EW+(;_KEA2165[7'6&=^J+QM4XB'_M6WRUE9&FY5F,-Y*Q!X8='BI:&VM.
[X.I?"))!T;]9BXX+"U4]6#16C&29J7T_M4V0BU9-L=9%Z>$QKXOQ0T=KHI%U5'T*%F925XMFA7"K]DBC&Z'G:;&;RZ3M8?
[VGVEKG>KA\K;LI.A3J=K_ME7$S,FL]IB0V-@\LYEV&WA]:JP<[\H.LR&ENU>EF,M.Z43/(T#W8!X5YF"ZV
M5HS4NBN*=ZVE$(UD$CCT*VOA%D2.,*(H&)M*Y_M%1:U6I&\Q[5Q$6I9B]+TY_M"U7,^/Q/KHF[K?D/U9-
]Y=IN^/:YN]N7N=X$SP,27ZR$ZR&6_Q>2O[PDKK-B_MSZJ>*8D;B"OU6+14JJ6G<3X^7PRTTHC9I]Y+*(GK8N&%L)V\V:]?
%]>OB_M_M9J=?>_([(*O/7DIB/#KXEX()GS9="&(\&73I2#"KXM[5$1<>JK_)=Z7NOK:_M9'Y=W+U8@,\"E\4"?
NU&OR[NGTXPUUWET:^+Z\M67[;Z=7']NKCO((,_HBZN_M>^OSX9:Z)LL!-S/$+X][I74X3I:B_?
U*9YPL*3NM3&1M*0@UF]D\9\C/9W(6_ML]SC(,3RH71_'X9':LE8I*6$720W'G^IE(;/N]^:=[\EZYXN#_LCO)O6$OEJ
M^,$R)'&82^?N0\U^K3&WV[,S-PQ]Y85P7!OB1+7UOX6T^=,WZ9>L^7B!8(>_
MW(+ZKY3$R!1S=T;_<60VER,N$>^J2G[>FMOE@6.,?W/+YU._;,UIR@._CT_# M"34:F;/+*#UMK()*)3BM:96$71R8O8E$8G]
<\1K73OBBQ@+GWNYW=5S.9EU_M0S_GI_:'6^?<]7&6SPNST,(<-ZR8.)_XEANR5O=N-9U6[0+_T1<+??I,[C.Y
M'\LXG[7R#B87!T_=IJJNDLWRJ!JNS&I<-)":V]5\(T'VSPAB#_55T#F9V"9<_M7P%3SC!UDC[HAS5\=\D/:QS=RLC:#)?
8XK57?"=!')O13DFH2VQ]GGE0F#ZW2_.RS$M%+7RF]9G6CW%\VFKX"-,&ALT2G]7:9CHBU/OC\;PXL%()NU9O
M*'1\\^'<)K)K4;AE,_SPAN_Y_+GAC;U.ISYY^^3M._9G4-%NZ7RWHM0K:CDZ_MJ:_"XX=X6.
(&8FMD65F^VIK;E6E/44+_2ZGYN/7R_W1&/%";\D^JB[U7:/;[_M5<$^;=G[-R5#E9*S;#X061C-
%B,\%NB2MNI*0[NV+'/"TO<^\UXU\YY_;^?F_MW1-7L'\3\TY2L>+J+0>8H;/)'LOQ:2O=Z%3M>K)L_KMW.PM#WWKAI9OCMI
MZL8=?TKQ[+>TZ?F&!;5/9K#LU^][7NHIB1G;G:]J"8G+AL:Y1;2HIGND6B:>_M-]S$V!-F5?J,?SG,\'7W,\Z^U7/S_>F,G?
R@W2&CM2X;D$9\KV4_M01@?&QC?A.A7+9ZOK9]_A*)"UU&N&SE3K#D(ISI%3:=G
M[Q"S(8\!:6^4">^N_;^VZE&MQ0"61=7TWRZ0>W;EU,%B"=L/A8!=[HH;P,2_
M.7G.+0VWL&GLE@UM"OZ[JT(X4.';6.P_U.8C0F,/E%AQU0.PK8JJ]E/;-56=
M[UZIN>5@!:L"L\QMY$1(V3'A@QL4_,-1(QVES'\WRLF#_(*?7ZS_3\K\8L7;_MI$;JT1IKNN2\M/DB51(H!ACZ=K-:!XR;+
[?!OP=7^T<06/Q/'$']+\62)W_M_M0'P+<8Q'7S@3VE\]\WH7+2>NJIS4%$4T,07<2*A]A"NL3U#Y5^J"QP*=^+!5
MC$OILC6(9DJ]6*_4J=K:1%1!QB?,%\9U<1CS)U<1WRM;L"T3#Y7I/J!@?OP;_MN?VR0N+'6K*'HHB#0D53)U71S^Q@+8P\Y;:?
DSZB"=0A84!!Y#'&X_DQ<$-=_M$)0MJ7.T+CG[*]C;B[>6.!/;E[3>S?7>)E?7M=Q_2IJB0=V)6AV0I/+8EN26_M*IC]=9F-
+RF1_LJVZXF:*?_C%:R-X1+$IKT+4>4U?:++II_X(J>,.$W-+@"V5,V0LZ$X(_M-__67O)TOMF%\BW5@/=/_M8_/XPBW4F2-8]
9K!!VX&)$H?/1Q2',=V'?-_!>51QPJF%R)L!F)/(>4B";(ZU]_M_&:)>C)$WU)-H%N=S_([4
RW%O\>\6V3ZE#G5,3O^M6X4KBTYV5P&>F#,(#P!A?8VUNO:W3V"49:!^"W2_M*E2;_/*6SX-T&YQK63@781)A,9$UT?
0"S2,MX=U]BS=)IP*3$U5DI]B-_M,D&[&Y=&9<&D-K'0!!+QC=0D_!]U(%L1M(DLK'=3$R8$$L0DM)^YUV!T'0ZY_MH8H-
F%3L&+D4Q4Y_M:&GKV8&N*1MZ_DAR0Z"](0_3O6--\,W_<^1@P0?-3T_H(/S6M(HBMQ_52TFX_MFTIM@$.,5AR#:UFPW4=:
(C8IFR)T_6NM'AH5UO!Y&.S7.17_MK5YY'&IEAN_TLNPMO1=E0/C+"#^0_W-@)OPOR#&48#:?HDP#%A\BW1+$_).A
M@PI.H^'*UA'P+&7_",!Z']9H$LFBB/V_*0_+4_#Z@84\2*F"21FP9")=O+RV_MRR^V4)4]=@M.].R%3Z#K&8PU;
Y4"1D1+@,"VM>>G(ZOFN#;8"-$=<)@SNYF_M!L_P1N+$%M8P9]@J3SOK_CA/_M:'F_8QS_\3#;_@J_M,]#C#%CL
=Y;@X6:@71VM2*H6,'FCS48UGNW#&?;BF;@D94DR$N*LUO+*8(Y_MTDAW.)@'&,$4;)0WW$)EN>*8PMFFD+Z!:%5476NN5V+_B+-
,#'%NRO"1P_2R3TOAP=WVX&6VH_MHO[2':*_9T69O')KA8:A\2(A2=?J,#QH)B:
HTN(5.@"631HG!;;+Q0/MD.B_:=2+DH/.BZW"YH9O=))*FH*-Q_MNRR!"DLL1*.+6JSKZF=P*@S;J0"?_ER*
(JG_VLUTY[%F1>YSTE(.-L(T4V\E_MY_-W*TPWL.-(P_P(0%?^M8"L7>&71NL2@P@)F[CZ#6YQ4#G>%^Y"M-EM9)OE
M2KMME0=JL9&;__CW1=4(K.TRFX<@AMB:'>*_?RH]3P_MTJQ.,&@_*,%09)SZ,T8JN\8+0-VR4RC+7OT=1TXV#_M>*.
[F7GWZ6ZJIT5KD>I7C565[@#>F-OH\WA#?]_1_OU]HW+3"A4X#NT21,QD_M_AJ7:":36Z
$MT%M"Q<>8W7$0WWA;J>3SN&:1FC%J95"V(-+0_M+Z)DS3"N02!MQR8_CH8!_C34B:$'A/;CN^6A^C^X7@_&V^1RG*J*BS<_MF_,
(E1LG4F'_\,LQIK8=6H(H]![!D[?=,]_%$]1IB$OD+P_]H4V,?FS,L0/._M+4?V@WH7U!T@#:U9XIOZ&3K@H@T=)+
[P'I00SD[P*?W9/C-PQEKG!(D'*LM&UO9FTZN9X,_MFBP:4(TMV\E;W0>=^,%N.&1=-H]H%<-YK3.'88*"A-?
^Q,74W4G6+/K+MM.V_M(C^'1\(KIY:H;\6CR.ZXY;H--#SHKK4/0P$J_P&EJ1V40U('CB21(V_:VP38
M(^"&]L@=MQM7TH(D0A\5=-P$!#DL8F)WL:?_D1$-LG:O>8ORFNS_/@A4@0N2)O"1!,:_>F&NZA'L@%CBAA_A-
];GE6GK.==$$=PD]!'CKY6B1_M%RM?9SB>G,]CO-8K.B^*_\LJ522H9]B;0X'Z!9AMR+8][\I_NI&65S-
2\-9\\%80('O1^O#'_(?H!\U_MP*.*E.VS:=M>_7+<01'1J&\T/XWIP.R.ZY5Q<=$>S]-9-A%4I,H#/4S.#^7K_M!#%C!P'=51?
=NI%-3Z1T,K*<)L.3R2*8WG(AZ'?8FR4!9E')"5U"%[BUE4E[_MK,Q![7$4U;-=3@KHTV(R-X^-@N$$O.N&#A[P#PP\M1!0M-
G6'9@P8%R0DUD"_M(+0%7D7'N3Q&L_#6_G@5VAEEPP+N',W&EH1]")N^R_FD[%Z6$O*Q1R=+)0[@WQKEKS/_M)3
(>D/3!U!I*VU5Q8,$4>5UG_C4"FA_MZ,)6@#,C7N^M,4,Z&?_:M6^[1@"_MB_0G1H:"?WV.0IYRU=0:J/B;^"
($R_LVQOJM!V:%F7Z*O[RS'9@A2"/EL&&B_MN7Z*,-[=G1.RL^G&(2E'+:(]\S7$$_($VT/K8+LPBQ=-*SFHT]EXL:$;';.V
M*+R;\3]*.F(C?3=H1*<+J)A@_#QXFG9X_JH.X')KC,Q%N153:_MS_S6_SCQMH4!3+]&P#,'D[M"E[@}
6TOP,@H!L_<(Q3==G'Z9.J=A]R;_^0<_M]^+0][[0#^Z_/&@:_@9WS'+/)&'1G)I>V-&]C*9OHWE=@>IP""@Z["?FT[L(
M71X/IOWR(F4J>#Y"W^[?&=N$@&Q<$7XD/-('SKBEO!>3=0,=KS*Q,.(G%OJ)_MA5>:6.ADZ]DG&"]F]CD9>Q?
B8>R(;N+X4G,!+,M3!_QW#KF-62:MW-^U--JB_MZ^-.8UF,32J?N,F[)92Q>,!!?3OB[Y?QB22GTH&..)E83RTI(H_\#CUCJJ'R
M^Y*3$!_MG!;&'\ZP._6,Z6C;>JQR2E.)='-1Z8%^$GIXKL!$SD!]S$'J,R;59EH=EP0Z_MFPG?-T6]$L\W3TY]
(TW*65HLFFDF5]9,DCI\NANO(F28E\D/3&''L7@WX7UU_M=/L3&;59\.DQ\(A="S#$"7
M81P(;1M.9'N=*&PGG3H9M@.FK4CIV@$2_M%A.2I[\Y7O'ZO21WP5(E59MO$D9$3"":X=D_1L$Y47$6B\'7'E_CU\2#1<
MTS=IDG8$T4Y!POB1[BR=Q'H/A-IO,%\$/3X2,C='P,B(O(QO\)9+>!0(][0/L0P_M7X4$Z?$+!RWP9$\05'=G?3M;U_&[&3?_M:
(*]H!&'!VLD,__X%/>)%GM+09/DC+0!KOT[LBV_M1A>,*=-B)79E9G,]K4%+]!!&[FTI\)!/94-J0)#8^WI:K7;NC:R0@)%[6V*G
M@)7"(-N@Z_2JF.DUN$QYCN_M-&D8K-[3;[6V/E/2<_M0J:L=$L,-M5D]G;?MD:JJN;+1=JJSHO=.)^*))/85FMO^EAM
M+*8C?"F7SE?O([E@<#*/)X=8GZ)+8#V(+J*_M=&JSWJQ=E,""?9K7.+'(9G#V/8AFRW-V^,"O5)JM9B/).S-B/02K,'(?HL%*
ML'V7,#KQ9I9O=YK"7:U;2&_]_[TM#9E!>< 5GPIT/JK%!A6IU8@]8.G>O9%_MYZZK#Y7I4SK9S9=HA1[+J3*.W-M\,%>-
/HV5N4K3B@=FL;(^KC^0AEO=6:3&6^VHWM;VE4&*J/BT"BGP[T^N%Q(5TMC7,)\/3V_M,5]\K_WB,[I_MR13:?
#M4'O)S&'DWN:9NB9U%Y%,@JZ;@72]*B>DD83OW-N_M0E<>XIIR/Y62[3K;GN2E4;^%[]S;?*/9GXC326'>;"5#RJ)
[5XK(4WSG>O,G_MOL:[N:M;'J"&Q;M!^%*G52:IOUD?<;IPAVGL[JG._KU>-??TF)_*5K@YC38&_M$CT6"_>#X?Z]WL/C_'N];
[TD&[V^>[UUO-07(/1#>4GLJZMNO/.>%<9,*+)V_MJFPG6:+SD5/Q9_=]R(H,EM%/,@H__K+/IOO:Q-SD(^\[HS?
V>>]L,V;7)R=W_M($<_;^+4.N>P.V_M::U:Q#2&=1K(ZH:;1RTO23Z63I)Z,Z..5VEKR]O_7V<_^X23)UV)A*Q#3
MN@.)*R]XZ<'*EN7_5F005\J\([2'=\11R_JJR=IGNY*+#V+6&*U.&[._M_'FQ(8LQ&>2.:_M)T"#W<[=O)T7:ZJ<%E(]4ZW-
N,%DD7C^8";HN:/R6B+_M=H;0!.]9D%>O\Z6"#,;+2,X11\EX*T??GQ>CBIM[<8[RX3U_)#-C>-_4X_N)@FF,1*D5*&OUK)QJ
M,2E$$TTM!8[<^=[*.K-ON2&8^TZU!%>67(()PDL&*FFQ#]H:20>'.^1C,%IP-:WF>G0DQ7U2MQKN\K_ECKGD.(-

]V#6D0X<.>)S7XMR0 5B%)2)K"WQA!T/5'@> MM+0SG7,0AI2P65.\2T2DY$]?G(E]"R]!Z0* B:3G8FKVYG%BMV(9 3"MJ0$>
M5#LW?V#U> W",W1=ML>9 @^*MX"POLKD2D&\@FY3BFNU>,0>WB'2G/-!^WC7 M]K[Q(O#.9@[[WV](])-][I5B3/ZW-
0+0K((K+DCV,(8S^MY/(LD9@W9C_-0 MP2E)4[- H]N]T;%[.&4'>JU5<.)0[IU'H0ZT%AYD';8VKD"]PQL95FSC^/+ M@]JZ
H*M'TGX=S_8^Q0KBG.S62NEZ_6,OG@,1./Q_'PO?'L)*M!N /"LC/3> M-+?](7RK04J1.;<"C3==)_?
F43BNVV0S'HC&!%R;ZQ)GR,CV?:*-Z,6!&W&(MWY"((@X#%,T->G)Z_9\WX-WCD <+E' MU.[? 0S5_[93Y-&L?
#4[W0ES;V5$#"%\V700B?*/I4C#A&TT7@05?,%T&(M!H\B--1\3$._O&OAKI^[I=
MQP[EO7Y)!\77[,5/PV#07M>+%>/L2^W[_ZXKQKF[Y3490?!_/\(_/KKSZ+G; M0,0.P&E@&@"K:%['3VQ>Q;;
%Z9MGX.=3R[NIA8U?-;64\-;^!XC% MEZH7R"=?"H,U][?Y1Z&O0U?-?/@.?BQ9.A5"]#/D$#LNM4M)J!M]FU+S4^9E
=Z/S^I612]V87'4T$GGM7%V@Y8G3NW&#YGR/LQ(F[MGV$K'G8E.6+>/+W@5C74MV:Z'JG\HIOU2C)'&\N)G?;J?
KM.FT1.L^]8.+FN M0MJ,1QL/=P-I*8KUQTZG&NK4$I'S;.5RI,1.-JI.4EAM-M/2T4;$>'BKAL2%C M\9\
(2HE8.'P2*>&;$W^\H/B^YL3A>QD?%11+NIE=9/-J6PJ,Z]66H(4ZM/'Q M_-).T_3U2 *BCB6HHC30=^<*7$A\[40[64.)(Y
MT8[RL6&0F?-I2TD4[ZNU;#X:.8.4: X[M62MUZLV(]E[QB,Z\N0L0?!^)MFS8CH@^ M7(%1JS<=X:?'VX59M_1D2DIW&.Q%1$-
AZ3,(/Z$O9D?A?7WXQ].VKP_'"YX61\:XTBJ M$Q+Z#W1RT.K,%\MFLUH\PPE$-4>WBFIR)4G95B!:F$2$4*R$E;WC6 !QO[V?
MKP]]F?&6>,'UR(P]?7B%Z03KGI2DF/.KU5*@&&PY=TC?RP\J?ORQGP_,ZL-<5 ,9MI:[7[MH+=,DCZ03CD MIQ_X\N+K\A/.OM?
+D1>G;:;Z87G1GEE):52OA^G\1)RUC?FX^9#$_C9^(H(O M,GP3XY)B$T?N#?QAD1$?
T8\E>31*TEDC.NEV[R+*0L4V6W$\:XR&]^N8^R:& M+R].E;-P]KU>CKPX;G2H/)JE:;0"1;_\,'GEH_46_R>8/'5B\\POGKQ
MU8O/+2>N3'?58+GF _,(>7]64 6=DTGK#JZOB*IHF#HI\?=GGY7[EV'*W/' MR0G/J;RF"'6WV4[!:46TE1'G<%E"
[2>V>,R)!CF9<5VU6!(;^>X#G1U,NL'. MG4 SL3-$HB;=49N^7W85FDT,A[HH5NO+:@+ X-S-/U5NW+D9Q1<0_N7[$UR^ M/YZ
*+0CH=[H;IJ3IIG'M*S/RU8L=H:C+4U5'CJ*UDC3BG:?GA1:3+*3F ,8 MR&EX)/12I-HW(KZSC/B^1L3+B?3'DQ'CBG#?
3LC==+,N&?ED5Q=*B6/1B"#'WS1]FHR9\S.*+R#*_9GCJ/\]H0;2ERWLV\6+/C
MTL^[=Z(LV(F;M#$G_9R%F2!K$])2]]@QEN\AZ0[4^T/^G<,CQ5MLH(M5K+6"JC)D!6Q'_\&SU1?-87 M%-L'EQF'>
(BC&O4RSWZT'M'0^G:&%M/Q@,8,S"(J(PL5&(ILPI66X MF&)3\TX_=8_>!T9APM&7K(IK3G[QJT6<.39]]OM(_EW-
"XCI7$HYB(R0+W5C MXIJWRH+5@ M5M5&,#B'A7ZS>@^^3/"-A'/':"ZEH$,C0&!@/8%FDQ6X/-LOMIJY]A 6^IT*
M.O@"P:_8<.Y8S,54;,C1,37<5O5F,J1E6+U;I9^F"5CHFRLV_&5R@-%_W6$E M2P%,\"= X-
@R3'&P_#QCGV%E]K/X^;=HPD/_IVMO9ZB9UWPN4%)OA)5F-C\ MS>QU\6Z,! KIFU.7U%#G5-.P V N\"B05?
P(^=$0#9/2!M1/\1=EPB*<$)DS M[L89.!-@%.8U]00,C5+"0M!YT4#"0J$,JS<6>),R-2<<"D<1YC9)\=GH MWP9A?
%&UX,4":2!#\J(TG8+MSD1>@.= +@Y'Y'EN,@'\XZO)M"#RJ#YP+IG^ MIPC+G @ZX7N5?VFUSB^J=SBE")QAZ0!
[;LB)*HR:Z$)?, 5=$54<338BPO.P M$LZD1+N<">P0Y+5A#"R9Q YE@0A @-K4 JP,1-S7U):@.\&@$%U:.#N.%4% M:
<_#K[9(V!$?_7%F?LQ_.-2"B\+G(XZ9>3@=*T>$+>N1J'_\P47*]F0)YQJ M4Q83M?>R6?
M_>1>_T7$!7I,U_;>KR#R[&ME,S1*=-@0*!5N$? S-&@ 5D8F+_MI]RO MB/)SO],,$1'\6Q=DDEN)
[]YZ*\&*J4U^L\QMY$1(V0EH!SC1CJJT/]N ME)//RU$5B5[>DJ/.5R ?"'L! 2=1(ZOF1IIR_WKP^R)5$B@&P+;9K-8!X^;+
M;?#OP=7^$50N_Q-'4/]+L>3)7SL0WT(P^2G)V MS*=5?0AV2W1W9"00,)[D='XJ+1L+,6 $BBK;GW?9+KL[,F.EM;(I,ER3BQJZ
M-%IE@0,\CMQ[IU9F8ZMHM%.6IH5:/C5DK$IF@AVM]MY9:])NE!%UOS[LW>MFK=3'*4"*;+^;M%
M>%Z,C10WV%)F;_;0?)1;I1K3")V]$YZT?DI^LD0LMK\WNY@9UO5.GX^DL],0 M'RED:E:@D("1>[/3]4%RU8W,HNERI6/-]-%\%
LD[+^VR,';(FK*ZW9()V? MTZVN%=,7BR*6XMM;IUI;11^7C\%4LYYIY!NSD<$.)EB$:V^==)C.19.Y'B]9 MP>;=2
&U/6U/R\JJ:3B% +='QI-Z[;''&\&T M,BTN)VRLG,8N;?.EFS6F(5'$M).A&=5I9)/9_$=^ZML_K43W?[3(M/ M+T>35D
S\Y/Y&.]_T;LCV<7#S!J'GFIT_B'03DN&$5=:F.2]M\[(4W40#MZ% MA\URFR0%F8(4G]2&]GV1[9%,
<&$*03M!2B>-1)$NBW4E%1IV8_NSWXV$7*S1 MR2=H+C:=R_%H*9*(H,>^-S*ZRI9B_4RET@0$)UFY7.M-4H5JEZ'WAP8:V45N
MQ3E@0R;)[2!'%1[1[85.F^'=6ZG<60GCYIJM@+Q8>5X$%1FK6TPB J M/_1I91"607UF$JW#H00^VQ4?DG-
NTA2ZX4PXGF)C\20*R+V]+U+CPKQFY8>2 M:"3H>#5BWN4JB4,"/!QDZ,IL6@AVCS$IUK1*+ MWUM&WV3FAYBO&[<*U=J
73:3O5XW/QH%S"R+*4CNCL#D=6Q_^[2=/-<#K_KI M,3^5K7!S&FT,)'HL%NX'PRX.97YLO(6$^=IH]A1&\+
[WM\XG<$PPL/UD\!@H M<"4L&9PK<# H'K[!H!!EZB(G&\1?L6V2F;#YT7U"FPG@(%#&1.!M!\+KIL!G M4>O?4AXW;NU*
[3MIU(B#&68*G$^F_ ,NYD^/&'RY29ELY)JDA+ MDM5/&/$P7TQ%>C"A8/#=,[I==[=19B.,*V[%=<(-E;F((O]T/7DB@\^BX
MP^@L\;8WMN5A<9:I;;M7Y)LMEVC?(]H/%9BZNS!G0L9V)M^6V!6BB6O\?#C: MXZUYWH^R9 !8&(]GSTW87U$7 (B&/:69GQ,7
F@"5>O,'B(\)'Q/="A"^;+@43/DM< M""(8YI9YL3R$CPF?);X7(IC;8-Q'Q"4@PI=-Q\7$.Z^MO1K=^!ZUS5\.+'P:
M!GM92O_TMEZYG>QEWWK=__>?OWK'V.VK%O*Y:Y9_% \I] MPO]^A/^J?7&4[;Z&\I< T")_"?T [OAH!0^^&99?,>>_!6.?
GM2OJ!>);]=^ MA5U[!3 XO=+_K (H67C^;LM#;7!=6N *", W?7W3UV>'*S*($[C;BCX@O#8 MF/>-9-]
(]HUDWTB^1B.9I/@:ODYX%O&\)N.7__>#_?%1(@C=LJ=5$-\T5'8- M N#BK<*:H'"B"BOR<>_;A=?(+Y=>%ULX=N%UV 7-
M6^H,M+7R]\=]OOCQI= MJV+\+.:QD L6(+,XVQN^;$K =N["D#,/2@'?!O)MH#_3!BI;IH$U
M*'TCZ+L;O6F[.*%O!7T_*Z@AZ(J/]F]M_N3 #A950^1]\\0%GSJ.;2M=,47\%%5;?3X)G&[\\FGCE ;5 M%=/)
(R=;.Y+C8V;6N7N@>"((-]0#IUJRH,UD'9/HZ_=S M_)XEI)"?T>5"$Z7>'TR5--M6*I/J?4I8!.;;;4L21K<\P-
*V0:=K"3/LQO7) MXUA(6\%&>)XU:^G4=*M1"?V./B4?+F'IV'<>&K9O5*Q;FM#KEB:#7,#2VH*<
MI"/%%7]7'36SJT*U&^VR=H^CX$V8CIZF]QG[37N?7<*^C]+)Z/J9/B7.Q+Y MVA0Y;-^I#A-JJ5Q9-)?
2?;A=3%2S]7CBTVS/GH?MW?1 YRC8#882^_Z ,-"[MLTA%B$XS4IXM]<.YQ=.#V<&JT.$?_T9OXZ?I(G\1_'
\3>B8^I?,%.\H0TP: M<7DH?3 KA%#-W&P+C,60SY(VKW72;OW;M)>)T-ZSKXQ M
,RNB9ONE!*1AYSZT%0&]UJS%4P&8EDD[BB(B>@ML]^2YP^A[:_7<7;^Y+GW M?10==P7L?.QF?!]0;^]JOW=$_;:.
[Q._\T#'/F6EUB9A,_8D<:M6KUFK"X_- M-C(]-J.(O=:M[X(/!]:=N"*VN^I4_R?]W83^=4;ZC^V.7A^+OL/W_'0/W:_T
M1+.D[6!.M?LI9'7-, Z8GWQ/GQ6%SLQ,1^3LLO=87B342K4;0U^4N0E&PS=L M/'(Z&_0/5\K?8I/7QOD?-=S'_.UW2OG&
<"RFCT1.]U(+)Z3"B M/&+'= M6$PU*KME>/V%$8_(_(;?"$X8AOR%*7&&SWA>JW.SCR*?], M#M/9O2/02P,!<-3_2UA,1-
T_2#G[58=0X?9\\G0E8U.MI6^LG .63&F5"8;H M^6(E3:6>T2Y:]1C72G09&AVC:"QV$PHQ)_2,_G)_BTVZ9^N7)Z#X1G+
M[CVANC Q!;QH005I^ZH0]8]A;<]*WA.]#%([94-+4)>>W.ON%K MO(+'@#$&;SO>-:YSP^X+KA]M>RY!\%SZFM63A4MP7;[J?
M+&="FT)^'H*E>M M2,M6II".U\L+LY&XY.M)L7AIE7Z8,TDZFT_.,S'M26@_5KL,@TY+Z";(LC?! MB'_Z8\+/?
KWDSY]/^D];'\=UY/*9K[>X;/I4#K0'-]%0U:R>A]-H# @AS'1 M/U@.^/>3/N6;7\'U)$T36\-$M2U(63D?
#:3J7.B!)9K.OI\4]N\G_6''3-_F M?A+BCV&OJ_+6HV]U+ S&[*'(=N V=0VF#CY]EB&9P]^\-1BT-E-_3\K-^E15NE*"R2-
&18N4^41G&'@N=!%X*!+\+?"XF=!.C]X^+ M_"CCQ6[RB![5U?#NG^@^>;CWG>Z3$4TO:7&H:9)07U;Y:8FV1D^$ITEY!_9/
MN5KW!\73_Q3'Z'FB?'N<%H/D>R1<?!/C798"! +!5* M<_)^YZ(YHCAJ[G93Y6SC9'U;DIJ@38VAGW,M_G^^PM,Y-?
5>P3$3H>C&*)!2 MPGQ_(K'3I\P@E6S2>7..9TPA]F+(^0;)$10"/_+EZ97(TUQ<2RA M#-.T&!\V],0JQX#'@_*40@E&+X<
05SJ C6P9'E)S0Z&RV_79M^>5=P79^Y: M/:.89P]J6R5_P\[][?MW)3%KRE:B"Q6K:EM3.11%<%G7 :/(>NPS(_\$(^^8R
M98X$"OQ:@5)@^I%!"?#Z_J$,,809EEF[(8^X*HAR51"IZ!7H:4 */FW&%#Z^"B3Z)>+BN1^C-5:LB/*)VG@W.!;]<9!W!
N2Q,!KV8#':-2;695L7JIT=%F4TGFEUDC.]-[N0,V+4/?LH?!KX1 M.3<40'PBP%,S05[>4@W@>%,S.9D2W4J&#H/0L?6Z< ?
5_[" .:9(>'=9R4]+ M@T#XZU7UYE)%]'T3+W)B(=RBJM,XWX53H9II3C*L%PT,%/&PQ__TK>'CLO> M*@) U3BM3&1M

M*0AU09^)O'!8.90TU79$R5H-(O"]OR26K,W8,U2]?4D .#-*D HXV?AQHG>B ;Y MAD>GS=2HGD!Y'M3
;*4X^,8Y)MV/44Z(E$NK,:"4 MO0WM!ATH7+AQ^X4B@7Y[_,$3J!$!+"*_W\/LQ[\U@![L!*G+M@!0/AC> [E+
MD'3H"2%:.75)CE.C?QLHFP^LG!H**E"^&W5R.>38Q.]^NP$?80"4J4:MWG0X MP!A'4IV0T'^@DX-69[Y8-I05XF$.F&M OH)Z-
#.7_(-IJNLZ>5X2;Q?TIZ46 MRR_2XJ*HI:7@4.C+8,0.-$L/($WO$;HC1T203U,+/%). 64)X";&"0Q/Q2][MG"$:-
Q38+1A&Z-LVIL/&CI R".Q%U=(L W#D_-JWSUC,#9IM[]<3TP()AC_ M@W64DF1=(")Q&"]K!LK#]8""0+*
(0,0)E+]@2[LFL$H&DT 9A9&UVXMB M@X$FR]J<^ 'V2;FEP ,PP3,<0:'RF>&I.]G&T7.$=NB5'PE]2Q;*@[5D/L0B M"6=-
#=Q" U9P)\-/3E)/KWNW#,ZS8R[I2UQV.*SJ7LE(,)< BC@"3_*VP$0J L2]^\ IB/\ M[ND")P50UOT]
09%NA7,_09,L4=C;Z=8U F;>CW3FD ML/_]5$I3\);Q$7$)B& BM]&PCXD+P(3/$CXB?$3LRJ:0CXGC8>*=MQ!?-9>N
MJUOY::3!%V+^/:@_K5'P)V[ZNA$-3A=^2?(./HCT^&W\M%?=8MO! AX\0$'? M@4AO:Y+MN)Z;V!!P,AO^^:OW\6I:OG#
["IK_+,KMFVW[_VZC_H(%W6%$W"J M$?#.<@Y9>,;*YY_E'A*+IYKV8=_UR,I+)*&C"=LK)B?,EZ5(TMPQ9/&Y:R]M
ME6U]X%2+TY<48R?7'(U3SKW)XQ5"<(3A15>9.M5E)(;M!IV\N,]D"BB/]8D4 M:Z_JDAA146*Q%"LR7,9>L,>)4)[EG?:[[;'6@
M9,A2TOFGTB@];6M)5EDHS4INW@W9C;J9('L38DY2-?XR^.KK2S5:,R5;RR>:*3H"4 M"6.F7ORE_PF&#RAIHO%,BW6^;&>
M;G0J>GS>C9"ZR#'F)A3>+P]PC":;E\%8WS7R<383YK(DCV_5G$$(?<2J"=UG
M:_W\DEE*2;V@KYZR+!,TJB"E_KC02>8$';O_@""*W['[6YHO:VYXP8+)U\I, MS,QWK'1V.8Z4.J%>2S2KW2A:,.'P3?Q
/87C&3!_N-9VK)4S,]^%F"Z7*X)\ M.^8KI1&V)O^($9-/5?HZ36=F:9&9L8^U^Y#
C5%0@1$3.H41&UE(L%+H)Q@Y5]039\]C[/CMW?F$FS-GW>A&I M,E\EBR[#5OI4IDRDRXG)I_G"2$^Y<#'()P::.40A]
<9PCUN4^S0%MS\M4BZA M,,_KM03M6GW.N@^5['O]%>:Z'/"KQ>,H M2,G!HU==NZBZ@Y7[?
B66*]_')#:8Z\NE8C61,ZN(XM@S=0=M00T_.375. ?] MGEH&GA(-O P/H>$QVNF %40A=HH:#
<_>*&%#GE"]+4*9V&X=AO_:JB^QIE\L MGJ7IOUUKQ[,KIZX%2PR?H1"PRU=P YCX-R?/N:7A[#(6NV5#FZY=[JH0#E08
MNTE3FX]__S@ 2JS+Y0'85FDN^ZGMXES.=Z_4T/"TNF"9V\B)D+*CQ8(;%/S# M42,=F?._&^7D\\4D7^KZ00JZ(>MCPT:T9-
::FO/6V7B1*@D4 XRW&)L#QLV7 MV^#?@ZO](TA1_B>.H/X7E"P^^6L'XEN(8SP6LS.A_=4SKW?1PKF&UK#,U,M6
MF*M+;'01,^BVUD^.JRC??M@ 6(\,/38#CU%ZD&FRX6 S"8S>TYAYE]T?6=.,
M7+*U>I#2HE:)3)/UHC$K);JD*^OV2"'6%;K:8SU/9_E(/G[/'A6*OST[&-#+38:!I)<*]>%YI=Y(A/'G=
M&VDEEHU"1L_SS99\Q_39V ,77E;M3)+MD>WE8*84:SI/E^G^@)8>U'ZXG[!/ M<\G('?W@%EE4PH-\!75;-$%LC?)&8:E
MV/;4I3D+^X5-!0Z,+V\!_JTV/5C$52'60%.:E+3[@P9OZHAZ0/7%-4(/>\/>4M)KA"8VBWRF:.BX58F6
M,WJ\)F5EK3V6Y@'#6,[]HJ%?6C0T?,N^6#7"KT+V987YZ)B/B M !!,AOH:/ MB;-CPF<)'Q$^(GS9=(F8);P*TL?$1'03?
%YS6[]VAI@7W28_K(4/GM-H?<7 M8 J_5H");#S$W)XW#?.S@"EA\[^B1IK_I;>;_^VD@WVN&)//%*?/H#B(_--5 M!SQ*K;
(@>]7L8^=('JGFW5>0RT77O6;CUTX,P6-(R7,GXZ7=<_N9AA8>TL#1 MZ/O<>SOF]2?VTJ]-OC'!9F+I0K=S-
V_GQ9HJIX54SU1K,VXP61SSIL$Z%V(3 MDG>2+)9T,[O(YM6V%!C7JRU!"W5HX^N;NJ_SWCSG RXK/*XYH<:90E%41<52 MULDU
=:3>E%ZU!N&OHJDFTNA,^L_/+:'127QX]_X?C-?*O#6_&H?1>]%$;=X M'D7-6?;^+BXE0\V E8UG&Y/&)%"J
HI>RE^\52M\+I07Z4AF$(L7%5UKQ ZKYN-(R/-4]'F+W+^" M^$U--*3 0!<$2D1'##LP XT+U^EJ']OO^#
[*YLLLV."Y)!D2>@;H/.>0^:NJ MAENHF6PS/I*:>;ZPZ(7:G9#,@JH)WIY%UWQ3#+VD:<9B+#/KTLJ\66Z8H6+^ MKMIZ2L_Q-
GGX="[&)>B5:]K"V9R'[R.\O\P,O2C1L"<3&GSWKCA*U\1IS**Y M;(ZSBF)@T(L,[1KCP=M3!1Z^NIOD4:W-
$VZ(SE2M2J7(%5E*ERQ'AF-%F94&Z7Q:7.5IL]^IF0G1J9%^6CER 9&Z M*PS1K3,%P/95J)^B:E\F/TX51S]&=VPW[P/7\ S=[-
:0Y8G\P;^Y].M!=L6JY4%\)T^&;"RL0T=-[73KUWB.=&D#$WB(*N?BT-!7B M0H3.FB6)':=:6K8QQ&X-P;TB"H%/%*@X &,
[MO1)&*_H9J;.K:8R;87* 3U? MJ42R](7!N-NOQ@;IIVB,7FJ=1* Y2)BK1?7'0Y%;9J](T%4*E7-4-0L&F[QF
M$;MCZIU*Q([CE0PCI;,:S47Z77J>:MR-A,1EL7\X&TP^WI?Z\70Y^30*2\EA M;W1'1"S].1'[.HR/(F)+;;F6+L^8?
#K/T+E[]7&9RT[GEP7CJ!KIQI^6UE)J M2>/[\D*S4B4Y\>/?Z#Z,KS/H^&'I\P4EZ0Z4=W@E!?L#&?F74HE"V'('M $I
M#N&M16%0NC#1!0.K^9 ?W3I?SECD:/3K+$[>>H?[-#C9Y.^].F'KF;&2%A:B ML N'W5*X+'V=2(#Y \B;SL\&-1?-D:CNS2V+
V%[;JQG1KC0+9S10*W#VW6! M,X"U[0@QQ5OZ#+,5*/ =83D49Y*A)H!]76/#7I*PGV)M+PZ+=&S-,Q(!@#HR MX&:L*)
*@%BMC]-)=0?R4<7OG=TDR1=+XC1'_\:0^X!3?6E/[_Q*C6 V5< J M;'V!ET'0P+0
'$[L4_@SSQDCJN_X[#;T^QK,H6HFY:!17E(3&2C8U."QO2>< MQ0#$8;! 5CJPL$SW+19U,H2I15YQXUTR9>'N.74#H_Y6'-Y3#.
[Z@[K,OJI0 M+07O60)PSQB2"7GT1R$4*C'2W9/6Y(1$;?74J3.R#OH#(T=[T9C;TPJDUZZO MX.<7:OJXJ'*$$M '#RP@$!
(^MT"]9F7@R'\TM:@UC D_4!47QA44$S^1T=/U M2N47D71<'Z0K<'AO221 3P-B1?[NBSH0IZ83"?)@@9 AKT9IC9)!Q(*'J")(
M!=.WRX-W5RF/=IG@=CP6=U$"KK3MR*%B;K._NULP$I-P:E+F#*,\ M(,]L"1/@;$53R<\)Y^':L"?J1:87:69K]?
(HEUNH(WW^\2+G]A1DZB0W068A M4L.H@8P&_855)3-$2.= 6G JOU<'F$@%4QNO*AE9:#2YU&J:G3UQRWX>+'>6
M"=^$XM']/"0;^(BM.E 535@ET>ZX%3+0ZT-@,OTC5KZ/D& M2^@&@S7$$Y\>GIM0EJE@6['8 MZ:(9**L1+.;RP-
,#A*S\Q7PVCJ_19;[2+4GY)M\T5_/:)"P" M$O<3I_^SMILW[Z=4TO3 PZO.F%TK];!D<"QA45&$0@@"%&U.T \">74*/MCE
MKQFT78$V@#@,"[A<%@R@TX-S'YX'%%)?0+=#5#O#GV"# W5HNKMN%$6W M5%G=EAM8>AOT%9#H]TG-$E?8)=;X.BC=
M[BNIII#JB)TTRY2#&?:^&ZJ.L)8V$[R)AD//2C=45:'@> MM3"1EXW?L.$#5SI?%3+NM(!CKV5S^U5HB=TO=-(%CIF
M;YAMOVBJG,HW?F?G]X-$\F!&U7F=T3OI[+S6JCU,4U;I#H1 :=_?I4^1MP, M'"%!4(D-
#/I@FTPPT((U6Y^KUWZ&4KN[CNMV07@,$5ZXZ_I"S:@+W,N1RUU=_M ,$<"^0GKC5!ES0!'8[^0<"8
M:/5ZJ\BHF=@K)/RV$KWK'@,_7LD+(J WMQ4YW,[(6M#N#3TYS@&>+Y M\6_L]M!AU$4OV2$0BE (Y2619XZP8B;T^6 .813-
&XH;*P*["RF[!=V6W=*HK &FVZ[1,83XN>8S=I>D,J5!+C>H(^02[:-DM=JK@3 M-8,7!?"PD]IMP>SO6*3/">J[I?>7G2Y
FQ^6P?;-(75X3QCII.&ND \'[SOW7C-^?TUE(YJX^MWI$J^O@+JF/'Z2.>C#81;!*QSXCQ,%H71C 2 M93V81L8ME7!94>2*![I-
9D=#=YGH@1 M?Z?IY,>PW2!S<3*FG4AQK5!6&=/)UBRBA^(/8G98?1XS+VN%]R'&#!42]P##
M47H:7X3FR63X82F"1@"VH6EZ#S>[0@48D,/Y8)5> ?.R]+BECF-3D*22]32^
M67$TL^+@HA+D<-0H#SS?'5182:.;G%3!JY*23_.>FNBD;&?K=IW\@X MC9'Q.0P.%OU6_&FDZ.E [6Y0Z^FUE#:H'I;6NQ+A@/D
;HDUP#0XPO3<)H#J M^& 7D";YI2[87G!@N\]?['4O+?">AK_>Z=:=$"G[9M+.?PZU9OU2T%P(ABZ7 M=DZQLNMLR!KW&
[+Z#5FOMR%K-]J/YKJ18$3HAB*A2#<>!..D%^9[7#04 M[\<'T:UFFL5$*9%-%].E1CV5JR>;]7JN7$J44O!UX:F>JY^@)Y
MLZ=V7BIEGFNDBQ1[2Q4YE;/5_SH2C,<=EF&X=F!"Y>2E(1+W/B.JG,IC9B90
MB)U&0<;4!,.2[5!!>1TJ6%=*0X3;"_^(S^<1__CW2;,H8Z19,C:^Y_H[/2_[MVP#A/
#1+)T:K(' ";P%%WP#%$S\151PVME3;JB8)1/B60T&8S9L]X1C[U;9S MIVHFN1' RQ;Z:H)L"/.1G6T$>X
EU@2,+&&"50:8G&+H0)5DIN &IQ98I& = M/NOG_:S:(^2E\YY?>+D WOH<0/ /#4_7*;3AG20P^'[W/<0QX&"-L!0\H@_(
MFB8AI#W;M.](6!,,B@%X>-MK)NFA]D3V[0$'JN:(,V'3,TV>V==!#+1]>4''
M:.75A"*0!A>"49"IPJGMCVYZ&S]XY;TC52G43%>L) MLB@,C%NJ# \[]TQ<&G#0M9BB0EX_H(09F9(G1-<7!P.
&C9NU462SSK0-06> MT-!3ASEX<4(0;D?L#.$ER&':M3,Q3C3C=%&S# IM?DTGRT9RL3U^?+\AF/@Z MH$/;6T!!P-
)_8]TK*F,_1+YB_K;AOD=DN^B]I3S\Q'.@E"S"?I,%.87)8%; @E0^@7T M.0*#>T,$)JP-:+V_- :._^(7)%,'D
&PB3XA[(/9T#5X/ LPX*Q!*">Z%K?\M"MX%G4#;Q)5D2D&ELPR,@%?=T:P@: L 0 ,&H\2*1,(8)H[61 0,5SPLYBHW_^Z(?
$.PHB2JLVQ M93;@!.#':R/RMKW'2OC8+97:[(Q<1B.)3X8)\L>69@@_*AJBJ8F@3<#X=+*? MR$\H]AU:@4T 8VX)+_RY0M#-
(B"28&TUT@&&@,CYOH<_V-^SNZ\Z\3VF=S!& M;I-E;!^SSU'FJQKJKSYEVZ\SA,Q$QNBL*[?6).C=;/+P;D';V+VQT9KQ8 2@

MS$1BA 6-)?:!'HB Y3Z%.$<6$(E"(3:*S:P9%G.P,T&;45#GVW<4[4 S:$Q> MZ&EX+7(N"!(59NW;B&]9(84AX9!R26:-!--
),IPO13<[/:^G.,O10/Y;Y.CH\])T!RYAOJIY!J- M7X"$B243M>^AP-_0;;[].9_OQ6P57$1 YI::9?X>B NA?
X@F/8Z/ZSS;NF0[MU\B30/3C+^\/G]K$,3*8_M]_QR/1^-^OY SM.;Z?B@R^P6L&&G+I<4-X(&O! MJ(G1X;_9 /D*R-?
5$D!X(!Y11F8**2J!PASO!]=Y31=^$78#/%)S4%S J[9M ML^:WGU[^#;/_H69@B;B,Q]+_ 87S?^ MTW3PEYUI0V@>6 ?
[<[H>Q_.0)[S^ MZL*]:PA&MM? !-=K"(5^W:Y#"'O)45_..;3/.!?%.,67!+>7*,&HU\%0(#9,
M;^F2)\4X2HG0K*IM4S0A^RU"#3$[A!IS"96A66"60XRR]]K#?!B,[;PZLN$! MEP\Y:H@J!9UC7?/D>Q1KN0"0E(BZ#WXQ-;3B5
,% IB1H.:=\[>?.+"2RF1^ MN0 (T0\AQST:<80H-\#EU<1;JXR$=Z0%@Z0\?[+Y-Q$8#)AK[AS>]Z+5OFT+ M.//#IF41[;R
CU8!K\;$X? Q-6\MI3'DN*)>7V0N\!"5TC%"_N>&NP? M_&]\"DTTM(]D6!6>OU(_$[E?X!D-,89&O"5-
UH;+@!VVF6;:X2:P&KS#2VQ+G5 S#05Z-N2RGC!S]S$H($4Q@@*B$] X3.I:PZS$*ZM)
MDMKI3Z[E:C.)G4BUYA!"K>22,G"*A_V.Z7!<*YVBJ[-))YX+;I$1KY\#[A_W M/N<&DY8]# !"Q+",M90#W+SBWSC2)FV!7!8 E
G'&T;*<9WH.KBL2]>]+Q!! M]3.=J!=^820^I<'A'11TV?]MVFK[3^8BP;N33K[Y#;]#5>TPO6
M6C#\"P,:K2_)D_*9Z<*8J7XJ#\I# MBML\1.]0<,BEX!#]:TM!;?M@\6>#!4'6&VL3=?&ZX2] M3Z+L#F6S:PJ-
A%^@[&!H^['0UF-0(^RK3/UB:3_URT_]NL;4+U^/?'<]DGCA MM-%."A&
<:!FH&>+E.TXY+^KZR+;K,R%BL"0;UOK..\R]4G99#;]S'KD^C@R& M?FU97&]R:T^B-
HGJC#R#S0U)>54:D8%^6,M7*9_EV'614HQ)"ZK@G*M,-'EI M84$KO"*'(6*P8>0E#ZO XXSML[P:^>S>(_%J)__BXRW%0,')@R
1^(PHN>8 MC_D (_IJZ-L3]?I\;/>TA7/CL#^!;.U<1U']M3Z%5"GP$F0[4QNRAG\I\MZ1FDWFM/USP4/L_^=0
M.L[*!#T08NV1S[V(.?BB\/LCLH>=0R*LUV[IA>0>EGE3P[1_^TQNW?D@HVEV MH9\4YJHF-D52B7&;225^V>T.
)MWZ*Z[A98;)$<7DW=1\G'N*987V <34U5- M#=A6-:;?$H.$8$G1^@)IG OX?HSCB1%.ID"Z]@ZKZGP7Y)_L$E6-#!;$9[R
M9"O^LCLZF(K3GX+#,#XOX+'CJYM0 +KN@3"'Y8](5CUL!7M)!.!)//95G?LB M1,H[1\PRYOQC:'9];"F0BOQ@MY%W
J;PG%IPDI0!,"0]6.%P?D53[=-NG-/J M8;H[J8SNM?)(#JVP$.W&&':2-.D@H<+_!%RB@@?I[O0[2FD=,+Y]'08[O(\5
MW@UK@LDL=K[ )PYQ7S^F]:2ADBQ4^^,&N1>5T;O-57.[@8QTXX9DH)/R3": B:IS0_B/>X\-5FF@-<^!1) %V_HG"5 S
M6R*NM3&NVLY/N?5LV.5(+ \K..7ZR+4V^X0:7X!SKO6*+DPM$5.[-B73UU(8 M:!Y$%-XFQ$Q"CA\)?;>N%$@0;+JD$"T$WO-
MV.X">TOY+H//SR_R=>[1NO*:&I;'.A:W/A=:5"ZM=?YY8-5FO(O4\-6=L. M'GE%PRU5@CV)ZHPS=C(0"5_W!$>FH$PPR(W:=
<>U_=/^FW5@;TLJN;__ :[* MYB+1QB3!N\C$/+6Q2NK2B6AY4XK=81,AQMS$:'I#@T &FF&/W_)C,85TFTCL M+D1)$ZG""
<$@R;=Y=B:[K5*3/?UW/(B!AS8WZ(=K_7>%"3$VQ.6FG,YQ.YI ML<[-W;@O&*O"WVPM (P(!IQ[O(''))9N;ERZ[&HJ]$-
!N2[R%+ E+"@Q!P7MO MCS304&WOR+F@32X7VAWO_G][7]K#0%ZPM!B)JOZGZ&U!3QI%&V M17H3Q*>BM91U%+>L#YG?
LO;47S&%G\RO +A4D)_NB[L5 M>"NR,CN+AL^8[+/2R$UQ7!\7=W21AQ.6R,KZZY>A?H^J2GX2!K$;LAOG) D5 MG,HWK;U?
WGS<%RT(9FX@C3IB'"[@CA?\D\^8VX*S &NZ$-T A %3G*LL3)0&
MC>I:&:'"K^R1[K"]5&9'!U($0%C\1^7Q",E,4B#I1NIE2[6/RWK3S5_41;+:Z7>O80W<6U&N7A&6N64L8$+4MO^TH@[CF@0Y409,:
M._[T=K_)(X8VT426NJIQ('+#U;K=AG7V_]XT.[W^H+7S?8 J >_*7C*U:N]P]UF='Z0L3K 52LZW79ZRI&^*3@3DO"/FCT-Q
M,3XAS73J6TP[%XY.V04"-/^0JU&Z](P217'Q]$T/*P?YJK&Z6%XB'TV+;@GE M3)ER@RGH764C&;[<^%4(?
B79JU(31'%ECI'F2O@WL"54L5'Y4 _)&917JV5!M0BIBB'*ZM71UJ_9:V&U$ MD4=E,V-L6I3JM7_X[C2.(AXV58\A5+HC5DHJ
MG5GJE(W%EB9:_ZWB*Z7=->8\%4V:18$CS4)?>&6<3%@4_";;:NT=?3Q)]]4) M5,\MB0#E<11Q2_=.L71Q.8NK?CE)R3 J-
&A@7B">5D;7%&ZE69XI+>8W(,Q:9>_))^0:Z8VR4Y/%4G%$TN(+KD+Z:XCI9&,9> MB4_UX4:'87ACFW]1P>U-,71)$-.
[^5=I=W&RY2'\CFYEN"G5\#D%I= O*VL' MG?;UK?4:PEZM\!1MU@+VT"+1P\2K"-D1UM@U#%Z(HD\&NW#^O, S_,XDCN7$
M^@*&)+:4/*(A\^A:(+FY_I(TWL/2\LHNIUS9F+1ZV;Q(\C?AOBR^)K93RF$9 M508;%ESUE'HPLZC\NCR*1?V8?5X?A"J5
"'_;T(M,JEE5I,6GT;QOU:)P8N^ M+,%*MGBE(58JU #A%1#1Z%M2>P-'0J)XP.-/&\5XJ^ M^TM]V8:L&&S5D#TYA?
N2E>Q1DQ75TVB:0,@GB+V27>FR6=BDZ+:,99<%+IH4 M8JL0GDA9!+QY'I/],&,9*,4HKXH=-"SJ'TH_:0*.:(A]*]
[Z&M9/\P2/\%HZ MPV2.#O>F$?5PN*T4)..&_G(9D,-,5KC?8O),C21HE>'=!BV_@^45S^&[IISY M0N9)I42$<=%.3.)+T?
ZN@#B *F$XPMO39N"?TN5?-@>5XH\+"4A271LZ7>H" MU>Z@4A= 3,$_S',WI-&*U(%11]&5JA]B7$/BM<2TOO,NQ+
(6M1,97=B2%?Z/ MJY)#-2@5CE-T8O=%P]9WWT!MB28T9&06B.J+O=-W1_M6DH.A+%0+T1!71294 MKU65J [&9J2M?
0%U)@"]CR) M-*UB'6<02JRFFZH;JP]QW%T>T7!=1)MXQNLG>/3-2>F25L4+I6!QRLJC;P$;
MB\K$*8^E8,SBOQ:F4H!24;1DIMBMS'HHL2@>C[&]+K;2\8 4BR2Z("7*)V8R MP\1OY+3R)2M7:NUP3, Q,O3S
Q@>^/"7S93A1@D_*!IH4E05KV2L;,Z=O/ M'*N;2#FKM'.27#N?H4#Y!_F_,*)7S %ONN*K>H MA:PTC6*U]3&A?
0Q7JDKMU.]-3(0[$,P?AVW=R'>UW,#BJ\REMCX/0^L;GMVN MR_N%]+XUU[XN;]!I]3L&$#4 !(A_QP"B#H!HMX9= XD:0,+PIIH
PO"FN@#" M*:;O,+PIIH PO"FN@#"*:;O,+PIIH PI!$72#AM+JV <3F $&5@M5"V._R
M]SW>J8=W./6#W'?"QFT>OT'O9'A+2[DNCC*&84< M/HJ0PSL*.111%(,,WWT)-ZGJ3Y)W*@!/ O &^PWJ'!+1>PQ9(
V!LFS,B0NVH>-?^&Y76!;ZE/XB[V##0GXI>IC="]#S.Q^/'5=66&C9MB""W?:[[S*_>A+]@V^=^ MN4&>_A'T4B.BE?
T(IU.I0"Q E_])/.$4X@?OH-SLAS;V;AAL6T8&]PVN&TY M#9#[!K,-9M<:LV^+S7N$SOL&GY\W%M@;Q@&T$K:-
S_LKNOV:3AKZW#(;0<3 MGVC,Z"9&8Q#8(+!!8(/ !H$- AO8[BAL']C5OT'8[F8(X*1H%ZG:'QX8 WS' M'4K&\;!M:?
0,,=#HCWH[C50:"/Q'C MO4;^K-UF0+7.N%S?X(',@B?GDC)8_:RQ&O4C@]0&J9\44J-I^_0Z,CUMX-XO MWWA@
@4U"Q1D4YY80>3%L\WE03T/V6&\2CO#>)R&,S1U#@;+GS:6VXWV:.-) M>P;+#9;7#,OMX<9S[PR 'P7 T6PWO?
[/J4U3&2,8T@L^\AVT-006S;B2HT&WT[=&3YFJG8VFLM4QWO$J8P"@![C_O_(T"\97XJ,@ J:;
M'9!%LF"I8"9385W**5Q1G%DSSB*XBG$>TH[KL+\?@\HFZ.>#((/UO-=+X_'$ M1#'[M?7CJV#I;^,XL;
(IA_\GG%LS6&V:6APVX5NG?)[QFP":R)#:ZLRR";6H>I%_(L2%O6 MG]SR]_"RRV>MUAT53RI=N?G"5:>W':#W=:.0&A])
[#@YP)C\TKH&OX,++=]BPO'@V9PDLF\6WQXV6=38-TF)/ MA"KS)(;@ML'0')<;2_8MYCULM?JJ:U:$<_*AX+(\L(@0EYF94D
ZJB(T") MD&7PYG)-6"-6)(U\SEL.:.$C2S/H[AZW >V'/ M"!;"@BR>PRZ0/M(\S,IWRY5Y@F04
4_WX!)@M=]8!*M<2;CN!>+Z[5:GN'[] MZH$J\C'S,D%TXDKQ#<7)799Y4SCR\C6"K(*;H[3/A0OIE(_K."PATJ!CP<;$
MSMJMTD:P@H_>DP>L)?BVAG%JJPC7-(N]KTV7-HYOA,,('%(L3F*'7,19N4C&OA7?
MU\01\I(X^@MH@58D$80GT;$0EN.P!Z(HC\.-2BFF1)4%VA$7]U9\M"S=D-#R M\$IG@_K^)K> WSK6LW!W.DT
!8UYFL+'L/:8PR(AX"$O[WX."F_@"4A&DLL$ M#%B#!30>7 19P--=(943+;FD0AR5/U0%HJWARV-@?V,9_9D&,F": 0YD!H13
M^P7Q'L%2L6#['DNG"%70Q?UT 2%1F 'B('XHN *2<&+4>\>?3_:%>(!5=)8/ MQPY!>#7A!>K; N"0_.!"_00_J)L'#&
<)F@]3":C"@$(8*9NK_<.#F$G5<=5. M5XL?" QQ.HM[_P]]\Z4]T_3B,$X.E*FGG6HJAGP[9.!,>-,%T'QMLC&\^("% ME^PJE:
<<#EM.$0\[*,O%O >KUQH.?[#*'_$VEJYRQKXUM0N3YE0SY./L0#RE M/B+S4'T6IP%RJP/2=@#\N'9E58(*J
$'CMWJ/Q!0%HBTH]FJS)*&/_TXC_/ M3HX63%>-;*,XF;%0+"OGJLN/7OQ\AE8>$L,1_!5 GA9V+?M9@^^U6$FWV 3K
MO]RMO,;RP^KU+]VK^",H$A[.;_S!^F\@&'QR?^'&*X"S-D!*S(%82H:IY Z\DOH/<3W=/U$&>G*$B3>R/ M+$C"NC2?
(7_^!U588*A*BX;CED5+A:B 3X+81Z/"!X4338\]TL_C/(4SI_MB MWHQ<6+(@X74"]A.R>]\U7[M(OSQM@YZ38 ^;-:(<0C
>*F]K4&$(\%B)LZM!I(&-[TO !A>%-= &%X4TT@ M87A330!A>%-= &%X4TT@87A330!A2*(ND+BIU,(XFZ
J'N)^/I3#^]PZAVH MQUH;P=KT)7AQB!_^]*+WXKX7,FCU^@]Z(\-;7(A;>4DU!O$)(PX?1<3A'44< M?
GSE&EQX(@.ZMG'D1Y_V5$? &^PWJ/!8):_#11:PF.UO-)?G1J\;TURV6)[^ MO9I-D3DAR*'3;BBZ,/J-
T6^,4#/8;U#!Z#?/A&L].+W>0EH+L"W_NUIS<>ZK MN=B D+NMN6"6YZYH*0;N&X5[Q\#]^<']I74T9=&$/S?8?Y?

6M#S3F.!O6$;WC[J+GY%;8.H,R MB/ZLSFT0_7F=VR!ZC1W%!O,-!CR:%;*S&%#WL,+"\/;UHRB,J\#XNFKC#[E7
M4D:WX3A#X_HR^/PT\-GN-FS'-OAL\/F)X'.[8;<'.XW/FZXCV#$(#IR=#CY\ M=S)0/<:K"T5^_9@H8Y4_]"C=1RWXJ<%
U<<_[Z9%C]-H=S:N2AGZJ V^&/KX M+OH8->Q>QY"'(0]#'JO+?8:#C3N6MDT>!@WNB@:;U2#J$/78H?*(!?/G+,[
M^(F7\JMVTZ^P-5'UI.72$^,^_8;3&^VT^\R@N4'S&W6M3L,9= V:&S1_TFAN M.XW1L+?3:&X@?"V$>WT3+-E^L
1'1,,+/L1I:HV3>*:-?GXREGR-'%V[S8!J MG8RYMF^#, Q,^PZ#U4\)JQT;[0"#U0:KGQ)6VUU4^Y\<5C]MZ-XK56JC[>%, MK&
#L8)LRA,KB+QXMKD4J>AU32C, M8/G3QO)>H]/=[4C8\P5P--M-M_]S:M!4!@F&](>//+/".#6!@0?/@.T Y?IQ
M[H9\.X+G85M^;_VL&_&_CAJ=?O_)>:H,21B2N+?S=M08.$_/>6M(PI#$?4EB MU.AW[2='$8]>&E$OZ-
_'5MVL.Z:.\8Y7&0/X/,#U_Y6GG3"^$A\%$?#<[,"N M3KPK4ID*ZU).UXKBS)IQ%L%5C/.0=ER'_?
T85#9!/Q\$&:SGO5X:>R)E4VY!2?DU@P6FZ86ASWXUBF?9WSF\L3JM!L6CB^U+EEJO71: M;OO.' 9QU(!E0'@2P:E\D?
V%2X7R%6R2<(Z]KZS+()M:AZD7\BQ(6]:?W/(# MW*[+9ZW6'15/*DVY^<)UI[<NH(#+U]AP_+BV9PEL&H6WQHQ6M;9-
$B+'1&>S), M[@?N'J#(<;&]8-]BULMNJZ?V63X01!8)1\S+Q,@]^(T2VG[7AA$R-LLEV7> M%&
8C^$ZHF#,HC1C&3X*?!*V3$F'Q8D_3W'=3OFX?H7S))XD;-: /8E-=5K# M8E,1SRH;*U;(D@#^5850V@$3'K),W!AL* -
;)$[Q,W%:<)\6VY Y6 M'.;CX>FO#0MX-X">[A$6A/?":^+Q.(6] ;3#^)(G:S=6O0+'M=X?GAX=?SH\ M>]=TY'=A7?R&^ 7?
DN8N;""2;T(< %JEX^/WQD&29M;?.6P%W@M[1E0AQ,SB M>8@(DO T#[/RW7)EGB!A1R!D/+@$6.TW@#)+KB2NX0H
@$#>PUBB+AR%$?- MXL!IEOM7&HYH5[@K/&!]>Y$*N[[F:P6\JXS :8TJ?*!C7\<'5G#1^[& M?1N MMP8KP0H4,.9I"A_#\<:
[JQ7F2 MQE'$PX(VU6UI;TG@%B.\,U9]>,J9[P'*9E4$%2P37KD:38,HS1/<70D8>0ZD M>P!:E ;$H> 3MG@V>)
[XZ(X@[XF6ZE%!U\H?JGC9:W6*>WMX=&PLXZ,.96!A M QY]/!/^#[^H\#8X6 M G=NPC+ KCG*L@<&ZC4PO&Y,]8?
@[SSP@^R*CN&Q.0(7V3BU; MMX>6T6_%84[%INDH>2IT!(2@;C+5@:I. ^0/B#_XPSPC'GW)K2D#?@X*2HR< MJBJ*X1\\#3Y3
>Q.9'J(2!8 [3IU(LO"-MT=1%_Q0?GP9R3E(:% *>!,GB& M" MZP2?
8R31P@RQ.Q/4):>LG.:C=R"BS%*7(!"R@?]3JL+OQ6*TM.5@#62Z0 M]0P_=_,4WI:"[A*"*<= J&!=1>D4_4EO*0DXKT??P
;$/!!8^59A2R!SD$OOOO.2X9_ MIXWY\)18Q^4@?,J%TCA$H71[(ZHV2'TF3E4B,N &(WT/X5R6 VD<.9LF<3Z9
M*BF(=PM_O,"[X<"6)%/RN9O)Q0 1 ^!:,+<5QB$+!@0^A2.!*<]1$P$H0 7 M$GM?2=7,PRNAFA!>PQ/+0'E9)24 2.V;EXR?30
.$]P@F@>%8(#WO[1'[5+E M:EF?DP"E&XDJ@)\\HGIA2M>$N V+OGOZ'4TJPEXF"=91%^<&%^A?^44@$J,42]!Y-);@+
M]QE"6GG.=W%O?^'OOG2G=7TXC!.#I2C3SO5 M5$@-A_Q;$]YTO1OXVF1C>/$!"R_952I/.1RVG"
(=XJ!P%N(]6+W6D$=@1Q@8450RX^ 6Q#B BH?P5\!Y&DA MH]G/&GRQO4JZQ:;=;I6[E==8?EB]_J5[%7\$6]+#L;P_6/\-
Y(]/[B_<> 5P MMN88E2\4'ZU9_L%HY1Y<^CBR#0,)/"?Y'' A(C@RR\DD08 DP"'ADW>""9\H M+GF*PLPZK(JB(]!1@-.]#
[)_)BB5?>M?;#9_#>NTD/T5$A\5;Y8U@8TU87M? M@7T6W'?O\.QC\9;]0BP4['?&KJP4U
3)EC.X'^*L^%^6$3=$N4GZ3\))#\CG M^(V7@U[II41L2Z=@0:2*A:Z4&>C$0G\%.2VB6$AP"_@)%\:*OE?=,PF[YD(_ MV"T?
Y6$JQ.>RP46"W"<-NB$L(93*%W ?42:T1 %((N64>W 7I'B1-!RTRYO7 ME2RTBD$O N HI6=9>4)P\,0+A$I8ZE$
A1#U2=+003-&SQ(J=* +I^.\XK'2 MW7PD]]V,@6 %X9T#;<8@YX5NATX'],FA5IP T))"OI+NZ\&S :HU:;-$1WF$ M2S@<*,=?
X0!6E-/=Q6/A';@"5H6*RMB";21T?-3DO6".Y\VF@+2P#BT LCD+ M(F&:DIOO2@&0P3B 5V?
+SCSX+Z@3G*Y\G&N$":74MK2*U;F$B)*",,W(GCA,& M*GM.J^L*'=G@V& 6 X;DF94@T+5J('=8M*?WII>0W=9O
/_M!0]R!47%#!O.PV MYD]]N,0?BMS@I!KE F: #>@%1&8S=);AK5>(68!4$73PC[#35L,&:5"[V@6F M$(;,C96=IX10*M C
Z#ZPDG.2\IK:.0*="MF$$".(AMA:1EKU@C<3)HC%" M'N8%6X3>V\3W@M$&0D(9OX(S%H8X&JB!FXNM)PF+)F+S#4&]
(;GBA.3)+ *#RG<0ARDC;84%$#3WK:2LM$ODX7&(\)/JY"'P1LB3M*VW(M3E=C@1<$/()_);RJ##$XK3@[E6)_[8*5J%P MY.Y?
B#S(#"+DR&$P"S)IR<;DC '(>O+WB-9F(K&'WHGB(07\0X9.;@?BH.1&]:V+&/5< M>IV"-8 W$!)77B>\5M!'*ETW\1PX6R:$1)
[,XB!4&A>R%I=T+F#^THE>D96N M+NWQE8)=+]Q?088 +&37J'#CKZ M#1[-X9*/Q[@?4"-!!5&?
2W;/?,!L9!@%*H'2P"/B+^@'N>U+&DKI=0G+/>'S M]L&JN,)0.RA$7+@#/#@"871B<43,"%^^0I=)U@619?
PQW8)S6B:#G^B\6'F? M20@K[AXB22#VX^W-D+>A6A(GNB=(C/N5FJAT!(C,'V*G\Y0?J!]>?]?AT'_: ME/X#N^7T%SPDU
9',_I/G!738!=G&<'X^ ;]U==D68J*G>#L+6KN?[R:W1W MK_0_2&>'T['' 3OO[SKB01D2;A<-0%#*6%="+=<;#! M
]S2!^$'R!9 G)$$(A)&DEVE2I($!T&61);C+C'POT=7A'!HS92\DUDKK&, M?;'*TCG(HP19)SH4DT+[E32=$)] ^EU\79D?
NI0R9?#?X/\=\'\%EJ+G)$5< M151__:09!:II2M0%\EF#?+Z'*W80ME:L H-!AL,W@P'1Y4(U6C 0^:)H"*H
M$PQT4L3(6'RL!<\H0E@J6Z2*$<<&/H]J.F74''TY =WBZ"/^2\%]XO)I0%X@ M&5=8)A)_*$5X8B#$5L MAB(P_:@P=LAM=W6-
KT6P]AG\2HP9L!6-*T1/4G@B(31U"(0E7 ,=Z,Z0!YTC$D*O8'4&,->#3H^&#K>QJ:[
MDMXW$@)8]OH4J(Q'MAY&'(82DB2"$+"BC@WZHU'9@-:+#:8/6&L'J" M8=H(^:MPQ6E(+K<,9(,"#E\Q5&"H8#-4$#+O*WF+
MBQ"4C(()]5>DAM19LQ@8[-M=["M46.2.2)18G-"T1"L6T3+D)(:,>],IF"541$9V4ZNM=Q62S\Y($L*"V/=&?WZ3IZ[
M,LOX@D<^5NEB,856;%M%*6D8WC]1>)!PBCRID0DSVC"*L6EK6\0-P8*D MI$ZL/_99XM>+^QI,?B*87.@&073!
2(31N7G89RJ?")9_2QRNCD@>K80HY8$ ML"INTEBDD!7?*3*VB^(5E;M(:&RR(W3*^S MV^M0BGLH?1NJY@[H@SJ7H2--
I&B(8L^"!UXPT%3=L"B@K*0>J\5$460JR_2R M@-CO8A$V<26M?
&QU9FG+>I\G^&8LO6OHI78J^X.88/44H@:LRB4YA8@6RA_$44\%8[F&EHLW@,P4?I]?6IL/X3B]A#D7ZPU!F _D)N*:W,N2BZ
ME.F-$AJWK,T719KQHFM,],BZ)F^8NAG(%EBB>UY$-9Z5MJUL+NI0J1A;@026 MAUK78N!JQ2'*U.66]0NU<13926S"1405
E6II%*VH+CBJM>7)BYE@Z]4=3EC M2BG6FE%4^Q:TK$//BZGX);RBDG-XQ0U])K007E?A#+A?1% MAP@MZZ32-*-1'K)Q@Y>H5L1
P571E$:Q]P+CA2Q"=I:(DNZBU=R8JK]5^S;$ M9>GXTKM,J/6J=;'%I]5+*A<0BI]8AHLR])3$#,-^8OC=L:S;4X7WHFN,!XH!
M(H56;R5YK$@QHOKGE&O'E WNL&FE0-GBI>Q*L#1\$VP=FZAI[Z,6$PD7?@N? MNOIX6$:-'05"[07U ?0;)LO.2/Y02"FK-
@X4E.'"50$U"[\\?I=_ \050&95 M>YK&-?UIV/J.-T65>>$+Q8L6+0 6Z\;AW97V+%10#NQ!8"A< 9Q3M0$J.F$$
M:9HS&37+L%GV[Z*;,@#R"T=%?GMMON_<;O,([WP,J]_6K<'F&77*450I$6 * M&R7K;#:C6(ZL32P.
(6D*2%S:7YC*$OO8AP^H,Z*X),>,[CWBOG&> HJE^W'Q%0(:0]AZ-\3N065? $P4>-JL@!]4@GP+\?WR\27H8SE)VI?ROZ2%M*M
M!LCU>JW!\+KA>)K:K*V/9C?>JIINHWZG018'(HOE$J[IQ@02S4 LOLK<- [! MO'[@7)+51$%?1'/OEA-\M,2E[QO7T6D-^P80-
0"$T^H80-0!$':0-1P82-0 M$H8WUOOOAC?5!!"&-VT8$G<X=0/RH4?. -^TY< 9A-^^-.+
MWHM[7DBWW>IL=YSY\!87=MU\CD_82_BC<"*\J_82%JUF.^V&&J/H:M=GJ&7[MU'(+V O0+?^[F@Z<^]*!K1>'["0=H'^NBN$&
[L\$[IU-<+9M3SG]Q#/A:MS+ M4^JUOZ_ZV&)FQ\'&T'K;Y]S82%]AR&S[.%N8V2WLABT<_/HYU6NYE,%6@ZT[
M@JUU5XJ+\N$^K7]2Q!G+>66[H/_4 3%0\H,]P"%?;HZ>MDL\MQI$O]>Q&UW; MWM\A>\S@Y7/ 2[O?Z \
[RWBY@W;#@CPX%BFS#R,/GI_N4@^=;6,J:%U5L=M1 M[&1/'X/F3QO-AOV'W!T_*8I)E>QAV"2(OX5BMBR48 M+)7%'HOC;
(W*N7F5LTHF'2 3/\XQ3WXK3&"#?I ZGG73LJ\O'/2,.69HP]#&
M"KW0;O2'W=4"4Y63/T()USTQN@X56C\&U;7R2(]:BXB5,55Q8%B=G< 9X+[TLMM MR_>K*L&B2KE2@;Q7P\LREF3-?"Y+_%6-
]>ZMY:R?W>GW7/?M'LN&V>8=L^[T^ZY%A)!AY6N1(SI M?WH.WX\&H.]R*P2^\3LYOP+T+3NVX MUO0#TZ/C3X=G[YJ.Y.VXBFA-
&2'#06PK4$>XNQL:LH<17"/GKBQWT!*8/&S ME&@E6U?MEB5S+[I*7V!@K]?N SGF8Q M[=?C@)2^$/:'*1!4)KK0>7$4R?
YT10.:XN^R.Z0VWM,7TF^E8%\N^.^T=ELK M"E;$@ZWF:K5HY7>)5 9VJW>S6K2B78(<9U9V'=KNG\>8UU$:M4A(\
MT"&U'\)FTEGL?57C"G61(IMN-+&?RWC,"U/D9;ME%^^!YXI="%2BY>*Y[&>$ M_8V0BVC,7'3B:"Q(%]D,!W=8 D"(L(417#?
MD2ZCU=981./Y\T""?AXJE'TB6P#9ZD_R4&N*9IT23)#U(/CIH]$D>Y M!@375:D<(=<3RAWMEAK=X30YU7L-&3?V*DN+6I8ZH-
6?""0^QXY1"!6)+L)= MD,G>>0%-3 I[)7<@VZV-5V]"=O-+92>F&?O*RRL57:_2-)_-Y:Q*[!'%: 8)O3^A

MQDK82W!&J$2=$E-@)&D#=$BM45T"VFF4XT]E)\1"0=6U'<3*,$Y!"1;M\%Q4 MSJDK5;$I.,TT
,Z6$%X4<[&$]@)_Q*:,.%50*-Y+V]=;7L78D@I#6'%$8E9T M%:/.?T'BY3-
LT^_A3@Y%!TRE_HMNCSA4F2<+31\+%E]N>,9\OC@J4?\KJ%K8 M!KIEU09]W]Y)VP>!BE?-
A9T2Q47OP,51(=X*8M;@FBBTGO%L&OL@E2=70LVF M_E'%%^45QRFVS$QA45=0!#IDG?;KCRQB$T)O_, >O$ZMMX!5.?
$^@L.AZL8- MZ/J^H(HCU42.OO-%@AJ^VR=;[>; M_RY$P!5GB;S M\"UQ?W9A;540];[#GC)!$$$(0$RFRHWHNC]-P-^1"WW\
<34 MS]X2EX[)LS(3+?XZJ.0G>YS8(PE2_T-N 7Y=*T3 .P;U2_O%#_*YRER FN/ MOGCRYA1_VV\!&U9L0WW86/-*E%K
*,3\5'J"^5(] T2+X&*HE_9%@%BO44DQ M+X3:W*$5D;LIL&Y4TJ12P"-0193GIN_%PC5"T9H52(CCHO7UE*LR:DM*-DEP
MP:B]MMQNRSHA/@K:HV*C@E^+WMDE E3ZPN9+-R)H>.VEJ#:,+"K?5/)2;6UI
M.*$FAE]F.=!LG!24GA0D6#10I=Z,,8ZDN."Z*"ZW#O8U]@ZDM4^E4Z3;[JJ+ M/&6)RP +FB??
0GY%AX&_..VV0PC$9D36C15[1W*I[%V;?42 +WNK?Q:^^B-) M9():=:7DHADW*WNJ$>+@\\K4,'A#>
M4&E6$,Q%]VG<+JDXM\%QNB9ZG1"O>'5B\AD=0@@!;$-L@2 MG$2E-7^7W2[W@GWJ#2ND5AC#<9-KV
7N>R^0SXSQLLGC*SL+!PF<*?9 C[A" MBTO$;\8WW5!A5"CV(\D%5 YLJ2@4CL9Z)5+K>4^[3%3G^_(BZ*AZ#W#A/UP'
M!MB1<&NJ#L]XBFHD:1$8]7$ _2F;(0.]85_8:V"YB!XI00LQ@L;C8+=1GQ6] M+ '8*=)7BMH+B?)B7,&EI(PLQN[83&@"\+
(T+;1>:04[G9[E2LL0NT-3#V]" MJ$6-8$B?R[TOOL;:ZQ!????3+^E*#9;#?9,+)/ A15T&5*8"?&AHC3G+I5B*6
M]NY(69DSSD@UYM+?!/ISF)-S AD7SJHJ/7^$2J W37E(C OCJT@)84 TR;\) ML_3EH-
TN;7Z)0L)P#>#@O^6@4G;:F<@7VPLNUIR3KE7*.[PL?'TDW ENZ?&@ M&&\<44H%YK[/W4S?L^[LH-=GTX3S)@%1$.$N!T8')C!J
J,F,/I]!@+VAF?* M?%PV;92UH*P_Y)B"I;!L)>,4K?+1];J&46*(#34SP=" 6Y:\4G;"EG)$2A!R M+6I/V-H3&G^;Q6E&/D$Q?
@)%/A>RH)!;I,G1C(BX'!= (F3MN;'_/@_("%#B M\3L/[/3*[2N=:L6A@PV=6?2$WRB<6M;Q6(GBZZY.(@B97?!UC[*EY8U?
8Y9> M+L-(C730[# R,50+?$VUKUABPF6'V[Q@0:BTPW4[)H/0=,X] VK#0 P#":MKG6 MQFQ<=VJA;"BK5KM,?>A-
:7FMMIGJZ6]..;<^Q: 2.H"1 MVJ .S3+^+ ,!C26'7!XIK"(W0#!;BUW'\+-EKQT:(.:XH/(91#C?3X,SLP+_ MIQ?G7K?
KN,SNG=N#'COONGU^/ARY_GG;Z?;'_2%O>]W>"R'*Q1/XQL[OZ&\(M,I*,@,&_TUQ8^NVMPCWY4-W0";DALD>=:C$X!(UT
MR9A]W8=%HRM*U"H,-LS2@9M^-)9RSXQG203<P/FG'=]>WS.!KY_ MWNN,[/YXZ W]3GN)"+I'TC,'=_090YH^HLKY:-AK.
[W:8W^W9:G]$Y#+$SP\ M:M\RGKVDD%*RJC&>BKT?,\71G0:;Y?"I[XZR9\N3@"J&9KS?$#>4IOBCF-]" M S^%BU\$=QOD-
92O)DU6C6])A:)8;NSTW5'IB2]O5LY#FPF8[#GJACTOG^4B M[BN2V6>S'%,YI8-93-U4P3Q]S)288D8!<@H!*V4LQN%"/%$>8?
GW4O3+OS=P M=1HMI488^G"0=$''*Z!0(E?+*H.+J,[&H);\H_QB*#+6(9^,BN+UMA#4M,)[2^ND][TO867 #4E\7E+-V;-
@M;XX2#\J@A*9>K22>PG%S*Z;K M8A*"X'"K# 1TS>RQ@J_*A)B;6::,^P'+7&25*U8>*ZJ4%:DL[? BEO3-
AXG,YQZB)GHTDQ@;? M\AZ(IXAL I[,4*U89%J6Y%?C?4NPJCU_7_X.= DB?T((0)IG-;3PKTHD0KE%
MU(T"$@<")AIE7UEA\%6F5"\]T+C;V2J6/=CU]=U^^=M-G3/NZ.V?SX:=,;G MMLU[[L@9C?C8J1@UGP^_G!T?GYS]^N[+\:?
W)U\^'IX=GWPZ'XR&MN/4U*#! M/0OFZ^5 MR^L]Y;N@N,"<'OAOX0EV.0VB#J*+.+P0E!;24>;E48 J@%,#1U#3JY%98VYV
M.5(946FA7A,A(M$S@X-KXAIA"R84:X>\X13= Y,AX3"!.RQ M%*R/E+B-E8)FI2I>,5H:GA) M2;
[%^%>:*EQ4'*#6+7@%>NHO65),\IX@_4=XZH4K%!3D..(9WB/ M*;R.WKW+ >.A"1B;@/$N!HRE4![TO)YKC_KG?
A'1V_6\LAI$'&C"!GC]98W*]6=[QV M(S3%6I0FBY0YC"4+R:*[6'1!O&BV?6 ML
VV6':P0UU6[F5E'H8XS'I2)K,5]5IO4&9FTX3^>@;HPN97TB$HD&JI@)TP M7&5[C,G^Y\!:J9H^%6ZH4C_
>8%8WZGR/1D6G!5+=+6Z_QV"[6.(^L$6 R2<6&N6^_? M'EJ3A-%X]!OQ!9!![R^C&$4&SQ5% 90I&23)-,Z ,6'_&
<$:9K%/SF?"*/^" M44N#,! FLIO$6"FS1WPX165#/ 2OO>?!>P>?>M\IOKG?L@Y7;U=S%%!.228_ M5TFE:*3+1/H0>Q>
(>B"P>]Q 'I)>+/]$,7G9B(<6HCP M)OPR!C7Y;(,+(&S MC'D3TS[AD)2Y!28)83JEITO;0;4A K2?2;M)-9;@ZIQR$
D)QOI8U4G_)) MT^=@*Z09W:4N\8(9DHJPLLCSP+\%J7*UBZV3K:.=3+T;A)E67X8\?Q[#16$R
M"WI@R!-3OJ@$M["@8%D7[@$Y#F8Y7]&%KNBHT4(9HVVF],"0LT@AFH"B2A,MN+ MHZ\RP%/.&2
$%1FL:A,"B'+PXF$1.2C+T,4*BF!"P1.J8,",9$RREHR:L@6T M+&[%9+<74=DM1HIEKS?R2B6-8U?J;OO"MA"SPO& B+$L9HQ
J:AN!>"ENIA- M93E&42DOD4*IL_*MA1 5OE#*8X]PD_ 1(HX6XZ";;26K*9:A^5B*=4JD:UD@ M5=#,$LQ-1T4,N2;DV?=E,
(3B+-H-+!R46IB5)3(SSK-4A@DE]Q0%.7]C]L]8 MD7QP!VMT%&HAD.6M8!% %H]@.E.!](/<]>-[QRQ2=-XW'9'/3;P
MS_OM(3OO>D[[W.V[SCGO#T?NL-_0=!E;,HV=/R+D<(C>W#_%UB/Q^!T5?I0Y M#K4WE1VLP2R/89VJ%BKB)'JZ!I+1'\(;*MW
.Y:O(](YRRXQN7[PI9*=K?5V M(,R^37^-LTKI>.4TQ1F7*Y&66I@L!;/_+KP!R;(W (W>35^,\FFIWN7.75/N
M;@5^B;O5/B^@XI#^)WT.>O<5O;',ULZ\Q/)68$+5E1190^4 .GM8.#6XEMPO M.YV($(9 &-
GGHDCN+H"7Z*6U:GTVDZO7Z_.]Q?Z@0'*Y+7!.1(M2)*[5 :U8'VLMM:1Q?M842&KU+ @>3+!0'E&4.HU.K;3Z+7;(,58PHMDD-
5M M?\AL 8U0I/=@ISUX<(X=)O!AT=.C7%Z4&.I=AXHS("V]''/7+IJP+#4Y9*47 @):^3R.R@0:D7Q%7874!JI-
9U3G,MF#B.ZJ<(*ON/]& M"@S<9[5S#A;V\:P\'H47 #)^[I7>A_)9O2EA$)6;D,:>:'136"5Z&YR%A3I: MRS9TYY&!6= 3-2]I
2)%Q7G++B8+35@KT)BS@!1!/X#3HR^QH7+1X"< <8K; MB2_).+7;/Y0&KHA7 3ZFJQDAA<,%_@9)N8?B>BLP%B"-
/]SW(!#&Z2KPX3AK)Z> MN[_7W;=6)J=BWN>B^U=PK\&V6X_<6?(=(X]-JLT0MZ/OW"&DCZRBDE1B.\RW M^P-^SD9=4-*''?
O<]7O\'&!O^Z[?X>YXN%PN\I:/&<; _P#V>PJF39R40#YW MAJ->QZZ]D@Z24AW#PG-8XB :NM8J&>,3FMF8+(LM'?
@NA_Q')N1000X['/)G M?-CQ>,\]9Q3R'W'O?-1V1N>>T^UTW';7\WO=Y>*BCT'$3]F89U=:'1HPW*'=
MJS^O[+8LW+\E#J!7TM6>1TJ@N2/8N@>";=@9.^?=-G/.77?$S_N=D>WVN.." M!K4$M!
[UFCHN@^LU!AOP,=D:2]OOAJ'SG;X"TA#MMML#$Q@,9,HPO,TT?O#O MQZI)82M<O#HGPL<>/YRPUO-ZIWSJ2)J
HD!!&G46Q;&$6;>JFL.R^PQ L;96 MP_HQ^ ;\/OJ44Q-/"D#!AK^@W("]$7Z=#\[M<]S!^5E\/CKOM,4OZ<7[=[-?
MW_P9M_/VZ5__=W;U<3C_?/C"$GCYTXO@&^)$# (A&K,PY2^LB,W@-KGG'X"& MBGM#-
+$/D^OLF469_SYDDQ=$EI]8DIS_SYOW_[[P/_]?^/7H[=7GH-V?7TW_
M^/W%S[*B_,=7E9W_C/>PG)*L_[_O;?]=TF\WAZ>__C[XS?_[MR^3%S]C M*GM $;VEPS#KQ?8/O$T8_?
DM_!#^/G=GQ,V'6;VFW>3JTF%\)>.HQB! MUM_M!O)L2X=<O+_5YYQ\^N5CG/8_C-_U[5]!TK#?!WP$Y\2,ACN?=:_H?XA
M3V559D&HQ-N[[2%2]Y>B$L#QUF]SK#D3-BSI*FVW_W;OHDG:7 O7OV8/1XBN[MC9!^ MRU*[?,P0Z3V9GQR4(;F&F(L('"-
D\Y0?J!_TC2"=2.4)Q*T@(\NSN(J) M]$D%>Y:1ATZ(NVF&["K.Y4-5W,D2M56Y!5L<_'8#@0>M=N^Z:=<:IFO+8X 4 M"V/4-
:K?:?KB@6":EW!Q-_(K*3XJ-,+<- [S;)%&=)%TNR&88KCGDS[=H/VD MC_>T@6055(\J2'T-]3*_.@FKWZ^\5N?
M*$&T$'B;PON-W%7E9L2IE_^]Z[:OYT9;A_%;"HW.*]ZU6@'E>PZW'H9W/^F- MC&GKI_U(]S!/"3 /ST4V>)XGP3+L=LNN-
;K=4;G8)I$SM68S MY5X3+AX+D@ZX4!-?ZR_ZU]]YG+V^\77B:Z]?2 ?9-,OFZ<&K5Y>7ERUX0VL2 M7[PZ3+PI=EU[Q?
T)2U[Y+&.O[&Z[;=O#5VW\3[O;[XV<;GO4MH?M5]G,Z3IV MWQGXSCG_9C>=UC2;K7*ZW?
%&;G31R6Z5F$8FT^)/9%ZCHJLT_VZ8#%J]>7:[M'>% Y::RD-!B0?\GQ027\>G%SZP V:@HWU0X F>/
{8^J8:5]:=DM1R6)R^S8HLWE%SW[_'1% M]GE'IF[")PNXHZ6E YMH.D.[-W3VGYAT,WI7766E 4QMF=+S5H@[=LT5XJ?%
M!QY:9TXGLZR)\JX]ZK2_\6\=V[?%:RX+DK'F4W6%7NZ+^GFAN$)OOMLM M6KP6S7?
+C^[0%QR42)GB4GF=G#JIYH"7TP76CIXT^N)V6/-[4N:P#@CK:IX8 MYS4Z05V9M %,;3G"LU?
6G&>+;L]"67L\!^5Z9:UL5(_JESXVC]T3IM';6J:I?=Z;5O MIZ"-VOV;%#3'*&C;4M#R) K2Z75*FGJI3!P8M4;SZPLG=H
/[[B&4+,3&P6O MIF-/I\\6XQZ=%1Q'F-5F_<^;+Q^L8^P^C(E$;V,OQZ0@E4ZCA6GG7,HLPAEWL,.\S1ZS(V$;7L
MV*K"]ZLS*/5]J7<]6ZPPKJ<=DN9/"?&,9E+3LQC-9!N:R>G1K\\6X[:JF9RQ M;W$4SZZL=]\R'J64N>Q-

^8P5JLJSA8O1#8QN\#P8@@%,?3F"T0V.#C\\6XRK MFVYPQ$)/M<'[$$1?71SH8#0%HRD83>%9L <#F/IR!*,IO'WW_MEB7-
TTA;?8 M1C$IP K$W?8/F,PJH*12$95J.M9C*KP^*I" M]]EBVZ.S@2,.-]\?^=_O(] MBZ]M=?J<_4%/L'YCVVG><=EYN
MLU;#Y_46#RCL$_YW'B34?CTM6CSTV1P^/0+G\<)0=SE5@IG$#W> WBYRZ5R2.HR)+] [$IY'
M\!0MS?)L&B=P(7YKHT,L*VB]C-7+[/[[YE'VGMQ 0TT#;/4'6SS=\I'4F(S[
M'JT"N>Z@U=G5>8UWG&9X/9)N09E;8K5WU/>!'^"'/[UP7MR(Q;4X_+5"YO"7 MXX_OSJPWQR>G1\?
O/AV].VU8QY^.6G<=$F=@7BN8;^SP-83\.L_1>I5FE3/I M+;JX*Y#*Z7\D:J.E ;V_)L%(B#P M+67C;?MDK])7UEMV
3OZ%1MSA,\ +1_4^UX+=-W\":]!;=3:ZH?7!J<-3F_4 M7'B<4V)J0(!0%E/UI@$?+[>9-
/AL\'E'\'GOFFZI=QH(:/#8X/$NGM)@ML%L M@]D[A=G&;;$;;HLST(Z3Y JT9)9[4_X,,-/PW&?@N3!H;=!Z-U4)X:XHIUX8
M=X7!X-W"'X+W;#V]9]%X\8LKG/<&QK;BH>'9>I^S3I2RQ';K.>X29ZY+.O9/) MN\XFDW?U/%"1.5O) JU\A.II1[#"Q8S?
BSCPUR3\EOE$;NQ?P7^FV2S\^?\# M4$L#!!0 (Y ;EELD G;GP@ &\O 8
#,Q9#$N:'1M[5K_4]NX$0]7].C<%6;B.%^@CW,H,VE(K\RTP(4P[^Y'Q=[$
M&F3+)\D)>7_]VY6U4CE$6LVPV8[;#5:^ZS1CEKMJ'' +KZPW:MA;\^)GYSWAG]<]/VX%U'!]E8#F+4ZX-V/<[5\./P2%*6&$E
M'!^%BV\O.U+)_/@H$5-F[%S"^YV,ZXG(ZN*J-TH; =;AEA]1^8FF(G$IE&S MT?BI4_ D$?
DDD#"VT4']\/"V2(M)NBQ3WK1(@^163('Z?F3DE1%0L%B(C55N M@S'/A)Q';XAV M*HP8"2GL/$I%DD". C^_.6PUVIVCD
1Q'HH--.%H;<09N149*)EC90TG1:,O:S7KS*!QY$Y]= MQ1C]#/2=N7],K5Y_,#S]>-
KK#D_/S]!E!I=7W;,A&YYOD8Z#J_]2]9L\Z"Y MO\OWV/F -0^2ZN'J[*0_8,-/?7;9[UT-3H>G*-O_O?>I>_9KGW5[0W;^D35_
M:>_7OJ%%3T)&]Y)U3\XOAOV3U?DG<]R:M!LM,L%9V!U\Z)[U+X/SWS_W_U@8 MUVHT6L]LV\.6G-;8"9*#.V*$#66 S:BO&^?
4ACE>U6H DM,FJX)2&CKFL5L$M"(:TSBP5 M%@(: :)4I7P*3,-4 MP PW6)L*PSXJG>$>'/S&QDIC$;#?2JX1W'+.+G
HE;!^GJ#T)106LA%HQ&>- MN2U9C=DEGZ!>EGTORLO"D ,8=IK']DXB&;\&!\MEGP;+$E0&AY0456D,$HB%
M1MJ)8@Z$)8)6,USM.&6FI(_;]C/04'5"!F3"(,^@B?9$58,I('8*4K^%]X)8 M(:1P4D;SU6EXQ?G3@-7^A^ ,:' P15H+6F?@
&%IS85)J06(9 M1GJ*]O2<"!-+94IL1WN 5M+CL= JA@2+#=M%^"6 >/88Z]]@YIQCUM_%\#HH
M)4HXDG^P"UX+Q_+I:6])1U:QC!)$8:(7Q>?!_H^&3[Y=^#P!@[.&B'#[\E^C MJ$:4(>:E^?HFM'>/
*%7C>39@"HU=H#1C\XC**:B%.2N'TIF;J/Q:D3W!PP(M]XH.W.*Q5D5[JA08F5$7HZ1(W.F5*4=&)()KO08(3UK<'I-
33Z4A(N&WJRR,OPU A+$V([M(7G96/[C M^?=W;H(-$=K&+E"?>,3<1QZE MD!5#=<#4;P"WHX"WWU)BPQ@@]*XS9]^1#)89T%
<>E)G2MQ,]]?6;*6"RE0SWL MR>"ZLC_](0C;W=A@C"Z"B>(=V4IEI./@\EY*B?-RJ=.>URCE9KG18%SGSJ4@ M<9NPVR2H+OR-?
^S\EY>2?Z\5C^P78YT=]D^>X(,%DX8.TV MS%+47W6$VXA+8/YJ9-7N\Z1*-XY,R2KM-P>2< 78898):P$>W,]&BFNW:20" M=7-
=[**SX/9A:'O";V)K"^^&/TN!JCM?+O/8I&(@6/U:'?H?CI?YM+%TI MH#G N5VLE+MEP4NK%@7^CH4K6;N)T;B%="7CWA"3-
H'DQ;,.?14+???U=^U?NI44%KL2L4-A80HH< M@NJYL98Q^#O8:RG#6M'RVG6!N5PPTL"O S[&)"#B4R62:@8/#^NM_>7>[\L:
M+@'W%\G=S?3C_P%02P,$% @ #D!N619%>@?V" -S, !@ !S9VUT
M+3(P,C0P.3,P>&5X,S%D,BYH=&WM6VU3XS@2_BLZIG8'JN(X;["LPU 50MBA M:@98"'6[=9]D6XE5R)97DA-
RO_ZZ)3MQ>)MA=IC-S$$522RWI%;KZ>Y'LGSP M+\\;90G-(A:3]^./'T@LHR)EF2&18M1 Z9R;A(QEGM.,?&1*<2'(D>+QE!'2
M;C7WFNW.;K/E>8<'T-:PK"2S@+3;?KOK=UJ='FEU@TXW:.V2BX]D^WH\W+'B MQ^?#\9\7(]?OQ?71A],AV?)_]_=H>\?
CX_=C5ZSU29C13/-#9<9%;X_.MLB M6XDQ>>#[_F\.>\VI9KZXTL_,:GH^4)*S9JQB;<.#[$/AF-#P]29BB)$JHT
M,^^VKLQ28)VJ_53/Z=QS+.I)]C$!+O-_?U5D>+39%DFW= "Q00U?,:P M[2=ZKO4 @GDE-
I&9\28TY6(10!WSE&ERQN;D4J8T>]MP)?"MF>*3MWTKK?E_ M&30$;;H^@G)@>+-J=L8U#[G@9A$D/(Y9!@(_O]GOM+K]
Q\%P0[Y [:(!*,J M"*5)^G?-\M!XO\XP#+LU'A5\"HVCA6OC(OC?[K@?V&.XUN.GP\'X]/P,7.;RZGIP-B;C M\PW2\?
+ZP^B*M+O4:_>VZOXYOR3MW;B\N#X['EV2\?L1N1H-KR]/QZ<@._IC M^'YP]MN(#(9CXUO.*)G(6-P10;'YQ?CT7'=_C@<.R?
=5@>'8$'\EI@XP3#D%[088)+:*$-4C$E.&3!3$) M-8'5PM!0,!)*%3/U;JNU!2)"E(%J>:US&I774$/!?
UPI7[KV/G19UJIPXINX M+CC#KB,JRHFP]L""3,X5S?N/M_DU;>9!>#(R#=!D_5J8=5VU MFRZRK0_B'U/GE"1TQHAB,\[FD&--
PC4YD2J%-.S]3B9201$COQ=4 ;[%@EQ M5S(FHRP&Z2N6&Y:&3 %$&\1F93DA5W0*>AERQ*6.. ,:H,EI%C7[JY'[.-F^
MQ<@K5!Z;F\YF0>6(:DO"2+H@-V FP8"N-1QB%,NE,L#SH-=, L^#YBG/",T6 MI,B,*ABH"23.DD" ""4I7"E.!9G0"
(H4D2FD1B.=W#V!C &*-(68 R(IO6$6 MELLV-93%H QT*3"P8A\H$'$%S!/$+ @+ *TB,-M10G2!'ZOZ) 3E"CD- M
#F(PVU5N\\S")T 86"D\#L2!89+0&<-)@U -L>0F@.XT"_07V =M 1^B3E] MIVOPK=A2W09*% ($ .T2(&F[TU:?
B.J$3(2HSV>!US'0FI"ZB'.4!)X?"8*QFQ&(HUV0;X MQ0SP[# VNH7%[2SI2!W+(($4)GA1?.[V M?C1\TLW"YS'38#5
A,W+GT91 RE#1 O]^54P=X<,H%?VY-B +!0T -$/MR0P MIH(4RVP[N)A91>-Z1'=[# #WD@ZL\-
@HHSW>Y!"901NP$5AJ!@H9B/A8*:>(LD)03!PP+*O$BI! #4=0 MZJP,?H4,!2&V0WT6OVPL__%\)=PL7QG-J"@LH'#FV60")
('/6 8$^7ZR+T/] M9[B'NWPX^ULW@8H ;>TX1B@+\WC_G^/ ="G-D$!-/DVL25A1,^ORS-D!].EC MXZ^@?
A:*HLT"];%#S'WDX1*R9 CVS@/@YKCWECEJC%@CB)X:8W8MN5)(5U& M4:$07;7X>:_-5&H#I;BO!RUIF%?RE]L$(=L/5IB
B\!"\8YLJ3+0<6;7O;@D MSHJE3CM.HX3J9:*!N$ZM2['8)CEK":IE!CA>P.KVAHER$7Q'OO$WC?/R3O3C ML?
S=S7*B+V3Y=@LPKARPLOJS&/7KCK"*N CFST96XSY/*G6CP)2,5"XYH(0M M@ ;3E!O#V*/Y+)14V:01<]#--K$-S@+I0V-
Z@F]D:Y5WL[*#JI;7RZRR"Z3 M=UY7#-_UBF$@!$$FSP',N!#$):7=;>8EEUDR]SFC-TA.F*["L5L#V%W':MOD M68
N2;9;'3\0FVD,%35;AN9'P.^>@&(%P##@K>'XD09RI(L41@P&L4,I4^&# MVTNOW.>[)_0#H#@3!:&O
!3H;EK+1G>AS=HC[3MPJIUBJ#6. M-L9MVNH81'7MH:\$(427&V\.5OSD>8X28+;C2I2&6HK"L)<_W/&?VG&-\O/) M
+%FMVZSV_V_M=S:L9B:(-Q\UB&99UN]M]?Y=MH5+WPB-81B,3O'X;?DZ?1[N$R/'S% MYH^.SH7A*PR_)ORW+Q0' .: P!46<3-
F$$6RR.PV M4 G-G0>P62V*'4'TNAFJF!>8MQMD"JHTFIM MA.LWRC4-;L@(GC&OO*X2L3.9TRSZU^Z,OP%="9Y'%IP?W]
M9J>W3/^NK&5WT=P+(?8-D\/_ 5!+ P04 " .0&Y9GC7'DAT& >)@ M& '-G;70M,C R-#
Y,S!X97@S,FOQ+FAT;>U:;7/:.!#^*WMTVB8S\7O@ M4D,S0PB9,I,"!>>N_2AL@345EBN+$/KK;^47
DF:N]XD%ZY#)H"15M+NZED] MN\:MWPRCF\0D"6D$'X*/EQ")<#&GB8)04J*P=)Q ?'L1S/!VJ&9?WI=2SK/#@O.HY-VX%
DB1CBHF$<,OJ]FM0BY5* M?G+:OZ+&0G(EJ=MB)V#9E:7)RVR39+%ZWB<(T7U).%+NF>NY'5MY8 M 0732FPJ$F5,R9SQE?
\V8'.:09\N823F)'E[5+3@9T8EF[YMYM(9^TYQ(IRS M6,,O#=.=U;37+&,3QIE:^3&+(IJ@P)M7)Z[M-5N6%D0_I
X(N242'\B5-R\ MZY:'['T:,Q2]40;A;(:3:P]OV 7ZY;C%A5YQLK7BDN8[,A$\PL[N38Q&*!<
MTVE9D\+$)UIQWT!OTQ#"Y@..KU.[UA^Q*ZG[N= MJZ#W1Q>;4:0[@G;_?*/_HM=OXR5>E?T[9-?P:C2^:O<#" 8[I)5S E?
FV.R8 M,.YVM,?!\>KV$;3'T#X?#(,NNO=%%/\I*%>ZO[,;&C#!ARZ,VZ.S=K\[-@:? M+[M?H-T)=
(]KV^X3&_%CE7L)A")):*@/@H)C5$SATX)(M)6O8$13(142"5P(M.4>F,3Z!F,*8S'!%!6=,9"&CR%L9])+0A
,]7)]+KMWLB#FRU2K_YC0/82ID M/ONW]>PIJBLBHF9#6FJ:+S"97@X>[FA$4RF#)>L9\>.Z;A0N*QA>N1)(+N M#?)
(@AR(:\U9EFDK\%]+1LB $%-)4=U-K0J+*J6. 6BF]>.8W?FR4244T2B50S[J9T*:-W''7(M2=R0A*: M&8,;3E?
0#I7NT3NN]2#J2 _3@A.:J7(0D_ U$4OTPHSZ.2@4F7 4$1*5?E^S M:Z@KYR6CK;]G*0G+[SA"XBNJL%1P@.N:'F*@'%
<%HJ6B3=%K[860\#($\FA M FPN8Z:HH=>@/BHG25K2H=LPZ_7[TSXEC@TD,R7FOH9Q3%] MS-,HBF"XZ8#S$JN,;O&M.2?
ELP276ZE^7!58:CXQV00\"@<>H'T>$: M0[<1L$9_"23GG7=AU13O\BM-RP- RM'SQY$CX/(W3T0L03/SSG)D8%G
MMB),GU:L..PJA!&6'ZN29AI,1[J;8*& PW!MPA%J68KHRHIC;\H2+#ET.TX8 MYIBTQ$- M-#,N^%)GJ=H^-
!R1)ZXDX4254.1MN8IO">HX?B./>49XE'.>XS[ZT!?7!4\ZQP5//H35Q_3V M3,_[CS4_6_D_J^5QPVPT7C=+^%3QD=Y

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sgmt-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001400118 us-gaap:RedeemableConvertiblePreferredStockMember 2023-09-30 0001400118 us-gaap:RedeemableConvertiblePreferredStockMember 2023-06-30 0001400118 us-gaap:RedeemableConvertiblePreferredStockMember 2023-03-31 0001400118 us-gaap:RedeemableConvertiblePreferredStockMember 2022-12-31 0001400118 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0001400118 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-01-012024-03-31 0001400118 us-gaap:CommonClassBMember 2023-07-182023-07-18 0001400118 us-gaap:CommonClassAMember 2023-07-182023-07-18 0001400118 2023-07-072023-07-07 0001400118 us-gaap:RetainedEarningsMember 2024-09-30 0001400118 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001400118 us-gaap:RetainedEarningsMember 2024-06-30 0001400118 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001400118 2024-06-30 0001400118 us-gaap:RetainedEarningsMember 2024-03-31 0001400118 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001400118 2024-03-31 0001400118 us-gaap:RetainedEarningsMember 2023-12-31 0001400118 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001400118 us-gaap:RetainedEarningsMember 2023-09-30 0001400118 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001400118 us-gaap:RetainedEarningsMember 2023-06-30 0001400118 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001400118 2023-06-30 0001400118 us-gaap:RetainedEarningsMember 2023-03-31 0001400118 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001400118 2023-03-31 0001400118 us-gaap:RetainedEarningsMember 2022-12-31 0001400118 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001400118 us-gaap:CommonClassAMember 2024-01-31 0001400118 us-gaap:CommonClassAMember 2023-08-31 0001400118 sgmt:EmployeeStockPurchasePlan2023Member 2023-07-132023-07-13 0001400118 sgmt:PerformanceBasedStockOptionsMember 2024-09-30 0001400118 sgmt:EmployeeStockPurchasePlan2023Memberus-gaap:CommonClassAMember 2024-01-01 0001400118 sgmt:EmployeeStockPurchasePlan2023Memberus-gaap:CommonClassAMember 2024-01-012024-01-01 0001400118 sgmt:EquityIncentivePlan2023Member 2024-01-012024-01-01 0001400118 srt:MinimumMemberus-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001400118 srt:MaximumMemberus-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001400118 srt:MinimumMemberus-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001400118 srt:MaximumMemberus-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001400118 sgmt:EquityIncentivePlan2023Member 2023-07-132023-07-13 0001400118 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001400118 sgmt:EmployeeStockPurchasePlan2023Memberus-gaap:CommonClassAMember 2024-01-012024-09-30 0001400118 sgmt:AtMarketArrangementMember 2024-07-012024-09-30 0001400118 sgmt:AtMarketArrangementMember 2024-01-012024-09-30 0001400118 us-gaap:CommonClassAMember 2023-07-012023-08-31 0001400118 sgmt:AscletisBioscienceCo.LtdMember 2023-07-012023-07-31 0001400118 sgmt:AscletisBioscienceCo.LtdMemberus-gaap:RelatedPartyMember 2024-01-012024-09-30 0001400118 sgmt:AscletisBioscienceCo.LtdMemberus-gaap:RelatedPartyMember 2023-01-012023-09-30 0001400118 2023-08-012023-08-31 0001400118 us-gaap:CommonClassAMember 2024-01-012024-01-31 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001400118 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0001400118 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001400118 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001400118 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001400118 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001400118 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001400118 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001400118 2019-03-12 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-

gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember 2024-09-30 0001400118 sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001400118 sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommercialPaperMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember 2024-09-30 0001400118 sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001400118 sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:AssetBackedSecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001400118 sgmt:LongTermMarketableSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0001400118 sgmt:LongTermMarketableSecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0001400118 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CommercialPaperMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001400118 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001400118 sgmt:SeriesCommonStockWarrantsMember 2023-07-012023-09-30 0001400118 sgmt:SeriesCommonStockWarrantsMember 2023-01-012023-09-30 0001400118 sgmt:RedeemablePreferredStockWarrantMember 2023-01-012023-09-30 0001400118 sgmt:TimeBasedStockOptionsMember 2024-09-30 0001400118 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001400118 sgmt:TimeBasedStockOptionsMember 2024-01-012024-09-30 0001400118 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-09-30 0001400118 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-09-30 0001400118 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-06-30 0001400118 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-06-30 0001400118 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-03-31 0001400118 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-03-31 0001400118 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-12-31 0001400118 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-12-31 0001400118 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-09-30 0001400118 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-09-30 0001400118 us-gaap:CommonStockMember 2023-06-30 0001400118 us-gaap:CommonStockMember 2023-03-31 0001400118 us-gaap:CommonStockMember 2022-12-31 0001400118 us-gaap:CommonClassBMember 2024-09-30 0001400118 us-gaap:CommonClassAMember 2024-09-30 0001400118 us-gaap:CommonClassBMember 2023-12-31 0001400118 us-gaap:CommonClassAMember 2023-12-31 0001400118 sgmt:InducementGrantsOutsideOf2023PlanMember 2024-09-30 0001400118 sgmt:EquityIncentivePlan2023Member 2024-09-30 0001400118 sgmt:EmployeeStockPurchasePlan2023Memberus-gaap:CommonClassAMember 2023-07-13 0001400118 sgmt:EquityIncentivePlan2023Member 2023-07-13 0001400118 sgmt:EmployeeStockPurchasePlan2023Member 2023-07-13 0001400118 sgmt:SeriesCommonStockWarrantsMember 2024-09-30 0001400118 2023-01-012023-12-31 0001400118 2022-01-012022-12-31 0001400118 2023-09-30 0001400118 2022-12-31 0001400118 us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2024-09-30 0001400118 us-

gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember 2024-09-30 0001400118 us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001400118 us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2023-12-31 0001400118 us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001400118 us-gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:MoneyMarketFundsMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember 2024-09-30 0001400118 sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001400118 sgmt:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMember 2024-09-30 0001400118 sgmt:LongTermMarketableSecuritiesMember 2024-09-30 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember 2023-12-31 0001400118 sgmt:ShortTermMarketableSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001400118 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001400118 us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001400118 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0001400118 us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001400118 us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001400118 us-gaap:WarrantMember 2024-07-012024-09-30 0001400118 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0001400118 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001400118 us-gaap:WarrantMember 2024-01-012024-09-30 0001400118 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001400118 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001400118 us-gaap:WarrantMember 2023-07-012023-09-30 0001400118 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001400118 us-gaap:WarrantMember 2023-01-012023-09-30 0001400118 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001400118 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0001400118 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001400118 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001400118 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001400118 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001400118 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001400118 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001400118 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001400118 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001400118 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001400118 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001400118 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001400118 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001400118 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001400118 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001400118 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001400118 2024-04-012024-06-30 0001400118 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001400118 2024-01-012024-03-31 0001400118 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001400118 2023-07-012023-09-30 0001400118 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001400118 2023-04-012023-06-30 0001400118 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001400118 2023-01-012023-03-31 0001400118 sgmt:AscletisBioscienceCo.LtdMemberus-gaap:RelatedPartyMember 2024-09-30 0001400118 us-gaap:RelatedPartyMember 2024-09-30 0001400118 sgmt:AscletisBioscienceCo.LtdMemberus-gaap:RelatedPartyMember 2023-12-31 0001400118 us-gaap:RelatedPartyMember 2023-12-31 0001400118 sgmt:AtMarketArrangementMember 2024-08-012024-08-31 0001400118 us-gaap:CommonStockMember 2023-04-012023-06-30 0001400118 us-gaap:CommonStockMember 2023-07-012023-09-30 0001400118 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-07-012023-09-30 0001400118 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-07-012023-09-30 0001400118 us-gaap:RedeemableConvertiblePreferredStockMember 2023-07-012023-09-30 0001400118 us-gaap:RedeemableConvertiblePreferredStockMember 2023-04-012023-06-30 0001400118 us-gaap:RedeemableConvertiblePreferredStockMember 2023-01-012023-03-31 0001400118 2024-04-012024-04-30 0001400118 2019-03-122019-03-12 0001400118 2023-01-012023-09-30 0001400118 2024-09-30 0001400118 2023-12-31 0001400118 2024-07-012024-09-30 0001400118 2024-11-08 0001400118 2024-01-012024-09-30 shares iso4217:USD iso4217:USD shares utr:sqft pure http://fasb.org/us-gaap/2024#LicenseMemberhttp://fasb.org/us-gaap/2024#LicenseMember0001400118--12-

31202403false0.012582306748551520490152049021375402000P38M10-Qtrue2024-09-30false001-41742Sagimet Biosciences Inc.DE20-5991472155 Bovet Road, Suite 303San MateoCA94402650561-8600Series A Common Stock,$0.0001 par value per shareSGMTNASDAQYesYesNon-accelerated Filertruetruefalsefalse3067485577014000751390007547200019758000470400017490001571900009664600017471000279110000-
24974400044100030000170683000910650001747750009671900020000002000000126530004958000242280001412100042416902000-7452000-36259000-212740001000-4000-
40002283000109500068930001546000228300010990006893000154900-14619000-6353000-29366000-19725000-0.45-0.35-0.95-3.223214333618194682310362716131541-14619000-6353000-29366000-
19725000464000041100084000-14155000-6353000-28955000-196410002137540220001520490340777000-
24974400030000910650009000000100010473100010473200017995114000114000759000759000-23000-23000-6629000-66290003039339730001520490446381000-25637300070001900180002700027000144900014490000-30000-30000-8118000-81180003039339730001520490447803000-264491000-
23000183292000281458154600015460004640004640000-14619000-14619000306748553000152049044934900027911000044100017068300013737306252146200001850841000350010000-221868000-84000-
18695000076700076700071000710000-6587000-65870001373730625214620000185084100035768000-228455000-13000-192699000252311300013000105700010570000-6785000-67850001373730625214620000210315100036825000-235240000-198414000-1373730625-21462000015117912100015204902146190002146200000-210315-
10002103151000102670006026772861610008616100076146000600012789185500018550000-6353000-635300000213754022000152049033946600000-24159300097875000-29366000-
19725000119700039000108000103000375400036790001000-40003261000390000-1351000-200000-98000-108000-31411000-16683000943290002279600032200000-
71533000322000001057500008616100010450001140006000104819000861670001875000101684000751390001580007701style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">SAGIMET BIOSCIENCES INC. NOTES TO THE CONDENSED FINANCIAL STATEMENTS (unaudited) <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;">Description of Business and Basis of Presentation</td></tr></table> Sagimet Biosciences Inc. (the Company), a Delaware corporation headquartered in San Mateo, California, is a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). In January 2024, the Company announced positive topline results from the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52. In June 2024, the Company presented additional 52-week intention to treat (ITT) and F3 subgroup efficacy data from the Phase 2b FASCINATE-2 clinical trial. In October 2024, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Breakthrough Therapy designation of denifanstat was supported by positive data from the Phase 2b FASCINATE-2 clinical trial in biopsy-confirmed MASH patients with stage 2 or stage 3 fibrosis. In October 2024, the Company completed successful end-of-Phase 2 interactions with the FDA, supporting the advancement of denifanstat into Phase 3 in MASH. The planned program will include two Phase 3 trials: FASCINATE-3, evaluating patients with F2/F3 (non-cirrhotic) MASH, and FASCINIT, evaluating patients with suspected or confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)/MASH. The Phase 3 program is expected to initiate by the end of 2024. In addition to MASH, the Company is exploring the use of its FASN inhibitors in acne and in select forms of cancer, diseases in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is currently being tested in China by the Company’s license partner, Ascletis BioScience Co. Ltd. (Ascletis), a subsidiary of Ascletis Pharma Inc. (Ascletis Pharma), in a Phase 3 clinical trial for moderate to severe acne vulgaris and a Phase 3 trial in recurrent glioblastoma multiforme (GBM) in combination with bevacizumab. In November 2024, Ascletis announced completion of enrollment of 480 patients in the acne Phase 3 clinical trial. The Company has completed Investigational New Drug (IND)-enabling studies for a second FASN inhibitor, TVB-3567. The accompanying financial statements have been prepared in accordance with accounting principles generally accepted (GAAP) in the United

States. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) promulgated by the Financial Accounting Standards Board (FASB). Certain prior year amounts have been reclassified to conform to the current year presentation. These unaudited interim financial statements and accompanying notes should be read in conjunction with the Company's annual financial statements and the notes thereto included in the Company's Form 10-K, as filed with the Securities and Exchange Commission (SEC) on March 25, 2024. The accompanying interim financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 are unaudited but include all adjustments that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2023 have been derived from the audited financial statements as of that date. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Such estimates include accruals of research and development expenses, accrued costs for services rendered under agreements with third-party contract research organizations (CROs), preferred stock and common stock valuations prior to the Company's initial public offering of Series A common stock (IPO) and stock option valuations and stock-based compensation. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Emerging growth company status The Company is an emerging growth company (EGC) as defined in the Jumpstart Our Business Startups Acts of 2012, as amended (the JOBS Act), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act and has elected to use the extended transition period for complying with new or revised accounting standards. As a result of this election, the Company's financial statements may not be comparable to those issued by companies that comply with the effective dates pursuant to public company FASB standards. Liquidity The accompanying unaudited financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company will require substantial additional capital to fund its research and development and ongoing operating expenses. As of September 30, 2024, the Company has relied on public and private equity and debt financings and proceeds from licensing arrangements to fund its operations. The Company has incurred recurring losses and negative cash flows from operations since inception, and, as of September 30, 2024, had an accumulated deficit of $279.1 million and cash, cash equivalents and marketable securities of $170.0 million. The Company expects to incur additional losses and negative cash flows from operations for the foreseeable future. In July and August 2023, the Company completed its IPO, and inclusive of the partial exercise of the underwriters' overallotment option, the Company sold an aggregate of 6,026,772 shares of Series A common stock at a public offering price of $16.00 per share and received $86.2 million in net proceeds. In January 2024, the Company completed a follow-on offering whereby it sold 9,000,000 shares of its Series A common stock at price of $12.50 per share and received $104.7 million in proceeds, net of issuance costs of $7.8 million. The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund the Company's operating expenses for at least the next 12 months from the issuance of these financial statements. In the future, the Company will need to raise additional funds until it is able to generate sufficient revenues to fund its development activities, if ever. The Company's future operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to predict the outcome of these actions to generate the liquidity ultimately required. In August 2024, the Company entered into a Controlled Equity

Offering Sales Agreement with Cantor Fitzgerald & Co. to establish an at-the-market offering (ATM Offering) through which the Company may sell, from time to time at its sole discretion up to $75.0 million of shares of its Series A common stock. There were no sales under the ATM Offering during the three and nine months ended September 30, 2024.

* -279100000170000000.0602677216.0086200000900000012.501047000007800000075000000.000<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;">Significant Accounting Policies </td></tr></table> The Company’s significant accounting policies are disclosed in the audited financial statements and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 25, 2024. Since the date of those audited financial statements, there have been no material changes to the Company’s significant accounting policies. Reverse stock split A one-for-79.4784 reverse stock split of the Company’s issued and outstanding common stock was effected on July 7, 2023. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. Accordingly, all share and per share amounts for all periods presented in the accompanying unaudited condensed financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the effects of the reverse stock split. Shares of common stock underlying outstanding stock options and common stock warrants were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company’s preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. Net loss per share and reclassification of common stock Basic and diluted net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The Company’s participating securities do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders for all periods presented. Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share attributable to common stockholders calculation, common stock options, restricted stock units and common stock warrants are considered to be potentially dilutive securities. As the Company has reported a net loss for the periods presented, basic and diluted net loss per share attributable to common stockholders is the same as all potentially dilutive securities would have an anti-dilutive impact. On July 18, 2023, each share of the Company’s common stock issued and outstanding became reclassified as one share of Series A common stock. Any stock certificate that immediately prior to July 18, 2023 represented shares of the Company’s common stock was deemed to represent shares of Series A common stock, without the need for surrender or exchange thereof. Additionally, in connection with the IPO, the Company’s outstanding redeemable convertible preferred stock automatically converted into 15,117,912 shares of Series A common stock and 1,520,490 shares of Series B common stock. The rights of the holders of Series A common stock and Series B common stock are substantially identical, except with respect to voting and conversion. Each share of Series A common stock is entitled to one vote and shares of Series B common stock are non-voting, except as may be required by law. Each share of Series B common stock may be converted at any time into one share of Series A common stock at the option of its holder, subject to certain ownership limitations. As such, basic and diluted net loss per share attributable to common stockholders is presented on a combined basis as undistributed earnings, when allocated to each series of common stock, result in the same net loss per share for all periods presented. The following table presents the calculation of basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 (in thousands, except share and per share data): <table style="border-collapse:collapse;font-*

size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> <span style="font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:40.68%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> Net loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt;"> (14,619) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,353)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (29,366) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (19,725) </td></tr><tr><td style="vertical-align:bottom;width:40.68%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> Weighted-average shares of Series A and Series B common stock outstanding, basic and diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,143,336 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,194,682 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,036,271 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,131,541 </td></tr><tr><td style="vertical-align:bottom;width:40.68%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss per share of Series A and Series B common stock outstanding, basic and diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.45)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.35) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.95)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (3.22) </td></tr></table> . The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of Series A and Series B common stock outstanding, as their effect would have been anti-dilutive: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-

wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> <b style="font-

weight:bold;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"> Options to purchase Series A common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4,322,367 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"> 3,766,505 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> 4,322,367 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"> 3,766,505 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.9%;margin:0pt;padding:0pt;"> Warrants to purchase Series A common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 1,000 </td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 844,382 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;border-

bottom:1px solid #000000;margin:0pt;padding:0pt;"> 844,382 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,167,749 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,767,505 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,167,749 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,767,505 </td></tr></table> 1 Recently adopted accounting pronouncements The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and either determined to be not applicable or expected to have minimal impact on the Company’s financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40); Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for fiscal years beginning after December 15, 2023, including interim periods within. The adoption of this standard had no impact on the Company’s financial statements and related disclosures. New accounting pronouncements not yet adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280)–Improvements to Reportable Segment Disclosures. ASU 2023-07 requires disclosure of incremental segment information on an interim and annual basis and provides new segment disclosure requirements for entities with a single reportable segment. ASU 2023-07 is effective for all public companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company is assessing the impact of the adoption of this standard on its disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740)–Improvements to Income Tax Disclosures, a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions and applies to all entities subject to income taxes. The new standard is effective for annual periods beginning after December 15, 2024. The Company is assessing the impact of the adoption of this standard on its disclosures. Reverse stock split A one-for-<span style="-sec-ix-

hidden;Hidden_lMVtu1gDAEKD_gkEsQFLpQ;">79.4784 reverse stock split of the Company's issued and outstanding common stock was effected on July 7, 2023. Stockholders entitled to fractional shares as a result of the reverse stock split received a cash payment in lieu of receiving fractional shares. Accordingly, all share and per share amounts for all periods presented in the accompanying unaudited condensed financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the effects of the reverse stock split. Shares of common stock underlying outstanding stock options and common stock warrants were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. Shares of common stock reserved for issuance upon the conversion of the Company's preferred stock were proportionately reduced and the respective conversion prices were proportionately increased. Net loss per share and reclassification of common stock Basic and diluted net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The Company's participating securities do not have a contractual obligation to share in the Company's losses. As such, the net loss was attributed entirely to common stockholders for all periods presented. Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share attributable to common stockholders calculation, common stock options, restricted stock units and common stock warrants are considered to be potentially dilutive securities. As the Company has reported a net loss for the periods presented, basic and diluted net loss per share attributable to common stockholders is the same as all potentially dilutive securities would have an anti-dilutive impact. On July 18, 2023, each share of the Company's common stock issued and outstanding became reclassified as one share of Series A common stock. Any stock certificate that immediately prior to July 18, 2023 represented shares of the Company's common stock was deemed to represent shares of Series A common stock, without the need for surrender or exchange thereof. Additionally, in connection with the IPO, the Company's outstanding redeemable convertible preferred stock automatically converted into 15,117,912 shares of Series A common stock and 1,520,490 shares of Series B common stock. The rights of the holders of Series A common stock and Series B common stock are substantially identical, except with respect to voting and conversion. Each share of Series A common stock is entitled to one vote and shares of Series B common stock are non-voting, except as may be required by law. Each share of Series B common stock may be converted at any time into one share of Series A common stock at the option of its holder, subject to certain ownership limitations. As such, basic and diluted net loss per share attributable to common stockholders is presented on a combined basis as undistributed earnings, when allocated to each series of common stock, result in the same net loss per share for all periods presented. The following table presents the calculation of basic and diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 (in thousands, except share and per share data): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td

colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:40.68%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> Net loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (6,353) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,366)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (19,725) </td></tr><tr><td style="vertical-align:bottom;width:40.68%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> Weighted-average shares of Series A and Series B common stock outstanding, basic and diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 32,143,336 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,194,682 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,036,271 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,131,541 </td></tr><tr><td style="vertical-align:bottom;width:40.68%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss per share of Series A and Series B common stock outstanding, basic and diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.45) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.35) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.95) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (3.22) </td></tr></table> $</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of Series A and Series B common stock outstanding, as their effect would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">$ <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"> Options to purchase Series A common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4,322,367 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"> 3,766,505 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> <span style="font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> 4,322,367 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"> 3,766,505 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.9%;margin:0pt;padding:0pt;"> Warrants to purchase Series A common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 1,000 </td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 844,382 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 844,382 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,167,749 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,767,505 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times

*New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,167,749 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,767,505 </td></tr>
</table>151179121520490 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-*

space:nowrap;width:27.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:40.68%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> Net loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (6,353) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,366)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (19,725) </td></tr><tr><td style="vertical-align:bottom;width:40.68%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.68%;margin:0pt;padding:0pt;"> Weighted-average shares of Series A and Series B common stock outstanding, basic and diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 32,143,336 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,194,682 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31,036,271 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,131,541 </td></tr><tr><td style="vertical-align:bottom;width:40.68%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss per share of Series A and Series B common stock outstanding, basic and diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.45) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.35) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.95) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt;"> (3.22) </td></tr></table>-14619000-6353000-29366000-19725000321433361819468231036271613154 1-0.45-0.35-0.95-3.22 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"> Options to purchase Series A common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4,322,367 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"> 3,766,505 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> 4,322,367 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"> 3,766,505 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.9%;margin:0pt;padding:0pt;"> Warrants to purchase Series A common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 1,000 </td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 844,382 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> .

</td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 844,382 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,167,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,767,505 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,167,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,767,505 </td></tr></table>

Recently adopted accounting pronouncements

The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and either determined to be not applicable or expected to have minimal impact on the Company’s financial statements.

In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40); Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for fiscal years beginning after December 15, 2023, including interim periods within. The adoption of this standard had no impact on the Company’s financial statements and related disclosures.

New accounting pronouncements not yet adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280)—Improvements to Reportable Segment Disclosures. ASU 2023-07 requires disclosure of incremental segment information on an interim and annual basis and provides new segment disclosure requirements for entities with a single reportable segment. ASU 2023-07 is effective for all public companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company is assessing the impact of the adoption of this standard on its disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures, a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions and

applies to all entities subject to income taxes. The new standard is effective for annual periods beginning after December 15, 2024. The Company is assessing the impact of the adoption of this standard on its disclosures. <table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"> 3. </td><td style="padding:0pt;"> Fair Value Measurements and Fair Value of Financial Instruments </td></tr></table> The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. As of September 30, 2024 and December 31, 2023, financial assets measured at fair value on a recurring basis consisted of cash equivalents and marketable securities. Cash equivalents consist primarily of money market funds and other investments that are readily convertible into cash and have maturities of three months or less at the time of acquisition. The fair value of cash equivalents was $76.4 million and $74.1 million as of September 30, 2024 and December 31, 2023, respectively. The Company considers marketable securities with maturities greater than three months at the time of acquisition to be available for sale securities. The fair value of available for sale securities was $92.9 million and $19.8 million as of September 30, 2024 and December 31, 2023, respectively. These available for sale securities have expected maturities ranging from 0.3 to 16.8 months, and securities with an expected maturity greater than 12 months as of the balance sheet date, are classified in long-term. The fair value of marketable securities, which are Level 2 financial instruments, is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker-dealer quotes, bids and/or offers. The Company evaluates securities with unrealized losses, if any, to determine whether the decline in fair value has resulted from credit loss or other factors, including various qualitative factors. As of September 30, 2024, the Company has not recognized any impairment or credit losses on the Company’s available for sale securities. While the Company classifies these securities as available for sale, the Company does not intend to sell its investments and based on its current plans, the Company currently believes it has the ability to hold these investments until maturity. The carrying values of the Company’s accounts payable and accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company’s Level 3 liabilities that are measured at fair value on a recurring basis consist of the Series A common stock warrant liability related to the warrant to purchase 1,000 shares of Series A common stock with an exercise price of $69.64 per share and an expiration date of July 18, 2026, the third anniversary date of the closing of the Company’s IPO. The fair value of Series A common stock warrant liability was immaterial as of September 30, 2024 and December 31, 2023, as well as the change in fair value during the three and nine months ended September 30, 2024 and 2023. There were no transfers within the hierarchy during the periods presented. The following tables set forth the Company’s financial assets that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-

wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-

align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Valuation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Hierarchy </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt

0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,427 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Total cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,427 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,427 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Short-term marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 19,469 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 56 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

*Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 19,525 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 9,442 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 9,462 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> U.S. Treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 32,447 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 32,580 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 11,396 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 22 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> <span

*style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 11,418 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,480 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,487 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Total short-term marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75,234 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 238 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75,472 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Long-term marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> <span

style="font-weight:bold;visibility:hidden;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 12,291 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 165 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 12,456 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,977 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px

solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 38 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,015 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Total long-term marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 203 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17,471 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total cash equivalents and marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 168,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 441 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 169,370 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Valuation </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Hierarchy </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 69,516 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Corporate debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">

4,622 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,622 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 74,138 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 74,138 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Short-term marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 9,879 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 19 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 9,898 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Corporate debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 2,945 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 2,949 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,904 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,911 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Total short-term marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,728 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,758 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash equivalents and marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">93,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 30 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 93,896 </td></tr></table> 7640000074100000929000001980000010006 9.64 The following tables set forth the Company’s financial assets that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Valuation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Hierarchy </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> <span

style="font-weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,427 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Total cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,427 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 76,427 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Short-term marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 19,469 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 56 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 19,525 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 9,442 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 20 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 9,462 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> U.S. Treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 32,447 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">| </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 32,580 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 11,396 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 22 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 11,418 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,480 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,487 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Total short-term marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75,234 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td

style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 238 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75,472 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Long-term marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury securities </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 12,291 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 165 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 12,456 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,977 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,015 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Total long-term marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 203 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17,471 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Total cash equivalents and marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 168,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 441 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> –</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 169,370 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:44.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Valuation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> <b

style="font-weight:bold;">Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Hierarchy </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 69,516 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Corporate debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,622 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,622 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 74,138 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 74,138 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 9,879 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> 19 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"> 9,898 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Corporate debt securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 2,945 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 2,949 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

*New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,904 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,911 </td></tr><tr><td style="vertical-align:bottom;width:40.43%;margin:0pt;padding:0pt;"> Total short-term marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,728 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,758</p></td></tr><tr><td style="vertical-align:bottom;width:40.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 93,866 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 30 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 93,896 </td></tr></table>76427000764270007642700076427000194690005600019525000944200020000946200032447000133000325800

<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"> 4. </td><td style="padding:0pt;"> Prepaid Expenses and Other Current Assets </td></tr></table>

Prepaid expenses and other current assets consisted of the following (in thousands):

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:45.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid clinical costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;margin:0pt;padding:0pt;"> 2,933 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;margin:0pt;padding:0pt;"> – </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Prepaid research and development costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> 684 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> 767 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid insurance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;margin:0pt;padding:0pt;"> 680 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;margin:0pt;padding:0pt;"> 585 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Deferred financing costs⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> 306 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> 323 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 74 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Total prepaid expenses and other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,749 </td></tr></table> _____ . <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Amount as of September 30, 2024 relates to deferred financing costs related to the ATM Offering entered into during August 2024. Amount as of December 31, 2023 relates to deferred financing costs related to the Company's January 2024 follow-on offering.</td></tr></table> Prepaid expenses and other current assets consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:45.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid clinical costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;margin:0pt;padding:0pt;"> – </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Prepaid research and development costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> 684 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> 767 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Prepaid insurance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;margin:0pt;padding:0pt;"> 680 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;margin:0pt;padding:0pt;"> 585 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Deferred financing costs⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> 306 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> 323 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 101 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 74 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Total prepaid expenses and other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,704 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,749 </td></tr></table> _____ 1 <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Amount as of September 30, 2024 relates to deferred financing costs related to the ATM Offering entered into during August 2024. Amount as of December 31, 2023 relates to deferred financing costs related to the Company’s January 2024 follow-on offering.</td></tr></table>
2933000684000767000680000585000306000323000101000740004704000174900<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"> 5. </td><td style="padding:0pt;"> Accrued Expenses and Other Current Liabilities </td></tr></table> Accrued expenses and other current liabilities consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> 1 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;">   </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:45.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> <span style="font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued payroll-related costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;margin:0pt;padding:0pt;"> 1,105 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Accrued clinical costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> 814 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> 2,668 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued research and development costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;margin:0pt;padding:0pt;"> 785 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;margin:0pt;padding:0pt;"> 632 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Accrued general and administrative costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> 219 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> 442 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued offering costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;margin:0pt;padding:0pt;"> 323 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 233 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Total accrued expenses and other current liabilities </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,403 </td></tr></table> Accrued expenses and other current liabilities consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:45.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> <span style="font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued payroll-related costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;margin:0pt;padding:0pt;"> 1,105 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Accrued clinical costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> 814 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> 2,668 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued research and development costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;margin:0pt;padding:0pt;"> 785 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;margin:0pt;padding:0pt;"> 632 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Accrued general and administrative costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;margin:0pt;padding:0pt;"> 219 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;margin:0pt;padding:0pt;"> 442 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued offering costs </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;margin:0pt;padding:0pt;"> 323 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 233 </td></tr><tr><td style="vertical-align:bottom;width:51.07%;background:#cceeff;margin:0pt;padding:0pt;"> Total accrued expenses and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,824 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:19.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,403 </td></tr></table> 995000110500081400026680007850006320002190004420003230001100023300028240005403000<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"> 6. </td><td style="padding:0pt;"> Commitments and Contingencies </td></tr></table> License and other agreements Ascletis BioScience Co. Ltd In January 2019, the Company entered into a license agreement that became effective in February 2019 with Ascletis BioScience Co. Ltd. (Ascletis), a subsidiary of Ascletis Pharma Inc. (Ascletis Pharma), a biotechnology company incorporated in the Cayman Islands and headquartered in Hangzhou, China. Ascletis Pharma, through a subsidiary, was the lead investor in the Company's Series E redeemable convertible preferred stock financing in February 2019. The parties entered into this agreement with the intention to develop, manufacture, and commercialize the Company's proprietary FASN inhibitor, denifanstat, which Ascletis refers to as ASC40. Under the terms of the license agreement, the Company granted Ascletis and its affiliates an exclusive, royalty-bearing sublicensable right and license under the Company's intellectual property to develop, manufacture, commercialize and otherwise exploit denifanstat and other products containing denifanstat-related compounds in Greater China, consisting of the People's Republic of China, Hong Kong, Macau and Taiwan. The Company is eligible to receive development and commercial milestone payments from Ascletis in aggregate of up to $122.0 million as well as tiered royalties ranging from percentages in the high single digits to mid-teens on future net sales of denifanstat in Greater China. The license and the research and development services components of this license agreement are representative of a relationship with a customer, and therefore, the Company evaluated the license agreement under the provisions of ASC 606, Revenue from Contracts with Customers. The developmental and commercial event-based milestone payments represent variable consideration, and the Company used the most likely amount method to estimate this variable consideration because the potential milestone payment is a binary event, as the Company will either receive the milestone payment or it will not. Given the high degree of uncertainty around achievement of these milestones, the Company determined the milestone amounts to be fully constrained and will not recognize revenue until the uncertainty associated with these payments is resolved. Any consideration related to royalties will be recognized if and when the related sales occur. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. In July 2023, the Company recognized $2.0 million of revenue related to a development milestone triggered by the initial dosing of a Phase 3 trial for recurrent glioblastoma multiforme (GBM), of which $1.7 million was received from Ascletis in August 2023, net of applicable taxes, which are recorded in general and administrative expense in the statement of operations and comprehensive loss. In July 2023, the Company entered into an Assignment and Assumption Agreement with Ascletis and Ascletis' affiliate Gannex Pharma Co., Ltd. (Gannex) under which Ascletis, while remaining responsible for performance under the license agreement, assigned all of its rights and obligations under the license agreement to Gannex and Gannex assumed such rights and obligations, effective as of October 2019. Contract Research Organization In June 2024, the Company entered into a contract with a global CRO to perform certain research and related services in connection with certain of the Company's clinical trials and research studies (CRO Services Agreement). The terms of the CRO Services Agreement require the Company to pay to the CRO certain direct fees, investigator grants and other pass-through costs, generally on an upfront prepaid basis. These payments are capitalized at the time of payment and expensed in the period in which the research and development activity is performed. The Company may terminate the CRO Services Agreement or underlying statement of work at

*will with 60 days' written notice. Facility lease agreement On March 12, 2019, the Company executed a 38-month non-cancelable operating lease agreement for 3,030 square feet of office space for its headquarters facility in San Mateo, California, which commenced April 1, 2019. The lease provides for monthly payments of approximately $12,000 with annual increases. In December 2021, the lease agreement was amended to extend the term of the lease through June 2024; in April 2024, the Company amended the lease agreement to (i) extend the lease through June 30, 2025 and (ii) increase the monthly lease payment to approximately $13,000 beginning on July 1, 2024, which resulted in an increase in the Company's operating lease right-of-use asset and corresponding operating lease liability of $0.1 million on the amendment date. Operating lease costs were $42,000 and $37,000 for the three months ended September 30, 2024 and 2023, respectively, and $116,000 and $111,000 for the nine months ended September 30, 2024 and 2023, respectively. Guarantees and indemnifications In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September 30, 2024, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities. Legal Proceedings From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business. The Company is not party to any material legal proceedings as of September 30, 2024.
122000000.02000000.0170000030301200013000100000420003700011600011100<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"> 7. </td><td style="padding:0pt;"> Stock-Based Compensation </td></tr></table> The 2023 Stock Option and Incentive Plan (2023 Plan) was adopted by the board of directors, approved by the Company's stockholders on July 4, 2023, and became effective on July 13, 2023, replacing the 2017 Equity Incentive Plan. The number of shares initially reserved for issuance under the 2023 Plan was 2,585,968, which automatically increased by 855,016 shares on January 1, 2024 and will increase each January 1 thereafter, by (i) 4% of the outstanding number of shares of the Company's Series A common stock on the immediately preceding December 31 or (ii) a lesser number of shares as determined by the compensation committee of the board of directors. As of September 30, 2024, the aggregate maximum number of shares reserved for issuance under the 2023 Plan was 3,440,984, of which 1,729,910 shares were available for future grant. Option grants issued under the 2023 Plan are exercisable for up to 10 years from the date of issuance. In March 2024, the Company established a pool of 1,000,000 shares of Series A common stock (Inducement Pool) from which grants of stock-based compensation awards may be issued as inducement for new employees to accept employment offers from the Company or individuals returning to employment after a bona fide period of non-employment with the Company. Inducement Pool grants are granted outside of the 2023 Plan and do not require approval from the Company's stockholders pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). As of September 30, 2024, 364,672 shares were available for future grants from the Inducement Pool. Total stock-based compensation recorded in the condensed statements of operations and comprehensive loss related to stock options and restricted stock units for employees and non-employees was as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New*

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> x </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> x </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"> 1,855 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"> 3,679 </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 230 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 851 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td></tr><tr><td style="vertical-align:bottom;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,855 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,679 </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> Included in: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> <span style="font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> General and administrative expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"> 1,649 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"> 3,103 </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> Research and development expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 235 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;">. </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 749 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">576</p></td></tr><tr><td style="vertical-align:bottom;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,546 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,754 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,679 </td></tr></table> . Stock options . The Company grants stock options which consist of (i) time-based options, which vest and become exercisable, subject to the participant’s continued employment or service through the applicable vesting date and (ii) performance-based options, which vest based on performance measures against predetermined objectives that include successful completion of qualified equity offerings or announced <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:justify;margin:0pt 0pt 12pt 0pt;">topline results for clinical trials and positive clinical results over a specified performance period. The Company's time-based options have various vesting schedules that range from vesting immediately to vesting over a four-year period. The following table summarizes stock option activity for the nine months ended September 30, 2024 (in thousands, except share and per share data): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> Underlying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> Contractual </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> Term </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b

style="font-weight:bold;">Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:40.88%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"> 3,753,507 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 8 </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> Options granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> 1,375,296 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> 4.43 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;background:#cceeff;margin:0pt;padding:0pt;"> Options exercised </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"> (17,995) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"> 6.36 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> Options forfeited/expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (788,441) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> 8.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,322,367 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.77 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 7.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and exercisable as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,314,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> 7.26 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 6.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> — </td></tr></table> _____ 1 <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Includes 492,729 performance-based options with a weighted-average exercise price of $6.42, of which 490,372 were fully vested and exercisable.</td></tr></table> During the nine months ended September 30, 2024 and 2023, the weighted average grant-date fair value per share of stock options granted was $3.42 and $10.28, respectively. The total intrinsic value of stock options exercised during the nine months ended September 30, 2024 and 2023, was $0.1 million and $0.1 million, respectively. Additionally, during the nine months ended September 30, 2024 and 2023, cash received from the exercise of stock options was $0.1 million and approximately

$6,000, respectively. As of September 30, 2024, there was $9.5 million of unrecognized compensation expense, which is expected to be recognized over a remaining weighted-average period of 2.4 years. Restricted stock units The Company’s restricted stock units generally vest over a four-year period in equal amounts on an annual basis, provided the employee remains continuously employed with the Company. The fair value of the restricted stock units is equal to the closing price of the Company’s Series A common stock on the grant date. The following table summarizes restricted stock unit activity: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.91%;margin:0pt;padding:0pt;"> Weighted-Average </td></tr><tr><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"> Restricted </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.91%;margin:0pt;padding:0pt;"> Grant Date </td></tr><tr><td style="vertical-

align:bottom;width:56.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Units </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:56.97%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"> 1,132,410 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"> 2.96 </td></tr><tr><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"> 49,330 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"> 5.23 </td></tr><tr><td style="vertical-align:bottom;width:56.97%;background:#cceeff;margin:0pt;padding:0pt;"> Vested/released </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"> (281,458) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"> 2.96 </td></tr><tr><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;"> Forfeited/expired </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (55,900) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4.96 </td></tr><tr><td style="vertical-align:bottom;width:56.97%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 844,382 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.96 </td></tr></table> . As of September 30, 2024, the total unrecognized compensation expense related to unvested restricted stock units was $2.3 million, which is expected to be recognized over a remaining weighted-average period of 2.8 years. Valuation assumptions The fair value of each stock option granted was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:55.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:41.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:55.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"> 91 - 96 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"> 89 - 91 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:55.21%;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> 3.9 - 4.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> 3.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-

align:bottom;width:55.21%;margin:0pt;padding:0pt;"> Expected term (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> 5.3 - 6.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> 5.0 - 7.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"> 1 </td></tr></table> 1 The expected term of the stock options represents the average of the contractual term of the options and the weighted-average expected vesting period. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected volatility rate was based on the historical volatilities of comparable companies in the Company’s industry. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero. Employee stock purchase plan 1 The 2023 Employee Stock Purchase Plan (the ESPP) was adopted by the board of directors in July 2023 with an initial total of 215,497 shares of Series A common stock reserved for issuance. Under the ESPP plan, the amount of shares reserved will automatically increase each January 1 through January 1, 2033, by the least of (i) 215,497 shares of Series A common stock, (ii) 1% of the outstanding number of shares of the Company’s Series A common stock on the immediately preceding December 31 or (iii) such lesser number of shares of Series A common stock as determined by the administrator of the ESPP. On January 1, 2024, in accordance with the ESPP, the authorized shares were increased by 213,754 shares for a total of 429,251 shares of Series A common stock available under the ESPP. No shares of Series A common stock have been issued under the ESPP to date. 25859688550160.0434409841729910P10Y1000000364672 Total stock-based compensation recorded in the condensed statements of operations and comprehensive loss related to stock options and restricted stock units for employees and non-employees was as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"> 1,855 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"> 3,679 </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> Restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 230 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 851 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> – </td></tr><tr><td style="vertical-align:bottom;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,855 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,679 </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> Included in: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> General and administrative expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"> 1,649 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"> 3,103 </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> Research and development expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 235 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 206 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 749 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 576 </td></tr><tr><td style="vertical-

align:bottom;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,546 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,855 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,754 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,679 </td></tr></table>1316000185500029030003679000230000851000154600018550003754000367900013110001649000300500031030 style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity for the nine months ended September 30, 2024 (in thousands, except share and per share data): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"> Weighted- </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> Underlying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> Contractual </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> <span style="font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> Term </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"> Intrinsic </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in Years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td></tr><tr><td style="vertical-align:bottom;width:40.88%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"> 3,753,507 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"> 7.99 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 7.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 8 </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> Options granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> 1,375,296 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> 4.43 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;background:#cceeff;margin:0pt;padding:0pt;"> Options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"> (17,995) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"> 6.36 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> Options forfeited/expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> (788,441) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> 8.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:40.88%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,322,367 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:40.88%;margin:0pt;padding:0pt;"> Vested and exercisable as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,314,801 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"> 7.26 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 6.3 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> — </td></tr></table> _____ <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Includes 492,729 performance-based options with a weighted-average exercise price of $6.42, of which 490,372 were fully vested and exercisable.</td></tr></table>
37535077.99P7Y1M6D800013752964.43179956.367884418.5043223676.77P7Y6M23148017.26P6Y3M18D4927296.4
style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">
<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;">
<tr style="height:1pt;"><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.91%;margin:0pt;padding:0pt;"> Weighted-Average </td></tr><tr><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;"> <span style="font-size:8pt;font-

weight:bold;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"> Restricted </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.91%;margin:0pt;padding:0pt;"> Grant Date </td></tr><tr><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Units </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr><td style="vertical-align:bottom;width:56.97%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"> 1,132,410 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"> 2.96 </td></tr><tr><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"> 49,330 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"> 5.23 </td></tr><tr><td style="vertical-align:bottom;width:56.97%;background:#cceeff;margin:0pt;padding:0pt;"> Vested/released </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"> (281,458) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"> 2.96 </td></tr><tr><td style="vertical-align:bottom;width:56.97%;margin:0pt;padding:0pt;"> Forfeited/expired </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (55,900) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4.96 </td></tr><tr><td style="vertical-align:bottom;width:56.97%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 844,382 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.96 </td></tr></table>11324102.96493305.232814582.96559004.968443822.962300000P2Y9M18D <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:41.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:55.21%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"> 91 - 96 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"> 89 - 91 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:55.21%;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> 3.9 - 4.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> 3.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:55.21%;background:#cceeff;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"> – </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.21%;margin:0pt;padding:0pt;"> Expected term (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> 5.3 - 6.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"> 5.0 - 7.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"> </td></tr>

</table>0.910.960.890.910.0390.0450.03600P5Y3M18DP6Y1M6DP5YP7Y02154972154970.012137544292510<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"> 8. </td><td style="padding:0pt;"> Related Party Transactions </td></tr></table> Jinzi J. Wu, Ph.D., a member of the Company's board of directors until June 2024, founded and serves as the chief executive officer of Ascletis, Gannex, and Ascletis Pharma. During the nine months ended September 30, 2024 and 2023, the Company recognized $0.1 million and nil of expenses, respectively, related to its portion of expenses owed under the Ascletis license agreement, which are recorded in research and development expense in the unaudited condensed statements of operations and comprehensive loss. As of September 30, 2024 and December 31, 2023, the Company recorded nil and $31,000, respectively, of accruals related to the Ascletis license agreement. During the nine months ended September 30, 2024 and 2023, the Company paid Ascletis $0.2 million and nil, respectively, under the Ascletis manufacturing arrangement. 10000000310002000000falsefalsefalsefalse